<SEC-DOCUMENT>0001213900-23-036733.txt : 20230505
<SEC-HEADER>0001213900-23-036733.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505114840
ACCESSION NUMBER:		0001213900-23-036733
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-271413
		FILM NUMBER:		23892181

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea177987-s1a1_modularmedical.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"> <B>As filed with the Securities
and Exchange Commission on <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 5, 202</FONT>3</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
No. 333-271413</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT
NO. 1 TO</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
FORM S-1</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt 0.5pt 0.5pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>MODULAR
    MEDICAL, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Exact
    name of registrant as specified in its charter)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt 0.5pt 0.5pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt 1.25pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt 0.5pt 0.5pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3841</B></FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt 1.25pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt 0.5pt 0.5pt; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>87-0620495</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(State or other
    jurisdiction of <BR>
    incorporation or organization)</I></FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Primary Standard
    Industrial <BR>
    Classification Code Number)</I></FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(I.R.S. Employer
    <BR>
    Identification Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>10740 Thornmint Road</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>San
Diego, California 92127</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(858)
800-3500</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Address,
including zip code, and telephone number, including</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>area
code, of registrant&rsquo;s principal executive offices)</I></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>James E. Besser</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>10740 Thornmint Road</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California 92127</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(858) 800-3500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Name,
address, including zip code, and telephone</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>number,
including area code, of agent for service)</I></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>With
copies to:</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding: 0.25pt 0.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joseph Lucosky</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lawrence Metelitsa</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lucosky Brookman LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>101 Wood Avenue South</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Woodbridge, NJ 08830</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(732) 395-4400</B></P></TD>
    <TD STYLE="width: 49%; padding: 0.25pt 0.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stephen E. Older</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>David S. Wolpa</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>McGuireWoods LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1251 Avenue of the Americas, 20th Floor</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10020</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 548-2100 </B></P></TD></TR>
  </TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0.25pt 0.5pt 0.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    soon as practicable after the effective date of this registration statement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Approximate date
    of commencement of proposed sale to the public)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9746;</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&nbsp;&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;&#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated Filer&nbsp;&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&nbsp;&#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company
    &nbsp;&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the
Commission, acting pursuan</B></FONT><B>t to said Section 8(a), may determine.</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">The information in this
preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with
the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to
buy these securities in any jurisdiction where the offer or sale is not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="color: Red"><B>SUBJECT TO COMPLETION,
DATED <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAY 5, 202</FONT>3</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>PRELIMINARY PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2,116,402 Units </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Each Unit Consisting of Two Shares of Common
Stock and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Warrant to Purchase One Share of Common
Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We are offering&nbsp;2,116,402&nbsp;units
(each a &ldquo;unit&rdquo; and collectively, the &ldquo;units&rdquo;) of Modular Medical, Inc. (the &ldquo;Company,&rdquo; &ldquo;Modular
Medical,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo;) with each unit consisting of two shares of our common stock,
par value $0.001 per share, which we refer to as the &ldquo;common stock,&rdquo; and one warrant (a &ldquo;warrant&rdquo;) to purchase
one share of our common stock. The public offering price is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per unit. The units have no stand-alone rights and will not be certificated
or issued as stand-alone securities. We do not intend to apply for listing of the warrants on any national securities exchange. The shares
of our common stock and the warrants comprising the units will be issued separately. The warrants included in the units are exercisable
immediately, will expire five years from the date of issuance and have an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (120% of the public offering
price per unit sold in this offering.) This offering also includes the shares of common stock issuable from time to time upon exercise
of the warrants. The warrants will be issued in book-entry form pursuant to a warrant agency agreement between us and Colonial Stock
Transfer Company, Inc. as warrant agent (the &ldquo;Warrant Agent&rdquo;). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our common stock is listed on the Nasdaq Capital
Market, or Nasdaq, under the symbol &ldquo;MODD.&rdquo; On <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
2, 2023, the last reported sale price of our common stock was $1.89 per share. The public offering price per unit will be determined
at the time of pricing and may be at a discount to the current market price. The recent market price used throughout this prospectus
may not be indicative of the final offering price. There is no established trading market for the warrants, and we do not expect a market
to develop.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective Price<BR>
Per Share and<BR>
Accompanying<BR>
Warrant</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering
    price<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts
    and commissions<SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
                                       &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
                                       &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before
    expenses)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
                                       &nbsp; &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
                                            &nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: justify">Based on a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
unit, with each unit consisting of two (2) shares of common stock and one warrant to purchase one share of common stock.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD STYLE="text-align: justify">The underwriter will receive compensation in addition to
the underwriting discount. See &ldquo;Underwriting&rdquo; beginning on page 71.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="text-align: justify">The amount of offering proceeds to us presented in this table
does not give effect to any exercise of the: (i) over-allotment Option we have granted to the underwriter as described below and (ii)
the Underwriter&rsquo;s Warrants (as defined herein) being issued to the underwriter as described below.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;<I>Risk Factors</I>,&rdquo; beginning on page 10.</B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter expects to deliver the units to
investors on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>,</B>
2023.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>Newbridge Securities
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2023</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 91%"><A HREF="#a_001">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 9%">1</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002">THE OFFERING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">6</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003">SUMMARY FINANCIAL DATA</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">7</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004">RISK FACTORS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">10</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">26</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006">USE OF PROCEEDS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">27</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_008">DIVIDEND POLICY</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">28</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_009">CAPITALIZATION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">29</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_010">DILUTION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">30</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_011">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">31</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_012">BUSINESS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">35</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_013">MANAGEMENT</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">56</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_014">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">67</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_015">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">68</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_016">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">70</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_017">UNDERWRITING</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">71</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_018">LEGAL MATTERS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">74</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_019">EXPERTS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">74</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_020">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">74</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_021">INDEX TO FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-1</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_022">PART II INFORMATION NOT REQUIRED IN PROSPECTUS</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">II-1</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have not authorized anyone to provide any
information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared.
We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
This prospectus is an offer to sell only the units offered hereby, but only under circumstances and in jurisdictions where it is lawful
to do so. The information contained in this prospectus is current only as of its date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For investors outside the United States: We have
not, and the underwriter has not, done anything that would permit this offering or possession or distribution of this prospectus in any
jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into
possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the units and the
distribution of this prospectus outside of the United States.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market and Other Industry Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, market data and certain
industry forecasts used throughout this prospectus were obtained from various sources, including from internal surveys, market research,
consultant surveys, publicly available information and industry publications and surveys. While we believe these sources to be reliable,
the accuracy and completeness of such information is not guaranteed. We have not independently verified any of the data from third-party
sources nor have we ascertained the underlying economic assumptions relied upon therein. Similarly, internal surveys, industry forecasts
and market research, which we believe to be reliable based upon our management&rsquo;s knowledge of the industry, have not been independently
verified. The future performance of the industry and markets in which we operate and intend to operate is necessarily subject to a high
degree of uncertainty and risk due to a variety of factors, including those described in the sections titled &ldquo;<I>Risk Factors</I>&rdquo;
and &ldquo;<I>Special Note Regarding Forward-looking Statements</I>&rdquo; and elsewhere in this prospectus. These and other factors could
cause results to differ materially from those expressed in these publications and reports.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All brand names or trademarks appearing in this
prospectus are the property of their respective holders. Use or display by us of other parties&rsquo; trademarks, trade dress, or products
in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark
or trade dress owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 3pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_001"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>This
summary highlights selected information contained elsewhere in this prospectus and does not contain all the information that you should
consider before making your investment decision. Before investing in our securities, you should carefully read this entire prospectus,
including the information set forth under the &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; sections of this prospectus and our consolidated financial statements and the accompanying
notes included in this prospectus. Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus
to &ldquo;Modular Medical,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Modular
Medical, Inc. and its wholly-owned subsidiary, Quasuras, Inc.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical is a development-stage, medical
device company focused on the design, development, and commercialization of an innovative insulin pump using modernized technology to
increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product candidate,
or &ldquo;MODD1,&rdquo; the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher
standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction,
prescription, reimbursement, training, and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly
motivated &ldquo;super users&rdquo; and expand the category into the mass market. The product candidate seeks to serve both the type
1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Differentiation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that there are a number of shortcomings
and issues with currently available insulin pumps that prevent a substantial number of people who require insulin on a daily basis from
choosing an insulin pump to treat their diabetes. We believe that by tailoring our insulin pump to address such factors, we can expand
the scope and adoption rate of insulin pump usage. We believe that to achieve broader market acceptance, an insulin pump must improve
the clinical experience of the user, be easier to learn and use, less time-consuming to operate, more intuitive to both patients and
physicians, and meet the standards for coverage by insurance providers so that co-payments required from patients are affordable and
the hurdles to insurance coverage are significantly reduced.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Among
the more prominent issues are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Complexity</I><FONT STYLE="font-style: normal">:
                                            Many existing pumps are highly complex and require significant technical expertise to use
                                            effectively. We believe such pumps were designed for &ldquo;super users,&rdquo; who have
                                            high levels of motivation</FONT>, technical competence and premium insurance coverage. The
                                            complexity of pumps proves daunting to less technically inclined users.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumbersome:
                                            </I>We believe that a majority of existing pumps are bulky and difficult to manage, in many
                                            cases requiring a pouch to hold the pump and up to 48 inches of tubing. The tubing and the
                                            cartridge, which holds the insulin, must be replaced every few days. This requires users
                                            to carry spare parts and other equipment adding to the difficulty of using the pump. In comparison,
                                            our product only requires a cartridge change every few days.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cost</I><FONT STYLE="font-style: normal">:
                                            Costs associated with insulin pump therapy are high and can be prohibitive, especially for
                                            those on fixed or limited incomes. These costs vary by pump, but multi-thousand-dollar upfront
                                            payments, often with substantial co-payments in addition to </FONT>co-payments on consumables,
                                            can easily place current pumps out of reach for patients. This can lead to limited or restricted
                                            reimbursement/coverage and high hurdles for the patients, whom could benefit the most, to
                                            gain access.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 3pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our team has substantial
knowledge of the diabetes industry and experience in developing, obtaining regulatory authorization for, and bringing insulin pumps to
market. Based on this experience, we believe that our innovative insulin pump, using a new, low cost and proprietary method of pumping
insulin, can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow)
and bolus (mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid
pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions in the future.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
goal is to become the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not
just care for the super users, but &ldquo;diabetes care for the rest of us.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MODD1 is a high-precision product that we
believe represents the best choice for new pump patients because it is easy to afford, easy to learn, easy to use, and has a revolutionary
design and technology that enable precision with low-cost manufacture and high reproducibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Diabetes
Classifications and Therapies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diabetes is typically classified as either type 1, or &ldquo;T1D,&rdquo;
or type 2, or &ldquo;T2D&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">T1D
is an auto-immune condition characterized by the body&rsquo;s nearly complete inability to produce insulin. It is frequently diagnosed
during childhood or adolescence, but can also onset in adulthood. Individuals with T1D require daily insulin therapy to survive.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">T2D
represents over 90% of all individuals diagnosed with diabetes and is characterized by the body&rsquo;s inability to either properly
utilize insulin or produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements in
diet and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their diabetes
advances, patients often progress to requiring insulin therapies such as once-daily long-acting insulin and ultimately to intensified
mealtime rapid-acting insulin therapy. This represents an important portion of the diabetes market in the United States with an estimated
1.6 million T2D intensively treated (multiple daily injections) with insulin.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Glucose,
the primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and
health. In people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition known as hyperglycemia,
and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications, including blindness, kidney
disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia
can lead to confusion or loss of consciousness, often requiring a visit to the emergency room or, in certain cases, result in seizures,
coma, and/or death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All people with T1D, which is our primary market,
require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18% of people with T2D in the United States,
or approximately 4.7 million people, also require insulin. These 4.7 million people comprise 3.1 million who require multiple daily injections
(&ldquo;MDI&rdquo;) and the remainder, 1.6 million, who require basal delivery only to manage their diabetes. In this prospectus, we
refer to people with T1D and people with T2D who require mealtime insulin as &ldquo;insulin-requiring people with diabetes.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
</div>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 3pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, there are two primary therapies available
for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body through syringes or insulin pens
(a type of syringe) or the use of an insulin pump to deliver mealtime insulin boluses (single doses) to help with glucose absorption after
carbohydrate consumption along with a continuous subcutaneous insulin infusion, or &ldquo;CSII therapy,&rdquo; into the body. Generally,
CSII therapy is considered to provide a number of advantages over MDI therapy, primarily an improvement in glycemic control, as measured
by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure and more recently Time in Range (TIR) where a continuous glucose
measuring device is used to calculate this test. Among other clinical benefits, a study conducted by Tandem Diabetes Care, Inc. in 2021
demonstrated that insulin pump use can decrease glucose variability, reduce the number of hypoglycemia events, and reduce the fear of
hypoglycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding these advantages, the
difficulty in use resulting from the complexity and cumbersome design of available insulin pumps, optimized for the well-motivated,
educated and well-insured, as well as high and often prohibitive costs for both the patient and insurance provider has resulted not
only in dissatisfaction among many existing pump users (fewer than half purchase a replacement pump after the warranty expires per a
Seagrove Partners estimate in 2020), but also has severely limited the adoption rate of insulin pumps by a large segment of the MDI
diabetes population, whom we refer to in this prospectus as &ldquo;Almost Pumpers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We define Almost Pumpers as individuals who treat
their diabetes with MDI. These individuals are aware of pumps, may have been on pumps and understand the potential benefits, however,
for a variety of reasons, they choose to continue giving themselves shots. In 2018, we undertook one-on-one interviews with over 200 of
these individuals to understand their past experiences on or considering pumps, existing pump shortcomings, the cost and insurance hurtles
challenges, complexity to learn and time and complexity to operate that drives them to remain on MDI. With this detailed understanding,
we brought a series of prototype models to them to react to, so we could refine the design and include features that would motivate them
to be able to use this technology to better care for their diabetes. To date, the MODD1 pump has been well received by these individuals
and our clinical advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is estimated that 33% of Americans with T1D
use insulin pump therapy. Clinicians were surveyed on potential pump users and identified that 28% of Americans with T1D, including 44%
of those who currently utilize MDI, can be classified as i) having an interest in pump adoption and ii) meeting the American Diabetes
Association guidelines for required glucose control. These individuals often do not want to closely manage their glucose levels and incur
the considerable time and effort involved with the existing offerings - they are the Almost Pumpers. We have developed what we believe
to be the most technologically advanced delivery system to overcome their objections and perform with the motivation level they can provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial focus for our insulin pump is the
Almost Pumper segment population located in the United States. We will then focus on a European introduction, and we believe our cost
position and reuse of part of the product, which eliminates waste, will have significant environmental and financial appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe this conversion process, engaging people to try and thereby receive the benefits of our technology will substantially increase
adoption of insulin pumps among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease
that appears throughout the world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to
create an insulin pump that appeals to all Almost Pumpers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
</div>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to many significant
risks, as more fully described in the section titled &ldquo;<I>Risk Factors</I>&rdquo; immediately following this prospectus summary.
You should read and carefully consider these summary risks, together with the risks set forth under the section titled &ldquo;<I>Risk
Factors</I>&rdquo; and all of the other information in this prospectus, including the financial statements and the related notes included
elsewhere in this prospectus, before deciding whether to invest in our securities. If any of the risks discussed in this prospectus actually
occur, our business, prospects, financial condition or operating results could be materially and adversely affected. In particular, our
risks include, but are not limited to, the following:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We might not be able to continue as a going concern;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are a developmental-stage, medical-device company and have a history of significant operating
                                            losses; we expect to continue to incur operating losses for the foreseeable future, and we
                                            may never achieve or maintain profitability;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need substantial additional funding to complete subsequent phases of our insulin pump
                                            product candidate and to operate our business, and such funding may not be available or,
                                            if it is available, is likely to substantially dilute our existing stockholders;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history and historical financial information upon which you may
                                            evaluate our performance;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations, financial condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise greater than we expect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are subject to extensive regulation by the FDA, which could restrict the sales and marketing
                                            of our insulin pump product candidate and could cause us to incur significant costs;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we are able to obtain all regulatory approvals and have completed all other steps needed
                                            to be taken to commercialize our insulin pump, if we or any contract manufacturers we select
                                            fails to comply with the FDA&rsquo;s quality system regulations, the manufacturing and distribution
                                            of our product candidate could be interrupted, and our product sales and operating results
                                            could suffer;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will need to outsource and rely on third parties for various aspects relating to the development,
                                            manufacture, sales and marketing of our insulin pump as well as in connection with assisting
                                            us in the preparation and filing of our FDA submission, and our future success will be dependent
                                            on the timeliness and effectiveness of the efforts of these third parties;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future cash requirements may differ significantly from our current estimates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not receive the necessary regulatory clearance or approvals for our insulin pump, and
                                            failure to timely obtain necessary clearances and/or approvals could harm our then operations,
                                            including our ability to commercialize</FONT> our product candidate;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            marketing authorization in the United States will not obviate the need to obtain marketing
                                            authorization in other jurisdictions We must obtain approval from foreign regulatory authorities
                                            before we can market and sell any of our product candidates in countries outside the United
                                            States. We will incur additional costs in seeking such approvals, may experience delays in
                                            obtaining such approvals and cannot be certain that such approvals will be granted;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
                                            our product candidate does not presently require clinical trials to apply to the FDA for
                                            clearance, and even if a clinical trial is conducted, the results of our clinical testing
                                            may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise
                                            not be sufficient for us to obtain approval of our product candidate;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to rely on third-party manufacturers and will be dependent on their quality and effectiveness;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to successfully scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay
or prevent us from developing our product candidate and commercializing our product candidate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            competitors may develop products that are more effective, safer and less expensive than ours;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited internal research and development personnel, making us dependent on consulting relationships;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies,
and we will be dependent on our corporate partners if we do;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
property rights do not necessarily address all potential threats to our competitive advantage;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to potential product liability and other claims that could materially impact our business and financial condition;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome
would have a significant adverse effect on our business;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
reform laws could adversely affect our product candidate and financial condition;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may bring infringement claims or other legal proceedings against third parties, causing us to spend substantial resources on litigation
and exposing our own intellectual property portfolio to challenge;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our current insulin pump is still in the pre clearance stage with the FDA, it does not have reimbursement and is not approved for insurance
coverage. If in the future we are cleared for and are otherwise able to commercialize our insulin pump, but are unable to obtain adequate
reimbursement or insurance coverage for such product candidate from third-party payors, we will be unable to generate significant revenue;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to establish and maintain an effective system of internal controls, we may not be able to report our financial results accurately
or prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely
affect the trading price of our common stock;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is able to adopt recapitalizations through forward or reverse splits of our outstanding shares of common stock without
stockholder approval;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &ldquo;smaller reporting company&rdquo; and, as a result of the reduced disclosure and governance requirements applicable to smaller
reporting companies, our common stock may be less attractive to investors;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our warrants will have no rights as a common stockholder until they acquire our common stock;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of the warrants offered by this prospectus could discourage an acquisition of us by a third party;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.75pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants offered by this prospectus are speculative in nature and may not have any value;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no public market for the warrants being offered in this offering;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may experience future dilution as a result of future equity offerings and other issuances of our common stock or other securities. In
addition, this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect
the price of our common stock.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our principal executive offices are located
at 10740 Thornmint Road, San Diego, CA 92127 and our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com.
Information contained on, or accessible through, our website does not constitute a part of this prospectus or our other filings with
the SEC, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus
or in deciding whether to purchase our securities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_002"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Securities offered by us: </P></TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 79%; text-align: justify"> 2,116,402 units, each consisting of two shares of common stock and one warrant to
    purchase one share of our common stock. The units will not be certificated or issued in stand-alone form. The shares of our common
    stock and the warrants comprising the units will be issued separately, but will be purchased together in this offering. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> Description of warrants included in units: </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> Warrants to purchase&nbsp;2,116,402&nbsp;shares of common stock. Warrants
may only be exercisable for a whole number of shares of common stock and, because the warrants will only be sold in units with two shares
of common stock, no fractional shares or warrants to purchase fractional shares will be issued in this offering. The exercise price of
the warrants is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (120% of the public offering price per unit). Each warrant will be exercisable immediately upon issuance
and will expire five years after the initial issuance date. This prospectus also relates to the offering of the shares of common stock
issuable upon exercise of the warrants. For more information regarding the warrants, you should carefully read the section titled &ldquo;<I>Description
of Our Securities &ndash; Warrants</I>&rdquo; in this prospectus. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"> Common stock outstanding prior to this offering<SUP>(1)</SUP>: </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> 10,949,389 shares of common stock outstanding as of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    4, 2023</FONT>. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: left"> Common stock to be outstanding<BR>
    after this offering<SUP>(1)</SUP>: </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,182,193&nbsp;shares,
    or 15,817,113&nbsp;shares, if the over-allotment option granted to the underwriter is exercised in full.</FONT> </TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> Use of proceeds: </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We estimate that the net proceeds from
    this offering will be approximately $7,031,490, after deducting underwriting discounts and commissions and the estimated offering
    expenses payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We intend to use the net proceeds of this offering
for general corporate purposes, including working capital, to fund our operations through the approval of our product by the FDA, develop
our initial sales and marketing infrastructure, to fund additional research and development activities, to develop our initial manufacturing
and production capabilities and make related capital expenditures. See &ldquo;Use of Proceeds&rdquo; for additional information.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> Over-allotment option </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> We have granted a 30-day option to the underwriter, exercisable one
or more times in whole or in part, to purchase up to an additional 634,920 shares of common stock at the effective public offering price
per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;and additional warrants to purchase up to&nbsp;317,460&nbsp;additional shares of common stock at a price of $0.01
per warrant, in each case less underwriting discounts and commissions, to cover over-allotments, if any. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Risk factors:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Investing in our securities involves substantial risk. You should read the &ldquo;<I>Risk Factors</I>&rdquo; section beginning on page 10 and other information included in this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Lock-ups</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">We and our directors and officers and holders of more than 5.0% of the Company&rsquo;s outstanding shares of common stock have agreed with the underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of three months after the date of this prospectus. See &ldquo;<I>Underwriting</I>&rdquo; section.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Nasdaq Capital Market Symbol</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">MODD</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> The number of shares of our
common stock outstanding before and after this offering is based on 10,949,389 shares of our common stock outstanding as of May 4, 2023
and excludes: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,116,402
shares of our common stock issuable upon the exercise of the warrants to be issued as part of the units;</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">296,296&nbsp;shares
                                            of common stock issuable upon exercise by the underwriter of the underwriter&rsquo;s warrants;</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">767,796
                                            shares of our common stock issuable upon the exercise of warrants with an exercise price
                                            of $6.00 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">5,449,478 </FONT>
                                            shares of our common stock issuable upon the exercise of warrants with an exercise price
                                            of $6.60 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,348,314
                                            shares of our common stock issuable upon exercise of pre-funded warrants with an exercise
                                            price of $0.01 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,647,700
                                            shares of our common stock issuable upon exercise of outstanding stock options with a weighted
                                            average exercise price of approximately $4.94 per share; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,996,055
                                            shares of our common stock reserved for issuance pursuant to future awards under our Amended
                                            and Restated 2017 Equity Incentive Plan, or the 2017 Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 3pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_003"></A>SUMMARY
FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following tables summarize our financial data for the periods presented and should be read together with the sections of this prospectus
titled &ldquo;<I>Risk Factors</I>&rdquo; and &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations</I>,&rdquo; and our financial statements and related notes thereto appearing elsewhere in this prospectus. The following
summary statements of operations data for the nine months ended December 31, 2022 and 2021 have been derived from our unaudited consolidated
financial statements and footnotes included elsewhere in this prospectus and the summary statements of operations data for the years
ended March 31, 2022 and 2021 have been derived from our audited consolidated financial statements and footnotes included elsewhere in
this prospectus. The summary balance sheet information as of December 31 and March 31, 2022 has been derived from our unaudited condensed
consolidated financial statements and footnotes included elsewhere in this prospectus. Our historical results are not necessarily indicative
of our future results or of the results we expect in the future and results of interim periods are not necessarily indicative of results
for the entire year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Twelve
    Months Ended<BR> March 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,729,240</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,083,303</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,197,162</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,253,412</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,926,402</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,336,715</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(14,926,402</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,336,715</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">368,920</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">130</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,752,229</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(39,791</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    on debt extinguishment</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,321,450</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss before income taxes</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,631,161</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,376,376</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provision
    for income taxes</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,600</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,600</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,632,761</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,377,976</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss per share</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2.74</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1.20</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    used in computing net loss per share</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic and diluted</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,807,710</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,211,562</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
</div>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<BR>
December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<BR>
December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,196,546</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,849,399</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,804,069</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,742,911</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,161,351</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,981,665</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,502,029</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,156,152</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,357,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,831,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,306,098</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,899,063</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,357,897</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,831,064</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,306,098</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,899,063</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(587</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,010,247</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,204,917</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss on debt extinguishment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,321,450</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,358,484</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,841,307</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,306,082</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,056,554</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,358,484</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,841,307</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(10,307,682</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(14,058,154</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.31</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.76</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.95</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2.22</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Shares used in computing net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,925,862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,354,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,863,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,331,982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 3pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,<BR> 2022<BR> (Unaudited)</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
    31,<BR> 2022</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; font-weight: bold; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSETS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; font-weight: bold; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CURRENT
    ASSETS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,690,957</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,076,372</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">180,164</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">313,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Security
    deposit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    CURRENT ASSETS</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,971,121</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,389,794</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property
    and equipment, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">716,409</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">235,959</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Right
    of use asset, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">51,312</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">120,693</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Security
    deposit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    NON-CURRENT ASSETS</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">767,721</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">456,652</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,738,842</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,846,446</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&rsquo; EQUITY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CURRENT
    LIABILITIES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">382,080</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">299,951</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">255,545</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">524,891</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Short-term
    lease liability</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">77,672</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">144,857</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    CURRENT LIABILITIES</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">715,297</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">969,699</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long-term
    lease liability</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">39,957</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">715,297</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,009,656</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments
    and Contingencies (Note 8)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">STOCKHOLDERS&rsquo;
    EQUITY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred
    Stock, $0.001&nbsp;par value,&nbsp;5,000,000&nbsp;shares authorized,&nbsp;none&nbsp;issued and outstanding</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock, $0.001&nbsp;par
    value,&nbsp;50,000,000&nbsp;shares authorized;&nbsp;10,932,098&nbsp;and&nbsp;10,461,898&nbsp;shares issued and outstanding as of
    December 31, 2022 and March 31, 2022, respectively</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,932</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,462</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">52,900,066</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,406,099</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44,887,453</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(34,579,771</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    STOCKHOLDERS&rsquo; EQUITY</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,023,545</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,836,790</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,738,842</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,846,446</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
</div>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><I>Investing in our securities
involves a high degree of risk. Before you invest in the units, the warrants and the common stock, you should carefully consider the following
risks, as well as general economic and business risks, and all of the other information contained in this registration statement. Any
of the following risks could harm our business, operating results and financial condition and cause the trading price of our common stock
to decline, which would cause you to lose all or part of your investment. When determining whether to invest, you should also refer to
the other information contained in this prospectus, including our financial statements and the related notes thereto.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Risks
Related To Our Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
might not be able to continue as a going concern.</I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our unaudited condensed consolidated financial
statements as of December 31, 2022 have been prepared under the assumption that we will continue as a going concern for the next twelve
months. At December 31, 2022, we had cash and cash equivalents of $7.7 million and an accumulated deficit of $44.9 million. Without the
proceeds of this offering, we do not believe that our cash, cash equivalents and investments would be sufficient to fund our operations
for the next 12 months, and we would need to raise additional capital.&nbsp;&nbsp;As a result of our expected operating losses and cash
burn for the foreseeable future and recurring losses from operations, if we are unable to raise sufficient capital through this offering
or additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain liquidity sufficient to operate
our business effectively, which raises substantial doubt as to our ability to continue as a going concern. If we cannot continue as a
viable entity, our stockholders would likely lose most or all of their investment in us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to generate sustainable operating
profit and sufficient cash flows, then our future success will depend on our ability to raise capital. In addition to this offering,
we are seeking additional financing and evaluating financing alternatives in order to meet our cash requirements for the next 12 months.
We cannot be certain that raising additional capital, whether through this offering, selling additional debt or equity securities or
obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional
securities to raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our
current stockholders may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required
to curtail our current product development programs, cut operating costs, forego future development and other opportunities or even terminate
our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
are a developmental stage medical device company and have a history of significant operating losses; we expect to continue to incur operating
losses, and we may never achieve or maintain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a development-stage enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception,
we have incurred operating losses in each year due to costs incurred in connection with research and development activities and general
and administrative expenses associated with our operations. For the nine months ended December 31, 2022 and year ended March 31, 2022,
we incurred net losses of approximately $10.3 million and $18.6 million, respectively. As a result, we need to raise additional capital
in the future, which may or may not be available to us at all or only on unfavorable terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to incur losses for the foreseeable
future as we continue the development of, and seek regulatory clearance and approvals for, our insulin pump. As our MODD1 insulin pump
is currently our only product, if it fails to gain regulatory approval and market acceptance, we will not be able to generate any revenue,
or explore other opportunities to enhance stockholder value, such as through a sale. If we fail to generate revenue and eventually become
profitable, or if we are unable to fund our continuing losses, our stockholders could lose all or a substantial part of their investment.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need substantial additional funding
to complete subsequent phases of the development of our insulin pump product candidate and to operate our business and such funding may
not be available or, if it is available, such financing is likely to substantially dilute our existing stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discovery, development, and commercialization
of new medical devices, such as our insulin pump, entails significant costs. While we believe that we have generally completed the engineering
and mechanical aspects of our insulin pump and cartridge along with production-level assembly equipment, we still must refine and finalize
our insulin pump to, among other things, meet the general needs and preferences of the Almost Pumper marketplace and the guidelines of
third-party payors. To enable us to accomplish these and other related items and continue to operate our business, we will need to raise
substantial additional capital and/or enter into strategic partnerships or joint ventures to enable us to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">fund
clinical studies and seek regulatory approvals;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">build
or access manufacturing and commercialization capabilities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">develop,
test, and, if approved, market our product candidate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">acquire
or license additional internal systems and other infrastructure; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">hire
and support additional management, engineering and scientific personnel.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until we can generate a sufficient amount of
product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs primarily through public
or private equity offerings, debt financings or through the establishment of possible strategic alliances. This offering is being conducted
to obtain such funding, although there can be no guarantee that we will successfully raise all the funding we require in this offering.
Depending on the amount of funding we receive in this offering, as well as other factors, we may in the future seek additional capital
from public or private offerings of our capital stock or borrow additional amounts under new credit lines or from other sources. If we
issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution, we may incur significant
financing costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders.
In addition, if we raise additional funds through collaborations, licensing, joint ventures, strategic alliances, partnership arrangements
or other similar arrangements, it may be necessary to relinquish valuable rights to the MODD1 pump or our potential future products or
proprietary technologies or grant licenses on terms that are not favorable to us.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that additional funding
will be available on acceptable terms, or at all. If we are not able to secure additional equity funding when needed, we may have to
delay, reduce the scope of, or eliminate one or more of our clinical studies, development programs or future commercialization initiatives.
In addition, any additional equity funding that we do obtain will dilute the ownership held by our existing equity holders. The amount
of this dilution may be substantially increased if the trading price of our common stock is lower at the time of any financing. Regardless,
the economic dilution to stockholders will be significant if our stock price does not increase significantly, or if the effective price
of any sale is below the price paid by a particular stockholder. Any debt financing that we obtain in the future could involve substantial
restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential sources for
such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing. If we
fail to obtain funding as needed, we may be forced to cease or scale back operations, and our business, prospects, results of operations,
financial condition and stock price would be adversely affected.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
have a limited operating history and historical financial information upon which you may evaluate our performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should consider, among other factors, our
prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages of development.
We may not successfully address these risks and uncertainties or successfully complete our studies and/or implement our existing and
new products. If we fail to do so, it could materially harm our business and impair the value of our common stock. Unanticipated problems,
expenses and delays are frequently encountered in establishing a new business, conducting research, and developing new products. These
include, but are not limited to, inadequate funding, failure to obtain regulatory approval, unforeseen research issues, lack of consumer,
physician or third-party payor acceptance, competition, sluggish product development, and inadequate sales and marketing. The failure
by us to meet any of these conditions would have a materially adverse effect upon us and may force us to reduce or curtail operations.
No assurance can be given that we can or will ever operate profitably.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>The
amount of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations, financial
condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise greater than we expect.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
future funding requirements will depend on many factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
testing costs for our insulin pump product candidate and other development activities conducted by us directly, and our ability to successfully
conclude the studies and activities and achieve favorable results;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to attract future strategic partners to pay for or share costs related to our product development efforts;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
costs and timing of seeking and obtaining regulatory clearance and approvals for our product candidate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
costs of filing, prosecuting, maintaining and enforcing any patents and other intellectual property rights that we may have and defending
against potential claims of infringement;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">decisions
to hire additional scientific, engineering or administrative personnel or consultants;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to manage administrative and other costs of our operations; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
presence or absence of adverse developments in our research program.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of these factors cause our funding needs to be greater than expected, our operations, financial condition, ability to continue operations
and stock price may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
future cash requirements may differ significantly from our current estimates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
cash requirements may differ significantly from our estimates from time to time, depending on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
costs and results of our clinical studies regarding our insulin pump product candidate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
time and costs involved in obtaining regulatory clearance and approvals;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
we are able to obtain funding under future licensing agreements, strategic partnerships, or other collaborative relationships, if any;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
costs of compliance with laws, regulations, or judicial decisions applicable to us; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of general and administrative infrastructure required to manage our business and protect corporate assets and stockholder interests.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to raise additional funds on a timely
basis, even after the completion of this offering, we will need to scale back our business plans, which would adversely affect our business,
prospects, results of operations, financial condition, and stock price, and we may even be forced to discontinue our operations and liquidate
our assets.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The diabetes treatment market is subject to rapid
technological change and product innovation. Our insulin pump is based on our proprietary technology, but a number of companies, medical
researchers and existing pharmaceutical companies are pursuing new delivery devices, delivery technologies, sensing technologies, procedures,
drugs and other therapeutics for the monitoring, treatment and/or prevention of insulin-dependent diabetes. Any technological breakthroughs
in diabetes monitoring, treatment or prevention could render our insulin pump obsolete, which, since our insulin pump is our only product
candidate, would have a material adverse effect on our business, prospectus, results of operations and financial condition and could
result in stockholders losing their entire investment.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Any
failure to attract and retain skilled directors, executives, employees and consultants could impair our product development and commercialization
activities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business depends on the skills, performance,
and dedication of our directors, executive officers and key engineering, scientific and technical advisors. Many of our current engineering
or scientific advisors are independent contractors and are either self-employed or employed by other organizations. As a result, they
may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, which may affect
their ability to provide services to us in a timely manner. We will need to recruit additional directors, executive management employees,
and advisers, particularly engineering, scientific and technical personnel, which will require additional financial resources. In addition,
there is currently intense competition for skilled directors, executives and employees with relevant engineering, scientific and technical
expertise, and this competition is likely to continue. If we are unable to attract and retain persons with sufficient engineering, scientific,
technical and managerial experience, we may be forced to limit or delay our product development activities or may experience difficulties
in successfully conducting our business, which would adversely affect our business, prospects, results of operations and financial condition.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our operations are substantially dependent
upon key personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our performance is substantially dependent on
the continued services and performance of our senior management and certain other key personnel The loss of services of any of our executive
officers or other key employees could have a material adverse effect on our business, financial condition and results of operations. In
addition, any future expansion of our business will depend on our ability to identify, attract, hire, train, retain and motivate other
highly skilled managerial, marketing, customer service and manufacturing personnel, and our inability to do so could have a material adverse
effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on the performance and
continued engagement of our Chairman, President and Principal Financial Officer.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are dependent on the performance and continued
engagement of Paul DiPerna, our Chairman, President and Principal Financial Officer. Although we believe we will be able to engage qualified
personnel for such purposes, an inability to do so could materially adversely affect our ability to market, sell, and enhance our products.
While Mr. DiPerna is currently devoting his full-time working efforts to us, other employees and consultants may only be available to
us on a part-time basis. The loss of one or more of our key employees, especially Mr. DiPerna, or our inability to hire and retain other
qualified employees, including but not limited to research and development, sales, manufacturing, and administrative support staff, could
have a material adverse effect on our business, prospects, results of operations and financial condition.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited internal research and development
personnel, making us dependent on consulting relationships.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consider research and development to be an
important part of the process of designing, developing, obtaining regulatory required approvals and the eventual commercialization of
our insulin pump. We continue to incur increased research and development expenditures, which are primarily attributable to effort and
expenses incurred in designing and developing our innovative insulin pump. We expect to continue to incur substantial costs related to
research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
will need to outsource and rely on third parties for various aspects relating to the development, manufacture, sales and marketing of
our insulin pump as well as in connection with assisting us in the preparation and filing of our FDA submission, and our future success
will be dependent on the timeliness and effectiveness of the efforts of these third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are dependent on consultants for important aspects of our product development strategy. We do not have the required financial resources
and personnel to carry out independently the development of our product candidate, and do not have the capability or resources to manufacture,
market or sell our current product candidate. As a result, we contract with and rely on third parties for important functions, including
in connection with the development and finalization of our insulin pump, the preparation and filing of our FDA submission and eventual
manufacturing and commercialization of our product candidate. We have recently entered into several agreements with third parties for
such services. If problems develop in our relationships with third parties, or if such parties fail to perform as expected, it could
lead to delays or lack of progress in obtaining FDA clearance, significant cost increases, changes in our strategies, and even failure
of our product initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies,
and we will be dependent on our corporate partners if we do.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may seek to enter into a strategic alliance
with a diabetes-related service providing company for the further development and approval of our insulin pump product candidate. At
this time, we have not entered into any such strategic alliance. Strategic alliances, if entered into, could potentially provide us with
additional funds, expertise, access, and other resources in exchange for exclusive or non-exclusive licenses or other rights to the product
that we are currently developing or a product we may explore in the future. We cannot give any assurance that we will be able to enter
into strategic relationships with a diabetes-related service providing company or others in the near future or at all. In addition, we
cannot assure you that any agreements that we do reach will allow us to achieve our goals or that such grants will be on terms that prove
to be economically beneficial to us. When we do enter into strategic or contractual relationships, we become dependent on the successful
performance of our partners or counter-parties. If they fail to perform as expected, such failure could adversely affect our financial
condition, lead to increases in our capital needs, or hinder or delay our development efforts. See &ldquo;<I>Our Business -Employees</I>&rdquo;
below.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
and/or approvals could harm our then operations, including our ability to commercialize our product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we can market a new medical device, such
as our insulin pump, we must first receive clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the &ldquo;FDCA.&rdquo;
In the 510(k) clearance process, before a device may be marketed, the FDA must determine that such proposed device is &ldquo;substantially
equivalent&rdquo; to a legally-marketed &ldquo;predicate&rdquo; device, which includes a device that has been previously cleared through
the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on
the U.S. market pursuant to a premarket approval (PMA) and later down-classified, or a 510(k)-exempt device. To be &ldquo;substantially
equivalent,&rdquo; the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or
effectiveness than the predicate device.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain future modifications made to our product
candidate, which we currently expect to be cleared through 510(k), may require a new 510(k) clearance. The 510(k) clearance process can
be expensive, lengthy and uncertain. The FDA&rsquo;s 510(k) clearance process usually takes from three to 12 months, but can last longer.
Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory
authorizations could harm our business, including our ability to commercialize our product candidate and our stockholders could lose
their entire investment. Furthermore, even if we are granted the required regulatory authorizations, such authorizations may be subject
to significant limitations on the indicated uses for the device, which may limit the market for our product candidate.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the FDA requires us to go through a lengthier, more rigorous examination for our product candidate than we had expected, product introductions
or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA can delay, limit or deny clearance or
approval for our insulin pump medical device for many reasons, including, for example:<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
inability to demonstrate to the satisfaction of the FDA that our product candidate is substantially equivalent to the proposed predicate
device;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
disagreement of the FDA with the design or implementation of our performance testing protocols or the interpretation of data from our
performance testing;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
data from performance testing may be insufficient to support a determination of substantial equivalence or that our device meets required
special controls or applicable performance standards;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to demonstrate that the benefits of our pump outweigh the risks;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    manufacturing process or facilities we intend to use may not meet applicable requirements; for example, we experienced issues maintaining
    insulin stability on an initial version of our pump product candidate, and we attributed this issue to the materials used in the
    production of our product; we believe we have made the necessary changes to our materials and process to address this issue and will
    be completing the required testing prior to our FDA submission; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential for approval policies or regulations of the FDA to change significantly in a manner rendering our data or regulatory filings
    insufficient for clearance or approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval or clearance of our product candidate or impact our ability to modify our product
candidate after clearance on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could
delay our ability to obtain clearance for our pump, increase the costs of compliance or restrict our ability to maintain our current
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based,
among other things, on the evaluation of data supporting the safety and performance of the product candidates during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended
performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Obtaining
marketing authorization in the United States will not obviate the need to obtain marketing authorization in other jurisdictions We must
obtain approval from foreign regulatory authorities before we can market and sell any of our product candidates in countries outside
the United States. We will incur additional costs in seeking such approvals, may experience delays in obtaining such approvals and cannot
be certain that such approvals will be granted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
development, manufacture, and marketing of our product candidates outside the United States is subject to government regulation. In most
foreign countries, we must complete rigorous pre-clinical testing and extensive human clinical trials that demonstrate the safety and
efficacy of a product in order to apply for regulatory approval to market the product. If foreign regulatory authorities grant regulatory
approval of a product, the approval may be limited to specific indications or limited with respect to its distribution. Expanded or additional
indications for approved devices may not be approved, which could limit our potential revenues. Foreign regulatory authorities may refuse
to grant any approval. Consequently, even if we believe that pre-clinical and clinical data are sufficient to support regulatory approval
for our products, foreign regulatory authorities may not ultimately grant approval for commercial sale in any jurisdiction. If our product
candidates are not approved in such jurisdictions, our ability to generate revenues will be limited and our business will be adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
competitors may develop products that are more effective, safer and less expensive than ours.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing
insulin pumps are expensive, with the more popular models having purchase prices exceeding $4,000 for individuals without health insurance
and often require significant patient copays. Others have daily use costs that exceed the reimbursement rates of many health insurance
plans, forcing some users to spend thousands of dollars a year in copays. We believe this makes insurers hesitant to pay for any pumps
and places pumps out of reach for many patients who cannot afford such out of pocket expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are engaged in the diabetes treatment sector of the healthcare marketplace, which is intensely competitive. There are current products
that are quite effective at addressing the effects of diabetes, and we expect that new developments by other companies and academic institutions
in the areas of diabetes treatment will continue. If approved for marketing by the FDA, depending on the approved clinical indication,
our product will be competing with existing and future products related to treatments for diabetes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
competitors may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">develop
product candidates and market products that increase the levels of safety or efficacy that our product candidates will need to show in
order to obtain regulatory approval;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">develop
product candidates and market products that are less expensive or more effective than ours;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">commercialize
competing products before we can launch any products we are working to develop;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">hold
or obtain proprietary rights that could prevent us from commercializing our products; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">introduce
therapies or market medical products that render our potential product candidates obsolete.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect to compete against large medical device companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet
Corporation and smaller companies that are collaborating with larger medical device companies, new companies, academic institutions,
government agencies and other public and private research organizations. These competitors, in nearly all cases, produce similar
products relative to the treatment of diabetes and have substantially greater financial resources than we do. Our competitors also
have significantly greater experience in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">developing
medical device and other product candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">undertaking
testing and clinical studies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">building
relationships with key customers and opinion-leading physicians;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">obtaining
and maintaining FDA and other regulatory approvals;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">formulating
and manufacturing medical devices;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">launching,
marketing and selling medical devices; </FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">providing
management oversight for all of the above-listed operational functions; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    insurance coverage and reimbursement for our product.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to achieve acceptance over other existing
or newly developed products, we may be unable to obtain regulatory approval or successfully commercialize our MODD1 insulin pump product
candidate or any future products. If our competitors&rsquo; market medical devices that are less expensive, safer or more effective than
our insulin pump, or that gain or maintain greater market acceptance, we may not be able to compete effectively, which would adversely
affect our business, prospects, results of operations and financial condition. See &ldquo;<I>Business - Competition</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
expect to rely on third-party manufacturers and will be dependent on their quality and effectiveness.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
insulin pump requires precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including
failure to detect or control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could result
in patient injury or death, discontinuance or delay of ongoing or planned clinical studies, delays or failures in product testing or
delivery, cost overruns, product recalls or withdrawals and other problems that could seriously hurt our business. Contract medical device
manufacturers often encounter difficulties involving production yields, quality control and quality assurance and shortages of qualified
personnel. These manufacturers are subject to stringent regulatory requirements, including the FDA&rsquo;s current good-manufacturing-practices
regulations. If our contract manufacturers fail to maintain ongoing compliance at any time, the production of our product could be interrupted,
resulting in delays or discontinuance of our clinical studies, additional costs and loss of potential revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may not be able to successfully scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay
or prevent us from developing our product candidate and commercializing our product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
order to conduct larger-scale or late-stage clinical studies and for commercialization of our insulin pump, if 510(k) clearance is granted,
we will need to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for our product
candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we are
unable to successfully scale up the manufacture of our product candidate in sufficient quality and quantity, the development and testing
of our product candidate and regulatory approval or commercial launch may be delayed, which could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent upon third-party suppliers
to manufacture our product, and this makes us vulnerable to supply shortages and price increases; we may not be able to obtain an adequate
supply of components on a timely basis or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The future manufacture of our product will require
the timely delivery of sufficient amounts of components from multiple suppliers in various countries. We intend to work closely with our
suppliers to ensure continuity of supply, but we cannot guarantee these efforts will be successful. Due to the supply chain issues experienced
by the semiconductor industry, at times, we have experienced delays obtaining integrated circuits from certain suppliers. We may need
to enter into &ldquo;take or pay&rdquo; contracts with suppliers. We have also seen price increases for various components. We do not
have supply agreements with any of our suppliers, and we make purchases based on individual purchase orders. An interruption, delay, or
inability to obtain components from our third-party suppliers at acceptable prices in a timely manner, could hinder our ability to manufacture
our products and have a material adverse effect on our business, prospects, financial condition and results of operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may be subject to potential product liability and other claims that could materially impact our business and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and sale of our insulin pump
exposes us to the risk of significant damages from product liability and other claims, and the use of our product candidate in clinical
studies may result in adverse effects from liability claims. We cannot predict all the possible harms or adverse effects that may result.
We intend to obtain product liability insurance to provide some protection from claims. Nonetheless, we may not have sufficient resources
to pay for any liabilities resulting from a personal injury or other claim, even if it is partially covered by insurance. In addition
to the possibility of direct claims, we may be required to indemnify third parties against damages and other liabilities arising out
of our development, commercialization and other business activities, which would increase our liability exposure. If third parties that
have agreed to indemnify us fail to do so, we may be held responsible for those damages and other liabilities as well.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Legislative,
regulatory, or medical cost reimbursement changes may adversely impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to the health
care system in the U.S. and in other jurisdictions may change the nature of and regulatory requirements relating to innovations in medical
devices, testing and regulatory approvals, limit or eliminate payments for medical procedures and treatments, or subject the pricing
of medical devices to government control. In addition, third-party payors in the U.S. are increasingly attempting to contain health care
costs by limiting both coverage and the level of reimbursement of new products. Consequently, significant uncertainty exists as to the
reimbursement status of newly approved health care products. Significant changes in the health care system in the U.S. or elsewhere,
including changes resulting from adverse trends in third-party reimbursement programs, could have a material adverse effect on our projected
future operating results and our ability to raise capital, commercialize products, and remain in business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
are subject to extensive regulation by the U.S. Food and Drug Administration, which could restrict the sales and marketing of our insulin
pump and could cause us to incur significant costs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
insulin pump is subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution
and shipping. Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States,
it must be cleared or approved by FDA through the applicable premarket review process (510(k), PMA, or de novo classification), unless
an exemption applies. If we receive 510(k) clearance for our insulin pump, we may be required to obtain new 510(k) clearances for significant
post-market modifications to the pump. Each premarket submission and review process can be expensive and lengthy, and entail significant
user fees, unless exempt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Medical
devices may be marketed only for the indications for which they are approved or cleared. Further, 510(k) clearances can be revoked if
safety or effectiveness problems develop once the device is on the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
current regulatory requirements to which we are subject may change in the future in a way that adversely affects us. If we fail to comply
with present or future regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA, which may
include any of the following sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">untitled
letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">customer
notification, or orders for repair, replacement or refunds;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">voluntary
or mandatory recall or seizure of our current or future products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">administrative
detention by the FDA of medical devices believed to be adulterated or misbranded;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">imposing
operating restrictions, suspension or shutdown of production;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusing
our requests for 510(k) clearance, PMA or <I>de novo</I> classification of any new products, new intended uses or modifications to our
insulin pump;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rescinding
510(k) clearance that has already been granted; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
prosecution.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of any of these events would have
a material adverse effect on our business, financial condition and results of operations and could result in stockholders losing their
entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Although our insulin pump product candidate
does not presently require clinical trials to apply to the FDA for clearance and even if a clinical trial is completed, the results of
our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be sufficient for
us to obtain approval of our product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
trials are almost always required to support a PMA application and may also be required to support 510(k) submissions although at this
time ours does not require a PMA. If the device presents a &ldquo;significant risk&rdquo; to human health as defined by the FDA, the
FDA requires the study sponsor to submit an investigational device exemption (&ldquo;IDE&rdquo;) application and obtain IDE approval
prior to commencing human clinical trials. The IDE must be supported by appropriate data, such as animal and laboratory testing results,
showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. An IDE will automatically
become effective 30 days after receipt by the FDA, unless the FDA denies the application or notifies the sponsor that the investigation
is on hold and may not begin until the sponsor provides supplemental information about the investigation that satisfies the agency&rsquo;s
concerns. The FDA may also notify the sponsor that the study is approved as proposed. If the FDA determines that there are deficiencies
or other concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional
approval. Furthermore, the agency may withdraw approval of an IDE under certain circumstances. Clinical trials for a significant risk
device may begin once an IDE is approved by the FDA and the appropriate Institutional Review Board (&ldquo;IRB&rdquo;) at each clinical
trial site. If the product is deemed a &ldquo;non-significant risk&rdquo; device, IDE approval from the FDA would not be required, but
the clinical trial would need to meet other requirements including IRB approval. Our clinical trials must be conducted in accordance
with FDA regulations and federal and state regulations concerning human subject protection, including informed consent and healthcare
privacy. A clinical trial may be suspended by the FDA or at a specific site by the relevant IRB at any time for various reasons, including
a determination that the risks to the trial participants outweigh the benefits of participation in the clinical trial. Even if a clinical
trial is completed, the results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal
or otherwise not be sufficient for us to obtain approval of our product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our product candidate
and research technologies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to the U.S. Patent and Trademark
Office (the USPTO) and various foreign patent agencies for patents on our proprietary fluid movement technology and our insulin delivery
methodology. To date, the USPTO has granted three patents to us, and we have additional applications pending and in various stages of
review by the USPTO and foreign patent agencies. There can be no assurance that we will be issued additional patents by the USPTO or
foreign patent agencies and that any of our patents will prevent other companies from competing with us. We will continue to attempt
to patent our innovations, as appropriate, to help ensure a sustainable competitive advantage.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due
to evolving legal standards relating to the patentability, validity and enforceability of patents covering health care product inventions,
our ability to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent applications
is uncertain and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth
of claims allowed in medical device patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications
owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable
by a court of law, will provide us with any significant protection against competing products, or will afford us a commercial advantage
over competitive products. If, at some point in the future, one or more products resulting from our product candidates is approved for
sale by the FDA and we do not have adequate intellectual property protection for those products, competitors could duplicate them for
approval and sale in the United States without repeating the extensive testing required of us to obtain FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
we are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome
would have a significant adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to commercialize our product candidate depends on our ability to use, manufacture and sell our product candidate without infringing
the patents or other proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned
by third parties exist in the diabetes medical device area. There may be existing patents, unknown to us, on which our activities with
our insulin pump candidate could infringe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a third party claims that our actions infringe
on its patents or other proprietary rights, we could face a number of issues that could materially harm our competitive position, including,
but not limited to:<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">infringement
and other intellectual property claims that, even if meritless, can be costly and time-consuming, delay the regulatory approval process
and divert management&rsquo;s attention from our core business operations;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    order that we pay substantial damages for infringement, including consequential damages for lost of profits or market share, if a
    court determines that our products or technologies infringe on a third party&rsquo;s patent or other proprietary rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
court prohibiting us from selling or licensing our products or technologies unless the holder licenses the patent or other proprietary
rights to us, which it is not required to do; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">even
if a license is available from a holder, we may have to pay substantial royalties or grant cross-licenses to our patents or other proprietary
rights.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of these events occur, it could significantly harm our operations and financial condition and negatively affect our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to patented technology, we rely on our unpatented technology, trade secrets and know-how. We generally seek to protect this
information by confidentiality, non-disclosure and assignment of invention agreements with our officers, employees, contractors and other
service providers and with parties with which we do business. These agreements may be breached, which breach may result in the misappropriation
of such information, and we may not have adequate remedies for any such breach. We cannot be certain that the steps we have taken will
prevent unauthorized use or reverse engineering of our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moreover,
our trade secrets may be disclosed to or otherwise become known or be independently developed by competitors. To the extent that our
officers, employees, contractors, other service providers, or other third parties with whom we do business use intellectual property
owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If, for any
of the above reasons, our intellectual property is disclosed or misappropriated, it would harm our ability to protect our rights and
have a material adverse effect on our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to gain and maintain a competitive advantage. The following examples are illustrative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">others
may be able to make devices that are similar to our insulin pump but that are not covered by the claims of the patents that we own;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
or any collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications
that we own;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
might not have been the first to file patent applications covering certain of our inventions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">others
may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
property rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">it
is possible that our pending patent applications will not lead to issued patents;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">issued
patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal
challenges;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent
infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and
then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
may not develop additional proprietary technologies that are patentable.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare reform and drug-pricing reform
laws could adversely affect our product candidate and financial condition.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, there have been, and continue
to be, a number of legislative initiatives to contain healthcare costs. In March 2010, the Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Affordability Reconciliation Act (ACA), was enacted in the United States, which made a number
of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect
our business, the ACA implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals,
physicians, and other providers to improve the coordination, quality, and efficiency of certain healthcare services through bundled payment
models and expanded the eligibility criteria for Medicaid programs. Since its enactment, there have been judicial, executive, and Congressional
challenges to certain aspects of the ACA. It is unclear how the ACA and its implementation, as well as efforts to repeal or replace, or
invalidate, the ACA, or portions thereof, will affect our insulin pump or our business. Additional legislative changes, regulatory changes,
and judicial challenges related to the ACA remain possible. It is possible that the ACA, as currently enacted or as it may be amended
in the future, and other healthcare reform measures that may be adopted in the future, could have an adverse effect on our industry generally
and on our ability to commercialize our insulin pump and achieve profitability. We have assumed in all of our financial projections that
there is not an increase in the reimbursement for our product through the pharmacy or durable medical equipment routes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President Biden intends, as his predecessor did,
to take action against drug prices which are considered &ldquo;high.&rdquo; Drug pricing continues to be a subject of debate at the executive
and legislative levels of U.S. government. The American Rescue Plan Act of 2021 includes a provision that will eliminate the statutory
cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. With the elimination of the rebate cap, manufacturers may
be required to compensate states in an amount greater than what the state Medicaid programs pay for the drug. Additionally, the Inflation
Reduction Act of 2022 contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within
the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &ldquo;maximum fair price&rdquo;
for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of
certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide
discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the Inflation Reduction
Act of 2022. The Inflation Reduction Act of 2022 could have the effect of reducing the prices we can charge and reimbursement we receive
for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition,
results of operations and growth prospects. The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry
in general is not yet known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. We expect that additional federal, state and foreign healthcare
reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or
additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These and other healthcare reform measures that
may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive
for any current product or future product candidate. Any reduction in reimbursement from Medicare or other government healthcare programs
may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Legislative and regulatory
proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure
whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or
what the impact of such changes on the marketing approvals of any current or future product candidates, if any, may be. In addition, increased
Congressional scrutiny of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as subject us
to more stringent product labeling and post-marketing testing and other requirements.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Even
if we are able to obtain all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin
pump, if we or any contract manufacturers we select fails to comply with the FDA&rsquo;s quality system regulations, the manufacturing
and distribution of our product candidate could be interrupted, and our product sales and operating results could suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
material step in the process of the commercialization of our product candidate will involve selecting a manufacturer or manufacturers
for our pump. We and any future contract manufacturers of our insulin pump will be required to comply with the FDA&rsquo;s quality system
regulations, which impose a complex regulatory framework that covers the procedures and documentation of the design, testing, production,
control, quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces its quality
system regulations through periodic unannounced inspections. We cannot assure you that, in the future, any manufacturing facilities owned
by us or any contract manufacturer will pass any quality system inspection. In the event that our or any contract manufacturer&rsquo;s
facilities fails a quality system inspection, the manufacturing or distribution of our product candidate could be interrupted and our
operations disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system inspection could
force a suspension or shutdown of any packaging and labeling operations or then manufacturing operations of any contract manufacturers,
or a recall of our insulin pump. If any of these events were to occur, we at such time would not be able to provide our customers with
the quantity of insulin pumps that they require on a timely basis, our reputation could be harmed and we could lose any customers we
then have, any or all of which could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may bring infringement claims or other
legal proceedings against third parties, causing us to spend substantial resources on litigation and exposing our own intellectual property
portfolio to challenge.</I></B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may come to believe that third parties are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized
use, we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result in meritorious
counterclaims against us and would distract management&rsquo;s attention. Also, in an infringement or misappropriation proceeding, a
court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties may be able to use our
technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other
party from using the technology at issue on the grounds that the other party&rsquo;s activities are not covered by our patents. See &ldquo;Business
- Patents,&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
may become involved in disputes with our present or future contract partners over intellectual property ownership or other matters, which
would have a significant effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inventions
discovered in the course of performance of contracts with third parties or contractors may become jointly owned by such third party contractors
and us, in some cases, and the exclusive property of one of us, in other cases. Under some circumstances, it may be difficult to determine
who owns a particular invention or whether it is jointly owned, and disputes could arise regarding ownership or use of those inventions
or jointly developed improvements thereto. Other disputes may also arise relating to the performance or alleged breach of our agreements
with third parties. Any disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Even
assuming we obtain FDA approval or clearance with regard to our insulin pump, the FDA has the authority to require the recall of our
pump if we commence manufacturing of our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations
pertaining to manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning
the safety or efficacy of the device. A government-mandated recall could occur if the FDA finds that there is a reasonable probability
that our device would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of manufacturing
defects, labeling deficiencies, packaging defects or other failures to comply with applicable regulations. Any recall would divert management&rsquo;s
attention and financial resources and harm our reputation with customers. A recall involving our insulin pump would be particularly harmful
to our business, financial condition and results of operations because it is currently our only product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Any
disruption and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital markets,
and thus adversely affect our business and liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Negative economic conditions and instability
or uncertainty in the financial markets could have a negative impact on our ability to access the capital markets, and thus have a negative
impact on our then operations and liquidity. We face certain risks in the event of a sustained deterioration of financial market liquidity,
as well as in the event of sustained deterioration in the liquidity, or failure, of our banking, cash management and custodial financial
institutions. A general shortage of liquidity and credit combined with the substantial losses in worldwide equity markets could lead
to an extended worldwide recession in the future. If such occurred, we would face significant challenges if conditions in the capital
markets did not improve. Our ability to access the capital markets under such circumstances could be severely restricted at a time when
we need to access such markets, which could have a negative impact on our business plans. Even if we are able to raise capital under
such circumstances, it may not be at a price or on terms that are favorable to us. We cannot predict the occurrence of future disruptions
or how long such negative conditions might continue.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because our current insulin pump is still
in the pre clearance stage with the FDA, it does not have reimbursement and is not approved for insurance coverage. If in the future
we are cleared for and are otherwise able to commercialize our insulin pump, but are unable to obtain adequate reimbursement or insurance
coverage for such product candidate from third-party payors, we will be unable to generate significant revenue.</I></B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our current insulin pump is still in
the pre clearance by the FDA stage, it does not have reimbursement and is not approved for insurance coverage. The future availability
of insurance coverage and reimbursement for newly approved medical devices is highly uncertain. In the United States, patients using
insulin pumps are generally reimbursed for all or part of the product cost by Medicare or other third-party payors. Any future commercial
success of our insulin pump will be substantially dependent on whether third-party coverage and reimbursement is available for future
customers. Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly attempting to contain healthcare
costs by limiting both coverage and the level of reimbursement of new medical devices, and, as a result, they may not cover or provide
adequate reimbursement for our insulin pump, assuming we are able to fully develop and obtain all regulatory approval to market it in
the United States. In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device products and
services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly
from payor to payor. In addition, payors continually review new technologies for possible coverage and can, without notice, deny coverage
for these new products and procedures. As a result, the coverage determination process is often a time-consuming and costly process that
will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be obtained, or maintained if obtained. Reimbursement systems in international markets vary
significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country basis.
In many international markets, a product must be approved for reimbursement before it can be approved for sale in that country. Further,
many international markets have government-managed healthcare systems that control reimbursement for new devices and procedures. Accordingly,
unless government and other third-party payors provide coverage and reimbursement for our insulin pump, patients may not use it, which
would cause investors to lose their entire investment.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to oversight by the SEC
and other regulatory agencies. Investigations by those agencies could divert management&rsquo;s focus and could have a material adverse
effect on our reputation and financial condition.</I></B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to the regulation and oversight of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may face
legal or administrative proceedings by these agencies. We are unable to predict the effect of any investigations on our business, financial
condition or reputation. In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could have a
material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are a &ldquo;smaller reporting company&rdquo;
and, as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common stock may
be less attractive to investors.</I></B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a &ldquo;smaller reporting company,&rdquo; and are subject to lesser disclosure obligations in our SEC filings compared to other
issuers. Specifically, &ldquo;smaller reporting companies&rdquo; are able to provide simplified executive compensation disclosures in
their filings, are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public
accounting firms provide an attestation report on the effectiveness of internal control over financial reporting and have certain other
decreased disclosure obligations in their SEC filings, including, among other things, only being required to provide two years of audited
financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as a &ldquo;smaller reporting company&rdquo;
may make it harder for investors to analyze our operating results and financial prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not expect any cash dividends to be
paid on our shares of common stock for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid a cash dividend
and we do not anticipate declaring or paying dividends on our common stock for the foreseeable future. We expect to use future financing
proceeds and earnings, if any, to fund operating expenses. Consequently, stockholders&rsquo; only opportunity to achieve a return on their
investment is if the price of our stock appreciates and they sell their shares at a profit. We cannot assure stockholders of a positive
return on their investment when they sell their shares or that stockholders will not lose the entire amount of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the beneficial ownership of our common
stock continues to be highly concentrated, it may prevent our stockholders from influencing significant corporate decisions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 24, 2023, our executive officers,
directors and certain persons who may be deemed affiliates beneficially own approximately 50% of our issued and outstanding common stock.
Specifically, James Besser, our chief executive officer, is the beneficial owner of approximately 29% of our outstanding capital stock.
As a result, such persons may exercise substantial influence over the outcome of corporate actions requiring stockholder approval including,
without limitation, the election of directors, certain mergers, consolidations and sales of all or substantially all of our assets or
any other significant corporate transactions. Such persons may also vote against a change of control, even if such a change of control
would benefit our other stockholders. Thus, investors in our common stock cannot reasonably expect to have any influence over the election
of our directors or other matters submitted to a vote of our stockholders. Instead, our existing significant stockholders may exert a
substantial influence on the election of our directors and any actions requiring or otherwise put to a stockholder vote, potentially in
a manner that you do not support. The concentrated amount of control over our affairs held by a relatively few number of significant investors
could serve to reduce the attractiveness or liquidity of our common stock, and thereby depress its trading price. Additionally, conflicts
of interest may arise between these executive officers, directors and other affiliates, on the one hand, and us and our other stockholders,
on the other hand. In resolving these conflicts of interests, these investors may favor their own interests and the interests of their
affiliates, over the interests of our other stockholders, which could cause a material adverse effect on our business, prospects, financial
condition and results of operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales of our securities could adversely
affect the market price of our common stock and our future capital-raising activities could involve the issuance of equity securities,
which would dilute your investment and could result in a decline in the trading price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell securities in the public or private
equity markets at prices per share below the current market price of our common stock, even if we do not have an immediate need for additional
capital at that time. Sales of substantial amounts of shares of our common stock, or the perception that such sales could occur, could
adversely affect the prevailing market price of our shares and our ability to raise capital. We may issue additional shares of common
stock in future financing transactions or as incentive compensation for our executive management and other key personnel, consultants
and advisors. Issuing any equity securities would be dilutive to the equity interests represented by our then-outstanding shares of common
stock. Moreover, sales of substantial amounts of shares in the public market, or the perception that such sales could occur, may adversely
affect the prevailing market price of our common stock and make it more difficult for us to raise additional capital. Such resulting significant
downward pressure on the price of our common stock could also encourage short sales by third parties. Such an event could place further
downward pressure on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, we and our directors and officers
and holders of more than 5% of the Company&rsquo;s outstanding shares of common stock have agreed with the underwriter not to offer for
sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock
for a period of three months after the date of this prospectus. The underwriter may, in its discretion, release the restrictions on any
such shares at any time without notice. See &ldquo;<I>Underwriting</I>.&rdquo; We cannot predict the effect that future sales of our common
stock would have on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our articles of incorporation allow for
our board of directors to create new series of preferred stock without further approval by our stockholders, which could adversely affect
the rights of the holders of our common stock.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has the authority to fix
and determine the relative rights and preferences of preferred stock. Currently, our board of directors has the authority to designate
and issue up to 5,000,000 shares of our preferred stock without further stockholder approval. In the future, our board of directors could
authorize the issuance of one or more series of preferred stock that would grant to holders, among other rights, the preferred right
to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock
and the right to the redemption of our preferred shares acquired by such persons, together with a premium, prior to the redemption of
our common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater voting
power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common
stock or result in dilution to our existing stockholders.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish and maintain an
effective system of internal controls, we may not be able to report our financial results accurately or prevent fraud. Any inability
to report and file our financial results accurately and timely could harm our reputation and adversely affect the trading price of our
common stock.</I></B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial
reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed,
and our business and reputation with investors may be harmed. If we are unable to maintain effective internal controls, we may not have
adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including
the requirements of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). In addition, we may be unable to accurately report our financial
results in future periods, or report them within the timeframes required by the requirements of the SEC or the Sarbanes-Oxley Act. Failure
to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the
SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter
in their implementation, could result in identification of additional material weaknesses or significant deficiencies, cause us to fail
to meet our reporting obligations or result in material misstatements in our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, Section 404 of the Sarbanes-Oxley Act and related regulations
require our management to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year.
Based on its evaluation, our management concluded that our internal controls over financial reporting were effective as of March 31, 2022.
We cannot provide assurance that, in the future, a material weakness or significant deficiency will not exist or otherwise be discovered.
If that were to happen, it could harm our operating results and cause stockholders to lose confidence in our reported financial information.
Any such loss of confidence would have a negative effect on the trading price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our board of directors is able to adopt
recapitalizations through forward or reverse splits of our outstanding shares of common stock without stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our amended and restated articles
of incorporation, our board of directors has the power, without obtaining stockholder approval, to effectuate recapitalizations of us
through forward or reverse splits of our outstanding common stock. As a result of such provision, our board of directors can implement
recapitalizations of us by effectuating a forward or reverse stock split of our outstanding common stock, which would increase or decrease
each of our stockholder&rsquo;s number of shares owned, and our stockholders will have no right to approve or disapprove any such action
even if such actions have a material adverse effect on them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Related to This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>After this offering, we will need to raise
additional capital in the future to execute our business plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We expect the net proceeds to us from this
offering will approximate $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.0 million, which assumes that
the over-allotment option is not exercised. Upon closing of this offering, we expect to have cash and cash equivalents of approximately
$14.7 million. After the closing of this offering, we believe we will have adequate funds to operate our business for the at least the
next nine&nbsp;months. During that timeframe, we intend to complete our 510(k) submission and obtain approval from the FDA, commence
our initial commercialization efforts and complete our manufacturing capability. We will require additional funding to fully commercialize
our pump product and bring it to market on a large scale.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that additional capital,
whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or,
if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these securities may have rights, preferences,
or privileges senior to those of our common stock, and our current stockholders may experience dilution. If we are unable to obtain funds
when needed or on acceptable terms, we may be required to curtail our current product development programs, cut operating costs, forego
future development and other opportunities or even terminate our operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>As
we have broad discretion in how we use the proceeds from this offering, we may use the proceeds in ways with which you disagree.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have not allocated the net proceeds from this offering for any specific
purpose, except as generally set forth under &ldquo;<I>Use of Proceeds</I>.&rdquo; As set forth therein, our management will have significant
flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management with regard to the use
of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are
being used in ways you would agree with or ways which are likely to increase the value of your investment. Because of the number and variability
of factors that will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently
intended use. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for our company
or your investment. The failure of our management to use such funds effectively could have a material adverse effect on our business,
financial condition, operating results and cash flow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>Holders of our warrants
will have no rights as a common stockholder until they acquire our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants included in the units in this offering
do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather
merely represent the right to acquire shares of our common stock at a fixed price for a limited period of time. Specifically, commencing
on the date of issuance, holders of the warrants may exercise their right to acquire the common stock and pay the exercise price per share,
prior to five years from the date of issuance, after which date any unexercised warrants will expire and have no further value. Until
holders of the warrants acquire common stock upon exercise of the warrants, the holders will have no rights with respect to the common
stock issuable upon exercise of the warrants. Upon exercise of the warrants, the holder will be entitled to exercise the rights of a stockholder
as to the security exercised only as to matters for which the record date occurs after the exercise. There can be no assurance that the
market price of the common stock will ever equal or exceed the exercise price of the warrants, and consequently, whether it will ever
be profitable for holders of the warrants to exercise the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions of the warrants offered by this
prospectus could discourage an acquisition of us by a third party</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the discussion of the provisions
of our governing organizational documents, certain provisions of the warrants offered by this prospectus could make it more difficult
or expensive for a third party to acquire us. The warrants prohibit us from engaging in certain transactions constituting &ldquo;fundamental
transactions&rdquo; unless, among other things, the surviving entity assumes our obligations under the warrants. These and other provisions
of the warrants offered by this prospectus could prevent or deter a third party from acquiring us even where the acquisition could be
beneficial to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants offered by this prospectus
are speculative in nature and may not have any value</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants offered by this prospectus will be
exercisable for five years from the date of issuance. There can be no assurance that the market price of our common stock will ever exceed
the exercise price of the warrants. In the event that our common stock price does not exceed the exercise price of the warrants during
the term of the warrants, the warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the warrants
being offered in this offering</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no public trading market for the warrants
offered by this prospectus, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants on a
national securities exchange. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>You will experience
immediate and substantial dilution in the net tangible book value per share of the common stock you purchase.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> As
                                            of December 31, 2022, our net tangible book value (deficit) was approximately $8.0 million,
                                            or approximately $0.73 per share <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
                                            common stock. As the effective price per share of our common stock being offered in this
                                            offering is substantially higher than the net tangible book value per share of our common
                                            stock, you will suffer substantial dilution with respect to the net tangible book value of
                                            the common stock you purchase in this offering. Based on the assumed public offering price
                                            of $3.78&nbsp;per unit being sold in this offering, and our net tangible book value per share
                                            as of December 31, 2022, if you purchase shares of common stock in this offering, you will
                                            suffer immediate and substantial dilution of $0.91&nbsp;per share with respect to the net
                                            tangible book value of the common stock (assuming no exercise of the underwriter&rsquo;s
                                            option to purchase additional shares).&nbsp;See the section titled &ldquo;<I>Dilution</I>&rdquo;
                                            below for a more detailed discussion of the dilution you will incur if you purchase common
                                            stock in this offering.</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>You may experience
future dilution as a result of future equity offerings and other issuances of our common stock or other securities. In addition, this
offering and future equity offerings and other issuances of our common stock or other securities may adversely affect the price of our
common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In order to raise additional
capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our
common stock (such as warrants, convertible debt or preferred stock) at prices that may not be the same as the price per share in this
offering. We may not be able to sell shares of common stock or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors in this offering, and investors purchasing shares of common stock or other securities
in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common
stock or securities convertible into common stock in future transactions may be higher or lower than the price per share in this offering.
In addition, the sale of shares of common stock in this offering and any future sales of a substantial number of shares of our common
stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot
predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for
sale will have on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_005"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, which we refer to as the &ldquo;Securities Act,&rdquo; and
Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the &ldquo;Exchange Act,&rdquo; that relate to future
events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future
results, levels of activity, performance or achievements expressed or implied by such forward-looking statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Words such as, but not limited to, &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;forecast,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo;
&ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;targets,&rdquo; &ldquo;likely,&rdquo;
&ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;continue,&rdquo; &ldquo;scheduled&rdquo; and
similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this prospectus, we caution you that these statements are based on our estimates or projections
of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results,
level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking
statement. Actual results, level of activity, performance, experience or achievements may differ materially from those expressed or implied
by any forward-looking statement as a result of various important factors, including risks and uncertainties relating, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
strategies, prospects, plans, expectations, forecasts or objectives;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to achieve a marketable product (i.e., our insulin pump) and the costs and timing thereof;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">acceptance
of our product candidate by our target market and our ability to compete in such market;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to raise additional financing when needed and the terms and timing thereof;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
ability to expand, protect and maintain our intellectual property rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements, our need for additional financing
or the period for which our existing cash resources will be sufficient to meet our operating requirements;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            analysis of the target market for our insulin pump;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to obtain all regulatory approvals and clearances relating to our insulin pump including those of the FDA;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments
    in the United States and other countries;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and costs of
    our obtaining all regulatory approvals and clearances identified immediately above;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our compliance with all
    applicable laws, rules and regulations, including those of the SEC and the FDA;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to compete
    in the diabetes marketplace with larger and more substantial medical device companies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic, business,
    political and social conditions;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on and our
    ability to retain (and if necessary, timely recruit and replace) our officers, directors and key employees and their ability to timely
    and competently perform at levels expected of them;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to generate significant revenues and achieve profitability;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manage the
    growth of our business;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commercialization,
    marketing and manufacturing capabilities and strategies;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expand,
    protect and maintain our intellectual property position;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; text-align: left">&#9679;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success
    of competing third-party products;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to fully remediate
    our identified internal control material weaknesses;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet the
    initial or continuing listing requirement of the Nasdaq Capital Market;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with
    regulatory requirements relating to our business, and the costs of compliance with those requirements, including those on data privacy
    and security;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the specific risk factors
    discussed under the heading &ldquo;<I>Risk Factors</I>&rdquo; set forth in this prospectus; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">various other matters,
    many of which are beyond our control.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We estimate that our net proceeds from this
offering will be approximately $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,031,490, based on an assumed
public offering price of $3.78&nbsp;per unit which is based on the last reported sale price of our common stock on the Nasdaq Capital
Market on&nbsp;May&nbsp;2, 2023, and after deducting underwriting discounts and commissions and estimated offering expenses payable by
us.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2022, we had cash and cash equivalents of approximately $7.7 million. We currently expect to use the net proceeds from
this offering, together with the $7.7 million of cash and cash equivalents, primarily for the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"> &#9679; </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> Approximately $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,900,000&nbsp;to
    fund research and development for new products and improvements to our initial pump product candidate including, but not limited
    to, hiring of key personnel, and costs for continued research activities;</FONT> </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> &#9679; </TD>
    <TD STYLE="text-align: justify"> Approximately $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000&nbsp;for
    the initial development of our sales, marketing and administrative capabilities and organization, including but not limited to adding
    additional staff, public relations and advertising;</FONT> </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> &#9679; </TD>
    <TD STYLE="text-align: justify"> Approximately $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000&nbsp;for
    the continued development of our manufacturing and production capability, including personnel costs and capital expenditures; and</FONT> </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The remainder for working
    capital, other capital expenditures and general corporate purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our existing cash and cash equivalents,
along with the net proceeds from this offering, together with interest on cash balances, will be sufficient to fund our operating expenses
and capital expenditure requirements through at least the next 12 months. The amount and timing of our actual expenditures and actual
use of the net proceeds of the offering will depend upon numerous factors, including the timing of our submission to the FDA for 510(k)
clearance of our product candidate, which is necessary to commence commercialization, the timing and results of our product launch, including
all commercialization activities, the progress of our continuing product research and development activities, our ability to establish
our outsourced manufacturing operations, and our ability to add the required staff to execute our business plan, any collaborations that
we may enter into with third parties, and any unforeseen delays or cash needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
expected use of the net proceeds from this offering represents our current intentions based upon our present plans and business conditions.
As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment
regarding the application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue these certain
of these activities if the net proceeds from this offering and the other sources of cash are less than, or do not last as long as, expected.
We have no current understandings, agreements or commitments for any material acquisitions or licenses of any products, businesses or
technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pending
their use, we plan to invest the net proceeds from this offering in high-quality, short-term interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_008"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividend on our capital stock. We do not anticipate paying any cash dividends in the foreseeable
future and we intend to retain all of our earnings, if any, to finance our growth and operations and to fund the expansion of our business.
Payment of any dividends will be made in the discretion of our board of directors, after its taking into account various factors, including
our financial condition, operating results, current and anticipated cash needs and plans for expansion. Any dividends that may be declared
or paid on our common stock, must also be paid in the same consideration or manner, as the case may be, on our shares of preferred stock,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_009"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth our cash and cash equivalents and capitalization as of December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt; font-size: 10pt; text-align: left">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify">an actual basis; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt"> &nbsp; </TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt; text-align: left"> &#9679; </TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify"> on a pro-forma basis to give effect to the issuance and sale of the units
    by us in this offering at the assumed public offering price of $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.78&nbsp;per
    unit, after deducting underwriting discussions and commissions and estimated offering expenses payable by us for net proceeds of
    $7,031,490, which assumes that the over-allotment option is not exercised.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The as adjusted information below is illustrative
only and our capitalization following the closing of this offering will be adjusted based on the actual public offering price and other
terms of this offering determined at pricing. You should read this information together with our financial statements and the related
notes thereto included elsewhere in this prospectus and the information set forth under the heading &ldquo;<I>Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</I>&rdquo; included elsewhere in this prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>As
    of December 31, 2022</B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"> Unaudited </TD><TD STYLE="font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Actual </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma<SUP>(1)</SUP></B></FONT> </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"> Cash and cash equivalents </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 7,690,957 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 14,722,447 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"> Stockholders&rsquo; equity: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt"> Preferred stock, par value $0.001; 5,000,000 shares authorized
    and undesignated, actual, pro forma; no shares issued and outstanding, actual or pro forma </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"> Common Stock, $0.001 par value, 50,000,000 shares authorized;
    10,932,098 shares issued and outstanding, actual; 14,979,718 shares issued and outstanding, pro forma </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,932 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 15,165 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"> Additional paid-in capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 52,900,066 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 59,927,323 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"> Accumulated deficit </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (44,887,453 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (44,887,453 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"> Total stockholders&rsquo; equity </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 8,023,545 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 15,055,035 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.5in"> Total capitalization </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 8,738,842 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 15,770,332 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> (1) </TD><TD STYLE="text-align: justify"> If the underwriter&rsquo;s
                                            option to purchase up to an additional&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">634,920
                                            shares of our common stock and warrants to purchase an additional 317,460 shares of our common
                                            stock is exercised in full, and assuming no exercise of the warrants, (i) we would receive
                                            approximately $1,116,000&nbsp;in additional net proceeds, based on the assumed initial public
                                            offering price per unit of $3.78, which is based on the last reported sale price of our common
                                            stock on the Nasdaq Capital Market on&nbsp;May 2, 2023, after deducting estimated underwriting
                                            discounts and commissions and estimated offering expenses payable by us; and (ii) cash and
                                            cash equivalents, total stockholders&rsquo; equity and total capitalization would each also
                                            increase by approximately $1,116,000.</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Each $1.00 increase (decrease) in the assumed
public offering price of $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.78 per unit would increase (decrease)
the as-adjusted amount of cash and cash equivalents, additional paid-in capital, total stockholders&rsquo; equity (deficit) and total
capitalization by approximately $1,968,000, assuming that the number of units offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by
us. We may also increase or decrease the number of units we are offering. Each increase (decrease) of 100,000 units in the number of
units we are offering would increase (decrease) the as adjusted amount of cash and cash equivalents, additional paid-in capital, total
stockholders&rsquo; equity and total capitalization by approximately $351,500, assuming that the assumed public offering price remains
the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The
as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other
terms of this offering determined at pricing.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of our common stock to be
outstanding after this offering is based on 10,932,098 shares of our common stock outstanding as of December 31, 2022, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> &#9679; </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,116,402&nbsp;shares
                                            of our common stock issuable upon the exercise of the warrants to be issued as part of the
                                            units;</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD STYLE="text-align: justify"> 296,296<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;shares
                                            of common stock issuable upon exercise by the underwriter of the underwriter&rsquo;s Warrants;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">2,174,198 shares of our common stock issuable upon exercise of outstanding stock options with a weighted
average exercise price of approximately $5.69 per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">767,796 shares of our common stock issuable upon the exercise of
warrants with an exercise price of $6.00 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><FONT STYLE="background-color: white">5,449,478</FONT> shares of our common stock issuable upon the exercise
of warrants with an exercise price of $6.60 per share;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">1,348,314 shares of our common stock issuable upon exercise of pre-funded
warrants with an exercise price of $0.01 per share; </FONT>and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">445,559 shares of our common stock reserved for issuance pursuant to future awards under our Amended 2017
Equity Incentive Plan, or the 2017 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_010"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Each
unit, with an assumed public offering price of $<FONT STYLE="font-size: 10pt">3.78 per unit, which is based on the last reported sale
price of our common stock on The Nasdaq Capital Market on&nbsp;May&nbsp;2, 2023, consists of two shares of common stock and one warrant
to purchase one share of common stock.</FONT></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our units, your interest will
be diluted immediately to the extent of the difference between the offering price per share of our common stock that is part of the unit
and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> As of December 31, 2022, our historical net
tangible book value, which represents our total tangible assets less total liabilities, was <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
$8.0 million, or $0.73 per share of common stock. Historical net tangible book value per share represents the amount of our total tangible
assets reduced by total liabilities, divided by 10,932,098, the number of shares of common stock outstanding on December 31, 2022.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> After giving effect to the sale of the units,
at the assumed offering price of $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.78&nbsp;per unit, which
is based on the last reported sale price of our common stock on The Nasdaq Capital Market on May 2, 2023, after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us, but assuming no exercise of the warrants offered hereby or the
underwriter&rsquo;s warrant, our net tangible book value as of December 31, 2022 would have been $15,055,060&nbsp;or $0.99 per share
of common stock. This amount represents an immediate increase in net tangible book value of $0.26 per share to our existing stockholders.
Investors purchasing our common stock in this offering will have paid $0.90 more than the as adjusted net tangible book value per share
of common stock after this offering.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table illustrates this dilution on a per share basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"> Assumed offering price per share </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 1.89 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Historical net tangible book value per share as of December 31, 2022 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.73 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Increase in net tangible book value per share attributable to new investors </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.26 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Net tangible book value per share after the offering </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.99 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Dilution per share to new investors </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.90 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The dilution information discussed above is illustrative
only and may change based on the actual initial public offering price and other terms of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Each $1.00 increase (decrease) in the assumed
public offering price of $<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.78&nbsp;per unit would increase
(decrease) our net tangible book value after this offering by approximately $1,968,000&nbsp;per share, and increase (decrease) the dilution
per share to new investors by approximately $0.13&nbsp;per share, after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us full.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of our common stock to be
outstanding after this offering is based on 10,932,098 shares of our common stock outstanding as of December 31, 2022, and excludes:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> &#9679; </TD><TD STYLE="text-align: justify"> 2,116,402<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;shares
                                            of our common stock issuable upon the exercise of the warrants to be issued as part of the
                                            units;</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> &#9679; </TD><TD STYLE="text-align: justify"> 296,296<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;shares
                                            of common stock issuable upon exercise by the underwriter of the underwriter&rsquo;s warrants;</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,174,198 shares of our common stock issuable upon exercise
of outstanding stock options with a weighted average exercise price of approximately $5.69 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">767,796 shares of our common stock issuable upon the exercise
of warrants with an exercise price of $6.00 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">5,449,478 shares of our common stock issuable upon the exercise
of warrants with an exercise price of $6.60 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">1,348,314 shares of our common stock issuable upon exercise of pre-funded
warrants with an exercise price of $0.01 per share; and</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">445,559 shares of our common stock reserved for issuance pursuant
to future awards under the 2017 Plan.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the shares described above that are reserved for issuance to the
holders of our options and under our 2017 Plan are issued, or we otherwise issue additional shares of common stock in the future, there
could be further dilution to investors participating in this offering. In addition, we anticipate needing to raise additional capital
before generating positive cash flows and we may choose to raise additional capital because of market conditions or strategic considerations,
even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the
sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> If the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">underwriter
exercises its option to purchase additional shares of our common stock and warrants full, the pro forma as adjusted net tangible book
value after this offering would be $1.02 per share, the increase in pro forma net tangible book value would be $0.29 per share and the
dilution to new investors would be $0.87 per share, in each case assuming an public offering price of $3.78 per unit, which is based
on the last reported sale price of our common stock on the Nasdaq Capital Market on&nbsp;May 2, 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_011"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should read the following discussion and
analysis in conjunction with our unaudited condensed consolidated financial statements and the notes to those financial statements for
the three and nine months ended December 31, 2022 and December 31, 2021 and our audited consolidated financial statements and notes to
those financial statements for the years ended March 31, 2022 and March 31, 2021, in each case, included elsewhere in this prospectus.
This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See &ldquo;Special
Note Regarding Forward-Looking Statements.&rdquo; Our actual results may differ materially from those contained in or implied by any forward-looking
statements. </I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company
Overview</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a development-stage medical device company focused on the design, development and commercialization of an innovative insulin pump
using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump,
our MODD1 product, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care
that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription,
reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated
&ldquo;super users&rdquo; and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing,
especially in terms of device adoption, type 2 diabetes markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Historically,
we have financed our operations principally through private placements and public offerings of our common stock and sales of convertible
promissory notes. Based on our current operating plan, we believe we have adequate cash for at least the next 12 months. Our long-term
ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities,
to support our future operations. If we are unable to secure additional capital, we will be required to curtail our research and development
initiatives and take additional measures to reduce costs. We have provided additional disclosure in Note 1 to the consolidated financial
statements in Item 1 of this Registration Statement and under&nbsp;<I>Liquidity and Capital Resources</I>&nbsp;below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Economic Disruptions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the
U.S. government in March 2020. This negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &ldquo;shelter-in- place&rdquo; and created
significant disruption of the financial markets during 2020, 2021 and into 2022. While the national emergency is set to expire in
May 2023 and most closures and &ldquo;shelter-in-place&rdquo; orders have ended, there can be no assurance that the COVID-19
pandemic will not impact on our operational and financial performance in the future, as the duration and spread of the pandemic and
related actions taken by U.S. and foreign government agencies to prevent disease spread are uncertain, out of our control, and
cannot be predicted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Russian invasion
of Ukraine in February 2022 has led to further economic disruptions. Mounting inflationary costs pressures and recessionary fears have
negatively impacted the global economy. During the third quarter of 2022, the U.S. Federal Reserve continued to aggressively address elevated
inflation by increasing interest rates. The U.S. Federal reserve increased interest rates by 75 basis points in each of its meetings held
in July, September and November 2022, 50 basis points in its meeting held in December 2022, and 25 basis points in its meeting held in
each of February 2023 and March 2023, as inflation remains elevated. We were able to raise additional capital through equity offerings
in February 2022 and May 2022, however, we will need to raise additional capital to commercialize our pump product candidate and support
our operations in the future. We may be unable to access the capital markets, and additional capital may only be available to us on terms
that could be significantly detrimental to our existing stockholders and to our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For additional information
on risks that could impact our future results, please refer to &ldquo;<I>Risk Factors</I>&rdquo; on page 10.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Critical
Accounting Policies and Estimates </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires
us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis,
we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual
results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant
accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements for the year ended March
31, 2022. As of December 31, 2022, there have been no material changes to our significant accounting policies and estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Results
of Operations</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Nine
Months Ended December 31, 2022 and December 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fiscal 2022 to Fiscal 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-indent: -8.65pt; padding-left: 8.65pt">Research and development &ndash; Three months ended</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,196,546</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,849,399</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">347,147</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.65pt; padding-left: 8.65pt">Research and development &ndash; Nine months ended</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,804,069</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,742,911</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,061,158</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.5</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses include personnel, consulting, product prototyping and other costs associated with the development
and initial production of our insulin pump product. We expense research and development costs as they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses increased for the three and nine months ended December 31, 2022 compared with the same period of
fiscal 2021, primarily due to increased engineering and operations personnel costs, prototype and production component and material costs
and higher stock-based compensation expenses. The increases in R&amp;D expenses were partially offset by a decrease in consulting costs,
as we reduced our utilization of consultants, as we increased our employee headcount and the consultants completed development of aspects
of our pump design and features. Our full-time R&amp;D employee headcount increased to 32 at December 31, 2022 from 18 at December 31,
2021. R&amp;D expenses included stock-based compensation expenses of $356,752 and $204,962 for the three months ended December 31, 2022
and 2021, respectively, and $1,034,674 and $459,989 for the nine months ended December 31, 2022 and 2021, respectively. We expect research
and development expenses to remain comparable for the remainder of fiscal 2023, as we continue to advance the development of our pump
product and develop our manufacturing process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General
and Administrative</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fiscal 2022 to Fiscal 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">General and administrative &ndash; Three months ended</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,161,351</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,981,665</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(820,314</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(41.4</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>General and administrative &ndash; Nine months ended</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,502,029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,156,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,654,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32.1</TD><TD STYLE="text-align: left">)%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of personnel and related overhead costs for finance, human resources, legal, marketing
and general management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative, or G&amp;A, expenses decreased for the three months ended December 31, 2022 compared with the same period of 2021,
primarily as a result of decreased stock-based compensation, personnel and benefit costs and legal fees, which in fiscal 2022 related
to our public offering and listing on the Nasdaq that was completed in February 2022. These decreases were partially offset by increased
consulting and professional services fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">G&amp;A
expenses decreased for the nine months ended December 31, 2022 compared with the same period of 2021, primarily as a result of decreased
stock-based compensation, personnel and benefit costs, consulting and legal fees and marketing costs. These decreases were partially
offset by increased accounting fees, travel costs and office-related expenses. Our full-time G&amp;A employee headcount increased to
3 at December 31, 2022 from 2 at December 31, 2021. G&amp;A expenses included stock-based compensation expenses of $282,753 and $1,016,774
for the three months ended December 31, 2022 and 2021, respectively and $1,085,839 and $2,280,098 for the nine months ended December
31, 2022 and 2021, respectively. We expect G&amp;A expenses to remain flat for the remainder of fiscal 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Years
Ended March 31, 2022 and March 31, 2021</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year-over-Year Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022&nbsp;to&nbsp;2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,729,240</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,083,303</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,645,937</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">89.3</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
research and development expenses include personnel, materials and supplies and other costs associated with the development of our insulin
pump product candidate. We expense research and development costs as they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development, or R&amp;D, expenses increased in fiscal 2022 compared with fiscal 2021 primarily due to increased consulting costs,
engineering and operations personnel, stock compensation expense and materials and supplies expenditures. Our R&amp;D employee headcount
increased to 23 at March 31, 2022, from 17 at March 31, 2021.&nbsp;R&amp;D expenses included stock-based compensation expenses of $758,938
and $390,045 for fiscal 2022 and fiscal 2021, respectively.&nbsp;We expect R&amp;D expenses to continue to increase in fiscal 2023, as
we complete the development of our pump product candidate, engage third parties to test our product and develop a low-volume manufacturing
process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General
and Administrative</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year-over-Year Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022&nbsp;to&nbsp;2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,197,162</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,253,412</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,943,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">121.2</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of personnel and related overhead costs for marketing, finance, human resources and general
management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses, or G&amp;A, increased in fiscal 2022 compared with fiscal 2021 primarily as a result of increased personnel
and consulting costs, stock-based compensation expenses and professional services fees, primarily related to our financing activities,
including our public offering that was completed in February 2022. G&amp;A expenses included stock-based compensation expenses of $3,272,964
and $837,533 for fiscal 2022 and fiscal 2021, respectively. We expect G&amp;A expenses to continue to increase in fiscal 2023, as we
will increase headcount as we expand our organization to support our anticipated growth and prepare for the expected commencement of
the commercialization of our product in late fiscal 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Interest
Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year-over-Year Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022&nbsp;to&nbsp;2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,752,229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">39,791</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,712,438</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,816.7</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Interest
expense consisted of interest expense incurred from our convertible promissory notes, including amortization of debt issuance costs,
and our promissory (bridge) note. We retired our outstanding debt in February 2022. See Notes 5 and 6 to the consolidated financial statements
included in this Registration Statement for additional disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>December 31, 2022</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a development-stage
enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred
operating losses and negative cash flows in each year due to costs incurred in connection with R&amp;D activities and G&amp;A expenses
associated with our operations. For the nine months ended December 31, 2022, we incurred a net loss of approximately $10.3 million. For
the years ended March 31, 2022 and 2021, we incurred net losses of approximately $18.6 million and $7.4 million, respectively. At December
31, 2022, we had a cash balance of approximately $7.7 million and an accumulated deficit of approximately $44.9 million. When considered
with our current operating plan, these conditions raise substantial doubt about our ability to continue as a going concern for a period
of at least one year from the date that of issuance of the consolidated financial statements included in in this prospectus. Our consolidated
financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should
we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to raise additional capital
through the sale of equity or debt securities to support our future operations, and we are currently seeking such additional financing.&nbsp;In
May 2022, we completed a registered direct offering of securities for net proceeds of approximately $7.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
operating needs include the planned costs to operate our business, including amounts required to fund research and development activities,
including clinical studies, working capital and capital expenditures. During the nine months ended December 31, we made capital expenditures
of approximately $574,000, as we have begun procuring equipment to develop a low-volume manufacturing production line to build our pump
product to demonstrate and develop our manufacturing process. We expect to incur increased capital expenditures for the remainder of
fiscal 2023. At December 31, 2022, we had outstanding, non-cancelable purchase orders for production equipment totaling $735,000, and
we expect to receive and pay for this equipment over the following six months. Our future capital requirements and the adequacy of our
available funds will depend on many factors, including, without limitation, our ability to successfully commercialize our product, competing
technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies
to enhance or complement our product offerings. If we are unable to secure additional capital timely, we will be required to curtail
our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the nine months ended December 31, 2022, we used $8,184,696 in operating activities, which primarily resulted from our net loss of $10,307,682,
as adjusted for stock-based compensation expenses of $2,120,513, $150,412 for issuances of shares of common stock in exchange for services
and depreciation and amortization expenses of $92,616, and increased by net changes in operating lease assets and liabilities of $37,761
and operating assets and liabilities $202,794 and other immaterial adjustments. For the nine months ended December 31, 2021, we used
$7,128,787 in operating activities, which primarily resulted from our net loss of $14,058,154, increased for a non-cash gain on the PPP
Note extinguishment of $368,780 and net changes in operating lease assets and liabilities of $34,422, as adjusted for changes to operating
assets and liabilities of $1,197,988, a loss on debt extinguishment of $1,321,450 stock-based compensation expenses of $2,740,086, $388,021
for issuances of shares of common stock in exchange for services, $149,994 for issuable shares of common stock in exchange for services,
depreciation and amortization expenses of $80,268 and interest expense of $1,454,762 for amortization of debt discount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the nine months ended December 31, 2022 and 2021, cash used in investing activities of $573,066 and $22,779, respectively, was for the
purchase of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
provided by financing activities of $7,372,347 for the nine months ended December 31, 2022 was attributable to net proceeds from the
issuance of common stock upon completion of an equity offering, net of underwriting fees and issuance costs. Cash provided by financing
activities of $5,887,199 for the nine months ended December 31, 2021 was primarily attributable to $4,137,199 of net proceeds from the
issuance of our convertible promissory notes, $250,000 from the sale of shares of common stock to officers of the Company and $1,500,000
from the issuance of a promissory bride note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Recently
Issued Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recently
Issued Accounting Pronouncements are detailed in Note 1 in the Notes to the Condensed Consolidated Financial Statements for the three
and nine months ended December 31, 2022, included in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_012"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular
Medical is a development<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-stage,</FONT> medical device
company focused on the design, development, and commercialization of an innovative insulin pump using modernized technology to
increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, the Company seeks to
fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently available
insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training
and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated &ldquo;super
users&rdquo; and expand the category into the mass market. The product candidate seeks to serve both the type 1 and the rapidly
growing, especially in terms of device adoption, type 2 diabetes markets.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Differentiation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that there are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of
people who require insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe, that by tailoring our
insulin pump to address such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader
market acceptance, an insulin pump must be easier to learn to use, be less time- consuming to operate, more intuitive to both patients
and physicians, and meet the standards for coverage by insurance providers so that co-payments required from patients are affordable
and the hurdles to insurance coverage are significantly reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Among
the more prominent issues are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt; font-size: 10pt; text-align: left">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><I>Complexity</I><FONT STYLE="font-style: normal">: Many existing pumps are highly complex and require significant technical expertise to use effectively. We believe such pumps were designed for &ldquo;super users,&rdquo; who have high levels of motivation and technical competence. The complexity of pumps </FONT>may be daunting to less technically inclined, less motivated users.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; padding: 0.25pt 0.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding: 0.25pt 0.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Cumbersome</I>: We believe that a majority of existing pumps are bulky and difficult to manage, requiring a means of carrying the pump around and up to 48 inches of tubing to the injection site to connect the catheter to a pump. The tubing and the cartridge, which holds the insulin, must be replaced every few days.&nbsp;&nbsp;This requires users to carry spare parts and other equipment adding to the difficulty of using the pump. In comparison, our product only requires a cartridge change every few days.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt 0.5pt">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify"><I>Cost</I><FONT STYLE="font-style: normal">: Costs associated with insulin pump therapy </FONT>can be high and prohibitive, especially for those on fixed or limited incomes. These costs vary by pump and insurance coverage, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible additional co-payments on consumables, can easily place current pumps out of reach for patients. This leads to limited or absent reimbursement/coverage and potentially high financial hurdles for patients to gain access.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify"><I>Outdated style</I><FONT STYLE="font-style: normal">: Consumer electronics devices have evolved in both form and function. Diabetes pumps have not experienced similar progress. We believe that consumers will be more receptive of products designed with the user experience in mind and that many have low tolerance for complex, difficult procedures for use and maintenance of products.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify"><I>Pump mechanism limitations</I><FONT STYLE="font-style: normal">: Traditional pumps generally utilize a syringe and plunger mechanism to deliver insulin. We believe this design limits the ability to reduce the size of the pump, and also potentially exposes the user to the unintended delivery of the full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse health events due to technical malfunctions related to traditional pump mechanism limitations deters the adoption of insulin pump therapy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
team has substantial knowledge of the diabetes industry and experience in developing, obtaining marketing authorization for, and bringing
insulin pumps to market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of
pumping insulin, can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady
flow) and bolus (mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid
pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to become the leader in expanding
access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super users, but &ldquo;diabetes
care for the rest of us.&rdquo; While our initial target market is people with Type 1 diabetes, we believe there is a substantial opportunity
to penetrate the type 2 marketplace, whether through our initial MODD1 pump or further simplification of our pump to address the type
2 marketplace.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
MODD1 is a high-precision pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to
learn, easy to use, and has a revolutionary design and technology that enable precision with low-cost manufacture and high reproducibility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Key
features include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Two
parts - one reusable, one disposable - snap together to form the working system;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">One
button interface, easy to learn and use;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">90-day
reusable, 3-day disposable;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposable
                                            portion removable at any time from an adhesive-backed retainer, which remains in place;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
external controller required, no charging, no battery replacement; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Slim
profile, lighter weight.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A proprietary survey of American healthcare payors representing 50
million covered lives (approximately 1/3 of U.S. covered lives) performed for us by industry leading survey firm ISA in 2019 has demonstrated
that payors are willing to grant equivalent or preferential coverage for a product with this feature set at launch in exchange for discounts
of approximately 20%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Diabetes
Classifications and Therapies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diabetes
is typically classified as either type 1 or type 2:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">T1D
is an auto-immune condition characterized by the body&rsquo;s nearly complete inability to produce insulin. It is frequently diagnosed
during childhood or adolescence<FONT STYLE="font-size: 10pt">, although it can sometimes have onset in adulthood. Individuals with T1D
require daily insulin therapy to survive.</FONT></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">T2D
represents over 90% of all individuals diagnosed with diabetes and is characterized by the body&rsquo;s inability to either properly
utilize insulin or produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements in
diet and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their diabetes
advances, patients often progress to requiring insulin therapies such as once-daily long-acting insulin and ultimately to intensified
mealtime rapid-acting insulin therapy. This represents an important portion of the diabetes market with an estimated 1.6 million T2D
intensively treated with insulin currently in the United States.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Glucose,
the primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and
health. In people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition known as hyperglycemia,
and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications, including blindness, kidney
disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia
can lead to confusion or loss of consciousness, often requiring a visit to the emergency room or, in certain cases, result in seizures,
coma, and/or death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
people with T1D, which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately
18% of people with T2D in the United States, or 4.7 million people, require insulin (basal alone represent 3.1 million and basal plus
mealtime represent 1.6 million) to manage their diabetes. In this prospectus, we refer to people with T1D and people with T2D who require
mealtime insulin as &ldquo;insulin-requiring people with diabetes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, there are two primary therapies
available for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body through syringes or
insulin pens, referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump to deliver mealtime insulin
boluses to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous insulin infusion, or CSII
therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy, primarily an
improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure and more
recently Time in Range (TIR) where a continuous glucose measuring device is used to calculate this test. Among other medical
benefits, a study conducted by Tandem Diabetes Care, Inc. in 2021 demonstrated that insulin pump use can decrease glucose
variability, reduce the number of hypoglycemic events, decrease the daily doses of insulin and reduce the fear of hypoglycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding these advantages, we believe the
difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well as high and often prohibitive
costs for both the patient and insurance provider has resulted not only in dissatisfaction among many existing pump users (fewer than
half purchase a new pump after the warranty expires, as noted in a Seagrove Partners 2021 study), but also has severely limited the adoption
rate of insulin pumps by a large segment of the MDI diabetes population, whom we refer to in this prospectus as &ldquo;Almost Pumpers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
define Almost Pumpers as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but because of past
experiences, pump shortcomings, cost, complexity, and time and learning required to adopt and utilize currently available insulin pumps,
continue to receive their daily insulin through MDI therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
initial focus for our insulin pump is the almost pumper segment population located in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research, along with marketplace data
provided by Seagrove Partners in 2023, estimates that 33% of Americans with T1D have an insulin pump and 28% of Americans with T1D
(44% of those who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes
Association guidelines of glucose control if their objections to the currently available suite of products can be overcome. They do
not want to closely manage their glucose levels and incur the associated time and effort involved. They are the Almost Pumpers. We
have developed what we believe to be the most technologically advanced delivery system overcome the objections and provided
motivation for this market. We believe that there are four addressable hurdles to adoption:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Usability:
the device needs to be easy to learn and to operate;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Affordability:
we will focus on overcoming copay and insurance hurdles rather than leaving the &ldquo;insurance journey&rdquo; to the clinician and
patient;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accessibility
and Education: we will seek to engage patients to sample this new technology by supplying clinicians with free samples and simple training
to allow people to see first-hand the typical barriers to adoption that have been overcome; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Service
and Support: where we will answer their questions and concerns during this diabetes experience.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe this conversion process, engaging people to try and thereby receive the benefits of our technology will substantially increase
adoption of insulin pumps among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease
that appears throughout the world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to
create an insulin pump that appeals to all Almost Pumpers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The International Diabetes Federation estimated
that, in 2019, approximately 460 million people were living with diabetes worldwide, and by 2045, this number will increase to approximately
700 million people.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An estimated 34 million people in the United States
live with diabetes. Within this group, T1D accounts for approximately 1.8 million people with the remainder being T2D. All people with
T1D require daily insulin. However, of the approximately 32.2 million people with T2D, about 1.6 million of them require multiple daily
injections of insulin to manage their diabetes. This represents a large and growing market with the effects of diabetes accounting for
roughly 25% of all healthcare dollars spent annually in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the National Diabetes HCP Survey
conducted by Seagrove Partners, LLC in 2021, approximately 25% of the 1.6 million highly insulin intensive T2D have considered going &ldquo;on
pump.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insulin pumps have been shown to provide a higher
level of care for insulin dependent people with diabetes and result in better glycemic control, fewer comorbidities, fewer trips to the
emergency room, and higher overall quality of life. They also result in lower overall costs to the healthcare system, reducing typical
expense per patient year from $27,195 to $16,992.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite these benefits, only 1 in 3 (33%) of the
1.8 million Americans with T1D and very few of the 1.6 million T2D intensively treated with insulin currently use an insulin pump, for
a total of approximately 670,000 current users, with only a slow increase of insulin pump use. The remaining 68% of T1D&rsquo;s and virtually
all of the T2D&rsquo;s rely on multiple daily injections (MDI) for glucose control. Decades of advances in technology advances have left
these non-pumpers at a significant disadvantage from a control perspective versus their &ldquo;pumping&rdquo; counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have identified a large segment of the market
that we refer to as &ldquo;Almost Pumpers.&rdquo; Almost Pumpers are those insulin-requiring people with diabetes (T1D and T2D) who feel
that they would adopt the pump if it were less expensive, less time consuming, less technically intimidating, and if there was no separate
controller. We believe that they represent approximately 32% of the T1D market correlating to a $1.9 billion growth opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insulin pumps on the market today require a
substantial amount of time to manage the therapy, have high out-of-pocket costs that place these technologies out of reach for a
large part of the population, and are feature-heavy with complex systems that we believe have hampered adoption and intimidated many
users. The most commonly used insulin pumps today require extensive training and hours of daily management. The average pump user
must go through 42 steps of setup and refill process every 72 hours to &ldquo;stay on track.&rdquo; Our product only requires nine steps for setup and refill every 72 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_004.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
current reluctance to adopt the insulin pump has had serious consequences on the healthcare system. In the United States, people living
with T1D have struggled to attain glycemic targets. A 2019 analysis of the large T1D Exchange clinical registry found that only 21% of
U.S. adults with T1D achieved the ADA A1c goal (&lt;7.0%). Further, according to a study published in JAMA Internal Medicine, researchers
found no significant improvements in diabetes care between 2005 and 2016, with persistent gaps in care related to socioeconomic status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another transition in the care of diabetes is
the measuring of glucose from finger-stick tests to continuous glucose monitoring, or &ldquo;CGM&rdquo;, sensors, which are wearable devices.
These sensors are placed under the skin and give a reading every five minutes of the user&rsquo;s glucose level. While Dexcom has been
a market leader in this field, the introduction and rapid adoption of the Freestyle Libre by Abbott Labs has made CGM easier and more
affordable, expanded the product category, and doubled the market size. The Freestyle Libre product is a more affordable, easier to use
and smaller version of the popular Dexcom, Inc. (Dexcom) CGM product. Now for the first time, there is an easy, less painful, i.e., no
more finger sticks, way for patients to have the data they need to understand more about their glucose levels and their insulin requirements.
Access to such data has motivated patients to ask their diabetes clinician how they can achieve better glycemic control and made them
more comfortable with using technology and wearables to treat their diabetes. Pumps offer a clear pathway to better control and better
overall care. We believe that the insulin pump market is ready for a similar transition as that experienced in the CGM space. MODD1 pump
represents a new and better offering to assist and induce a wide variety of patients to make the transition and bridge the void to superior
control by becoming a &ldquo;pumper.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the present pump marketplace is approximately
a $1.9 billion market, comprising 33% of T1D pumpers and a small group of T2D pumpers. Seagrove Partners estimates in its 2021 report
that 28% of T1D patients and 25% of T2D patients would adopt technology that was easier to use, access and pay for. We believe the total
addressable market approximates $3 billion, assuming revenue of $4,128 per patient, per year. We expect to spend approximately 15% of
our total revenue on discounts and free samples to encourage adoption of our pump product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are dedicated to helping all people with diabetes gain access to high quality care. We aim to help people with diabetes - especially
Almost Pumpers and the historically underserved communities - gain access to insulin pump technology by making it affordable and easy
to use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Diabetes
Care is at an Inflection Point</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that the insulin pump market stands at a crossroads as a confluence of events makes the timing for a new product introduction
ideal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020
was a very difficult year in diabetes. Between COVID-19 and a loss of glycemic control during quarantines and isolation, deaths from
diabetes rose by 17% in 2020 versus the prior year. This was sharpest among the young who saw deaths rise 29% in the 25-44 year old demographic.
This has created a pain point and a desire to find new and better solutions and has raised awareness among patients, caregivers, payors,
and policy makers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COVID-19
also encouraged (and required) trial and adoption of telehealth models and a great many people have found them to their liking with a
high proportion of patients and of health care providers (HCPs) that want to continue to use these technologies. We expect much of this
shift and newfound comfort with distance care models to persist and believes that this can provide a patient acquisition and engagement
model for insulin pumps and diabetes care, especially for pumps optimized for free trial and easy learning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
the same time, reimbursement for patch pumps has been increasingly moving to a pharmacy benefits manager (PBM) model, which simplifies
reimbursement which will further aid in a &ldquo;frictionless launch.&rdquo; This represents a fundamental shift in the insulin pump
market, making onboarding rapid and simplifying a previously complex and time-consuming &ldquo;insurance journey.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe these CGM users are increasingly interested
in adopting technology and wearables to manage their diabetes. We believe they are a natural market for a new type of pump if it can meet
their needs and address their objections and that the conjunction of the above trends represents a unique opportunity in the insulin pump
market&rsquo;s history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Diabetes
technology companies understand that we are at a turning point with new markets (T2D, T1D that are currently not using technologies).
This can be seen with increased discussion around this topic during recent national diabetes conferences, as well as but also an increase
in marketing promotion. For example, Dexcom purchased a $5.5 million 30-second spot during the 2021 Super Bowl.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All these recent changes support the high proportion
of T1D and T2D intensively treated with insulin that are considered as Almost Pumpers, a number that may grow in the next years and that
may be more reachable with adequate marketing strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Insulin Pump </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Instead
of building complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and
the user in mind. Using proprietary and patented methods of insulin measurement, we were able to eschew complex mechanisms and instead
built a product candidate using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality
curve that has existed in the insulin pump space and representing the first truly modern insulin pump design. This is a new kind of product
for a new kind of patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The production models of our low-cost insulin
pump are now undergoing the testing required to submit to the FDA for 510(k) clearance to market them in the United States. We continue
to devote, substantial time and resources to better understand the needs and preferences of Almost Pumpers and the specific patent/provider/payor
requirements to motivate change from MDI. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">MODD1
has several distinguishing features:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> 1 - The pump has a simple button to press
to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating cam to motivate the insulin into
the patient along with a low power Bluetooth and near-field communication (NFC) chips to optionally allow the patient to communicate
with their smart phone, tablet, or other mobile computing platform. Our mobile device application will be included in our 510(k) submission
and will be a part of our introductory product. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2
- The pump snaps together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power
source and a simple coin cell that allows it to run through the 80-hour life of the cartridge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3 - There is an infusion set (not shown) that
contains a soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle used to transfer insulin to the body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">4
- MODD1 comes with a variety of methods for the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching
to the body that has features for holding the pump to the patient; overwraps to hold the product candidate to the patient; and a velcro
strap with a base plate suitable for wrapping around the arm or leg of the patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
system will deliver a small continuous rate called a basal that will provide approximately 50% of the total daily dose required and the
user will use the on-pump button to administer boluses, typically before and after meals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
objective is to make the product candidate simple to acquire and take home, simple to learn and most importantly, simple to use to expand
the pump market, drive adoption and ultimately better clinical outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Technological
Advantages</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The adoption of new ultra-high volume technologies will result in far
easier manufacturing scale up as parts sourcing and assembly processes are far easier. The MODD1 was designed from the beginning for mass
manufacturing processes and &ldquo;lights out&rdquo; or near lights out production assembly lines whereby a minimal number of workers
will be required in our production facility. This advantage is compounded by the high availability and already optimized cost reduction
in its components. This has resulted in a cost of goods, estimated on the competitors&rsquo; announced margins and sales, 50% lower than
our closest patch pump competitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
adoption of modern, miniaturized technologies has led to numerous other advantages as well. Our MODD1 pump is smaller in overall volume
than Insulet&rsquo;s popular Omnipod product and has a lower profile to the skin. Despite this, it holds a full 3mL (300 units) of insulin
in line with full sized pumps such as Tandem and Medtronic, 50% more than the 2mL reservoir in the Omnipod. We believe that this volume
advantage over other patch pumps will be significant as 24% of type 1 and over 50% of the rapidly growing type 2 market require more
than 2mL of insulin every three days (the expected wear time of patch pumps).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, our new and patented pumping modality will provide what we believe is the most even (and thus closest to the function of a
healthy pancreas) delivery of basal insulin in the industry. Basal rate can be delivered almost continuously while other pumps are delivering
micro-boluses every 5 minutes for the Omnipod, Tandem and Medtronic pumps. We plan to demonstrate the impact of our system on glycemic
control in a future clinical study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The technology allows the patient to simply
add insulin and operate. The battery is included in each cartridge and the device is operated without a controller. Nothing needs
charging. MODD1 has been made push button simple to appeal to a wider audience of users.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
new technology has also made the MODD1 lighter than existing offerings. Compared to the Insulet Omnipod, MODD1 weighs 20 grams (vs. 26
grams) empty and 23 grams (vs. 28 grams) fully filled (despite carrying 50% more insulin), a reduction of 23% and 18%, respectively.
Also, unlike existing patch pumps, the MODD1 can be removed from the needle and taken off and replaced later if the user desires. This
avoids loss of insulin in a pump due to accidental dislodging of the soft canula, an issue that users have expressed considerable dissatisfaction
with on other patch pumps.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our approach to the care of diabetes can be further
enhanced by leveraging the MODD1 single-pumping chamber technology and reusable pump approach to apply to dual (or more) chamber pumping
solutions. We believe that such multi-chamber pumps will be integral to the realization of high time-in-range artificial pancreas solutions
that require no human intervention because of the application of, for instance, drugs to raise glucose levels coupled with drugs to lower
glucose. They will be the next step forward from the cumbersome and awkward solutions today that require the user to announce meals, count
and input carbohydrates, and adjust delivery for exercise and sleep to prevent overdosing of insulin. Instead, if a user overdosed insulin,
the user would simply pump in a drug to release sugar stores to raise it up. We believe that a pre-filled peel and stick patch pump with
the ability to function in a fully autonomous closed loop system with a CGM device, which is measuring and transmitting glucose-level
information, represents the next generation of diabetes care. We believe that we have demonstrated our technology and are securing intellectual
property protection on our approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe this technology, especially in dual
chamber, will open up numerous applications outside of diabetes where medication compliance of complex therapy regimes is difficult. Example
applications would include weight loss, fertility, and simplifying the delivery of complex multi-drug cocktails, especially those with
diverse and challenging dosing schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Solution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our proposed pump is being designed and developed
to address the aforementioned shortcomings of the existing pump market and to appeal to: (i) the substantial group of &ldquo;Almost-Pumpers&rdquo;
who may be interested in using an insulin pump, but have not done so because of the complexity, cost or cumbersome nature of existing
products, and (ii) people who are using one of the currently available insulin pumps but are dissatisfied with such products. We believe
that, owing to our new proprietary technology, our proposed insulin pump will be the simplest and least expensive product on the market
and the easiest for providers to prescribe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current pump has been built to test what
we believe to be our novel approach to insulin pumps. By providing a pump that we believe will establish industry standards in terms
of technology, simplicity to understand, ease of use and price, we believe our proposed pump will offer the vast majority of benefits
afforded by more expensive and complex pumps but remain accessible to a substantially greater percentage of diabetes sufferers requiring
daily insulin therapy.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe people generally will not use technology
that intimidates them. In addition, we believe that physicians are hesitant to prescribe such technology due to the level of training
and support required with the present pump product offerings. We believe mass-market products, such as is intended for our proposed pump,
must be &ldquo;user friendly&rdquo; and affordable. We believe this approach is fundamentally different from that applied to the existing
pump market today, where most pumps are continuously adding complex features appealing to super users and leaving the other people with
diabetes further behind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
current goal is to successfully design, develop and obtain all required regulatory approvals for our proposed insulin pump, and, thereafter,
commercialize the finished product. Our long-term goal is to become a leading provider of insulin pump therapy by focusing on both consumer
and clinical needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
achieve our above stated immediate and current goals, we intend to pursue the following business strategies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Use
of innovative proprietary technology.</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the substantial experience of Paul
DiPerna, our President, Chief Financial Officer, Treasurer and Chairman of our Board of Directors, in engineering design and innovative
technology in the medical device industry and, in particular, with the invention, market vision and technical development of insulin pumps,
we have generated proprietary technology that has been incorporated into our proposed insulin pump. We believe this technology allowing
for a two-part, yet small enough to wear, pump product, along with simplified mechanics for pumping, will greatly assist us in creating
a simpler, user-friendly pump. We believe the proposed design, engineering and technology being incorporated into our proposed pump will
make it substantially simpler and more affordable than those currently available. These features, together with the safety and reliability
of our proposed pump, are designed to create the next generation of insulin pumps that will feature important and well-differentiated
attributes compared to those currently available and make it available to consumers across mostly all socioeconomic groups in the United
States and around the world.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Keep
costs low during our design and development process.</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
attempt to ensure that we have sufficient funds to design, develop, and obtain all required regulatory approvals for our proposed insulin
pump without having to sacrifice quality and efficiency, we intend to maintain a tight budget and limit expenditures where possible.
We believe this will be possible because of the extensive knowledge and experience of Mr. DiPerna, not only in the diabetes industry
and more specifically in the insulin pump device market, but also his experience in designing and developing insulin pumps and other
medical devices and his ability to manage a small, focused development team. We currently expect that various other expenses, such as
product scale up, and sales and marketing costs, will not be incurred until such time as development work is completed and regulatory
approvals obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Employ
experienced engineers selected, supervised, and led by Mr. DiPerna, a highly experienced and respected engineer and executive in the
insulin pump industry.</I></B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
attempt to ensure our proposed insulin pump is &ldquo;state of the art,&rdquo; functional, and efficient, as well as to conserve funds,
substantially all of our employees will initially be hand-picked engineers under the leadership of Mr. DiPerna. We believe that there
is a strong pool of engineers with significant applicable experience and knowledge who we will be able to initially employ on a contract
and/or outsource basis to help us design and develop our proposed insulin pump. We believe by hiring such persons on an out-source basis,
we will save substantial resources and by having Mr. DiPerna lead and focus the team on technological and mechanical aspects of our proposed
insulin pump, we believe our team will be well guided, focused, cost efficient, and able to efficiently design and develop our product
candidate that we believe can eventually be a competitive and popular choice for people with insulin requiring diabetes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Commercialization
Strategy: Overcoming the Insurance Hurdles</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
goal is to establish MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and Type
2) and the newly motivated CGM users. We seek to grow the market by providing first-line insulin pump therapy that is well suited to
meet the needs of both diabetes patients requiring insulin and their clinicians.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that MODD1 is approximately 50% less expensive to manufacture than Omnipod. This low cost allows us to spend more on patients
and sampling. We believe that this will save money for payers because we expect to offer the pump with no upfront cost to patients. Expected
benefits of MODD1 include:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">20%
discount vs Insulet (PODD) will drive preferred status;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Designed to use Pharmacy Benefit Manager (PBM) codes as a disposable;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">No new code needed to be reimbursed at launch because MODD1 will be able to use existing CMS codes; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Saves provider an estimated $1,062/patient/year vs Omnipod, as we will offer providers discounts from the existing reimbursement code.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The MODD1 will be sampled and given to patients by the doctor or diabetes nurse educator at the time of the patient visit. When a patient is motivated to make change, our starter kit will make it easy for the clinician to initiate the new therapy that same day. We seek to eliminate the currently challenging &ldquo;insurance journey&rdquo; and product acquisition timeline and significantly reduce training time for the busy clinician, which we believe are all major hurdles to pump adoption. We intend to add telehealth support to help the patient throughout adoption and use and to facilitate greater collaboration between patients and their physicians.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Europe represents another large potential market
for MODD1, as approximately 60 million people in Europe live with diabetes. $161 billion is spent annually on diabetes healthcare costs
in the Europe based on data from a Seagrove Partners 2023 study. At present, cost containment is restricting pump uptake across Europe.
Current pump usage hovers between 10% and 20% in many markets. Single payor healthcare systems across the Europe traditionally attempt
to contain costs in the short term and seek low price technologies with moderate medical benefits. We anticipate MODD1 will offer a rebalance
of this risk/reward strategy in that payors will incur only minor incremental short-term costs with the benefit of longer -term cost savings
associated with reliable pump use. We intend to employ a partnership strategy across Europe following in-house managed regulatory and
pricing activities in the major markets (e.g., UK) and more cost receptive markets (e.g., Nordics). We are targeting European and United
Kingdom approval towards mid 2024. Our initial target market for our insulin pump is the Almost Pumper population located in the United
States followed quickly by an effort to obtain CE mark approval for distribution throughout Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Marketing
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">MODD1
tackles the most significant barriers to pump use-access and affordability-and makes it easier for clinicians, caregivers and individuals
to manage diabetes care. Our commercialization plan will drive adoption and is designed to expand the market and is intended to do the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Maximize
adoption with a comprehensive frictionless launch program. </B>We will seek to decrease the level of reimbursement effort and cost to
encourage HCPs to offer our pumps and encourage patient trials. Our product candidate reduces the technical hurdles to widen appeal,
new starts and increase adherence. We will encourage MDI patients who want or need more control to make the switch to the pump earlier
in their treatment-ideally right at diagnosis.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Leverage
technology to support sales and new patient acquisition</B>. We intend to set up tech-enabled sales teams backed with a full omnichannel
program to drive awareness and trial with HCPs and patients. We will focus on educating providers that our product candidate is simple
to teach and easy to support making it an ideal front line offering.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Facilitate
patient trials. To facilitate patient trials, we intend to:</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provide
a free <FONT STYLE="font-size: 10pt">sample pump, insurance verification, co-pay coupons and telehealth support, as may be allowed under
federal and state law, to patients thereby reducing outlay of time and money;</FONT></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Partner
with connected care companies to provide superb support of patients from trial through the first year; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that MODD1 will be the only insulin pump that patients can take home immediately from the doctor&rsquo;s office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Leverage MODD1 300-unit chamber to
                                                                                                                                                       increase adoption with Type 2 patients</B>. We believe MODD1 has a major advantage over existing patch pumps in that the chamber
                                                                                                                                                       carries enough insulin to meet the high doses many Type 2 patients need. We intend to promote this advantage and capture a
                                                                                                                                                       significant share of the existing Type 2 pump users as well as new starts.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Work
with key organizations and policy makers to pave the way for greater access to pumps. </B>We will<B>&nbsp;</B>promote MODD1 technology
among the underserved, who are typically low users of health technology. We will identify individuals, patient organizations, professional
societies, and policy and DEI organizations that are critically important to the adoption of new technologies in the diabetes space and
build relationships with these influential stakeholders.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Initiate
a clinical study program (with key diabetes centers</B>) to provide additional clinical support for MODD1 in special patient types and
clinical setting. After obtaining 510(k) clearance, we intend to conduct a soft launch and clinical research program in major markets
to pave the way for the full launch in late 2024. We will work with our advisors and key diabetes associations to educate the community
about the MODD1. In addition, we will conduct clinical studies to develop competitive claims and market expansion.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Work
with major health plans to establish MODD1 as the first line pump for Type 2 patients</B>. We believe MODD1 will be payor preferred for
both Type 1 and Type 2 patients. It was designed to attain preferential reimbursement and avoid the coverage pitfalls many other pumps
have experienced.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">o</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Payors want an effective product whereby the users realize the clinical benefit. We intend to launch with a discount program for payors of 20% to drive uptake.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Designed
to use existing PBM codes as a disposable</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
new reimbursement code: Reimbursed at launch</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tie-in
with the massive movement to telehealth. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020
saw personal telehealth go from beta test to mainstream. Customers and providers have become comfortable with it. There are only 4,000
patient-facing endocrinologists in the United States. The treatment of diabetes will be significantly enhanced with telehealth to drive
more volume and clinical enhancements through their practices. Telemedicine is a force multiplier for a small group of doctors to better
serve a large market. MODD1 was designed to be affordable enough for free sampling and trial, and simple enough for self-guided user
training. We believe that by combining telehealth support with MODD1, we will decrease the burden of diabetes care and improve the lives
of people with diabetes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-Launch/Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to initiate a &ldquo;soft launch&rdquo; following FDA clearance of the MODD1 device. Our plan is to select a group of clinicians
who are well trained, experienced and have the support infrastructure to take on initial patients and monitor them carefully to provide
clinical feedback on our performance to further refine our product candidate and support infrastructure prior to full commercial launch.
Many of these clinicians will have been those who assisted in the development of the MODD1 offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to continue to modify, refine and finalize our system to best meet:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
general needs and preferences of our Almost Pumper target market based upon our knowledge of the diabetes industry and information available
and/or obtained by us from Almost Pumpers and their caregivers; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">o</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The general guidelines of third-party payors, private and public insurance companies, preferred provider organizations and other managed care providers with particular focus on the guidelines established by the Center for Medicare and Medicaid Services, or &ldquo;CMS,&rdquo; which administrates the United States Medicare program. To assist us in making such modifications and refinements, we have retained independent consultants to focus on ensuring that our product candidate satisfies the existing coverage and reimbursement criteria of such third-party payors.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pump product comprises the pump, a disposable
cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user&rsquo;s body and the infusion set, which
includes a cannula to infuse the insulin into the body. We intend to manufacture the pump, the cartridge and the baseplate and purchase
the infusion set from third parties. Prior to shipment, our pump product will be packaged with an infusion set. In connection therewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">We have implemented automation machines in our facility that will be capable of assembling the cartridges at a rate sufficient to supply 15,000 patients (150,000 per month). </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Product packaging will initially be performed manually by our personnel, while the cartridge automation is refined. We expect to purchase and implement packaging automation equipment as the second phase of automation of the cartridge.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The infusion sets will be purchased from a third-party supplier to cost-effectively introduce our product and focus on our core expertise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have commenced working with a tier-one medical
product manufacturer to develop the tooling equipment required to produce the components used in our product. As discussed above, we
are in the process of implementing the cartridge assembly tooling equipment in our facility. Prior to product launch, we expect to transfer
the cartridge automation equipment to this contract manufacturer in early 2024 to verify and validate into our manufacturing process.
The medical product manufacturer would perform all manufacturing responsibilities to ensure compliance with FDA regulations. To date,
we have entered into a development agreement with this contract manufacturer for these development activities, but we have not yet entered
into a contract manufacturing agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FDA Clearance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FDA requires us to meet all applicable regulations for insulin pumps, a subcategory of infusion pumps, which are generally considered
Class II devices by the FDA. The design of the MODD1 pump has been completed, units have been built and testing is underway to verify
that the design meets all FDA requirements prior to submission. There are 17 specific tests required to submit for 510(k) clearance.
One of the more important tests addresses insulin stability, and we must demonstrate that our MODD1 pump does not damage the insulin
molecules during infusion. We have performed preliminary tests on insulin stability to increase the likelihood that we will pass these
tests. In an earlier version of our pump product candidate, we experienced issues demonstrating insulin stability. To address those issues,
we began working with a medical product manufacturer to develop a full commercial version of our product utilizing alternative component
parts. In addition, we must demonstrate: i) biocompatibility, meaning that we don&rsquo;t use materials that compromise long-term patient
safety, ii) occlusion detection, meaning that our device will inform the patient of a lack of insulin delivery and iii) cybersecurity
controls to ensure that our product has adequate security protection to ensure it cannot be hacked by a third party. Appropriate design
control and standard operating procedures have been implemented to allow us, when testing is completed, to submit for clearance under
the premarket notification (or 510(k)) process. To achieve this, we will continue to work closely with our regulatory consultants to
complete, finalize and file our submission to the FDA for 510(k) clearance and all other documentation necessary to obtain marketing
authorization of our insulin pump.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">We have engaged the FDA in three pre-submission conferences to ensure that we understand and meet the FDA&rsquo;s requirements, expectations and standards with regard to clearance of our product candidate. At these meetings, our team, including our FDA regulatory consultant, received FDA comments and guidance regarding our proposed submission during the pre-market notification period for 510(k) clearance (including any suggested modifications to the device description, indications for use or summary of supporting data contained in the notification);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">We are currently preparing our premarket notification, which will be part of our FDA submission.&nbsp;&nbsp;The purpose of the premarket notification is to demonstrate that our insulin pump is substantially equivalent to an insulin pump that has: i) previously been cleared and approved for use by the FDA and ii) legally marketed to the public and generally safe and effective for its intended use. We are also preparing other parts of our submission to the FDA, which will include the relevant results of our performance and human factor tests relating to, among other things, user effectiveness, sterility, pump efficiency and shipping compatibility demonstrating the accuracy and usability of our insulin pump, which we believe will satisfy the mandates of the FDCA and any applicable performance standards.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commercialization Steps</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To commercialize our product, we must successfully
complete a number of material steps including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Continue to refine and finalize the production version of our product to ensure it meets FDA requirements for 510(k) clearance;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: justify">the general needs and preferences of our Almost-Pumper target
market based upon our knowledge of the diabetes industry and information available and/or obtained by us from Almost Pumpers and their
caregivers;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">o</TD><TD STYLE="text-align: justify">the general guidelines of third-party payors, private and public
insurance companies, preferred provider organizations and other managed care providers with particular focus on the guidelines established
by the Center for Medicare and Medicaid Services, or CMS which administers the United States Medicare program, or Medicare. To assist
us in making such modifications and refinements, we have retained independent consultants to focus on ensuring that our product candidate
satisfies the existing coverage and reimbursement criteria of such third-party payors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Refine our manufacturing process during the submission process to qualify and test our product for transfer to a&nbsp;&nbsp;manufacturer; We recently moved to a larger facility and have purchased production-level tools and assembly equipment to manufacture our disposable cartridge and reusable pump.&nbsp;&nbsp;It is our intention to transfer these tools to a tier 1 medical product manufacturer prior to product launch;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Take such actions, if any, as may be required by the FDA as a condition to granting approval and providing 510(k) clearance for our insulin pump; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Hire and retain appropriate sales and marketing personnel to develop, implement and launch a promotional campaign for our insulin pump substantially focused on our target market.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As with any medical device attempting to enter
and successfully compete with existing products in an established and competitive marketplace, we will face significant hurdles to accomplish
the above steps to commercialization including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Obtaining FDA 510(k) clearance to market and sell our insulin pump to the public;</TD></TR>
  </TABLE>
<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Obtaining any other FDA-required authorizations with regard to our product candidate, as required by the FDCA;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Educating endocrinologists, physician&rsquo;s assistants, nurse practitioners and nurse educators, who typically prescribe pump usage, and certified diabetes educators and dieticians, who provide education and guidance to diabetes patients, as to what we believe to be the superior qualities of our product candidate;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Demonstrating to select general practitioners, who have historically been skeptical of the heightened support inherent in insulin pumps, our product candidate&rsquo;s ease of use and convenience;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; font-size: 10pt; text-align: justify">Ensuring that our final product does, in fact, meet the needs of Almost-Pumpers;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Overcoming the historic obstacles and reluctance of Almost-Pumpers to using insulin pumps to treat their diabetes; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">Ensuring that third party payors agree to cover all or a substantial portion of the purchase price and recurring costs of the use of our insulin pump.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Looking
Forward</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Going
forward, we expect to continue to evolve the MODD1 pumps and their capabilities and functionality both in response to patient needs and
as part of our current platform roadmap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">With our future MODD1+ product, we intend to seek to add phone-based control and Alternative Controller Enabled (&ldquo;ACE&rdquo;) and Automated Insulin Deliver (&ldquo;AID&rdquo;) capability to allow integration with popular continuous glucose monitors. This will expand our available market to include many existing pumpers. The new model has the same modular design and low-cost components as MODD1 and provides a much desired breakthrough for patients - two-factor command authentication that allows the wearer to use an application on his/her cell phone as the controller.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Additionally, adds AID control functionality via an &ldquo;ACE&rdquo; designation on the pump</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Any approved algorithm controller can drive insulin delivery in &ldquo;auto&rdquo; mode</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>CGM integration allows the controller to potentially adjust basal insulin rate for meals and exercise with an approved algorithm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">With our future MODD2 product, we will seek to move to a full-featured,
multi-chamber pump optimized for high time in range fully autonomous close loop insulin delivery utilizing the form factor and cost advantages
of its pumping designs to create an affordable, easy to use drug delivery system to realize the aspiration of true &ldquo;artificial
pancreas&rdquo; systems. We envision moving to a drug prefill model such that cartridges can be filled with insulin or other drugs and
shipped cold chain to patients, further simplifying the use process.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_008.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">As
of March 31, 2023, we had 38 employees all of whom are located in the United States and 37 of whom are full-time employees, consisting
of 36 in research and development and manufacturing operations and 2 in general and administrative functions.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today, in the United States, only three companies
are commercializing insulin pumps to T1D patients and insulin treated T2D patients:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Medtronic - commercializes the durable Minimed 770G and also
offers older durable pumps (670G, 630G etc.). In 2020, they held approximately 51% of the US insulin pump market.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Tandem - commercializes the durable t:slim X2 pump (with or without algorithms - Basal-IQ and Control-IQ). In 2020, they held approximately 28% of the US insulin pump market.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">Insulet - commercializes the disposable Omnipod patch pump with about 19% of the US market in 2020.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Older insulin pumps are also still being used
by a minority of patients previously provided by Roche or Animas though these pumps are not commercialized any longer. To a lesser extent,
the pumps described below are also used in small numbers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt; width: 50%"><IMG SRC="image_009.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><IMG SRC="image_010.jpg" ALT="">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">Medtronic pump and infusion set</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Tandem pump and infusion set</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These three insulin pump offerings are vying for
the attention of the most motivated and well insured in hope of converting them away from their reliance on MDI. The t:slim X2 and Minimed
770G each have a ~$5,000 list price that is covered through Durable Medical Equipment (DME) reimbursement and daily consumables, which
comprise cartridge, tubing and set for each three-day period, as well. These products have controllers integrated into the pump, making
them cumbersome and bulky, along with long (&gt; 20 inch) tubing between the pump and the cannular site. The Omnipod is the third offering,
a patch pump that attaches to your body for 72 hours and uses a separate controller to manage the insulin delivery process. Insurance
coverage for Omnipod can be provided via DME but also via Pharmacy Benefit (PB). The Omnipod patch pump is more expensive per day and
less accurate than other insulin pumps, according to a Mende 2022 study. Around 33% of people living with T1D are currently using insulin
pumps; of these, the vast majority are using one of these three offerings, a statistic that has not changed significantly over the last
5+ years.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_011.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of these pump products require extensive training
to initiate, two to four hours per day to use and manage on an ongoing basis. We believe this level of sophistication and effort along
with the cost and awkwardness of these products contribute to the limited uptake.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although there are purely mechanical pumps available
to patients with a small percentage of T2D patients using the Mannkind V-Go patch pump, a fixed basal rate and a button to deliver small
boluses. This pump is simple to use though gives little performance decision to the user (no possibility to change the basal rate, no
possibility to stop bolus doses, small reservoir, pump that needs to be changed every day, etc.). The last available patch pump is provided
by Cequr, called Simplicity, a bolus only delivery option without basal delivery that is yet to be commercially available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, Medtronic intends to launch a new
version of their insulin pump, the Minimed 780G, already available in some European countries with an advanced algorithm, but no obvious
change in hardware. Tandem is currently developing a patch pump called Mobi, coupled with an algorithm with potential launch expected
in 2024. The Mobi is expected to have a small 2mL reservoir and would be controlled by a separate unit, similar to the current Omnipod
product. Insulet has also launched the Omnipod 5, a similar patch pump to their offering today, that includes an AID algorithm.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximately 79% of the people who rely upon
MDI choose to not administer a shot outside of their house, which creates a poorly controlled group. MODD1 is designed to focus upon a
segment of these people and mobilize them via a simple, easy to use, affordable product.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_012.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on our ability to
obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary rights against infringers, and operate
without infringing on the proprietary rights of third parties. Because of the length of time and expense associated with developing new
products and bringing them through the regulatory approval process, the health care industry places considerable emphasis on obtaining
patent protection and maintaining trade secret protection for new technologies, products, processes, know-how, and methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2023, we held three U.S. utility
and no foreign patents, and we also held 22 pending applications in the United States and abroad. The patents and patent applications
cover various aspects of our technology, including our proprietary fluid movement technology and associated features of our insulin delivery
methodology. There can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued
to or licensed by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently
broad to protect our technology or provide us with a competitive advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our research
and development partners do business. The laws and regulations governing our business and interpretations of those laws and regulations
and are subject to frequent change. Our ability to operate profitably will depend in part upon our ability, and that of our research
and development partners and affiliates, to operate in compliance with applicable laws and regulations. The laws and regulations relating
to medical products and healthcare services that apply to our business and that of our partners and affiliates continue to evolve, and
we must, therefore, devote significant resources to monitoring developments in legislation, enforcement, and regulation in such areas.
As the applicable laws and regulations change, we are likely to make conforming modifications in our business processes from time to
time. We cannot provide assurance that a review of our business by courts or regulatory authorities will not result in determinations
that could adversely affect our operations or that the regulatory environment will not change in a way that restricts our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>FDA
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the United States, medical devices are strictly regulated by the FDA. Under the FDCA, a medical device is defined as &ldquo;an instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part
or accessory which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, in man or other animals; or intended to affect the structure or any function of the body of man
or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other
animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.&rdquo; This definition
provides a clear distinction between a medical device and other FDA regulated products such as drugs. If the primary intended use of
a medical product is achieved through chemical action or by being metabolized by the body, the product is usually a drug or biologic.
If not, it is generally a medical device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently developing an insulin pump delivery system, which is regulated by the FDA as a medical device under the FDCA, as implemented
and enforced by the FDA. The FDA regulates the development, testing, manufacturing, labeling, packaging, storage, installation, servicing,
advertising, promotion, marketing, distribution, import, export, and market surveillance of our medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Device
Premarket Regulatory Requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before being introduced into the U.S. market,
each medical device must obtain marketing clearance or approval from the FDA through the premarket notification (or 510(k)) process,
the <I>de novo</I> classification process, or the premarket approval, or &ldquo;PMA,&rdquo; process, unless they are determined to be
Class I devices or to otherwise qualify for an exemption from one of these available forms of premarket review and authorization by the
FDA. Under the FDCA, medical devices are classified into one of three classes - Class I, Class II or Class III - depending on the degree
of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness.
Classification of a device is important because the class to which a device is assigned determines, among other things, the necessity
and type of FDA review required prior to marketing the device. Class I devices are those for which reasonable assurance of safety and
effectiveness can be maintained through adherence to general controls which include compliance with the applicable portions of the FDA&rsquo;s
Quality System Regulation (the &ldquo;QSR&rdquo;), as well as regulations requiring facility registration and product listing, reporting
of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. The Class I
designation also applies to devices for which there is insufficient information to determine that general controls are sufficient to
provide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such assurance,
but that are not life-supporting or life-sustaining or for a use which is of substantial importance in preventing impairment of human
health, and that do not present a potential, unreasonable risk of illness or injury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class
II devices are those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and
there is sufficient information to establish &ldquo;special controls.&rdquo; These special controls can include performance standards,
post-market surveillance requirements, patient registries and FDA guidance documents describing device-specific special controls. While
most Class I devices are exempt from the premarket notification requirement, most Class II devices require a premarket notification prior
to commercialization in the United States; however, the FDA has the authority to exempt Class II devices from the premarket notification
requirement under certain circumstances. As a result, manufacturers of most Class II devices must submit premarket notifications to the
FDA under Section 510(k) of the FDCA (21 U.S.C. &sect; 360(k)) in order to obtain the necessary clearance to market or commercially distribute
such devices. To obtain 510(k) clearance, manufacturers must submit to the FDA adequate information demonstrating that the proposed device
is &ldquo;substantially equivalent&rdquo; to a &ldquo;predicate device&rdquo; that is already on the market. A predicate device is a
legally marketed device that is not subject to PMA, meaning, (i) a device that was legally marketed prior to May 28, 1976 (&ldquo;pre-amendments
device&rdquo;) and for which a PMA is not required, (ii) a device that has been reclassified from Class III to Class II or I or (iii)
a device that was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent
to the predicate device identified by the applicant in a premarket notification submission, the agency will grant 510(k) clearance for
the new device, permitting the applicant to commercialize the device. Premarket notifications are subject to user fees, unless a specific
exemption applies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
there is no adequate predicate to which a manufacturer can compare its proposed device, the proposed device is automatically classified
as a Class III device. In such cases, a device manufacturer must then fulfill the more rigorous PMA requirements or can request a risk-based
classification determination for its device in accordance with the de novo classification process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Devices
that are intended to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable
risk of harm or are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent to
a predicate device and for which safety and effectiveness cannot be assured solely by the general controls and special controls are placed
in Class III. Such devices generally require FDA approval through the PMA process, unless the device is a pre-amendments device not yet
subject to a regulation requiring premarket approval. The PMA process is more demanding than the 510(k) process. For a PMA, the manufacturer
must demonstrate through extensive data, including data from preclinical studies and one or more clinical trials, that the device is
safe and effective for its proposed indication. The PMA must also contain a full description of the device and its components, a full
description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA submission,
the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application
for review, it has 180 days under the FDCA to complete its review and determine whether the proposed device can be approved for commercialization,
although in practice, PMA reviews often take significantly longer, and it can take up to several years for the FDA to issue a final decision.
Before approving a PMA, the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance
with the QSR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>de novo</I> classification process allows
a manufacturer whose novel device is automatically classified into Class III to request down-classification of its device to Class I or
Class II, on the basis that the device presents low or moderate risk, as an alternative to following the typical Class III device pathway
requiring the submission and approval of a PMA application. We expect our MODD1 insulin pump product candidate to be a Class II device,
and we do not expect to be required to apply for down-classification under the <I>de novo</I> classification process.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinical trials are almost always required to support PMAs and are
sometimes required to support 510(k) and <I>de novo</I> classification submissions. All clinical investigations of devices to determine
safety and effectiveness must be conducted in accordance with the FDA&rsquo;s investigational device exemption (&ldquo;IDE&rdquo;) regulations
that govern investigational device labeling, prohibit promotion of investigational devices, and specify recordkeeping, reporting and
monitoring responsibilities of study sponsors and study investigators. If the device presents a &ldquo;significant risk,&rdquo; as defined
by the FDA, the agency requires the study sponsor to submit an IDE application to the FDA, which must become effective prior to commencing
human clinical trials. The IDE will automatically become effective 30 days after receipt by the FDA, unless the FDA denies the application
or notifies the sponsor that the investigation is on hold and may not begin until the sponsor provides supplemental information about
the investigation that satisfies the agency&rsquo;s concerns. If the FDA determines that there are deficiencies or other concerns with
an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval. The FDA may
also notify the sponsor that the study is approved as proposed or approved with specific requested modification. Furthermore, the agency
may withdraw approval of an IDE under certain circumstances. In addition, the study must be approved by, and conducted under the oversight
of, an institutional review board, or IRB, for each clinical site. If the device presents a non-significant risk to the patient according
to criteria established by the FDA as part of the IDE regulations, a sponsor may begin the clinical trial after obtaining approval for
the trial by one or more IRBs without separate authorization from the FDA, but must still comply with abbreviated IDE requirements, such
as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Post-Marketing
Restrictions and Enforcement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
a device is placed on the market, numerous regulatory requirements apply. These include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">submitting
and updating establishment registration and device listings with the FDA;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">compliance
with the QSR, which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including
maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">unannounced
routine or for-cause device facility inspections by the FDA, which may include our suppliers&rsquo; facilities; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">labeling
regulations, which prohibit the promotion of products for uncleared or unapproved (or &ldquo;off-label&rdquo;) uses and impose other
restrictions relating to promotional activities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">corrections
and removal reporting regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken to
reduce a risk to health posed by a device or to remedy a violation of the FDCA that may present a risk to health; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">post-market
surveillance regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional
safety and effectiveness data for the device.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under the FDA medical device reporting
(&ldquo;MDR&rdquo;) regulations, medical device manufacturers are required to report to the FDA information that a device has or may have
caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious
injury if the malfunction of the device or a similar device of such manufacturer were to recur. The decision to file an MDR involves a
judgment by the manufacturer. If the FDA disagrees with the manufacturer&rsquo;s determination, the FDA can take enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
MDR requirements also extend to health care facilities that use medical devices in providing care to patients, or &ldquo;device user
facilities,&rdquo; which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient
treatment facilities, but not physician offices. A device user facility must report any device-related death to both the FDA and the
device manufacturer, or any device-related serious injury to the manufacturer (or, if the manufacturer is unknown, to the FDA) within
10 days of the event. Device user facilities are not required to report device malfunctions that would likely cause or contribute to
death or serious injury if the malfunction were to recur but may voluntarily report such malfunctions through MedWatch, the FDA&rsquo;s
Safety Information and Adverse Event Reporting Program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
FDA also has the authority to require the recall of commercialized medical device products in the event of material deficiencies or defects
in design or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable probability that
the device would cause serious adverse health consequences or death. Manufacturers may, under their own initiative, recall a product
if any distributed devices fail to meet established specifications, are otherwise misbranded or adulterated under the FDCA, or if any
other material deficiency is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working
days after the recall is initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following
sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">warning
letters, fines, injunctions or civil penalties;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">recalls,
detentions or seizures of products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">operating
restrictions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays
in the introduction of products into the market;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">total
or partial suspension of production;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delay
or refusal of the FDA or other regulators to grant 510(k) clearance, PMA approvals, or other marketing authorization to new products;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">withdrawals
of marketing authorizations; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">in
the most serious cases, criminal prosecution.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled
and unannounced inspections by the FDA, and these inspections may include the manufacturing facilities of subcontractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Federal
Trade Commission Regulatory Oversight</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our advertising for our products and services
is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (the &ldquo;FTC&rdquo;) as well as comparable
state consumer protection laws. Under the Federal Trade Commission Act (the &ldquo;FTC Act&rdquo;), the FTC is empowered, among other
things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary
redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating
to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority,
and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or
judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products
in the future, or criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Healthcare
Law and Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>United
States</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
our MODD1 product candidate or our other future product candidates are approved in the United States, we will have to comply with various
U.S. federal and state laws, rules and regulations pertaining to healthcare fraud and abuse, including anti-kickback laws and physician
self-referral laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including,
in some instances, exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid. These laws
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or
providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or
the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare
program such as Medicare and Medicaid;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities
for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making
a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme
to defraud any healthcare benefit program or making false statements relating to healthcare matters;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations,
including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable
health information;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics
and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information
related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners
and physician ownership and investment interests; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">analogous
state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Some
state laws require pharmaceutical or medical device companies to comply with the relevant industry&rsquo;s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and device manufacturers to
report information related to payments to physicians and other health care providers or marketing expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">State
and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other
in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. We also may be subject to, or may in
the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose,
store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or
reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand
our customer base and thereby decrease our future revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
European Union approves the use of medical devices in a very different way. They have similar regulations and requirements to adhere
to, however a Notified Body, in the form of a private company, will represent their interests and is required to have sufficient expertise
to review all applications and the company&rsquo;s internal processes to ensure the safety of the product for which approval is being
requested. We are in the process of identifying a Notified Body to represent us, and we will follow our FDA submission process with regard
to preparing the materials and processes required to meet the regulations and gain clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>European
Union</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>EEA</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the European Economic Area, (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein),
or EEA, manufacturers of medical devices need to comply with the Essential Requirements laid out in Annex I to the EU Medical Devices
Directive (Council Directive 93/42/EEC) or with the General Safety and Performance Requirements (GSPR) of the new EU Medical Devices
Regulation (EU 2017/745). Compliance with these requirements is a prerequisite to be able to affix the CE mark to medical devices, without
which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements and the GSPR and obtain the
right to affix the CE Mark, manufacturers of medical devices must undergo a conformity assessment procedure, which varies according to
the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which
are not sterile), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its
products with the Essential Requirements and the GSPR, a conformity assessment procedure requires the intervention of a Notified Body,
which is an organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant
conformity assessment procedure, the Notified Body would audit and examine the Technical File and the quality system for the manufacture,
design and final inspection of the devices. The Notified Body issues a CE Certificate of Conformity following successful completion of
a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential
Requirements and GSPR. This Certificate entitles the manufacturer to affix the CE mark to its medical devices after having prepared and
signed a related EC Declaration of Conformity. As a general rule, demonstration of conformity of medical devices and their manufacturers
with the Essential Requirements and GSPR must be based, among other things, on the evaluation of clinical data supporting the safety
and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves
its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized
and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety
of the device are supported by suitable evidence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
manufacturers placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this
system, incidents must be reported to the relevant authorities of the member states of the EEA, and manufacturers are required to take
Field Safety Corrective Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with
the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics
and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly,
might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of
health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated
by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices.
Where appropriate, our products commercialized in Europe are CE marked and classified as either Class I or Class II.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
2017, the European Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike
directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e.,
without the need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate current
differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things, is intended
to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and in vitro
diagnostic devices and ensure a high level of safety and health while supporting innovation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Medical Device Regulation was meant to become applicable three years after publication (in May 2020). However, in April 2020, to allow
EEA national authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19
pandemic, the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the Medical Device Regulation
by one year. The Medical Device Regulation became applicable on May 26, 2021. Devices lawfully placed on the market pursuant to the EU
Medical Devices Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service until May
26, 2025. The Medical Devices Regulation, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">strengthens
the rules on placing devices on the market and reinforces surveillance once they are available;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishes
explicit provisions on manufacturers' responsibilities for the follow-up of the quality, performance and safety of devices placed on
the market;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">improves
the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">sets
up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
in the EU; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">strengthens
rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before
they are placed on the market.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Available
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as well as section 16 reports on Form 3, 4, or 5, are available free of charge on our website at www.modular-medical.com.
as soon as it is reasonably practicable after they are filed or furnished with the SEC. Our Code of Business Conduct and Ethics and the
charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee are also available on our website. The
Code of Business Conduct and charters are also available in print to any stockholder upon request without charge. Requests for such documents
should be directed to James Sullivan, at Modular Medical, Inc., 10740 Thornmint Road, San Diego CA 92127. Our Internet website and the
information contained on it or connected to it are not part of, or incorporated by, reference into this prospectus. Our filings with the
SEC are also available on the SEC&rsquo;s website at http://www.sec.gov.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
History and Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed as a corporation under the laws
of the State of Nevada in October 1998 under the name Bear Lake Recreation Inc. We had no material business operations from 2002 until
July 2017, when we acquired Quasuras, Inc., a Delaware corporation (&ldquo;Quasuras&rdquo;), in the Acquisition (as defined below). Prior
to the Acquisition, and, since at least 2002, we were a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange
Act of 1934 (the &ldquo;Exchange Act&rdquo;).<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Control Block Acquisition.</I></B><I>&nbsp;</I>On
April 26, 2017, pursuant to a Common Stock Purchase Agreement, dated as of April 5, 2017, by and among Manchester Explorer, LP, a Delaware
limited partnership, we and certain persons named therein, Manchester Explorer, LP purchased from us 966,667 shares of our common stock,
representing a number of shares in excess of a majority of our then issued and outstanding common stock, for a purchase price of $375,000
(the &ldquo;Control Block Acquisition&rdquo;), resulting in a change in control of the Company. In connection with the Control Block Acquisition,
James E. Besser was appointed president and a director and Morgan C. Frank was appointed the chief executive officer, chief financial
officer, secretary, treasurer and a director of ours and immediately following such appointments, our then officers and directors resigned.
Mr. Besser is the managing member of and Mr. Frank is the portfolio manager and a consultant to Manchester Management Company, LLC, a
Delaware limited liability company also referred to herein as MMC. MMC is the general partner of Manchester Explorer, LP and Jeb Partners,
L.P. (Jeb Partners, and together with Manchester Explorer, LP, collectively, the Purchasing Funds).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Acquisition. </I></B>On July 24, 2017,
pursuant to a Reorganization and Share Exchange Agreement, by and among us, Paul M. DiPerna, the sole officer, director and a controlling
stockholder of Quasuras, Messrs. Besser and Frank (Messrs. Besser, Frank and DiPerna, collectively, the &ldquo;3 Quasuras Shareholders&rdquo;),
and Quasuras (the &ldquo;Share Exchange Agreement&rdquo;), we acquired all of the issued and outstanding shares of Quasuras owned by
the 3 Quasuras Shareholders, resulting in Quasuras becoming our wholly-owned subsidiary (the &ldquo;Acquisition&rdquo;). Simultaneously
with the closing of the Acquisition, Manchester Explorer, LP cancelled the 2,900,000 shares of our common stock purchased in the Control
Block Acquisition, Mr. Besser resigned as our president and a director and Mr. Frank resigned as our chief executive officer, chief financial
officer, secretary, and treasurer, but remained a director, and Mr. DiPerna was appointed our chairman of the board of directors, chief
executive officer, chief financial officer, secretary and treasurer. Mr. DiPerna served as our chief executive officer until August 2021.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Quasuras,
Inc., a Delaware corporation, is our only subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2023, we entered into a new lease
agreement with a 48-month term, effective February 1, 2023, pursuant to which we leased approximately 24,000 square feet of a building
located in San Diego, California. We occupied this space in March 2023, as the lease for our former corporate facility in San Diego,
California expires June 30, 2023. In addition to the minimum lease payments under these leases, we are responsible for property taxes,
insurance and certain other operating costs under. We believe that our existing facilities are adequate to meet our current needs.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a Nevada corporation. Our corporate headquarters
and operating facilities are located at 10740 Thornmint Road, San Diego, CA 92127 Our telephone number is (858) 800-3500. We maintain
a website at www.modular-medical.com.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="a_013"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The following table sets forth information
on our executive officers and directors as of May 4, 2023. The term for each of our directors is generally three years or until their
successors are duly elected and qualified. We do not have any promoters or control persons. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.25pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.25pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 62%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">James Besser</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">47</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Paul DiPerna</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">64</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer, President, Treasurer and Director (Chairman
    of the Board of Directors)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">William J. Febbo(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Steven Felsher(2)(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">74</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Morgan C. Frank</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">50</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Philip Sheibley(2)(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">64</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Carmen Volkart(1)(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">62</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ellen O&rsquo; Connor Vos</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">67</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="padding-top: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Member of Compensation Committee</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Member of Audit Committee</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Member of Nominating and Governance Committee</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no family relationships between or
among any of our officers and members of our Board of Directors.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
principal occupations and positions for at least the past five years of our directors are described below. There are no family relationships
among any of our directors or executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>James &ldquo;Jeb&rdquo; Besser</I>. Mr. Besser
has served as our chief executive officer since February 23, 2022 and combines over 25 years of experience in alternative investments,
strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a Managing Member at Manchester Management Company,
LLC (&ldquo;Manchester&rdquo;), an investment management firm. Mr. Besser is also currently a director of River Stone Biotech, a development
stage specialty bioprocessing company. He holds a B.A. in history from Brown University. We believe that Mr. Besser is qualified to serve
as member of our board of directors due to his extensive prior experience conducting financial analysis of public companies (certain
of which were in the development stage), including such public companies&rsquo; management teams, products, including products in the
development stage, the potential markets for such products and other factors that could affect the likelihood and timing of success and
market penetration of such entities&rsquo; products as well as his capital raising activities. We believe this provides us with valuable
insights into the financial markets and investment criteria of institutional and other investors as well as capital raising activities.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Paul DiPerna.</I> Mr. DiPerna has been our
chairman, chief financial officer, president and treasurer since we acquired Quasuras in July 2017. He also served as our chief executive
officer from July 2017 until August 2021, and as our Secretary from July 2017 to October 2021. In 2015, he founded Quasuras, an early-stage
medical device company developing an insulin pump product, and, until its acquisition by us, he served as its chief executive officer
and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early stage medical device products and accumulate
technical talent. Our current pump product was one of such proposed products and was spun-out to Quasuras in 2015. From 2012 to 2015,
he served as a co-inventor at a private company with property rights in a medical device used for blood borne infection control called
the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes Care, Inc. (&ldquo;Tandem&rdquo;)
and held various positions, including as director, chief executive officer and chief technology officer and was primarily responsible
for the design concept and development of Tandem&rsquo;s initial insulin pump. Prior to that, he held executive and management positions
at Baxter Healthcare Corporation (&ldquo;Baxter&rdquo;) where he was tasked with identifying synergistic opportunities in the diabetes
industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to
acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment
and blood separation sciences industries. Mr. DiPerna holds approximately 70 patents in medical device and microfluidic technology and
has achieved numerous product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna
received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of
Massachusetts and has spent over 35 years in the medical-device industry. We believe that Mr. DiPerna is qualified to serve as the chairman
of our board of directors due to his extensive knowledge and experience in the medical-device industry generally, and, in particular,
with regard to insulin pumps and the diabetes industry, as well as his management and leadership experience from holding director and
senior executive positions in other public and private companies and leading project development teams of medical device companies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>William
J. Febbo. </I>Mr. Febbo was appointed to our board of directors in January 2020. He is currently the Chief Executive Officer and a director
of OptimizeRx Corporation, a digital health company focused on bringing life sciences support to patients and providers, having joined
the company in 2016. Since April 2022, he has served as member of the board of directors of Augmedix, Inc., a Nasdaq-listed provider
of automated medical documentation and data services. Mr. Febbo founded Plexuus, LLC, a payment processing business for medical professionals
in September 2015 and remained its Chairman from September 2015 to December 2020. From April 2007 to September 2015, he served as Chief
Operating Officer of Merriman Holdings, Inc., an investment banking firm, where he assisted with capital raises in the technology, biotechnology,
clean technology, consumer and resources industries. Mr. Febbo was a co-founder of, and from September 2013 to September 2015 served
as Chief Executive Officer of, Digital Capital Network, Inc. a transaction platform for institutional and accredited investors. He was
a co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel, LLC, a provider of market intelligence
and communications for the pharmaceutical, biomedical, and medical device industries. Since 2017, Mr. Febbo has been a faculty member
of the Massachusetts Institute of Technology&rsquo;s linQ program, which is a collaborative initiative focused on increasing the potential
of innovative research to benefit society and the economy. Since 2004, he has been a board member of the United Nations Association of
Greater Boston, a resource for the citizens of Greater Boston on the broad agenda of critical global issues addressed by the United Nations
and its agencies. He holds a B.A. in international studies and Spanish from Dickinson College. We believe that Mr. Febbo is qualified
to serve on our board of directors because of his wealth of experience in building and managing health services and financial businesses.
Mr. Febbo brings more than 20 years of experience in building and managing health services and financial businesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2018, the Financial Industry Regulatory
Authority (&ldquo;FINRA&rdquo;) accepted a Letter of Acceptance, Waiver and Consent (the &ldquo;Consent&rdquo;) submitted by Mr. Febbo.
Without admitting or denying the findings, Mr. Febbo consented to the sanctions and to the entry of findings that he permitted Merriman
Capital, Inc. to conduct a securities business while below its net capital requirement. From August 2012 to October 2015, he was the
Financial and Operations Principal (&ldquo;FinOp&rdquo;) for a registered broker-dealer, Merriman Capital, Inc. (&ldquo;Merriman&rdquo;).
During certain months, while Mr. Febbo was FinOp, FINRA found that certain of Merriman&rsquo;s net capital filings with FINRA were inaccurate
because of the method by which Merriman calculated net capital and that, when corrected, it was retroactively determined that Merriman
had operated below its minimum net capital requirements. Mr. Febbo, as FinOp, signed certain of these reports and was thus held responsible.
Based on the Consent, in settlement, Mr. Febbo, who was then no longer registered with any broker-dealer, accepted a fine of $5,000,
a 10-business day suspension from acting as FinOp for any FINRA member and required to requalify by examination for the Series 27 license
before again acting in a FinOp capacity.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Steven
Felsher. </I> Mr. Felsher was appointed to our board of directors in November 2021. Mr. Felsher is an experienced executive with respect
to finance, administration, governance and other aspects of public and private company management. He has served as a member of the board
of directors of Signal Hill Acquisition Corp., a special purpose acquisition company, since March 2021. From August 2018 to July 2020,
he served as a member of the board of directors of Sito Mobile, Inc., a publicly-traded company that provided customized, data-driven
solutions for brands spanning all forms of media. From January 2011 to June 2019, Mr. Felsher was a senior advisor at Quadrangle Group
LLC, a private investment firm focused on the information and communications technology sectors. He spent a substantial portion of his
career with Grey Global Group Inc., a global marketing services company, where he served as a senior executive from 1979 until 2007,
most recently as vice chairman and chief financial officer. He holds a BA in classical Greek from Dickinson College and a J.D. from Yale
University School of Law. We believe that Mr. Felsher is qualified to serve on our board of directors because of his extensive business
experience with administration, governance, capital allocation and other aspects of public and private company management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Morgan
C. Frank.</I> Mr. Frank was appointed to our board of directors in April 2017. In August 2022, he was appointed as chairman of the board
of directors of SANUWAVE Health, Inc., a publicly-traded provider of wound-care products. Mr. Frank has worked with Manchester, LP since
May 2002, and, prior to such time, he was a founder and managing director at First Principles Group, a boutique consultancy and principal
investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin outs. Prior to such
time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco based hedge fund
and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing in primary research to develop
investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at Paine Webber, Mr. Frank was a
currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from Brown University. We believe that
Mr. Frank is qualified to serve as member of our board of directors due to his extensive prior experience conducting financial analysis
of public companies (certain of which were in the development stage), including such public companies&rsquo; management teams, products,
including products in the development stage, the potential markets for such products and other factors that could affect the likelihood
and timing of success and market penetration of such entities&rsquo; products as well as his capital raising activities. We believe this
provides us with valuable insights into the financial markets and investment criteria of institutional and other investors as well as
capital raising activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Philip
Sheibley.</I> Mr. Sheibley was appointed to our board of directors in November 2021. Mr. Sheibley is an experienced executive and venture
capitalist. Since 2011, he has served as a principal at Alumni Investment Partners, a private equity firm. From 1981 to 2010, Mr. Sheibley
served as a management and technology consultant with Accenture, where he focused on the life sciences area, holding a variety of leadership
positions, including North American industry director for life sciences and global lead for management consulting. Mr. Sheibley holds
a B.S. in industrial and systems engineering with a business minor from Lehigh University. We believe that Mr. Sheibley is qualified
to serve on our board of directors because of his extensive business experience in the life sciences area and experience with venture
capital investment and consulting, including financing transactions for early-stage and scale-up stage companies, assisting with scale-up
strategy/execution, and participating as a board member in the medical products industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Carmen
Volkart.</I> Ms. Volkart<B>&nbsp;</B>was appointed to our board of directors in December 2019. She has served as chief financial officer
of Natureworks LLC, an advanced materials company offering a portfolio of renewably-sourced polymers, since October 2018. Ms. Volkart
served as a member of the board of directors, including as a member of the audit committee of Antares Pharma, Inc., a Nasdaq-listed,
specialty pharmaceutical company, from October 2021 to May 2022, when it was acquired by another Nasdaq-listed company. From October
2012 to July 2018, she served as chief financial officer and, for a portion of that time, as senior vice president of commercialization
for NxThera, Inc., a medical device company pioneering the application of convective radiofrequency thermotherapy to treat endurological
conditions. Ms. Volkart served as global chief financial officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial
officer, corporate secretary, compliance officer and treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, she held various
executive and financial positions at American Medical Systems, Inc., Medtronic, Inc. and Honeywell, Inc. Ms. Volkart holds a B.S. in
accounting from the University of North Dakota and an MBA with a concentration in strategic management from the University of Minnesota.
We believe that Ms. Volkart is qualified to serve on our board of directors because of her substantial financial and public-company experience,
as she has served as chief financial officer at multiple medical device and other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Ellen
O&rsquo;Connor Vos.</I> Ms. Vos was appointed to our board of directors in May 2021 and served as our chief executive officer from August
2021 until February 23, 2022. Ms. Vos has served as a member of VosHealth LLC since November 2020. Prior to that, she served as the president
and chief executive officer of the Muscular Dystrophy Association from October 2017 to November 2020. Previously, Ms. Vos had been chief
executive officer of ghg | greyhealth group from 1996 to 2017, and she has been a champion of using digital capabilities to improve the
public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a publicly-traded digital health company, and the Jed Foundation,
a leading nonprofit dedicated to protecting the emotional health of college students, and was a founding board member of MMRF, a pioneering
cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred University. We believe that Ms. Vos is qualified to serve on
our board of directors because of her executive experience and extensive executive skills in digital marketing, commercialization and
communications in the healthcare industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Involvement
in Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as described above with regard to Mr. Febbo, to our knowledge, none of our executive officers or our directors has, during the last ten
years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">had
any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association
of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that
time;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">been
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or
federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type
of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with
persons engaged in any such activity;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">been
found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated
a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">been
the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation
of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance
companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty
or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire
fraud or fraud in connection with any business entity; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">been
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange
Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated
with a member.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
our knowledge, there are no material proceedings to which any director, officer or affiliate of ours, any owner of record or beneficially
of more than 5% of any class of voting securities of us, or any associate of any such director, officer, affiliate of ours, or security
holder is a party adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Arrangements
for Appointment of Directors and Officers </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Reorganization and Share Exchange
Agreement, hereinafter referred to as the Share Agreement, dated as of July 24, 2017, by and among us, Quasuras, Mr. DiPerna and the
other stockholders of Quasuras, until July 24, 2022, our board of directors was required to consist of no more than five and no less
than two directors of which (i) Manchester Explorer, LP has the right to appoint two directors, pursuant to which Manchester Explorer,
LP appointed Mr. Frank and Ms. Volkart, and (ii) Mr. DiPerna, in addition to being our chairman of the board, had the right to appoint
two additional directors, pursuant to which he appointed Liam Burns, who resigned from our board of directors in December 2021, and Mr.
Febbo. In May 2021, the parties amended the Share Agreement and removed Manchester Explorer, LP&rsquo;s and Mr. DiPerna&rsquo;s rights
to appoint directors. In addition, the parties agreed that Mr. DiPerna shall remain chairman of our board of directors until July 2022;
provided, that in the event Mr. DiPerna resigns or is otherwise replaced as our chief executive officer, Mr. DiPerna shall remain as
chairman of our board of directors for an additional period of three years. Following such amendment, our board of directors increased
the size of the board to six members and, on May 18, 2021, appointed Ms. Vos as a director to our board.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
DiPerna Employment and Related Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into an employment agreement dated
August 1, 2018, with Mr. DiPerna pursuant to which Mr. DiPerna is employed by us as our president for an initial two-year term with automatic
one-year renewals. Pursuant to such agreement, we agreed to pay Mr. DiPerna: (i) an annual salary of $200,000 in cash, (ii) $100,000
per year in fully-vested stock options granted monthly at an exercise price determined by our board of directors in its sole discretion
and (iii) an annual bonus of $300,000, payable at the discretion of our board of directors, either in shares or in cash. If the board
chooses to pay the bonus in shares, such shares will be valued at a price determined by our board of directors. Pursuant to such employment
agreement (i) if (a) we terminate Mr. DiPerna&rsquo;s employment without cause or he resigns with good reason, we will pay Mr. DiPerna
a lump sum of $200,000, and (b) we terminate Mr. DiPerna&rsquo;s employment for cause, we are not obligated to make any severance payment
and Mr. DiPerna will receive only his base compensation through the last day of his employment, (ii) upon Mr. DiPerna&rsquo;s death or
disability, he will receive his base compensation through the last day of his employment and will remain eligible for all applicable
benefits relative to death or disability pursuant to any plans that we have in place at such time, and (iii) upon a change of control
(as defined in the employment agreement), Mr. DiPerna will be paid a lump sum of $100,000 within sixty days of the time at which such
change of control takes place.&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
May 2020, we amended our employment agreement with Mr. DiPerna to provide that in the event of a change in control:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">within
60 days of the date the change in control occurs, Mr. DiPerna shall be paid by us or our successor in interest a lump sum cash payment
equal to 12 months of Mr. DiPerna&rsquo;s then annual Base Compensation (as defined in the employment agreement); and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
prior to such change of control, any unvested stock options or other unvested securities of ours issued to Mr. DiPerna shall automatically
accelerate and immediately become fully vested and exercisable.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
June 2020, our board of directors approved an amendment to the employment agreement to provide that Mr. DiPerna&rsquo;s base salary would
be paid entirely in cash commencing July 1, 2020. The payment of the additional cash component of Mr. DiPerna&rsquo;s annual base salary
($8,333.33 per month) was initially deferred (the &ldquo;Deferred Salary&rdquo;) and accrue for Mr. DiPerna&rsquo;s benefit until we
have received $5,000,000 of cumulative gross proceeds of financing, at which time the Deferred Salary shall be paid to Mr. DiPerna and
the salary deferrals will cease. <FONT STYLE="background-color: white">The salary deferrals ceased and the Deferred Salary was paid to
Mr. DiPerna in May 2021. In August 2021, Mr. DiPerna resigned as our chief executive officer, and he continues to serve as our president,
chief financial officer, treasurer and chairman of our board of directors.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 15, 2021, our board of directors authorized a $50,000 bonus for Mr. DiPerna for fiscal 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a change of control occurred on March 31, 2022, under his employment agreement, Mr. DiPerna would be entitled to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">payment
of a lump sum of $300,000 within 60 days of the time at which such change of control takes place; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">accelerated
vesting of 27,778 shares of common stock under an unvested stock option. The value of the shares subject to accelerated vesting is calculated
as the intrinsic value per share multiplied by the number of shares that would become fully vested upon a change of control. The intrinsic
value per share would be calculated as the excess of the closing price of the common stock of $4.40 on the Nasdaq Capital Market on March
31, 2022 over the exercise price of the option. As of March 31, 2022, the intrinsic value was zero.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with our acquisition of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as of July 24, 2017, with
Quasuras and Mr. DiPerna, pursuant to which Mr. DiPerna transferred to us all intellectual property rights owned directly and/or indirectly
by him related to our business. Separately, we agreed to pay Mr. DiPerna, as part of his compensation for services to be performed for
us, pursuant to a royalty agreement, certain fees based upon future sales, if any, of our potential product subject to a maximum $10,000,000
cap on the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Vos Employment Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 11, 2021, we entered into a two-year employment agreement (the &ldquo;Agreement&rdquo;) with Ms. Vos for her service as our chief
executive officer, and the Agreement renews for one-year terms, unless either party provides the other with 90-day prior written notice
of termination. The Agreement provided that Ms. Vos was entitled to total base compensation of $300,000 annually, as follows: a cash
salary of $250,000 per year (the &ldquo;Cash Salary&rdquo;), plus deferred salary of $50,000 per year (the &ldquo;Deferred Salary&rdquo;
and, together with the Cash Salary, the &ldquo;Base Compensation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">On
February 23, 2022, Ellen O&rsquo;Connor Vos informed the board of directors the Company that she was resigning from her position as chief
executive officer of the Company, effective immediately (the &ldquo;Resignation&rdquo;). In connection with the Resignation, the Company
and Ms. Vos entered into a Severance and Release Agreement dated February 23, 2022 (the &ldquo;Separation Agreement&rdquo;). Pursuant
to the Separation Agreement, Ms. Vos is entitled to receive separation payments in an aggregate gross amount of $375,000. Under the terms
of the Separation Agreement, the vesting of an option to purchase 362,452 shares of the Company&rsquo;s common stock, which was granted
to Ms. Vos on August 11, 2021, ceased on May 24, 2022 and the remaining unvested shares were forfeited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>James
Besser</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
compensation for his services as Chief Executive Officer, Mr. Besser is paid de minimis compensation of $1.00 per year.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Communications
with our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stockholders who desire
to communicate with the board of directors, or a specific director, may do so by sending the communication addressed to either the board
of directors or any individual director, c/o Modular Medical, Inc., 10740 Thornmint Road, San Diego, California 92127. These communications
will be delivered to the board of directors, or any individual director, as specified.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has undertaken a review of the independence
of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to
exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our board of directors has determined
that William Febbo, Steven Felsher, Philip Sheibley and Carmen Volkart are &ldquo;independent directors,&rdquo; as defined under the
rules of Nasdaq.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Board
Leadership Structure and Role in Risk Oversight</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Due
to the small size and early stage of the Company, we have not adopted a formal policy on whether the chairman and chief executive officer
positions should be separate or combined. Since 2017, Mr. DiPerna has been serving as our chairman, and, since February 23, 2022, Mr.
Besser has been serving as our chief executive officer. Our board of directors has oversight responsibility for our risk management processes.
Our board of directors receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate,
regarding our assessment of risks. Our board of directors will focus on the most significant risks facing us and our general risk management
strategy, and also ensure that risks undertaken by us are consistent with our appetite for risk. While our board of directors oversees
our risk management processes, management is responsible for day-to-day risk management processes. We believe this division of responsibilities
is the most effective approach for addressing the risks facing us and that the leadership structure of our board of directors supports
this approach.<B>&nbsp;<I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have established an audit committee, a compensation committee, and a nominating and governance committee. Each committee&rsquo;s members
and functions are described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
board of directors established the audit committee (the &ldquo;Audit Committee&rdquo;) for the purpose of overseeing the accounting and
financial reporting processes and audits of our financial statements. The Audit Committee also is charged with reviewing any internal
control violations under our whistleblower policy. The responsibilities of our audit committee are described in the Audit Committee Charter
adopted by our board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Volkart, Mr. Felsher and Mr. Sheibley are
the current members of the Audit Committee. Mr. Felsher serves as the chairperson and has been designated by the board of directors as
the &ldquo;audit committee financial expert,&rdquo; as defined by Item 407(d)(5) of Regulation S-K under the Securities Act and the Exchange
Act. That status does not impose duties, liabilities or obligations that are greater than the duties, liabilities or obligations otherwise
imposed on her as a member of the audit committee and the board of directors, however. Our board of directors has determined that each
of our Audit Committee members satisfies the &ldquo;independence&rdquo; requirements of the Nasdaq listing rules and meets the independence
standards under Rule 10A-3 under the Exchange Act.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
board of directors established the compensation committee for the purpose of reviewing, recommending and approving our compensation policies
and benefits, including the compensation of all of our executive officers and directors. Mr. Febbo and Ms. Volkart are the current members
of the compensation committee, and Mr. Febbo serves as the chairperson. Each of our Compensation Committee members satisfies the &ldquo;independence&rdquo;
requirements of the Nasdaq listing rules and meets the independence standards under Rule 10A-3 under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
compensation committee is responsible for reviewing, recommending and approving our compensation policies and benefits, including the
compensation of all of our executive officers and directors, and it also has the principal responsibility for the administration of our
equity incentive plan. The responsibilities of our compensation committee are more fully described in the Compensation Committee Charter
adopted by our board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Nominating
and Corporate Governance Committee</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Nominating and Governance Committee consists of Mr. Sheibley and Mr. Felsher, and Mr. Sheibley serves as the chairperson. Each of the
members of our Nominating and Governance Committee satisfies the &ldquo;independence&rdquo; requirements of the Nasdaq listing rules
and meets the independence standards under Rule 10A-3 under the Exchange Act. The Nominating and Governance Committee will consider persons
recommended by stockholders for inclusion as nominees for election to our board of directors if the information required by our bylaws
is submitted in writing in a timely manner addressed and delivered to our secretary at the address of our executive offices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Nominating and Governance
Committee will identify and evaluate nominees for our board of directors, including nominees recommended by stockholders, based on numerous
factors it considers appropriate, some of which may include strength of character, mature judgment, career specialization, relevant technical
skills, diversity, and the extent to which the nominee would fill a present need on our board of directors. The responsibilities of our
Nominating and Governance committee are more fully described in the Nominating and Governance Committee Charter adopted by our board
of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Code of Business Conduct
and Ethics for Employees, Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have adopted a Code
of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and members of our board
of directors. The Code of Conduct is available on our website at www.modular-medical.com. Our Nominating and Governance Committee is responsible
for overseeing the Code of Conduct, and our board of directors must approve any waivers of the Code of Conduct. In addition, we intend
to post on our website all disclosures that are required by law concerning any amendments to, or waivers from, any provision of the Code
of Conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Board Diversity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We seek diversity in
experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our board of directors. We
believe directors should have various qualifications, including individual character and integrity; business experience; leadership ability;
strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters; communications
and interpersonal skills; and the ability and willingness to devote time to our company. We also believe the skill sets, backgrounds,
and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional experience,
background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis of race, religion,
national origin, sex, sexual orientation, disability, or any other basis proscribed by law. The assessment of prospective directors is
made in the context of the perceived needs of our board of directors from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">All of our directors
have held high-level positions in business or professional service firms and have experience in dealing with complex issues. We believe
that all of our directors are individuals of high character and integrity, are able to work well with others, and have committed to devote
sufficient time to the business and affairs of our company. In addition to these attributes, the description of each director&rsquo;s
background set forth above indicates the specific qualifications, skills, perspectives, and experience necessary to conclude that each
individual should continue to serve as a director of ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Summary Compensation
Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table sets
forth compensation information for the years ended March 31, 2022 and 2021 for each of our named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<BR> Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Awards<BR> ($)(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<BR> Incentive<BR> Plan<BR> Compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All<BR> Other<BR> Compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Paul DiPerna,<BR> President,&nbsp;Chief&nbsp;Financial&nbsp;Officer,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">2022</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">370,833</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">370,833</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Treasurer and Chairman(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">James E. Besser,<BR> Chief Executive Officer(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Ellen O&rsquo;Connor Vos,<BR> Chief Executive Officer(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,414,645</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">409,662</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,957,961</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stephen Daly, <BR> Chief Commercial Officer(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">234,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">(1)</TD>
    <TD STYLE="text-align: justify">Award amounts reflect the aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC Topic 718. The assumptions used to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated financial statements included in this Registration Statement. These amounts do not reflect actual compensation earned or to be earned by our named executive officers.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(2)</TD>
    <TD STYLE="text-align: justify">From August 2018 until June 30, 2020, Mr. DiPerna&rsquo;s $300,000 annual salary was paid $200,000 in cash and $100,000 in fully-vested stock options granted monthly.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(3)</TD>
    <TD STYLE="text-align: justify">Includes payment of $70,833 of deferred salary.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(4)</TD>
    <TD STYLE="text-align: justify">Earned as a bonus of which $22,000 was paid on April 30, 2021, and the remainder was paid in quarterly installments commencing on July 15, 2021.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(5)</TD>
    <TD STYLE="text-align: justify">Ms. Besser was appointed our chief executive officer in February 2022 and is paid&nbsp;<I>de minimis</I>&nbsp;compensation of $1.00 per year.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(6)</TD>
    <TD STYLE="text-align: justify">Ms. Vos was appointed our chief executive officer in August 2021 at an annual cash salary of $250,000 per year plus deferred salary of $50,000 per year. She resigned as our chief executive officer in February 2022. The compensation amounts disclosed in the table above exclude amounts paid to Ms. Vos for her service as a non-employee director.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(7)</TD>
    <TD STYLE="text-align: justify">Represents payment during fiscal 2022 of i) accrued holiday and vacation pay, ii) deferred salary and iii) three months of salary for the notice period and accrued severance of $300,000 that will be paid in fiscal 2023.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(8)</TD>
    <TD STYLE="text-align: justify">Mr. Daly became our chief commercial officer in March 2020 at an annual base salary of $250,000. In February 2021, Mr. Daly converted to part time, and his annual base salary was reduced to $125,000. Mr. Daly resigned as our Chief Commercial Officer in September 2021, and we and Mr. Daly entered into a consulting arrangement pursuant to which Mr. Daly provides services to us on a part-time basis.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table shows
certain information regarding outstanding equity awards held by our named executive officers as of March 31, 2022.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of Securities Underlying Unexercised Options (#) Exercisable</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of Securities Underlying Unexercised Options (#) Unexercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Option Exercise Price($)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Option Expiration Date(1)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Paul DiPerna</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,155</TD>
    <TD STYLE="width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 11%">6/1/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,169</TD>
    <TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/1/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,170</TD>
    <TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/1/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,660</TD>
    <TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/2/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,745</TD>
    <TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/1/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,727</TD>
    <TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/1/2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,809</TD>
    <TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/1/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,811</TD>
    <TD STYLE="text-align: left">(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/1/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,721</TD>
    <TD STYLE="text-align: left">(10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/1/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,662</TD>
    <TD STYLE="text-align: left">(11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,666</TD>
    <TD STYLE="text-align: left">(12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,660</TD>
    <TD STYLE="text-align: left">(13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,650</TD>
    <TD STYLE="text-align: left">(14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,677</TD>
    <TD STYLE="text-align: left">(15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,624</TD>
    <TD STYLE="text-align: left">(16)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,694</TD>
    <TD STYLE="text-align: left">(17)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,641</TD>
    <TD STYLE="text-align: left">(18)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,603</TD>
    <TD STYLE="text-align: left">(19)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1/15/2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,775</TD>
    <TD STYLE="text-align: left">(20)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/15/2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,775</TD>
    <TD STYLE="text-align: left">(21)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/15/2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,005</TD>
    <TD STYLE="text-align: left">(22)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/15/2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,005</TD>
    <TD STYLE="text-align: left">(23)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">09/15/2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,005</TD>
    <TD STYLE="text-align: left">(24)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.98</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/15/2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,222</TD>
    <TD STYLE="text-align: left">(25)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,778</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/25/2029</TD></TR>
  </TABLE>


<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The standard option term is ten years, but all of the options
expire automatically unless exercised within 90 days after the cessation of service as an employee, director or consultant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The option was granted on June 1, 2020, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(3)</TD><TD STYLE="text-align: justify">The option was granted on May 1, 2020, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(4)</TD><TD STYLE="text-align: justify">The option was granted on April 1, 2020, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(5)</TD><TD STYLE="text-align: justify">The option was granted on March 2, 2020, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(6)</TD><TD STYLE="text-align: justify">The option was granted on February 1,2020, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(7)</TD><TD STYLE="text-align: justify">The option was granted on January 1, 2020, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(8)</TD><TD STYLE="text-align: justify">The option was granted on December 1, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(9)</TD><TD STYLE="text-align: justify">The option was granted on November 1, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(10)</TD><TD STYLE="text-align: justify">The option was granted on October 1, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(11)</TD><TD STYLE="text-align: justify">The option was granted on September 15, 2019, and the shares
subject to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(12)</TD><TD STYLE="text-align: justify">The option was granted on August 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(13)</TD><TD STYLE="text-align: justify">The option was granted on July 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(14)</TD><TD STYLE="text-align: justify">The option was granted on June 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(15)</TD><TD STYLE="text-align: justify">The option was granted on May 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(16)</TD><TD STYLE="text-align: justify">The option was granted on April 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(17)</TD><TD STYLE="text-align: justify">The option was granted on March 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(18)</TD><TD STYLE="text-align: justify">The option was granted on February 15, 2019, and the shares
subject to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(19)</TD><TD STYLE="text-align: justify">The option was granted on January 15, 2019, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(20)</TD><TD STYLE="text-align: justify">The option was granted on December 15, 2018, and the shares
subject to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(21)</TD><TD STYLE="text-align: justify">The option was granted on November 15, 2018, and the shares
subject to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(22)</TD><TD STYLE="text-align: justify">The option was granted on October 15, 2018, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(23)</TD><TD STYLE="text-align: justify">The option was granted on September 15, 2018, and the shares
subject to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(24)</TD><TD STYLE="text-align: justify">The option was granted on August 15, 2018, and the shares subject
to this option were fully vested on the grant date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(25)</TD><TD STYLE="text-align: justify">The option was granted on November 25, 2019, and the shares
subject to this option vest monthly over three years commencing January 1, 2020, subject to continued service as an employee, director
or consultant.</TD>
</TR></TABLE>


<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">We
have entered into our standard form of employment, confidential information and invention assignment agreement with each of our named
executive officers. We also have entered into agreements to indemnify our directors and certain executive officers, in addition to the
indemnification provided for in our articles of incorporation and bylaws. These agreements, among other things, provide for indemnification
of our directors and certain executive officers for many expenses, including attorneys&rsquo; fees, judgments, fines and settlement amounts
incurred by any such person in any action or proceeding, including any action by or in the right of us, arising out of such person&rsquo;s
services as a director or executive officer of ours, any subsidiary of ours or any other company or enterprise to which such person provided
services at our request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective
April 1, 2021, our board of directors approved our outside (non-employee) director compensation plan (the &ldquo;Director Plan&rdquo;).
Pursuant to the Director Plan, outside directors are paid the following annual retainers:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$25,000 for service as a member of the board of directors;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$5,000 for service as chair of the audit committee; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">$5,000 for service as chair of the compensation committee.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The annual retainers
will be paid in quarterly installments in either cash, options to purchase shares of our common stock or in shares of our common stock,
as directed by each director based on an annual election. In addition, under the Director Plan, each director will also receive an annual
service equity award of $100,000 paid in quarterly installments in either options to purchase shares of our common stock or shares of
our common stock, as directed by each director based on an annual election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, upon appointment to our board of
directors, we award our non-employee directors a stock option grant under our Amended 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;).
During fiscal 2022, we awarded each of the new non-employee directors a stock option to purchase 16,667 shares of our common stock. These
options vest annually over three years from the date of appointment to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes
the compensation we paid to our non-employee directors for the year ended March 31, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fee<BR>
Compensation<BR>
($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted<BR>
Stock&nbsp;Awards<BR>
($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<BR>
Awards<BR>
($)(1)(2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other<BR>
Compensation<BR>
(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<BR>
 ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Liam Burns(4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">222,291</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">241,041</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">William Febbo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Steven Felsher(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194,981</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,638</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Morgan Frank</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Philip Sheibley(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,424</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,588</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Carmen Volkart</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">296,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,094</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ellen O&rsquo;Connor Vos(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,953</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">281,339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284,292</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Award amounts reflect the aggregate grant date fair value with
respect to awards granted, as determined pursuant to FASB ASC Topic 718. The assumptions used to calculate the aggregate grant date fair
value of option awards are set forth in the notes to the consolidated financial statements included in this Registration Statement. These
amounts do not reflect actual compensation earned or to be earned by our directors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">As of March 31, 2022, our non-employee directors each held outstanding
options to purchase the following number of shares of our common stock: William Febbo, 66,667; Steven Felsher, 38,084; Morgan Frank,
100,699; Philip Sheibley, 16,667; Carmen Volkart; 90,558 and Ellen O&rsquo;Connor Vos, 111,873.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Represents stock awards; we calculated the estimated fair value
of the stock awards issued to our non-employee directors using the closing price per share of our common stock on the day prior to the
grant date in accordance with the Director Plan.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Mr. Burns resigned as a director on December 31, 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Messrs. Felsher and Sheibley were appointed to our board of
directors on November 29, 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Ms. Vos was appointed to our board of directors in May 2021
and as our chief executive officer in August 2021. In February 2022, Ms. Vos resigned as our chief executive officer.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table shows
the number of securities to be issued upon exercise or vesting of outstanding equity awards under the 2017 Plan as of March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; font-weight: bold">Plan Category</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<BR>
securities to be<BR>
issued upon <BR>
exercise or <BR>
vesting of<BR>
outstanding<BR>
equity awards<BR>
(a)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted-<BR> average<BR> exercise price<BR> of outstanding<BR> options<BR> (b)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<BR>

    securities<BR> remaining available<BR> for future issuance<BR>
under equity<BR>
 compensation plans<BR> (excluding securities<BR>
    reflected in<BR>
column(a))<BR> (c)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Equity compensation plans not approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,650,705</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">989,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manchester as the general partner of Manchester
Explorer, L.P. (&ldquo;Explorer&rdquo;), combined with the holdings of its affiliates, JEB Partners LP, Mr. Besser and Mr. Frank, owns
approximately 25% of the Company&rsquo;s outstanding shares of common stock. Mr. Besser is our chief executive officer and a managing
member of Manchester. Mr. Frank is one of our directors and serves as the portfolio manager of Explorer and as a managing member of Manchester.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Mr.
DiPerna&rsquo;s daughter is an employee of ours, and, during the year ended March 31, 2022, we paid her $169,589, which includes the aggregate
grant date fair value, as determined pursuant to FASB ASC Topic 718, of a stock option granted in November 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In October 2021, we issued
a secured promissory note (the &ldquo;Bridge Note&rdquo;) to Explorer that provided the Company with a $3,000,000 revolving credit facility
with all amounts being drawn down by us thereunder being due and payable, subject to acceleration in the event of a default, on March
15, 2022. Interest at the rate of 12% was payable on each amount drawn down without regard to the draw-down date or the date when interest
is paid. During the period from October 2021 to February 2022, we made draws of $2,100,000 on the Bridge Note, and we repaid to Explorer
the draws and accrued interest in the amount of $2,352,000 in February 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In October 2021, we sold
12,346 shares of common stock to Mr. DiPerna and 18,519 shares to Ms. Vos at a price per share of $8.10 in a private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, Mr. Febbo purchased $200,000 aggregate
principal amount of our convertible notes and received a warrant to purchase 23,229 shares of our common stock (the &ldquo;Director Warrant&rdquo;).
In connection with a public offering of our equity securities in February 2022, the convertible note held by Mr. Febbo was converted into
our equity securities. Upon conversion, Mr. Febbo received 45,586 shares of our common stock and a warrant to purchase 45,586 shares of
our common stock at an exercise price of $6.60 per share. In addition, the exercise price of the Director Warrant was reduced to $6.00
per share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2021, Mr. DiPerna and Explorer
                                                                                              (the &ldquo;Related Party Holders&rdquo;), which is represented by Mr. Frank on our board of directors, purchased $100,000 and
                                                                                              $1,000,000, aggregate principal amount of our convertible notes and received warrants to purchase 119,237 and 11,924 shares of our
                                                                                              common stock (the &ldquo;Note Warrants&rdquo;), respectively. Effective April 30, 2021, the Related Party Holders entered into
                                                                                              revocation agreements with the Company pursuant to which their collective $1,100,000 aggregate principal amount of convertible notes
                                                                                              and accrued interest of $50,091 were replaced with new convertible notes. In connection with a public offering of our equity
                                                                                              securities in February 2022, the convertible notes and accrued interest held by the Related Party Holders were converted into our
                                                                                              equity securities and Mr. DiPerna received 23,429 shares of our common stock and a warrant to purchase 23,429 shares of our common
                                                                                              stock at an exercise price of $6.60 per share and Explorer received 234,274 shares of our common stock and a warrant to purchase
                                                                                              234,274 shares of our common stock at an exercise price of $6.60 per share. In addition, the exercise prices of the Note Warrants
                                                                                              were reduced to $6.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;Management&rdquo;
above for other related party transactions involving our executive officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            following table sets forth certain information as of May 4, 2023 concerning the ownership
                                            of our common stock by: </FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
stockholder known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock (currently our only
class of voting securities);</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
of our directors;</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
of our executive officers; and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
directors and executive officers as a group.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Beneficial
                                            ownership is determined in accordance with Rule 13d-3 of the Exchange Act, and includes all
                                            shares over which the beneficial owner exercises voting or investment power. Shares that
                                            are issuable upon the exercise of options, warrants and other rights to acquire common stock
                                            that are presently exercisable or exercisable within 60 days of May 4, 2023 are reflected
                                            in a separate column in the table below. These shares are taken into account in the calculation
                                            of the total number of shares beneficially owned by a particular holder and the total number
                                            of shares outstanding for the purpose of calculating percentage ownership of the particular
                                            holder. We have relied on information supplied by our officers, directors and certain stockholders
                                            and on information contained in filings with the SEC. Except as otherwise indicated, and
                                            subject to community property laws where applicable, we believe, based on information provided
                                            by these persons, that the persons named in the table have sole voting and investment power
                                            with respect to all shares of common stock shown as beneficially owned by them. The percentage
                                            of beneficial ownership is based on 10,949,389 shares of common stock outstanding as of May 4, 2023. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Unless otherwise stated,
the business address of each of our directors and executive officers listed in the table is 10740 Thornmint Road, San Diego, California
92127.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name and principal position </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Number of Shares Beneficially
    Owned (Excluding Outstanding Options and warrants)(1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Number of Shares Issuable on Exercise
    of Outstanding Options and Warrants(2) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Percent of Class </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"> JEB Partners, L.P. </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 2,720,577 </TD><TD STYLE="width: 1%; text-align: left"> (3) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 653,511 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 29.08 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Manchester Explorer, L.P. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,720,577 </TD><TD STYLE="text-align: left"> (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 653,511 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29.08 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Manchester Management LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,720,577 </TD><TD STYLE="text-align: left"> (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 653,511 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29.08 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Sio Capital Management, LLC </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 689,352 </TD><TD STYLE="text-align: left"> (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 402,127 </TD><TD STYLE="text-align: left"> (5) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9.62 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"> Directors and officers: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> James Besser </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,720,577 </TD><TD STYLE="text-align: left"> (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 653,511 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29.08 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Paul DiPerna </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,553,586 </TD><TD STYLE="text-align: left"> (6) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 203,262 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 24.71 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Kevin Schmid </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &mdash; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> William J. Febbo </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 89,105 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 135,482 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.03 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Steven Felsher </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,877 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 56,973 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Morgan C. Frank </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,720,577 </TD><TD STYLE="text-align: left"> (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 793,469 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29.92 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Philip Sheibley </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 21,139 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,556 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Carmen Volkart </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 7,085 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 120,558 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.15 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Ellen O&rsquo;Connor Vos </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 18,519 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 124,910 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.30 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> All current directors and executive officers as a group (9 persons) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,415,888 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,440,209 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 59.93 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Represents less than 1%</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
                                            shares subject to outstanding options and warrants to acquire common stock that are exercisable
                                            within 60 days of May 1, 2023.</FONT> </TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            the number of shares subject to outstanding options and warrants to acquire common stock
                                            that are exercisable within 60 days of May 1, 2023.</FONT> </TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">(3)</TD>
    <TD STYLE="width: 97%; font-size: 10pt; text-align: justify">Includes (i) 124,750 shares directly held by Mr. Besser, of which: (a) 60,277 shares were received in exchange for Mr. Besser&rsquo;s shares as a result of our acquisition of Quasuras; (b) 29,630 shares purchased in a private placement in 2018 (the &ldquo;2018 Placement&rdquo;) and (c) 34,843 shares were purchased in a private placement in 2020 (the &ldquo;2020 Placement&rdquo;); (ii) 2,218,077 held by Manchester Explorer, L.P. of which: (a) 1,515,152 shares were purchased in a private placement in 2017 (the &ldquo;2017 Placement&rdquo;), (b) 157,037 shares were purchased in the 2018 Placement, (c) 11,614 were purchased in the 2020 Placement, (d) 300,000 shares were purchased in a public offering in February 2022, and (e) 234,274 shares were acquired upon the conversion of a convertible note in February 2022; (iii) 317,473 shares held by JEB Partners, L.P. of which (a) 252,526 shares were purchased in the 2017 Placement, (b) 53,333 shares were purchased in the 2018 Placement and (c) 11,614 shares were purchased in the 2020 Placement; and (iv) 60,277 shares held by Mr. Frank, which shares were received in our acquisition of Quasuras in exchange for Mr. Frank&rsquo;s shares of Quasuras. Mr. Besser, as the managing member, and Mr. Frank, as the portfolio manager and consultant of Manchester Management, LLC, (&ldquo;MMC&rdquo;) the general partner of Manchester Explorer, L.P. and JEB Partners, L. P., have shared voting and dispositive power over shares held by Manchester Explorer, L.P. and JEB Partners, L.P. The address for Manchester Explorer, L.P is c/o MMC, 2 Calle Candina, No. 1701, San Juan, Puerto Rico 00907.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt">(4)</TD>
    <TD STYLE="width: 97%; font-size: 10pt; text-align: justify">Based on information reported by Sio Capital Management, LLC (&ldquo;Sio&rdquo;) on Schedule 13G filed with the SEC on February 15, 2023. Sio and Sio GP, LLC (the &ldquo;GP&rdquo;) act as investment advisor and general partner, respectively, to various clients that are the record owners of the shares of our common stock reported on this Schedule 13G. Because Sio&rsquo;s investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the common stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of our common stock. The address for Sio, Sio GP and Mr. Castor is 600 Third Avenue, New York, New York 10016.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"> (5) </TD>
    <TD STYLE="width: 97%; font-size: 10pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> These
                                            shares are issuable upon exercise of outstanding pre-funded warrants to purchase shares of
                                            our common stock. As of May 1, 2023, Sio held 1,348,314 pre-funded warrants to purchase shares
                                            of our common stock. Pursuant to the terms of the pre-funded warrants, Sio cannot exercise
                                            such pre-funded warrants if Sio would beneficially own, after such exercise, more than 9.99%
                                            of the outstanding shares of our common stock. Accordingly, pre-funded warrants to purchase
                                            946,187 shares of our common stock have been excluded from the table above. </P></TD></TR>
  </TABLE>





<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(6)</TD>
    <TD STYLE="text-align: justify">Includes (i) 2,000,000 shares directly held by the Paul DiPerna Irrevocable Trust, (ii) 333,334 shares directly held by Mr. DiPerna&rsquo;s adult daughters, Kelsie DiPerna and Alaria DiPerna, which shares Mr. DiPerna has sole voting power over; (iii) 207,906 shares directly held by the Paul DiPerna Trust, of which 101,010 shares were purchased in the 2017 Placement and 23,429 shares were acquired upon the conversion off a convertible note in February 2022 and (iv) 12,346 shares held by Mr. DiPerna. The 2,000,000 shares held by the Paul DiPerna Irrevocable Trust, 333,334 shares held by Mr. DiPerna&rsquo;s adult daughters and 73,480 shares held by the Paul DiPerna Trust that were issued in 2017 to Mr. DiPerna in the Control Block Acquisition and transferred to such persons in December 2020 by Mr. DiPerna. Mr. DiPerna is the chairman of our board of directors, and also serves as our president, chief financial officer and treasurer. Mr. DiPerna is the trustee of both the Paul DiPerna Irrevocable Trust and the Paul DiPerna Trust.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We are offering&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,116,402
units, with each unit consisting of two shares of common stock and one warrant to purchase one share of our common stock. The units have
no stand-alone rights and will not be certificated or issued as stand-alone securities. This offering also includes the offer and sale
of the shares of common stock issuable from time to time upon exercise of the warrants.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, we had 10,932,098 shares
of common stock issued and outstanding, 7,565,588 shares of common Stock issuable upon exercise of outstanding warrants, and 2,174,198
shares of common stock issuable upon exercise of outstanding stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of our certificate of incorporation,
holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including
the election of directors, and do not have cumulative voting rights. The holders of outstanding shares of common stock are entitled to
receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as our Board
of Directors from time to time may determine. Our common stock is not entitled to pre-emptive rights and is not subject to conversion
or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution to stockholders
are distributable ratably among the holders of our common stock after payment of liquidation preferences, if any, on any outstanding
payment of other claims of creditors. The rights, preferences and privileges of holders of common stock are subject to and may be adversely
affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary of certain terms and
provisions of the warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions
of the warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective
investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions
of the warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <I>Duration and Exercise Price.</I> Each
warrant offered hereby will have an initial exercise price per share equal to $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (120% of the public offering price per unit sold in this offering. The
warrants will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise price
and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting our common stock and the exercise price. The warrants will be issued
separately from the common stock and may be transferred separately immediately thereafter. One warrant to purchase one share of our
common stock will be issued for every two shares of common stock purchased in this offering. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercisability</I>. The warrants will be exercisable,
at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the
number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder
(together with its affiliates) may not exercise any portion of the warrant to the extent that the holder would own more than 4.99% of
the outstanding common stock immediately after exercise, except that upon at least 61 days&rsquo; prior notice from the holder to us,
the holder may increase the amount of ownership of outstanding stock after exercising the holder&rsquo;s warrants up to 9.99% of the number
of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the warrants. No fractional shares of common stock will be issued in connection with the exercise of a
warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cashless Exercise</I>. If, at the time a holder
exercises its warrants, a registration statement registering the issuance of the shares of common stock underlying the warrants under
the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available for
the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment
of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number
of shares of common stock determined according to a formula set forth in the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Transferability</I>. Subject to applicable
laws, a warrant in book entry form may be transferred at the option of the holder through the facilities of the Depository Trust Company
and warrants in physical form may be transferred upon surrender of the warrant to the Warrant Agent together with the appropriate instruments
of transfer. Pursuant to a warrant agency agreement between us and the Warrant Agent, the warrants initially will be issued in book-entry
form and will be represented by one or more global certificates deposited with The Depository Trust Company (&ldquo;DTC&rdquo;) and registered
in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exchange Listing</I>. There is no established
public trading market for the warrants, and we do not expect a market to develop. In addition, we do not intend to list the warrants on
any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the warrants will
be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Right as a Stockholder</I>. Except as otherwise
provided in the warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders of the warrants do not
have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fundamental Transaction.</I> In the event we
consummate a merger or consolidation with or into another person or other reorganization event in which shares of our common stock are
converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or otherwise dispose
of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding common shares (each, a &ldquo;Fundamental
Transaction&rdquo;), then following such Fundamental Transaction the holders of the warrants will be entitled to receive upon exercise
of the warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the
warrants immediately prior to such Fundamental Transaction. Any successor to us or surviving entity will assume the obligations under
the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>UNDERWRITING</B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newbridge Securities Corporation
(&ldquo;Newbridge&rdquo; or the &ldquo;underwriter&rdquo;) is acting as sole underwriter of this offering. We entered into an
underwriting agreement with Newbridge with respect to the securities subject to this offering. Subject to the terms and conditions
stated in the underwriting agreement dated the date of this prospectus, the underwriter has agreed to purchase, and we have agreed
to sell to the underwriter, the number of units shown in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Underwriter </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Number of <BR> Units </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 1.5pt"> Newbridge Securities Corporation </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"> 2,116,402 </TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 2,116,402 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriting agreement provides that the
obligations of the underwriter to purchase the units included in this offering are subject to approval of legal matters by counsel
and to other conditions. The underwriting agreement provides that the underwriter will purchase all of the units if any of them are
purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Units sold by the underwriter to the public
will initially be offered at the public offering price set forth on the cover of this prospectus. In addition, the underwriter may
offer some of the securities to other securities dealers at such price less a concession of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit. After the initial offering of the units,
the public offering price or any other term of the offering may be changed by the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Underwriting discounts and commissions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We
                                            are offering 2,116,402 units pursuant to this prospectus. Each unit comprises two shares
                                            of common stock and one warrant to purchase one share. The following table shows the effective
                                            public offering price per share of common stock and accompanying warrant and total public
                                            offering price, underwriting discounts and commissions, and proceeds before expenses to us. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Effective Price Per Share and accompanying Warrant</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Total Without Option</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Total With Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Public offering price<SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discounts and commissions<FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Based on a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
unit comprising two shares of common stock and one warrant to purchase one share of common stock.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">We have agreed to pay the underwriters a commission of 7%
of the gross proceeds of this offering.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the discount set forth in the above
table, we have granted to the underwriters an option, exercisable not later than 30 days after the date of this prospectus, to purchase
up to a number of additional shares of common stock equal to 15% of the shares of common stock included in the units sold in this offering
and/or a number of additional warrants equal to 15% of the warrants included in the units sold in this offering, in any combination thereof,
firmly committed in this offering at a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share or
$0.01 per warrant to purchase one share of common stock, in each case, less the underwriting discounts and commissions. The underwriters
may exercise the option solely to cover over-allotments, if any, made in connection with this offering. If any additional shares of our
common stock and/or warrants are purchased pursuant to the over-allotment option, the underwriters will offer these additional shares
of our common stock and/or warrants on the same terms as those on which the other shares of common stock and Warrants are being offered
hereby.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Underwriter&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the closing of this offering, we have
agreed to issue to Newbridge, or its designees, warrants (the &ldquo;underwriter&rsquo;s warrants&rdquo;) to purchase a number of
shares of common stock equal to an aggregate of 7% of the total shares sold in this public offering. The underwriter&rsquo;s
warrants will be exercisable at a per share exercise price equal to 125% of the public offering price per share of common stock sold
in this offering. The underwriter&rsquo;s warrants are exercisable at any time and from time to time, in whole or in part, during
the three and one-half-year period commencing six months after the effective date of the registration statement related to this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are registering hereby the issuance of the
underwriter&rsquo;s warrants and the shares of common stock issuable upon exercise of such warrants. The underwriter&rsquo;s warrants
and the shares of common stock underlying the underwriter&rsquo;s warrants have been deemed compensation by the Financial Industry Regulatory
Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. Neither Newbridge or its permitted
assignees under such rule, may sell, transfer, assign, pledge, or hypothecate the underwriter&rsquo;s warrants or the securities underlying
the underwriter&rsquo;s warrants, nor will Newbridge engage in any hedging, short sale, derivative, put, or call transaction that would
result in the effective economic disposition of the underwriter&rsquo;s warrants or the underlying shares for a period of 180 days from
the effective date of the registration statement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the underwriter&rsquo;s warrants
may not be sold, transferred, assigned, pledged or hypothecated for a 180-day period following the effective date of the registration
statement except to any underwriter and selected dealer participating in this offering and their bona fide officers or partners. The underwriter&rsquo;s
warrants will provide for adjustment in the number and price of the underwriter&rsquo;s warrants and the shares of common stock underlying
such underwriter&rsquo;s warrants in the event of recapitalization, merger, stock split or other structural transaction, or a future financing
undertaken by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-Ups</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our officers, directors and holders of more
than 5.0% of our outstanding shares of common stock have agreed that, for a period of 90 days from the date of this prospectus, they
will not, subject to certain exceptions, offer, pledge, sell, contract to sell, sell any option, right or warrant to purchase, lend
or otherwise transfer or dispose, directly or indirectly, any shares of our capital stock or any securities convertible into or
exercisable or exchangeable for shares of capital stock without the prior written consent of Newbridge. Additionally, we have also
agreed that, for a period of 90 days from the date of this prospectus, we will not, subject to certain exceptions, offer, pledge,
sell, contract to sell, sell any option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or
indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital
stock without the prior written consent of Newbridge. Newbridge, in its sole discretion, may release any of the securities subject
to these lock-up agreements at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nasdaq Capital Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on Nasdaq Capital Market
under the symbol &ldquo;MODD.&rdquo; There is no established trading market for the warrants, and we do not intend to apply for listing
of the Warrants on The Nasdaq Capital Market or on any national securities exchange. Without a trading market, the liquidity of the warrants
will be extremely limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Expenses and Reimbursements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> We estimate that our portion of the total
expenses of this offering will be approximately $400,000, which includes the fees and expenses for which we have agreed to reimburse
the underwriter, including the fees and disbursements of counsel for the underwriter, in connection with the offering in an amount not
to exceed $125,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Price Stabilization, Short Positions and Penalty
Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until the distribution of shares of common stock
in this offering is complete, SEC rules may limit the ability of the underwriter to bid for and purchase shares of our common stock. As
an exception to these rules, underwriters are permitted to engage in certain transactions which stabilize the price of the shares of common
stock, which may include short sales, covering transactions and stabilizing transactions. Short sales involve sales of shares of common
stock in excess of the number of shares to be purchased by the underwriter in the offering, which creates a short position. &ldquo;Covered&rdquo;
short sales are sales made in an amount not greater than the underwriter&rsquo;s option to purchase additional shares of common stock
from us in the offering. An underwriter may close out any covered short position by either exercising its option to purchase additional
shares of common stock or purchasing shares of common stock in the open market. In determining the source of shares of common stock to
close out the covered short position, the underwriter will consider, among other things, the price of shares of common stock available
for purchase in the open market as compared to the share price at which the underwriter may purchase through its option to purchase additional
shares. &ldquo;Naked&rdquo; short sales are any sales in excess of such option. The underwriter must close out any naked short position
by purchasing shares of common stock in the open market. A naked short position is more likely to be created if the underwriter is concerned
that there may be downward pressure on the price of the shares of common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of the shares of common stock
made by the underwriters in the open market prior to the completion of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may also impose a penalty bid.
This occurs when a particular underwriter repays to another underwriter a portion of the underwriting discount received by it because
the representative has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above might have on our
shares of common stock. Any of these activities may have the effect of preventing or retarding a decline in the market price of our
shares of common stock. They may also cause the price of the shares of common stock to be higher than the price that would otherwise
exist in the open market in the absence of these transactions. If an underwriter commences any of these transactions, it may
discontinue them at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that delivery of the shares will be
made to investors on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2023 (such settlement being referred to as &ldquo;T+2&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the underwriter
or any securities dealers may distribute prospectuses by electronic means, such as e-mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter is a full service financial institution
engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment
management, principal investment, hedging, financing and brokerage activities. The underwriter and its affiliates may, from time to time,
engage in transactions with and perform services for us in the ordinary course of its business for which it may receive customary fees
and reimbursement of expenses. In the ordinary course of its various business activities, the underwriter and its affiliates may make
or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(which may include bank loans and/or credit default swaps) for its own account and for the accounts of its customers and may at any time
hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or
instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No action has been taken in any jurisdiction (except
in the United States) that would permit a public offering of our common stock or accompanying warrants, or the possession, circulation
or distribution of this prospectus or any other material relating to us or our common stock in any jurisdiction where action for that
purpose is required. Accordingly, the shares of common stock and accompanying warrants may not be offered or sold, directly or indirectly,
and neither this prospectus nor any other offering material or advertisements in connection with our common stock and accompanying warrants
may be distributed or published, in or from any country or jurisdiction, except in compliance with any applicable rules and regulations
of any such country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may arrange to sell the common
stock and accompanying warrants offered hereby in certain jurisdictions outside the United States, either directly or through affiliates,
where it is permitted to do so.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the shares of common stock and
warrants offered by this prospectus has been passed upon for us by Lucosky Bookman LLP, Woodbridge, New Jersey. McGuireWoods LLP is acting
as counsel for the underwriters in connection with this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated balance sheets of Modular Medical,
Inc. as of March 31, 2022 and 2021, and the related consolidated statements of operations, changes in stockholders&rsquo; equity (deficit)
and cash flows for the years then ended have been audited by Farber Hass Harley LLP, an independent registered public accounting firm,
as stated in their report which is incorporated herein. Such consolidated financial statements have been incorporated herein in reliance
on the report of such firm given upon their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration statement
on Form S-1, including and schedules, under the Securities Act that registers the offer and sale of the securities to be sold in this
offering. This prospectus does not contain all of the information contained in the registration statement and the exhibits and schedules
filed as part of the registration statement. For further information with respect to us and our common stock and warrants, we refer you
to the registration statement and the exhibits and schedules filed as part of the registration statement. Statements contained in this
prospectus as to the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed
as an exhibit to the registration statement, we refer you to the copies of the contract or document that has been filed. Each statement
in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read and copy all materials that we file
with the SEC, including the registration statement and its exhibits and schedules, on the website maintained by the SEC at www.sec.gov.
Information contained on any website referenced in this prospectus does not and will not constitute a part of this prospectus or the registration
statement on Form S-1 of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, upon the closing of this offering,
we will be subject to the information reporting requirements of the Exchange Act and we will file periodic reports, proxy statements
and other information with the SEC. These periodic reports, proxy statements and other information will be available for inspection and
copying at the public reference room and the website of the SEC referred to above. We also maintain a website at www.modular-medical.com,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not a part of, and is not incorporated
into, this prospectus. Additionally, you may request a copy of any of our filings with the SEC at no cost, by writing or telephoning
us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn.: CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">San Diego, California 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(858) 800-3500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this prospectus or to which we have referred you. We have not and the underwriters have not authorized any person to provide you with
different information or to make any representation not contained in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_021"></A>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 93%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 7%"><B>Page</B></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B>Nine Months ended December 31, 2022 and December 31, 2021</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_023">Condensed Consolidated Balance Sheets as of December 31, 2022 (Unaudited) and March 31, 2022</A> </B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-2</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_024">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2022 and 2021 (Unaudited)</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-3</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_025">Condensed Consolidated Statements of Stockholders&rsquo; Equity (Deficit) for the Three and Nine Months Ended December 31, 2022 and 2021 (Unaudited)</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-4</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_026">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2022 and 2021 (Unaudited)</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-5</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_027">Notes to Condensed Consolidated Financial Statements (Unaudited)</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-6</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B>Years ended March 31, 2022 and March 31, 2021</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_028">Report of Independent Registered Public Accounting Firm</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-16</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_029">Consolidated Balance Sheets as of March 31, 2022 and March 31, 2021</A> </B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-18</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_030">Consolidated Statements of Operations for the Years Ended March 31, 2022 and March 31, 2021</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-19</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_031">Consolidated Statements of Stockholders&rsquo; Equity (Deficit) for the Years Ended March 31, 2022 and March 31, 2021</A> </B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-20</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_032">Consolidated Statements of Cash Flows for the Years Ended March 31, 2022 and March 31, 2021</A> </B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-21</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><B><A HREF="#a_033">Notes to Consolidated Financial Statements</A></B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">F-22</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 78; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_023"></A>Modular Medical, Inc.<BR>
Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<BR> 2022<BR> (Unaudited)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<BR> 2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,690,957</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,076,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313,422</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Security deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,971,121</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,389,794</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">716,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,959</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Right of use asset, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,693</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Security deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NON-CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">767,721</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">456,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,738,842</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,846,446</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">382,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">299,951</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">524,891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Short-term lease liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">77,672</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">144,857</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">715,297</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">969,699</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Long-term lease liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39,957</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">715,297</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,009,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Commitments and Contingencies (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred Stock, $0.001&nbsp;par value,&nbsp;5,000,000&nbsp;shares authorized,&nbsp;none&nbsp;issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Common Stock, $0.001&nbsp;par value,&nbsp;50,000,000&nbsp;shares authorized;&nbsp;10,932,098&nbsp;and&nbsp;10,461,898&nbsp;shares issued and outstanding as of December 31, 2022 and March 31, 2022, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,462</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,900,066</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,406,099</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(44,887,453</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(34,579,771</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,023,545</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,836,790</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,738,842</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,846,446</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_024"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Condensed Consolidated
Statements of Operations<BR>
(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nine Months Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,196,546</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,849,399</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,804,069</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,742,911</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,161,351</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,981,665</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,502,029</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,156,152</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,357,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,831,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,306,098</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,899,063</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,357,897</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,831,064</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,306,098</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,899,063</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(587</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,010,247</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,204,917</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss on debt extinguishment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,321,450</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,358,484</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,841,307</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,306,082</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,056,554</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,358,484</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,841,307</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(10,307,682</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(14,058,154</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.31</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.76</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.95</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2.22</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Shares used in computing net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,925,862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,354,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,863,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,331,982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_025"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Condensed Consolidated
Statements of Stockholders&rsquo; Equity (Deficit)<BR>
(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<BR> Paid-In</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Common<BR> Stock</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 41%">Balance as of March 31, 2022</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">10,461,898</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">10,462</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">43,406,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(34,579,771</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">8,836,790</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for services</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,576</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,576</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock and warrants in equity offering, net</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449,438</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,371,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,372,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock under equity incentive plan</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,664</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">724,819</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">724,819</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,498,791</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,498,791</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Balance as of June 30, 2022</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,914,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">51,518,139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(38,078,562</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,450,491</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock under equity incentive plan</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,380</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">692,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">692,060</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,450,407</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,450,407</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Balance as of September 30, 2022</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,925,723</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,926</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">52,260,567</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(41,528,969</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,742,524</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock under equity incentive plan</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">626,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">626,762</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,358,484</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,358,484</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance as of December 31, 2022</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,932,098</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,932</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">52,900,066</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(44,887,453</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,023,545</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<BR> Paid-In</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Common<BR> Stock</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 40%">Balance as of March 31, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">6,302,050</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">6,302</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">14,665,559</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(15,947,010</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(1,275,149</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrants issued with convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,700,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,700,632</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock under equity incentive plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,497</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">623,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">623,423</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,835,091</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,835,091</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Balance as of June 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,323,886</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,324</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,194,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,782,101</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,581,488</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">862,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">862,431</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,381,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,381,757</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Balance as of September 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,327,521</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,328</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,056,716</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,163,858</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,100,814</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Private placement of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,756</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issuable for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,994</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for reverse stock split</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,221,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,221,735</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,841,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,841,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance as of December 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,373,706</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,374</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">21,602,162</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">149,994</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(30,005,165</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(8,246,635</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 76.05pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_026"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Condensed Consolidated
Statements of Cash Flows<BR>
(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nine Months Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(10,307,682</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(14,058,154</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on PPP note forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(368,780</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,321,450</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,120,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,740,086</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,268</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Shares issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,412</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">388,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Shares issuable for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,994</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,404</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(107,142</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(92,826</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,454,762</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other assets and prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,577</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,995</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(187,217</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,223,983</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,184,696</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,128,787</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(573,066</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,779</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(573,066</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,779</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of common stock and warrants, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,372,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceed from private placement, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of convertible notes, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,137,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of promissory note</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,372,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,887,199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net decrease in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,385,415</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,264,367</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,076,372</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,468,465</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,690,957</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">204,098</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Supplemental disclosure:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Noncash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Fair value of detachable warrants issued with convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,700,632</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_027"></A>MODULAR MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>NOTES TO CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS<BR>
(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
1 &ndash;&nbsp;THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc. (the Company) was incorporated
in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately
2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major stockholder
of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the
Company recognized the assets and liabilities of Quasuras acquired in the merger at their historical carrying amounts. Prior to the acquisition
of Quasuras and, since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange
Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin
pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent
people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their
daily insulin in two ways, through a continuous &ldquo;basal&rdquo; delivery allowing a small amount of insulin to be in the blood at
all times and a &ldquo;bolus&rdquo; delivery to address meal time glucose input and to address when the blood glucose level becomes excessively
high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically
savvy, less motivated part of the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In February
2022, the Company completed a public offering of its equity securities, and its common stock was approved to list on the Nasdaq Capital
Market under the symbol &ldquo;MODD&rdquo; and began trading there on February 10, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&nbsp;<I>Going Concern</I>, requires management
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&rsquo;s
ability to continue as a going concern within one year after the date that the financial statements are issued. If management identifies
conditions or events that raise substantial doubt about an entity&rsquo;s ability to continue as a going concern, management must consider
if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate the conditions or events
raising the substantial doubt about the entity&rsquo;s ability to continue as a going concern. If the substantial doubt is not alleviated
after consideration of management&rsquo;s plans, the entity must include a statement in the notes to the financial statements indicating
that there is substantial doubt about the entity&rsquo;s ability to continue as a going concern within one year after the date that the
financial statements are issued including: 1) the principal conditions or events that raise substantial doubt about the entity&rsquo;s
ability to continue as a going concern, 2) management&rsquo;s evaluation of the significance of those conditions or events in relation
to the entity&rsquo;s ability to meet its obligations, and 3) management&rsquo;s plans to attempt to mitigate the conditions or events
causing the substantial doubt about the entity&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest
in the development and subsequent commercialization of its product. The Company expects that its research and development and general
and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve
profitability. The Company&rsquo;s expected operating losses and cash burn raise substantial doubt about the Company&rsquo;s ability to
continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&rsquo;s
plans and its ability to continue as a going concern will depend upon the Company&rsquo;s ability to raise additional capital, through
the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital,
whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered
on terms and conditions acceptable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s
operating needs include the planned costs to operate its business, fund working capital and capital expenditures. The Company&rsquo;s
future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&rsquo;s ability
to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce
costs in order to conserve its cash. These condensed consolidated financial statements do not include any adjustments that might result
from this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial
statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2023 refers to the fiscal year
ending March 31, 2023). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary,
Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The accompanying
condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles
in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim
financial reporting. The condensed consolidated balance sheet as of March 31, 2022 has been derived from the audited consolidated financial
statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP
have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read
in conjunction with the Company&rsquo;s consolidated financial statements and notes thereto included in its most recent annual report
on Form 10-K filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In the opinion
of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal
recurring adjustments) necessary to summarize fairly the Company&rsquo;s financial position, results of operations and cash flows for
the interim periods presented. The operating results for the three months ended December 31, 2022 are not necessarily indicative of the
results that may be expected for the year ending March 31, 2023 or for any other future period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Reverse Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of
State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&rsquo;s shares of common stock.&nbsp;Such amendment
and ratio were previously approved by a majority of the Company&rsquo;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&rsquo;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the reverse split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&rsquo;s equity incentive plans
and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common
stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split. All share numbers,
share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Use of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The preparation
of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed
consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include
those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Reportable Segment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The Company operates in one business
segment and uses one measurement of profitability for its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Research and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The Company expenses research
and development expenditures as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>General and Administrative</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Concentration of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation up
to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution
failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Risks and Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing,
liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &ldquo;shelter-in- place&rdquo; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on the Company&rsquo;s operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government
agencies to prevent disease spread, all of which are uncertain, out of the Company&rsquo;s control, and cannot be predicted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Cash and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Cash and
cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Property and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Property
and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes
machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are
ready for their intended use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Fixed assets
comprised:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Machinery and equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">487,855</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">346,358</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Construction-in-process</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">427,670</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139,197</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139,197</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,054,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">485,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(338,313</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(249,596</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">716,409</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">235,959</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Fair Value of Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used
to measure fair value into three broad levels:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 1 inputs to the valuation methodology are quoted prices
for identical assets or liabilities in active markets.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 2 inputs to the valuation methodology include quoted
prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the financial instrument.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 3 inputs to the valuation methodology are unobservable
and significant to the fair value measurement.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Right-of-Use
Asset</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s
right-of-use assets consist of leased assets recognized in accordance with FASB Accounting Standards Codification (ASC) No. 842, Leases
which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use
assets represent the Company&rsquo;s right to use an underlying asset for the lease term and the lease liability represents the Company&rsquo;s
obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum
lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded
on the condensed consolidated balance sheets and are expensed on a straight-line basis over the lease term in the condensed consolidated
statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the
lease does not provide an implicit interest rate, the Company uses the Company&rsquo;s incremental borrowing rate based on the information
available at commencement date in determining the present value of future payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite
service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the
date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant
using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective
variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and projected
stock option exercise behaviors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Per-Share Amounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Basic net
loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">For the
nine months ended December 31, 2022 and 2021, the following table sets forth securities outstanding which were excluded from the computation
of diluted net loss per share as their inclusion would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nine Months Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Options to purchase common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,174,198</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,967,188</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Common stock warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,565,588</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">767,796</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 8.65pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,739,786</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,734,984</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Reclassifications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended December 31, 2022 and
2021, the Company&rsquo;s comprehensive loss was the same as its net loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Recently
Issued Accounting Pronouncement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In June
2016, the FASB issued ASU No. 2016-13,&nbsp;<I>Financial Instruments&mdash;Credit Losses</I>. This ASU added a new impairment model (known
as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance,
an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables,
lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition
of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective
for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies.
The adoption of this ASU is not expected to have a material impact on the Company&rsquo;s results of operations and financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
2 &ndash;&nbsp;LEASES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
accounts for the lease of its corporate facility in San Diego, California in accordance with ASC No. 842. The 39- month lease term commenced
April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400 with annual rent increases of approximately
3%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs.
The right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum
lease payments. A discount rate of 11%, which approximated the Company&rsquo;s incremental borrowing rate, was used to measure the lease
asset and liability. Lease expense is recognized on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
obtained a right-of-use asset of $270,950 in exchange for its obligations under the operating lease. The landlord also provided a lease
incentive of approximately $139,000, which was paid to the Company in June 2020, for the Company to make improvements to the leased space.
In addition, the Company paid a $100,000 security deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Future minimum
payments under the facility operating lease, as of December 31, 2022, are listed in the table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" SUMMARY="xdx: Disclosure - LEASES (Details)" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; padding-left: 8.65pt; text-indent: -8.65pt"><B>Annual Fiscal Years</B></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><B>Operating<BR>
Lease</B></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; padding-left: 8.65pt; text-indent: -8.65pt">2023</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">39,507</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">2024</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">40,692</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Less:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 17.3pt; text-indent: -8.65pt">Imputed interest</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,527</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 8.65pt; text-indent: -8.65pt">Present value of lease liabilities</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">77,672</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash paid
for amounts included in the measurement of lease liabilities was $118,521&nbsp;for the nine months ended December 31, 2022. Rent expense
was $80,698&nbsp;for each of the nine-month periods ended December 31, 2022 and 2021 and $26,930&nbsp;for each of the three-month periods
ended December 31, 2022 and 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
3 &ndash;&nbsp;PPP NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On April
24, 2020, the Company received a $368,780&nbsp;unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&rsquo;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the
Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck
Protection Program Note (the Agreement) with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022
and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10
months after the covered period during which the Company used the proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In May 2021,
the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest for the
PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470:&nbsp;<I>Debt&nbsp;</I>(ASC
470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statement
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
4 &ndash;&nbsp;CONVERTIBLE PROMISSORY NOTES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">From February
through April 2021, the Company sold $2,310,000&nbsp;of convertible promissory notes (each an Original Note and, collectively, the Original
Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities
Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder of an Original
Note and the Company, the $2,310,000 of Original Notes and accrued interest thereon as of April 30, 2021 were replaced with $2,360,550
aggregate principal amount of Notes and 2021 Warrants (as defined below). The Company accounted for the replacement of the Original Notes
in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450&nbsp;and interest expense of $70,647&nbsp;for unamortized
debt issuance costs as of April 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In April
and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to
investors $4,250,000&nbsp;aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its
common stock (the 2021 Warrants). The Notes were unsecured obligations of the Company with each Note having a stated maturity date of
12 months from its issue date and accrued interest at a rate of 12% per annum, payable on maturity. If the Company completed an offering
of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as defined in the Notes),
each Note holder would be required to convert its Adjusted Note Amount (as defined below) into the securities of such Qualified Capital
Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest on a Note, multiplied
by (ii) 1.25.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In connection
with the issuance of the Notes, the Company issued the 2021 Warrants to purchase in the aggregate 767,796 shares of its common stock at
an initial exercise price of $24.00 per share. The fair value of the 2021 Warrants was $3,700,632, of which $2,379,182 was recorded as
a debt discount and amortized to interest expense, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated
the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of&nbsp;88.98%,
risk-free interest rate of&nbsp;0.86%, a term of&nbsp;5.75 years&nbsp;and a dividend yield of&nbsp;zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Upon the
closing of a public offering in February 2022, which was a Qualified Capital Raise, in accordance with their terms, the Notes converted
into 1,511,276 shares of common stock and the holders of the Notes received an additional 1,511,276 common stock purchase warrants with
an exercise price of $6.60 per share. In addition, as a result of the February 2022 equity offering, the exercise price of the 767,796
outstanding 2021 Warrants was reduced to $6.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
5 &ndash;&nbsp;STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Placements
of Common Stock and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On May 2,
2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor, pursuant to which
the Company sold, in a registered direct offering (the Registered Offering), which closed on May 5, 2022, an aggregate of 449,438 shares
(the Shares) of the Company&rsquo;s common stock, par value $0.001 per share, at a purchase price per Share of $4.45 and pre-funded warrants
(the Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants will be exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In a concurrent
private placement under the Purchase Agreement, the Company issued to the Investor warrants (the Private Placement Warrants) to purchase
an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants will be exercisable
beginning on the six-month anniversary of the date of issuance (the Initial Exercise Date) and will expire on the five-year anniversary
of the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">As of December 31, 2022, the
Company had the following warrants outstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Type</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration Date</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 63%; text-align: left">Common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,348,314</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">&mdash;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">767,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">January - February 2027</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,011,276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 2027</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Common stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,438,202</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">6.60</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">November 2027</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,565,588</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Other</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">During the
nine months ended December 31, 2022 and 2021, the Company issued&nbsp;348&nbsp;and&nbsp;28,334&nbsp;shares of common stock, respectively,
with a fair value of approximately $1,576&nbsp;and $245,956, respectively, to service providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
6 &ndash;&nbsp;STOCK-BASED COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Amended 2017 Equity Incentive
Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In October
2017, the Company&rsquo;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan), as amended, with&nbsp;1,000,000&nbsp;shares
of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved
for issuance under the Plan by&nbsp;333,334&nbsp;and&nbsp;1,333,334&nbsp;shares, respectively. Under the Plan, eligible employees, directors
and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based
awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Stock-Based Compensation Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based
on the grant date fair value. As of December 31, 2022, the unamortized compensation cost was $3,443,902 related to stock options and is
expected to be recognized as expense over a weighted-average period of approximately 2.07 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">During the
three and nine months ended December 31, 2022, the Company awarded 6,375 and 20,414 shares, respectively, to members of the Board in accordance
with the compensation plan for non-employee directors. During the nine months ended December 31, 2022, the Company granted options with
10-year terms to purchase 677,199 shares of its common stock to employees, directors and consultants. The fair value of the options granted
and shares awarded was $2,503,979. The following assumptions were used in the fair value calculations of the options granted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nine Months Ended<BR> December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk-free interest rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.93%&nbsp;-&nbsp;3.99</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.26%&nbsp;-&nbsp;1.36</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.82%&nbsp;-&nbsp;4.06</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.8%&nbsp;-&nbsp;1.36</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">149</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">197%&nbsp;-&nbsp;253</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">149%&nbsp;-&nbsp;223</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">89%&nbsp;-&nbsp;370</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0&nbsp;-&nbsp;5.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0&nbsp;-&nbsp;6.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0&nbsp;-&nbsp;5.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0&nbsp;-&nbsp;6.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The fair
values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish
the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates,
as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend
yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future.
The Company accounts for forfeitures as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">A summary of stock option activity
under the Plan is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares<BR> Available<BR> for Grant</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<BR> Shares</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<BR> Average<BR> Exercise<BR> Prices</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 64%">Balance at March 31, 2022</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">989,466</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,650,705</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(265,634</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,634</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,664</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Options cancelled and returned to the Plan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">96,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(96,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">7.69</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Balance at June 30, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">817,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,819,671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.19</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(241,023</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Options cancelled and returned to the Plan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(30,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">4.67</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Balance at September 30, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">595,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,030,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(170,542</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">170,542</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Options cancelled and returned to the Plan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,594</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,594</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">5.82</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance at December 31, 2022</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">445,559</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,174,198</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">5.69</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">There were no stock options exercised
during the nine months ended December 31, 2022 and 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The following table summarizes
the range of outstanding and exercisable options as of December 31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><B>Range of Exercise Price</B></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<BR> Outstanding</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Life (in Years)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<BR> Exercisable</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<BR> Intrinsic<BR> value</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">$1.98&nbsp;- $17.70</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,174,198</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,360,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>$</TD>
    <TD STYLE="text-align: right">5.87</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 8%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 8%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 8%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&rsquo;s principal trading market over
the exercise price of the option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31, 2022 and
2021, there were no such tax benefits associated with the exercise of stock options, as no stock options were exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
7 &ndash;&nbsp;INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&rsquo;s
assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A
valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred
tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not
that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016
to fiscal 2022 may be subject to examination by the U.S. federal and state tax authorities. As of December 31, 2022, the Company has not
recorded any liability for unrecognized tax benefits related to uncertain tax positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE 8 &ndash;&nbsp;COMMITMENTS
&amp; CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>Litigations, Claims and Assessments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business.
The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>Indemnification</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any
losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising
from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims
relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into
indemnification agreements with its officers and directors. No amounts were reflected in the Company&rsquo;s consolidated financial statements
for the nine months ended December 31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential
amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements, and
no claims for payment have been made under such agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>Purchase Obligations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s
primary purchase obligations include purchase orders for machinery and equipment. At December 31, 2022, the Company had outstanding purchase
orders for machinery and equipment and related expenditures of approximately $735,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.9pt 0pt 7.95pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE 9 &ndash;&nbsp;SUBSEQUENT
EVENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>New
Lease Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">On
January 5, 2023, the Company entered into a lease agreement (the Thornhill Lease) with Michael Summers (the Lessor) for a new headquarters
facility pursuant to which the Company will lease approximately 24,000 square feet of a building located in San Diego, California, commencing
on or about February 1, 2023. The monthly base rent is $36,000 for the first 12 months of the lease and will increase by 4% of the prior
year&rsquo;s base rent at the beginning of each 12-month period thereafter. The lease term is 48 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">Under
the Thornhill Lease, the Company will pay the Lessor a monthly fee for its pro-rated share of specified common area charges, including
maintenance costs, property taxes and insurance, in addition to base rent. The monthly fee for the common area charges is approximately
$10,700 and will be adjusted based on actual costs incurred by the Lessor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>Amended
2017 Equity Incentive Plan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">In
January 2023, the Company&rsquo;s stockholders&nbsp;approved an increase in the number of shares reserved for issuance under the Plan
by&nbsp;2,000,000&nbsp;shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_028"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">To the Audit Committee and<BR>
Stockholders of Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Opinion on the Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have audited the accompanying
consolidated balance sheets of Modular Medical, Inc. (the &ldquo;Company&rdquo;) as of March 31, 2022 and 2021, and the related consolidated
statements of operations, stockholders&rsquo; equity (deficit), and cash flows for the years then ended, and the related notes (collectively
referred to as the &ldquo;consolidated financial statements&rdquo;). In our opinion, the consolidated financial statements present fairly,
in all material respects, the financial position of the Company as of March 31, 2022 and 2021, and the results of its operations and its
cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">These consolidated financial
statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We conducted our audits
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we
are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Critical Audit Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The critical audit matters
communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or
required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated
financial statements and (ii) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the
critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they
relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Going Concern</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As described further
in Note 1 to the financial statements, the Company has incurred losses since inception, and expects to continue to incur operating losses
for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent commercialization
of its product. The Company expects that its research and development and general and administrative expenses will continue to increase,
and, as a result, it will eventually need to generate significant product revenues to achieve profitability. As of March 31, 2022, the
Company had cash balances of approximately $9,076,000, as a result of the capital raised in the public offering in February 2022. In addition,
subsequent to March 31, 2022, the Company raised net proceeds from an equity offering of approximately $7,372,000. The Company has concluded
that these plans alleviate the doubt related to its ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We identified management&rsquo;s
assessment of the Company&rsquo;s ability to continue as a going concern as a critical audit matter due to inherent complexities and uncertainties
related to the Company&rsquo;s projections of operations. Auditing management&rsquo;s going concern assessment involved a high degree
of auditor judgment and audit effort due to the impact of these assumptions on the determination of the degree of doubt regarding the
ability of the entity to continue as a going concern. The primary procedures we performed to address this critical audit matter included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We evaluated the reasonableness of key assumptions underlying
management&rsquo;s conclusion.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We evaluated that the disclosures included in the Form 10-K
were complete and accurate and in accordance with accounting principles generally accepted in the United States of America.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We evaluated the impact of the Company&rsquo;s existing financing
arrangements and future capital needs over the next 12 months on its ability to continue as a going concern.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Stock Based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As discussed in Note
8, during the year ended March 31, 2022, the Company granted 827,427 options to purchase shares of its common stock with 10-year terms
and a grant-date fair value of $8,507,311 to employees, directors and consultants. Management is required to analyze the fair value of
each option granted and amortize it over its vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We identified the grant
of stock options as a&nbsp;critical&nbsp;audit&nbsp;matter. Management&rsquo;s estimates regarding fair value of options result in the
application of a high degree of auditor judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The primary procedures
we performed to address this&nbsp;critical&nbsp;audit&nbsp;matter included the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We gained an understanding of Company&rsquo;s processes and
controls in place for determining the fair value of each granted option.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We evaluated the option price model the management selected
to determine the fair value, and analyzed the underlying data used in the calculations.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We also recalculated the fair value of each option granted.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>/s/&nbsp;Farber Hass Hurley LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Firm Id&nbsp;223</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We have served as the Company&rsquo;s auditor since 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chatsworth, California</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">June 28, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_029"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consolidated Balance
Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; font-weight: bold"></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,076,372</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,468,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,158</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">958</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,466</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,389,794</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,649,089</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Property and equipment,&nbsp;net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">298,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Right of use asset, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,693</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,124</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Security deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NON-CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">456,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">599,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,846,446</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,248,171</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">299,951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">169,284</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">524,891</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499,948</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Short-term lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,857</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">PPP note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,780</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Convertible notes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,133,453</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">969,699</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,296,965</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Long-term lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Bonus payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL&nbsp; LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,009,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,523,320</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; font-weight: bold; text-align: left">Commitments and Contingencies (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred Stock, $0.001&nbsp;par value,&nbsp;5,000,000&nbsp;shares authorized,&nbsp;none&nbsp;issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Common Stock, $0.001&nbsp;par value,&nbsp;50,000,000&nbsp;shares authorized,&nbsp;10,461,898&nbsp;shares and&nbsp;6,302,050&nbsp;shares issued and outstanding as of March 31, 2022 and 2021, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,302</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,406,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,665,559</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(34,579,771</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15,947,010</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,836,790</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,275,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,846,446</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,248,171</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these audited consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_030"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consolidated Statements
of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Twelve Months Ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,729,240</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,083,303</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,197,162</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,253,412</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; font-weight: bold; text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,926,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,336,715</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,926,402</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,336,715</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,752,229</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,791</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loss on debt extinguishment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,321,450</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,631,161</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,376,376</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,600</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,632,761</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,377,976</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2.74</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.20</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shares used in computing net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,807,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,211,562</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these audited consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_031"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consolidated Statements
of Stockholders&rsquo; Equity (Deficit)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<BR> Paid-In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Issuable</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Equity (Deficit)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">Balance as of&nbsp;March 31, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">5,956,754</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">5,957</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">10,517,505</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">923,994</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(8,569,034</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">2,878,422</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Placement of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,709,555</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(923,994</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,785,882</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,921</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,945</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,227,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,227,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,377,976</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,377,976</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Balance as of March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,302,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,665,559</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(15,947,010</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,275,149</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock upon public offering, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,657,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,660,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock in settlement of convertible notes and accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,511,276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,506,254</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,507,765</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Placement of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,864</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrants issued with convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,700,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,700,632</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">594,310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">594,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for reverse stock split</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of common stock under equity incentive plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,091</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,859,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,859,785</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,632,761</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,632,761</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">Balance as of March 31, 2022</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,461,898</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,462</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">43,406,099</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(34,579,771</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,836,790</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these audited consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_032"></A>Modular Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consolidated Statements
of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash Flows from operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(18,632,761</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(7,377,976</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Gain on PPP note forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(368,780</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,321,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,031,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,227,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,490</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">666,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Shares issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">395,950</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,880</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Amortization of lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,826</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Change in lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(125,040</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Amortization of debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,833,618</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,253</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Other </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Other assets and prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">354,948</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(86,747</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,259,528</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,908,662</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(54,764</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,669</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(54,764</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,669</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from private placements, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,785,882</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from issuance of convertible notes, net of placement fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,137,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,210,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from issuance of promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Repayment of promissory note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,100,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from issuance of PPP note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,780</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of common stock upon public offering, net of issuance costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,535,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,922,199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,364,662</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase (decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,607,907</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,653,669</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, at beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,468,465</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,122,134</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents, at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,076,372</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,468,465</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Noncash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Fair value of detachable warrants issued with convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,700,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Conversion of convertible notes and accrued interest into common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,253,876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,600</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,600</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Interest paid</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">252,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The accompanying notes
are an integral part of these audited consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_033"></A>MODULAR MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Note&nbsp;1 &ndash;&nbsp;THE
COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc. (the Company) was incorporated
in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately
2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras). As the major stockholder
of Quasuras retained control of both the Company and Quasuras, the share exchange was accounted for as a reverse merger. As such, the
Company recognized the assets and liabilities of Quasuras, acquired in the merger, at their historical carrying amounts. Prior to the
acquisition of Quasuras and, since at least 2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities
Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical,
Inc.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin
pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent
people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their
daily insulin in two ways, through a continuous &ldquo;basal&rdquo; delivery allowing a small amount of insulin to be in the blood at
all times and a &ldquo;bolus&rdquo; delivery to address meal time glucose input and to address when the blood glucose level becomes excessively
high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically
savvy, less motivated part of the market.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">As discussed
in Note 7, in February 2022, the Company completed a public offering of its equity securities, and its common stock was approved to list
on the Nasdaq Capital Market under the symbol &ldquo;MODD&rdquo; and began trading there on February 10, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The accompanying
financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities
in the normal course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent
on, among other things, the Company&rsquo;s ability to operate profitably, to generate cash flows from operations, and to pursue financing
arrangements to support its working capital requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">At issuance
of the Company&rsquo;s financial statements for the year ended March 31, 2021, management had determined that there was significant doubt
as to the ability of the Company to meet its obligations and continue as a going concern. As a result of the Offering (see Note 7), which
was completed in February 2022, and the Registered Offering (see Note 13), which was completed in May 2022, and resulting improved financial
position, the Company believes it has sufficient liquidity to meet its obligations as they come due and conduct its business for a period
of at least 12 months from the date of issuance of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures.
The Company&rsquo;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&rsquo;s
ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce
costs in order to conserve its cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Basis
of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America. The Company&rsquo;s fiscal year ends on March 31 of each calendar year.<B>&nbsp;</B>Each reference to a fiscal year in these
notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal
2022 refers to the fiscal year ending March 31, 2022). The consolidated financial statements include the accounts of the Company and its
wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Reverse Stock Split</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of
State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&rsquo;s shares of common stock.&nbsp;Such amendment
and ratio were previously approved by a majority of the Company&rsquo;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&rsquo;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&rsquo;s equity incentive plans
and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of common
stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split.&nbsp;All share numbers,
share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3 reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Use of
Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting
period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from
those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Reportable Segment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The Company operates in one business
segment and uses one measurement of profitability for its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
expenses research and development expenditures as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>General
and Administrative</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Concentration
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its
cash at high quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC)
up to limits of approximately $250,000.&nbsp;No reserve has been made in the financial statements for any possible loss due to financial
institution failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Risks
and Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing,
liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>COVID-19</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020.&nbsp;&nbsp;This has negatively affected the U.S. and global economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &ldquo;shelter-in-place&rdquo; and created
significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&rsquo;s operational and financial
performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and
foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&rsquo;s control, and cannot be predicted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Cash and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Cash and
cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Property and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Property
and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations.
Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the
lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Fair Value of Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used
to measure fair value into three broad levels:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 1 inputs to the valuation methodology are quoted prices
for identical assets or liabilities in active markets.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 2 inputs to the valuation methodology include quoted
prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the financial instrument.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Level 3 inputs to the valuation methodology are unobservable
and significant to the fair value measurement.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Debt
Modifications and Extinguishments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">When
the Company modifies or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) Topic 470-50,&nbsp;<I>Debt &mdash; Modifications and Extinguishments,</I>&nbsp;which requires
modification to debt instruments to be evaluated to assess whether the modifications are considered &ldquo;substantial
modifications.&rdquo; A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance
relied upon and the analysis performed, if the Company believes the embedded conversion feature has no fair value on the date of
issuance (measurement date) and the embedded conversion feature has no beneficial conversion feature, the embedded conversion
feature does not meet the criteria in ASC 470-50-40-10 or 470-20-25 and the issuance of the convertible note payable is considered a
modification, and not an extinguishment that would require the recognition of a gain or loss. If the Company determines the change
in terms meet the criteria for substantial modification under ASC 470 it will treat the modification as extinguishment and recognize
a loss from debt extinguishment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Effective&nbsp;April&nbsp;1,
2019, the Company adopted ASC No. 842,&nbsp;<I>Leases&nbsp;</I>(ASC 842). ASC 842 requires an entity to recognize a&nbsp;right-of-use&nbsp;asset
and a lease liability for all leases with terms longer than 12 months. The Company adopted ASC 842 utilizing the modified retrospective
transition method. The Company elected the practical expedient afforded in ASC 842 in which the Company did not reassess whether any contracts
that existed prior to adoption have or contain leases or the classification of its existing leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite
service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the
date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant
using an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective
variables. These variables include, but are not limited to, the expected stock price&nbsp;volatility over the term of the awards, and
projected stock option exercise behaviors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Per-Share
Amounts&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Basic net
loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during
the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially
dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The following
table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would
be anti-dilutive: &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Options to purchase common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,650,705</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,197,252</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,779,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,429,777</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,197,252</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Reclassification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&rsquo;s
assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A
valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred
tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not
that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
accounts for uncertain tax positions in accordance with FASB ASC Topic 740,&nbsp;<I>Income Taxes</I>. When tax returns are filed, it is
likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty
about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position
is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes
it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes,
if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition
threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with
the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described
above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated
interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in general and administrative expenses in the consolidated statements of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.&nbsp;&nbsp;All tax returns from
2016 to 2021 may be subject to examination by the U.S. federal and state tax authorities.&nbsp; As of March 31, 2022 and 2021, the Company
had not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Comprehensive&nbsp;Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2022 and 2021, the Company&rsquo;s
comprehensive loss was the same as its net loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Recently
Issued Accounting Pronouncement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In June
2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13,&nbsp;<I>Financial Instruments&mdash;Credit Losses</I>. This ASU added
a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred
losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt
instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not
have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that
have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within
those fiscal years for smaller reporting companies. The Company is still evaluating the impact of this accounting guidance on its results
of operations and financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE&nbsp;2 &ndash;&nbsp;CONSOLIDATED
BALANCE SHEET DETAIL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B>Property and equipment, net:</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Leasehold improvements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">139,197</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">139,197</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,476</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Computer equipment and software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,383</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Machinery and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">230,947</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">202,993</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 8.65pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">485,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">451,049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 8.65pt">Less: accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(249,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(152,091</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">235,959</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">298,958</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><B>Accrued expenses:</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Accrued wages and bonus</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">457,891</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">372,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued placement fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,538</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">67,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,047</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">524,891</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">499,948</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
3 &ndash;&nbsp;LEASES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
accounts for the lease for its corporate facility in San Diego, California in accordance with ASC 842. The&nbsp;39-month&nbsp;lease term
commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400&nbsp;annual rent increases of approximately&nbsp;3%.&nbsp;In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&rsquo;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
obtained a right-of-use asset of $270,950&nbsp;in exchange for its obligations under the operating lease. The landlord also provided a
lease incentive of approximately $139,000, which was paid to the Company in June 2020, for the Company to make improvements to the leased
space. In addition, the Company paid a $100,000 security deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Future minimum
payments under the facility operating lease, as of March 31, 2022, are listed in the table below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold">Annual Fiscal Years</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Operating<BR>
 lease</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">2023</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">158,028</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,692</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Less:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(13,906</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">184,814</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Cash paid
for amounts included in the measurement of lease liabilities was $153,432&nbsp;for the year ended March 31, 2022. Rent expense was $107,820&nbsp;and
$107,540&nbsp;for the years ended March 31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE 4 &ndash;&nbsp;PPP NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In April
2020, the Company received a $368,780&nbsp;unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established
under the U.S. government&rsquo;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was
made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program
Note with the Lender evidencing the PPP Note.&nbsp;The full amount of the PPP Note was due in April 2022 and interest accrued on the outstanding
principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred for 10 months after the covered period during
which the Company used the proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In May 2021,
the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest for the
PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470:&nbsp;<I>Debt&nbsp;</I>(ASC
470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated statement
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
5 &ndash;&nbsp;CONVERTIBLE PROMISSORY NOTES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company accounted for the replacement
of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $1,321,450&nbsp;and interest expense of $70,647&nbsp;for
unamortized debt issuance costs as of April 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In April
and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold to
investors $4,250,000&nbsp;aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of its
common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months
from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company
fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by law.
Each Note may be prepaid at the Company&rsquo;s option during the first 270 calendar days following its Issue Date (the 270<SUP>th</SUP>&nbsp;day,
the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued interest then outstanding. No Note may be
prepaid in whole or in part after the Trigger Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Notes outstanding
after the Trigger Date may be converted into shares of the Company&rsquo;s common stock at an initial conversion price of $8.61 per share;
provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess of 4.99% of the
Company&rsquo;s outstanding common stock. The conversion price and number of shares of Company common stock issuable upon conversion of
the Notes are subject to adjustment from time to time for subdivisions and consolidations of shares and other standard dilutive and corporate
events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if while a Note is outstanding, the Company
sells, issues or grants any shares of its common stock or other securities to acquire shares of common stock at a price per share less
than the then conversion price, such conversion price shall be reduced to such lesser price, and the number of conversion shares issuable
upon conversion of the Notes shall be increased, as provided in the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital Raise, as
defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below) into the securities of
such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest
on a Note, multiplied by (ii) 1.25.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Notes
contained a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or
interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material
restatements of the Company&rsquo;s consolidated financial statements filed with the SEC, (vi) a holder&rsquo;s inability to rely on Rule
144 for sales of shares underlying the Notes, (vii) the Company&rsquo;s common stock is suspended or halted from trading and/or fails
to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or the NYSE
American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares of common
stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration statement
to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations and
sales of all or substantially all of the Company&rsquo;s assets in the event the Company is not the survivor of such transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Upon an
Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied
by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers,
issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&rsquo;s Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Notes
include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In connection
with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock at an initial
exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date, provided that, if
prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled or (ii) prepays
a holder&rsquo;s Note(s) in whole or in part, such holder&rsquo;s pro-rata number of Warrants shall be cancelled. The fair value of the
Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being amortized to interest expense over the term
of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair value of the Warrants utilizing
the Black-Scholes valuation model with the following assumptions: volatility of&nbsp;88.98%, risk-free interest rate of&nbsp;0.86%, a
term of&nbsp;5.75&nbsp;years and a dividend yield of&nbsp;zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In connection
with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance costs
of $116,000, which were recorded as a debt discount and were amortized to interest expense over the term of the Notes using the effective
interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants, during
the year ended March 31, 2022 was $1,833,618.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Upon the
closing of the Offering (see Note 7), which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into 1,511,276
shares of common stock and the holders of the Notes received 1,511,276 Offering Warrants (as defined in Note 7).&nbsp;As a result of the
Offering, the exercise price of the 767,796 outstanding Warrants was reduced to $6.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
6 &ndash;&nbsp;PROMISSORY NOTE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In October
2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (Manchester) that provided the Company
with a $3,000,000&nbsp;revolving credit facility with all amounts being drawn down by the Company thereunder being due and payable, subject
to acceleration in the event of a default, on&nbsp;March 15, 2022&nbsp;(the Maturity Date). Interest at the rate of&nbsp;12%&nbsp;was
payable on each drawn down without regard to the draw down date or the date when interest is paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The principal
amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity Date and (ii)
the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related transactions occurring
prior to the Maturity Date, which such transactions constitute equity financings or other issuances of the Company&rsquo;s equity securities.
Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred, on any date prior to the Maturity Date, upon
no less than three days written notice by the Company specifying the draw amount, Manchester will advance the draw amount to the Company.
No draw amount can be in an amount less than $100,000 or exceed an amount equal to $3,000,000 minus the aggregate principal amount outstanding
under the Bridge Note at the time of such draw request. If an Event of Default occurs and is continuing, Manchester may declare all of
the Bridge Note, including any interest and other amounts due, to be due and payable immediately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In connection
with the issuance of the Note, on October 28, 2021, the Company entered into a security agreement with Manchester (the Security Agreement)
under which the Company granted Manchester a continuing and unconditional first priority security interest in and to any and all of the
Company&rsquo;s property of any kind or description, tangible or intangible, wheresoever located and whether now existing or hereafter
arising or acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">During fiscal
2022, the Company made draws on the Bridge Note of $2,100,000&nbsp;and incurred interest charges of $252,000. In February 2022, subsequent
to the completion of the Offering (see Note 7), the Bridge Note and accrued interest was paid in full, and the Security Agreement was
terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
7 &ndash;&nbsp;STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Public
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On February
9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement) with Oppenheimer &amp; Co. Inc., who acted as
the representative of the several underwriters (the Underwriters), in a firm commitment underwritten public offering (the Offering) pursuant
to which, on February 14, 2022, the Company sold to the Underwriters an aggregate of 2,500,000 shares of the Company&rsquo;s common stock
and 2,500,000 warrants (the Offering Warrants and, collectively with the shares of common stock, the Units), each to purchase one share
of common stock. The price to the public in the Offering was $6.00 per Unit, before underwriting discounts and commissions. The common
stock and the Offering Warrants comprising the Units were immediately separable upon issuance and were issued separately. The Offering
Warrants were exercisable immediately, have an exercise price of $6.60 per share and expire on February 14, 2027.&nbsp;The gross proceeds
from the Offering were $15,000,000, before deducting underwriting discounts and commissions and other offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Placements
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Between
March and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
962,387 shares of common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement agent
fees on the 2020 Placement of $52,256 during fiscal 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In October
2021, the Company sold&nbsp;30,864&nbsp;shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&rsquo;s board of directors (the Board), president, chief financial officer and treasurer,&nbsp;at a purchase price of $8.10
per share, for gross proceeds of approximately $250,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">During the
year ended March 31, 2022, the Company issued to service providers&nbsp;90,000&nbsp;shares of common stock with a fair value of approximately
$594,400.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
8 &ndash;&nbsp;STOCK-BASED COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Amended
2017 Equity Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In October
2017, the Company&rsquo;s Board approved the 2017 Equity Incentive Plan (the Plan) with&nbsp;1,000,000&nbsp;shares of common stock reserved
for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance under the Plan
by&nbsp;333,334&nbsp;and&nbsp;1,333,334&nbsp;shares, respectively. Under the Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted
stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Stock-Based
Compensation Expense</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based
on the grant date fair value. The unamortized compensation cost, as of March 31, 2022 was $3,286,370&nbsp;related to stock options and
is expected to be recognized as expense over a weighted-average period of approximately&nbsp;two years.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">During the
year ended March 31, 2022, the Company granted options to purchase&nbsp;827,427&nbsp;shares of its common stock to employees, directors
and consultants. The options had 10-year terms and&nbsp;137,292&nbsp;options vested immediately when granted. The grant-date fair value
was determined to be $8,507,311&nbsp;of which $2,739,490&nbsp;was recorded as stock-based compensation expense and included in the consolidated
statements of operations for the year ended March 31, 2022.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The following assumptions were
used in the fair-value method calculations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Risk-free interest rates</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.8%&nbsp;-&nbsp;2.42</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.28%&nbsp;-&nbsp;0.71</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89%&nbsp;-&nbsp;370</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87%&nbsp;-&nbsp;127</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0&nbsp;-&nbsp;6.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0&nbsp;-&nbsp;6.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The fair
values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish
the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from
the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the
expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention
to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">A summary of stock option activity
under the 2017 Plan is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares<BR>
Available</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of </TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted <BR>
Average <BR>
Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">for Grant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Balance at March 31, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">274,019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,059,315</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.74</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(163,492</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.64</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 8.65pt">Options cancelled and returned to the Plan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.75</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Balance at March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,197,252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,333,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(827,427</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">827,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Share awards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26,497</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Options cancelled and returned to the Plan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">373,974</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(373,974</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.73</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance at March 31, 2022</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">989,466</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,650,705</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6.58</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">There were
no stock options exercised during the years ended March 31, 2022 and 2021.&nbsp;The Company issued 26,497 shares to its non-employee directors
under the Company&rsquo;s outside director compensation plan and approximately $172,100 was recorded as stock-based compensation expense
for these share awards during the year ended March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The following
table summarizes the range of outstanding and exercisable options as of March 31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Exercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold">Range of Exercise Price</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Number<BR>
 Outstanding</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Weighted<BR>
 Average<BR>
 Remaining<BR>
 Contractual<BR>
 Life<BR>
 (in Years)</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Weighted<BR>
 Average<BR>
 Exercise<BR>
 Price</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Number<BR>
 Exercisable</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Weighted<BR>
 Average<BR>
 Exercise<BR>
 Price</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Aggregate<BR>
 Intrinsic<BR>
 value</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-bottom: 4pt">$1.98&nbsp;- $17.70</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">1,650,705</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 7%; text-align: right">8.01</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 7%; text-align: right">6.58</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">1,193,680</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 7%; text-align: right">5.69</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 7%; text-align: right">1,090,966</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The intrinsic value per share
is calculated as the excess of the closing price of the common stock on the Company&rsquo;s principal trading market over the exercise
price of the option at March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2022 and 2021, there
were no such tax benefits associated with the exercise of stock options.<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE 9 &ndash;&nbsp;INCOME
TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The income tax provision consisted
of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current portion:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">State</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,600</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">1,600</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred portion:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,109,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,931,390</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1.5pt">State</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,300,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(576,868</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,409,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,508,258</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,409,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,508,258</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,600</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,600</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">At March&nbsp;31,
2022, the Company had net operating loss carryforwards (NOLs) of approximately $27,600,000&nbsp;for federal income tax purposes and $27,800,000&nbsp;for
state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2042, except federal NOLs from fiscal 2018, 2019, 2020, 2021 and 2022, which will never expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The Company
also had federal research and development tax credit carryforwards of approximately $800,000, which will begin expiring at various times
from 2038 through 2041, and state research and development credits of approximately $200,000, which do not have an expiration date.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A reconciliation
of income taxes provided at the federal statutory rate (21% for each of fiscal 2022 and 2021) to the actual income tax provision is as
follows:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21</TD><TD STYLE="width: 1%; text-align: left">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State tax rate, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development tax credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Section 179 assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Effective income tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The losses before income tax
provision for the years ended March 31, 2022 and 2021 were solely attributable to US operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Significant components of the
Company&rsquo;s deferred tax assets and liabilities were:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,731,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,909,434</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,824,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">554,892</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,039</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reserves, accruals &amp; other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(104,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(79,878</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Research and development tax credits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">646,296</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,519,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,012,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Section 179 assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(97,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(97,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,422,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,012,705</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Deferred tax assets, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Based on
the available information and other factors, management believes it is more likely than not that the net deferred tax assets at March
31, 2022 and 2021, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred
tax assets at March 31, 2022 and 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Management
has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&rsquo;s consolidated
financial statements at March 31, 2022 and 2021. The Company does not expect any significant changes in its unrecognized tax benefits
within twelve months of the reporting date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE 10 &ndash;&nbsp;ROYALTY
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the Company entered into a royalty
agreement with its founder, then-chief executive officer, president and major stockholder (the Founder). Pursuant to the agreement, the
Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for future royalty payments on the
Company&rsquo;s product. The Company is obligated to make royalty payments under the agreement to the Founder on any sales of the royalty
product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of a royalty product or (b) 5% of the gross sale
price of the royalty product, whichever is less. The royalty payments will cease, and the agreement will terminate, at such time as the
total sum of royalty payments actually paid to the Founder, pursuant to the agreement, reaches $10,000,000. The Company has the option
to terminate the agreement at any time upon payment, to the Founder, of the difference between total royalty payments actually made to
him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter, will be made by the Company
to the Founder within thirty days after the end of each calendar quarter.&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
11 &ndash;&nbsp;COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>Litigations,
Claims and Assessments&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business.
The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I>Indemnification</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any
losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising
from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims
relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into
indemnification agreements with its officers and directors. No amounts were reflected in the Company&rsquo;s consolidated financial statements
for the years ended March&nbsp;31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential
amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>NOTE&nbsp;12 &ndash;&nbsp;RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">In
February 2021, the Company&rsquo;s chairman of the Board and president and Manchester, which is represented by a member of the Company&rsquo;s
board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively. Effective April
30, 2021, the related party holders entered into revocation agreements with the Company pursuant to which their aggregate principal amount
of Original Notes and accrued interest were replaced with Notes. On February 14, 2022, Manchester and the executive officer held Notes
in an aggregate principal amount of $1,026,630&nbsp;and $102,663, respectively, with $97,881&nbsp;and $9,788&nbsp;of interest payable
thereon. In connection with the Offering, Manchester and the executive officer received&nbsp;234,274&nbsp;and&nbsp;23,429&nbsp;shares
of common stock, respectively, and&nbsp;234,274&nbsp;and&nbsp;23,429&nbsp;Offering Warrants, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">In
May 2021, a member of the Board purchased $200,000&nbsp;aggregate principal amount of Notes (the Director Note). On February 14, 2022,
in connection with the Offering, the Director Note and $18,805&nbsp;of accrued interest thereon were converted into&nbsp;45,586&nbsp;shares
of common stock&nbsp;45,586&nbsp;Offering Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The daughter
of the Company&rsquo;s president, chief financial officer, treasurer and chairman of the Board is an employee of the Company. During fiscal
2022, the Company paid her $169,589, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718,
of a stock option granted in November 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NOTE
13 &ndash;&nbsp;SUBSEQUENT EVENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On May 2,
2022, the Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor (the Investor)
pursuant to which the Company sold, in a registered direct offering (the Registered Offering), for gross proceeds of $8,000,000 an aggregate
of 449,438 shares (the Shares) of the Company&rsquo;s common stock, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants were exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">In
a concurrent private placement under the Purchase Agreement, the Company issued warrants (the Private Placement Warrants) to the Investor
to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants will
be exercisable commencing November 5, 2022 and have a five-year term</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt"><B>2,116,402 Units</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Each Unit Consisting of Two Shares of Common
Stock and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Warrant to Purchase One Share of Common
Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newbridge Securities Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_022"></A>PART II<BR>
<BR>
INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
13. Other Expenses of Issuance and Distribution</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all costs and expenses,
other than underwriting discounts and commissions, paid or payable by the Registrant in connection with the sale of the securities being
registered. All amounts shown are estimates except for the SEC registration fee and the FINRA filing fee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Amount to be<BR> Paid </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left"> SEC Registration Fee </TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 1,711 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> FINRA Filing Fee </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,628 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Printing and Engraving Fees and Expenses </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 25,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Legal Fees and Expenses </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 300,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Accounting Fees and Expenses </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Transfer Agent and Registrar Fees and Expenses </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 10,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Miscellaneous Fees and Expenses </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 50,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 409,339 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item 14.</B> <B>Indemnification of Officers and Directors.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Second Amended and Restated Articles of Incorporation
and our Amended and Restated Bylaws provide that each person who was or is made a party or is threatened to be made a party to or is otherwise
involved (including, without limitation, as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative,
by reason of the fact that he or she is or was one of our directors or officers or is or was serving at our request as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, whether the basis of such action, suit
or proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as a
director, officer or trustee, shall be indemnified and held harmless by us to the fullest extent authorized by the Nevada Revised Statutes,
or NRS, against all expense, liability and loss (including attorneys&rsquo; fees and amounts paid in settlement) reasonably incurred or
suffered by such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.7502 permits a corporation to indemnify
any director or officer of the corporation against expenses (including attorneys&rsquo; fees) and amounts paid in settlement actually
and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that such person is or was a director
or officer of the corporation, if such person (i) is not liable pursuant to NRS 78.138 and (ii) acted in good faith and in a manner which
he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe the conduct was unlawful. In a derivative action (i.e., one brought by or on behalf
of the corporation), indemnification may be provided only for expenses actually and reasonably incurred by any director or officer in
connection with the defense or settlement of such an action or the suit if such person (i) is not liable pursuant to NRS 78.138 and (ii)
acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation,
except that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only
to the extent that the court in which the action or suit was brought or some other court of competent jurisdiction determines that such
person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Second Amended and Restated Articles of Incorporation
provide that the liability of our directors and officers shall be eliminated or limited to the fullest extent permitted by the NRS. NRS
78.138(7) provides that, subject to limited statutory exceptions and unless the articles of incorporation or an amendment thereto (in
each case filed on or after October 1, 2003) provide for greater individual liability, a director or officer is not individually liable
to a corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a
director or officer unless it is proven that: (i) the act or failure to act constituted a breach of his or her fiduciary duties as a director
or officer and (ii) the breach of those duties involved intentional misconduct, fraud or a knowing violation of law.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing discussion of our Second Amended
and Restated Articles of Incorporation, Amended and Restated Bylaws and Nevada law is not intended to be exhaustive and is qualified in
its entirety by such Second Amended and Restated Articles of Incorporation, Amended and Restated Bylaws, indemnification agreements, indemnity
agreement, or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nevada Revised Statutes provide that a corporation
may purchase and maintain insurance or make other<B>&nbsp;</B>financial arrangements on behalf of any person who is or was a director,
officer, employee or agent of<B>&nbsp;</B>the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him
and liability and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as
such, whether or not the corporation has the authority to indemnify him against such liability and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been advised that in the opinion of the
SEC, insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and other
persons pursuant to the foregoing provisions, or otherwise, such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable. In the event a claim for indemnification against such liabilities (other than payment of expenses
incurred or paid by a director or officer in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or other person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In any underwriting agreement we enter into in
connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions,
us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, against certain
liabilities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Item 15.</B> <B>Recent Sales of Unregistered Securities</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set forth below is information regarding shares
of common stock , convertible notes and warrants issued, and options granted, by us within the past three years that were not registered
under the Securities Act. Also included is the consideration, if any, received by us for such shares, convertible notes, warrants and
options, and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which
exemption from registration was claimed.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Director Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On
December 30, 2022, we issued 6,375 shares of our common stock to four of our non-employee directors in accordance with our Outside Director
Compensation Plan (the &ldquo;Director Plan&rdquo;). On September 30, 2022, we issued 6,375 shares of our restricted common stock to
four of our non-employee directors in accordance with the Director Plan. On August 8, 2022, we issued 5,000 shares of our restricted
common stock to two of our non-employee directors in accordance with the Director Plan. On June 30, 2022, we issued 2,664 shares of our
common stock to non-employee members of our board of directors for service as directors in accordance with the Director Plan.&nbsp;On
March 31, 2022, we issued 15,250 shares of our common stock to non-employee members of our board of directors for service as directors
in accordance with the Director Plan. On December 31, 2021, we issued 5,775 shares of our common stock to non-employee members of our
board of directors for service as directors in accordance with the Director Plan. On September 30, 2021, we issued 3,636 shares of our
common stock to non-employee members of our board of directors for service as directors in accordance with the Director Plan. On June
30, 2021, we issued 1,836 shares of our common stock to non-employee members of our board of directors for service as directors in accordance
with the Director Plan.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Service Providers</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2023, we issued 10,000 shares of
our common stock to a service provider. On March 13, 2023, we issued 478 shares of our common stock to a service provider. On February
13, 2023, we issued 438 shares of our common stock to a service provider. On May 9, 2022, we issued 348 shares of our common stock to
a service provider. On January 5, 2022, we issued 16,666 shares of our common stock to service providers.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>2022
Placement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><I>&nbsp;</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2022, the Company issued warrants in a
private placement to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The warrants
were exercisable six months from the date of issuance and have a five-year term from the date the warrants become exercisable.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Officer Purchases of Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On
October 28, 2021, we sold to two of our executive officers a total of 30,864 shares of our common stock at a purchase price of $8.10
per share, which resulted in gross proceeds to us of $250,000.&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>2021 Placement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between
February and May 2021, we issued to accredited investors in a private placement (the &ldquo;2021 Placement&rdquo;) $6,610,550 aggregate
principal amount of our 12% unsecured convertible promissory notes, due 12 months from each respective issuance date, at par and warrants
to purchase in the aggregate 761,912 shares of our common stock at an exercise price of $24.00 per share, exercisable for a 5-year period,
as provided in such warrants.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
16. <U>Exhibits</U></B>.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Index to Exhibits listing the exhibits required
by Item 601 of Regulation S-K is located on the page immediately following the signature page to this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Item
17. <U>Undertakings</U>.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">To include any prospectus required by Section 10(a)(3) of
the Securities Act of 1933, as amended (the Securities Act);</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising
after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high and of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent
change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective
Registration Statement; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">To include any material information with respect to the plan
of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration
Statement; <I>provided</I>, <I>however</I>, that the information required to be included in a post-effective amendment by paragraphs
(a)(1)(i), (a)(1) (ii) and (a)(1) (iii) above may be contained in periodic reports filed with or furnished to the SEC by the registrant
pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">(2)</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona-fide offering thereof.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">(3)</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">(4)</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">That, for the purpose of determining liability under the Securities Act to any purchaser:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">each prospectus filed by the registrant pursuant to Rule
424(b)(3) shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included
in the Registration Statement; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i),
(vii), or (x) (&sect;230.415(a)(1)(i), (vii), or (x)) for the purpose of providing the information required by section 10(a) of the Securities
Act shall be deemed to be part of and included in this Registration Statement as of the earlier of the date such form of prospectus is
first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As
provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed
to be a new effective date of this Registration Statement relating to the securities in this Registration Statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however,
that no statement made in a registration statement or prospectus that is part of this Registration Statement or made in a document incorporated
or deemed incorporated by reference into this Registration Statement or prospectus that is part of this Registration Statement will,
as to a purchaser with a time of contract of sale prior to such effective date, supersede, supplement or modify any statement that was
made in this Registration Statement or prospectus that was part of this Registration Statement or made in any such document immediately
prior to such effective date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify; width: 0.25in">(5)</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">(6)</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant to Rule 424;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Any free writing prospectus relating to the offering prepared
by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">The portion of any other free writing prospectus relating
to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned
registrant; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">Any other communication that is an offer in the offering
made by the undersigned registrant to the purchaser.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of
the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify">(a)
Exhibits.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See the Exhibit Index included
immediately prior to the signature page to this registration statement, which is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; margin-left: 0in; text-indent: 0in; text-align: justify">(b)
Financial Statement Schedules.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No financial statement schedules are provided
because the information called for is not required or is shown either in the financial statements or notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(a)&nbsp;<B>Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%"><B>Exhibit No.</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 89%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 1.1* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="ea177987ex1-1_modular.htm"> Form of Underwriting Agreement </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>2.1(1)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm">Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other stockholders of Quasuras, Inc.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>2.2(2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex2_2.htm">Addendum No. 1 to Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other Stockholders of Quasuras, Inc. dated May 3, 2021</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>3.1(3)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm">Third Amended and Restated Articles of Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3.2(4)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000620/ex3_1.htm">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Modular Medical, Inc., filed with the Secretary of State of the State of Nevada on November 24, 2021</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>3.3(5)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101041209000212/ex32amendedbylaws.htm">Amended Bylaws</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 4.1**+ </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1074871/000121390023031913/ea175878ex4-1_modular.htm"> 2017 Equity Incentive Plan, as amended </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.2(18)</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex4_2.htm">Form of Warrant to Purchase Common Stock</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.3(20)</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_1.htm">Form of Pre-Funded Warrant dated May 2, 2022</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4.4(20)</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_2.htm">Form of Private Placement Warrant dated May 2, 2022</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 4.5* </TD>
    <TD> &nbsp; </TD>
    <TD><A HREF="ea177987ex4-5_modular.htm"> Form of Warrant </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> 4.6* </TD>
    <TD> &nbsp; </TD>
    <TD><A HREF="ea177987ex4-6_modular.htm"> Form of Underwriter&rsquo;s Warrant </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 5.1* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="ea177987ex5-1_modular.htm"> Opinion of Lucosky Brookman LLP </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.4(9) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_4.htm">Employment Agreement dated August 1, 2018, by and between the Registrant and Paul DiPerna</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.5(1)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_3.htm">Intellectual Property Assignment Agreement dated July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.6(1) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_4.htm">Technology Royalty Agreement dated as of July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.9(10)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_9.htm">Lease between MCP Socal Industrial - Bernardo, LLC and the Registrant dated January 10, 2020</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.10(10) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_13.htm">Service Agreement effective December 31, 2019 between the Registrant and Carmen Volkart</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.11(10) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_14.htm">Service Agreement effective January 23, 2020 between the Registrant and William Febbo</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.12(10) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_15.htm">Form of Indemnification Agreement between the Registrant and each of its directors and officers used from January 23, 2020</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.13(10) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_16.htm">Form of Notice of Stock Option Grant and Stock Option Agreement under the Amended 2017 Equity Incentive Plan</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.14(12) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000364/ex10_18.htm">First Amendment to Employment Agreement between the Registrant and Paul DiPerna effective as of May 12, 2020</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.15(14)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000102/ex10_21.htm">Form of Promissory Note dated February 8, 2021</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.16(2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_21.htm">Form of Convertible Promissory Note issued in the 2021 Private Placement</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.17(2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_22.htm">Form of Common Stock Purchase Warrant issued in the 2021 Private Placement</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.18(2)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_24.htm">Form of Registration Rights Agreement for the 2021 Private Placement</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.19(15) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/ex10_26.htm">Service Agreement effective May 18, 2021 between the Registrant and Ellen O&rsquo;Connor Vos</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.20(16) +</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000475/ex10_27.htm">Employment Agreement between the Registrant and Ellen O&rsquo;Connor Vos dated August 11, 2021</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.21(17)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_27.htm">Promissory Note dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.22(17)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_28.htm">Security Agreement dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.23(18)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex10_1.htm">Form of Warrant Agency Agreement</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.24(19)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex10_31.htm">Form of Warrant Omnibus Amendment Agreement</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.25(20)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex10_1.htm">Form of Securities Purchase Agreement dated May 2, 2022</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10.26(21)+</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000444/ex10_33.htm">Severance and Release Agreement between the Registrant and Ellen O&rsquo;Connor Vos dated February 23, 2022</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.27(22)+</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000518/ex10_1.htm" STYLE="-sec-extract: exhibit">Offer Letter Agreement between the Registrant and Kevin Schmid dated July 13, 2022</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> 10.28** </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1074871/000121390023031913/ea175878ex10-28_modular.htm"> Standard Industrial/Commercial Single-Tenant Lease between the Registrant and Michael Summers dated January 5, 2023 </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 10.29* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="ea177987ex10-29_modular.htm"> Form of Warrant Agent Agreement </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>21.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1074871/000101905622000478/modular_10k.htm#modulara011">Sole Subsidiary of the Registrant (as disclosed in the Notes to Consolidated Financial Statements as of March 31, 2022 in the Registrant&rsquo;s Annual Report on Form 10-K)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 23.1* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="ea177987ex23-1_modular.htm"> Consent of Farber Hass Hurley LLP </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> 23.2* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="ea177987ex5-1_modular.htm"> Consent of Lucosky Brookman LLP (included in Exhibit 5.1) </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> 24.1** </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1074871/000121390023031913/ea175878-s1_modularmedical.htm#poa"> Power of Attorney (included in signature of previous filing) </A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> 107* </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"><A HREF="ea177987ex-fee_modular.htm">Calculation of Filing Fee Tables</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Current Report on Form 8-K filed July 28, 2017, and incorporated
                                            herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Current Report on Form 8-K filed May 12, 2021, and incorporated
                                            herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Current Report on Form 8-K filed June 29, 2017, and incorporated
                                            herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Current Report on Form 8-K filed December 1, 2021, and
                                            incorporated herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Annual Report on Form 10-K/A for the year ended June 30,
                                            2008, and incorporated herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Quarterly Report on Form 10-Q filed November 12, 2018,
                                            and incorporated herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Current Report on Form 8-K filed April 5, 2017, and incorporated
                                            herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Current Report on Form 8-K filed November 20, 2018 and
                                            incorporated herein by reference.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            filed with the Registrant&rsquo;s Registration Statement on Form S-1, as amended, originally
                                            filed June 27, 2019, declared effective October 22, 2019 (Commission File No. 333-232377).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(10)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Quarterly Report on
Form 10-Q for the quarter ended December 31, 2019, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(11)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Registration Statement
on Form S-1, as amended, originally filed April 9, 2020, declared effective May 11, 2020 (Commission File No. 333-237615).</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(12)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Current Report on Form
8-K filed May 27, 2020, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(13)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Current Report on Form
8-K filed May 12, 2020, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(14)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Quarterly Report on
Form 10-Q for the quarter ended December 31, 2020, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(15)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Annual Report on Form
10-K filed June 29, 2021, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(16)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Current Report on Form
8-K filed August 16, 2021, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(17)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Current Report on Form
8-K filed October 29, 2021, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(18)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Current Report on Form
8-K filed February 14, 2022, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(19)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Registration Statement
on Form S-1 filed February 9, 2022, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(20)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Current Report on Form
8-K filed May 5, 2022, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(21)</TD><TD STYLE="text-align: justify">As filed with the Registrant&rsquo;s Registration Statement
on Form S-1 filed June 6, 2022, and incorporated herein by reference.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"> (22) </TD><TD STYLE="text-align: justify"> As filed with the
                                            Registrant&rsquo;s Current Report on Form 8-K filed July 26, 2022, and incorporated herein
                                            by reference. </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> Filed herewith. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"> ** </TD><TD STYLE="text-align: justify"> Previously filed. </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">+</TD><TD STYLE="text-align: justify">Management contract, compensatory plan or arrangement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly
authorized in the City of San Diego, State of California, on May 5, 2023. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><B>MODULAR MEDICAL, INC.</B></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; width: 60%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 4%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 36%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: top">/s/ <I>James E. Besser</I></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">James E. Besser</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Chief Executive Officer<BR>
 (principal executive officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 4%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 31%; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 43%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 18%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    E. Besser</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    executive officer)</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President, and Chief Financial Officer</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    DiPerna</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    financial officer and principal accounting officer)</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    J. Febbo</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Felsher</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
    C. Frank</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip
    Sheibley</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmen
    Volkart</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By&nbsp;:</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">May
    5, 2023</FONT> </TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen
    O&rsquo;Connor Vos</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%"> * </TD>
  <TD STYLE="width: 4%"> By: </TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%"> /s/ James E. Besser </TD>
  <TD STYLE="width: 30%"> &nbsp; </TD>
  <TD STYLE="width: 30%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD> &nbsp; </TD>
  <TD> &nbsp; </TD>
  <TD> James E. <FONT STYLE="font-weight: normal">Besser</FONT> </TD>
  <TD> &nbsp; </TD>
  <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD> &nbsp; </TD>
  <TD> &nbsp; </TD>
  <TD> attorney-in-fact </TD>
  <TD> &nbsp; </TD>
  <TD> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


























































































































































































































































































































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea177987ex1-1_modular.htm
<DESCRIPTION>FORM OF UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>MODULAR
MEDICAL, inC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>NEWBRIDGE
SECURITIES CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[<FONT STYLE="font-family: Wingdings"></FONT>&#9679;],
2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Newbridge Securities Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 North Federal Highway, Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boca Raton, Florida 33432</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, Modular Medical,
Inc., a corporation formed under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this
&ldquo;<B>Agreement</B>&rdquo;) with Newbridge Securities Corporation (hereinafter referred to as &ldquo;<B>you</B>&rdquo; or the &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Purchase and Sale of Shares</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.1
<U>Firm Units</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.1.
<U>Nature and Purchase of Firm Units</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(i)
<FONT STYLE="font-size: 10pt">On the basis of the representations and warranties herein contained, but subject to the terms and conditions
herein set forth, the Company agrees to issue and sell to the Underwriter an aggregate of [&#9679;] units (the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Firm
Units<FONT STYLE="font-weight: normal">&rdquo;) consisting of (A) an aggregate of [&#9679;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">]
shares (the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Firm Shares<FONT STYLE="font-weight: normal">&rdquo;)
of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;</FONT>Common Stock<FONT STYLE="font-weight: normal">&rdquo;),
and (B) warrants exercisable to purchase an aggregate of </FONT></FONT><FONT STYLE="font-size: 10pt; font-weight: normal">[&#9679;] <FONT STYLE="font-family: Times New Roman, Times, Serif">shares
of Common Stock, in the form attached hereto as <U>Exhibit A</U> (the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants<FONT STYLE="font-weight: normal">&rdquo;),
which Warrants will have an exercise price of $</FONT></FONT><FONT STYLE="font-size: 10pt; font-weight: normal">[&#9679;] <FONT STYLE="font-family: Times New Roman, Times, Serif">per
share, subject to adjustment as provided for therein (the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Firm
Warrants<FONT STYLE="font-weight: normal">&rdquo;). Each individual Firm Unit shall consist of: (i) two (2) Firm Shares and (ii) one
(1) Firm Warrant to purchase one (1) share of Common Stock, which shall be immediately separable upon issuance. The Firm Shares and the
Common Stock issuable upon the exercise of the Warrants (the &ldquo;</FONT>Warrant Shares<FONT STYLE="font-weight: normal">&rdquo;) consist
of authorized but unissued shares of Common Stock to be issued and sold by the Company.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(ii)<FONT STYLE="font-size: 10pt">
The Underwriter agrees to purchase from the Company the Firm Units at a purchase price of $</FONT></FONT><FONT STYLE="font-size: 10pt; font-weight: normal">[&#9679;<FONT STYLE="font-family: Wingdings"></FONT>]
<FONT STYLE="font-family: Times New Roman, Times, Serif">per Firm Unit (with $0.01 allocated to the value of a full Warrant to purchase
one share of common Stock). The Firm Units are to be offered to the public (the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering<FONT STYLE="font-weight: normal">&rdquo;)
at the offering price set forth on the cover page of the Prospectus (as defined in <U>Section 2.1.1</U>).</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.2.
<U>Firm Units Payment and Delivery.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(i)
<FONT STYLE="font-size: 10pt">Delivery and payment for the Firm Units shall be made at 10:00 a.m., Eastern time, on </FONT></FONT><FONT STYLE="font-size: 10pt; font-weight: normal">[&#9679;]<FONT STYLE="font-family: Times New Roman, Times, Serif">,
2023 or at such earlier time as shall be agreed upon by the Underwriter and the Company, at the offices of McGuireWoods LLP, 1251 Avenue
of the Americas, 20<SUP>th</SUP> Floor, New York, New York 10020 (&ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter&rsquo;s
Counsel</B><FONT STYLE="font-weight: normal">&rdquo;), or at such other place (or remotely by electronic transmission) as shall be agreed
upon in writing by the Underwriter and the Company. The hour and date of delivery and payment for the Firm Units is called the &ldquo;</FONT><B>Closing
Date</B><FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(ii)<FONT STYLE="font-size: 10pt">
Payment for the Firm Units shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the
Company upon delivery of the certificates (in form and substance satisfactory to the Underwriter) representing the Firm Shares and the
Firm Warrants (or through the facilities of The Depository Trust Company (&ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">DTC<FONT STYLE="font-weight: normal">&rdquo;))
for the account of the Underwriter. The Firm Shares and the Firm Warrants shall each be registered in such name or names and in such authorized
denominations as the Underwriter may request in writing at least two (2) Business Days prior to the Closing Date. The Company shall not
be obligated to sell or deliver the Firm Units except upon tender of payment by the Underwriter for all of the Firm Units. The term &ldquo;</FONT>Business
Day<FONT STYLE="font-weight: normal">&rdquo; means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking
institutions are authorized or obligated by law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.2
<U>Over-allotment Option</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">1.2.1.
<U>Option Shares</U>. The Company hereby grants to the Underwriter an option (the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Over-allotment
Option<FONT STYLE="font-weight: normal">&rdquo;) to purchase from the Company (i) up to an additional </FONT></FONT><FONT STYLE="font-weight: normal">[&#9679;<FONT STYLE="font-family: Wingdings"></FONT>]
<FONT STYLE="font-family: Times New Roman, Times, Serif">shares of Common Stock, representing up to 15% of the Firm Shares sold in the
Offering (the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Option Shares<FONT STYLE="font-weight: normal">&rdquo;),
and (ii) additional Warrants to purchase up to </FONT></FONT><FONT STYLE="font-weight: normal">[&#9679;<FONT STYLE="font-family: Wingdings"></FONT>]
<FONT STYLE="font-family: Times New Roman, Times, Serif">shares of Common Stock, representing up to fifteen percent (15%) of the Firm
Warrants sold in the Offering (the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Option Warrants<FONT STYLE="font-weight: normal">,&rdquo;
and together with the Option Shares, the &ldquo;</FONT>Option Securities<FONT STYLE="font-weight: normal">&rdquo;), for the purpose of
covering over-allotments of such securities, if any. The purchase price to be paid for the Option Shares and/or Option Warrants will be
the price set forth in <U>Section 1.1.1</U> for such securities. The Over-allotment Option may be elected with respect to, at the Underwriter&rsquo;s
sole discretion, Option Shares and Option Warrants together, solely Option Shares, solely Option Warrants, or any combination thereof.
The Firm Shares, the Firm Warrants, the Option Shares, the Option Warrants and the Warrant Shares are hereinafter referred to collectively
as the &ldquo;</FONT>Public Securities<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.2.
<U>Exercise of the Option</U>. The Over-allotment Option granted pursuant to <U>Section 1.2.1</U> may be exercised by the Underwriter
as to all (at any time) or any part (from time to time) of the Option Shares and/or Option Warrants within 30 days after the date hereof.
The Underwriter shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option.
The Over-allotment Option granted hereby shall be exercised by the giving of electronic notice to the Company from the Underwriter, which
shall be confirmed in writing by overnight mail or facsimile or other electronic transmission, setting forth the number of Option Securities
to be purchased and the date and time for delivery of and payment for the Option Securities (the &ldquo;</FONT>Option Closing Date<FONT STYLE="font-weight: normal">&rdquo;),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the
Company and the Underwriter, at the offices of Underwriter&rsquo;s Counsel or at such other place (including remotely by electronic transmission)
as shall be agreed upon by the Company and the Underwriter. If such delivery and payment for the Option Securities does not occur on the
Closing Date, the applicable Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect
to all or any portion of the Option Securities, subject to the terms and conditions set forth herein, the Company shall become obligated
to sell to the Underwriter the number of Option Shares and/or Option Warrants specified in such notice.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.3. <U>Payment
and Delivery</U>. Payment for the Option Securities shall be made on each Option Closing Date by wire transfer in Federal (same day)
funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the
Underwriter) representing the Option Shares and/or Option Warrants (or through the facilities of DTC) for the account of the
Underwriter. The Option Securities shall be registered in such name or names and in such authorized denominations as the Underwriter
may request in writing at least two (2) Business Days prior to each Option Closing Date. The Company shall not be obligated to sell
or deliver the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Shares and/or Option Warrants except
upon tender of payment by the Underwriter for applicable Option Securities. An Option Closing Date may be simultaneous with, but not
earlier than, the Closing Date; and in the event that such time and date are simultaneous with the Closing Date, the term
&ldquo;Closing Date&rdquo; shall refer to the time and date of delivery of the Firm Units and Option Securities.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.3
<U>Underwriter Warrants</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.1.
<U>Purchase Warrants</U>. The Company hereby agrees to issue to the Underwriter (and/or its affiliates, employees or third-party designees)
on the Closing Date and each Option Closing Date, if any, an option (&ldquo;</FONT>Underwriter&rsquo;s Warrant<FONT STYLE="font-weight: normal">&rdquo;)
for the purchase of an aggregate of a number of shares of Common Stock, representing 7% of the Firm Shares sold on the Closing Date and
7% of the Option Shares sold each Option Closing Date, if any. The Underwriter&rsquo;s Warrant, in the form attached hereto as <U>Exhibit
C</U>, shall be exercisable, in whole or in part, commencing on the date that is 180 days after the Effective Date and expiring on the
four-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[&#9679;], which is equal to 125%
of the public offering price of the Firm Units. The Underwriter&rsquo;s Warrant and the shares of Common Stock issuable upon exercise
thereof are hereinafter referred to together as the &ldquo;</FONT>Underwriter&rsquo;s Securities<FONT STYLE="font-weight: normal">.&rdquo;
The Underwriter understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Underwriter&rsquo;s
Warrant and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance
thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Underwriter&rsquo;s Warrant, or any portion thereof,
or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter
or a selected dealer in connection with the Offering or (ii) a bona fide officer, partner, employee or registered representative of the
Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.2.
<U>Delivery</U>. Delivery of the Underwriter&rsquo;s Warrant shall be made on the Closing Date and each Option Closing Date, if any, and
shall be issued in the name or names and in such authorized denominations as the Underwriter may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">2. <U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriter as of the Applicable Time (as defined
below), as of the Closing Date and as of each Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.1
<U>Filing of Registration Statement</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.1.
The Company has prepared and filed with the U.S. Securities and Exchange Commission (the &ldquo;</FONT>Commission<FONT STYLE="font-weight: normal">&rdquo;)
a registration statement on Form S-1, including a prospectus, for the registration under the Securities Act of 1933, as amended (the
&ldquo;</FONT>Securities Act<FONT STYLE="font-weight: normal">&rdquo;) of the offering and sale of the Public Securities and the Underwriter&rsquo;s
Securities, including each of the exhibits, financial statements and schedules thereto, including any material incorporated by reference
therein, which registration statement was prepared by the Company in all material respects in conformity with the requirements of the
Securities Act and the rules and regulations of the Commission under the Securities Act (the &ldquo;</FONT>Securities Act Regulations<FONT STYLE="font-weight: normal">&rdquo;)
and contains or will contain all material statements that are required to be stated therein in accordance with the Securities Act and
the Securities Act Regulations. Except as the context may otherwise require, such registration statement on file with the Commission
at any given time, including (i) any amendments thereto to such time, exhibits and schedules thereto at such time, documents filed as
a part thereof or incorporated pursuant to Item 12 of Form S-1 under the Securities Act at such time and the documents and information
otherwise deemed to be a part thereof or included therein pursuant to Rule 430A of the Securities Act Regulations (the &ldquo;</FONT>Rule
430A Information<FONT STYLE="font-weight: normal">&rdquo;) or otherwise pursuant to the Securities Act Regulations at such time, is referred
to herein as the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration Statement</B><FONT STYLE="font-weight: normal">.&rdquo;
If the Company files any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the
term &ldquo;Registration Statement&rdquo; shall include such registration statement filed pursuant to Rule 462(b). &ldquo;</FONT>Preliminary
Prospectus<FONT STYLE="font-weight: normal"><I>&rdquo;</I> means any preliminary prospectus, including any material incorporated by reference
therein, included in the Registration Statement prior to the time at which the Commission declared the Registration Statement effective.
&ldquo;</FONT>Prospectus<FONT STYLE="font-weight: normal">&rdquo; means the prospectus that discloses the public offering price and other
final terms of the Securities and the offering and otherwise satisfies Section 10(a) of the Securities Act. All references in this Agreement
to the Registration Statement, the Preliminary Prospectus, the Prospectus or any amendment or supplement to any of the foregoing, is
deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System or any
successor system thereto (&ldquo;</FONT>EDGAR<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Applicable Time</B>&rdquo;
means <B>[&#9679;<FONT STYLE="font-family: Wingdings"></FONT>]</B>, Eastern time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Disclosure
Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Preliminary
Prospectus dated <B>[&#9679;<FONT STYLE="font-family: Wingdings"></FONT>]</B>, 2023 and the information included on <U>Schedule
1-A</U> hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Effective Date</B>&rdquo;
means the date that the Registration Statement became effective under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Free Writing
Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act Regulations
(&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the
Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the Company, (ii)
a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed
with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of
the Public Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed
with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer General Use
Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors
(other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433), as evidenced by its being specified in <U>Schedule
1-B</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Limited Use
Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.2.
<U>Pursuant to the Exchange Act.</U> The Common Stock is registered pursuant to Section 12(b) under the Securities Exchange Act of 1934,
as amended (the &ldquo;</FONT>Exchange Act<FONT STYLE="font-weight: normal">&rdquo;). The Company has taken no action designed to, or
likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any
notification that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.2
<U>Stock Exchange Listing.</U> The Common Stock is listed on The Nasdaq Capital Market (the &ldquo;</FONT><FONT STYLE="font-style: normal">NasdaqCM<FONT STYLE="font-weight: normal">&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the Common Stock from the NasdaqCM, nor has
the Company received any notification that the NasdaqCM is contemplating terminating such listing, except as described in the Registration
Statement, the Disclosure Package and the Prospectus.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.3 <U>No
Stop Orders, etc</U>. Neither the Commission nor any state regulatory authority has issued any order preventing or suspending the
use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company&rsquo;s
knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if
any) from the Commission for additional information.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.4
<U>Disclosures in Registration Statement</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.1.
<U>Compliance with Securities Act; 10b-5 Representation</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)
<FONT STYLE="font-size: 10pt">Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective,
at the date of this Agreement and at the Closing Date and each Option Closing Date, complied and will comply in all material respects
with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus and the Prospectus, at the
time each was filed or will be filed with the Commission, at the date of this Agreement and at the Closing Date and each Option Closing
Date, complied or will comply in all material respects with the requirements of the Securities Act and the Securities Act Regulations.
The Preliminary Prospectus delivered to the Underwriter for use in connection with this Offering and the Prospectus was or will be identical
to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation
S-T.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)<FONT STYLE="font-size: 10pt">
Neither the Registration Statement nor any amendment thereto, at its Effective Date, as of the Applicable Time, or at the Closing Date
or any Option Closing Date contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)<FONT STYLE="font-size: 10pt">
The Disclosure Package, as of the Applicable Time, as of the date of this Agreement, at the Closing Date or at any Option Closing Date
did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free
Writing Prospectus hereto does not conflict with the information contained in the Registration Statement, the Preliminary Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as
of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; <I><U>provided</U></I>, <I><U>however</U></I>,
that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with
written information furnished to the Company with respect to the Underwriter by the Underwriter expressly for use in the Registration
Statement, the Disclosure Package or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree
that such information provided by or on behalf of the Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: the third full paragraph under the heading &ldquo;Underwriting,&rdquo; the statements under the subheading
titled &ldquo;Price Stabilization, Short Positions and Penalty Bids&rdquo; and the statements under the subheading titled &ldquo;Electronic
Distribution&rdquo; (collectively, the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s Information<FONT STYLE="font-weight: normal">&rdquo;);
and</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv) <FONT STYLE="font-size: 10pt">Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any
filing with the Commission pursuant to Rule 424(b) or at the Closing Date or any Option Closing Date, included, includes or will
include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>,
that this representation and warranty shall not apply to the&nbsp;Underwriter&rsquo;s Information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.2.
<U>Disclosure of Agreements</U>. The agreements and documents described in the Registration Statement, the Disclosure Package and the
Prospectus conform in all material respects to the descriptions thereof contained therein, and there are no agreements or other documents
required by the Securities Act, the Securities Act Regulations or the Exchange Act to be described in the Registration Statement, the
Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been
so described or filed. Each agreement or other instrument (however characterized or described) to which the Company or the Subsidiary
is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred to or incorporated by reference in the Registration
Statement, the Disclosure Package or the Prospectus, or (ii)&nbsp;is material to the Company&rsquo;s business, has been duly authorized
and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and,
to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability may
be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y)&nbsp;as enforceability
of any indemnification or contribution provision may be limited under the federal or state securities laws, and (z)&nbsp;that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company,
and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge,
no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. Performance
by the Company of the material provisions of such agreements or instruments will not result in a material violation of any existing applicable
law, rule, regulation, judgment, order or decree of any governmental or regulatory agency, body or court, domestic or foreign, having
jurisdiction over the Company or any of its assets or business (each, a &ldquo;</FONT>Governmental Entity<FONT STYLE="font-weight: normal">&rdquo;),
including, without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.3.
<U>Prior Securities Transactions</U>. Since January 1, 2021, no securities of the Company have been sold by the Company or by or on behalf
of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.4.
<U>Regulations</U>. The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects of
federal, state, local and all foreign laws, rules and regulations relating to the Company&rsquo;s business as currently conducted or contemplated
to be conducted are correct and complete in all material respects and no other such laws, rules or regulations are required to be disclosed
in the Registration Statement, the Disclosure Package and the Prospectus that are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.5.
<U>No Other Distribution of Offering Materials.</U> The Company has not, directly or indirectly, distributed and will not distribute any
offering material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Package, the Prospectus and other
materials, if any, permitted under the Securities Act and consistent with <U>Section 3.2</U> below. </FONT>[<FONT STYLE="font-weight: normal">The
Company is not an &ldquo;ineligible issuer&rdquo; in connection with the Offering pursuant to Rules 164, 405 and 433 under the Securities
Act.</FONT>]<B STYLE="font: normal 10pt Times New Roman, Times, Serif"><SUP>1</SUP></B> <FONT STYLE="font-weight: normal">The Company will file with the Commission all Issuer Free General
Use Writing Prospectuses and all Issuer Limited Use Free Writing Prospectuses (other than a &ldquo;road show&rdquo; as defined in Rule
433(d) of the Securities Act Regulations, if any) in the time and manner required under Rule 433(d) of the Securities Act Regulations.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: right"><SUP>1</SUP></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B>Note</B>:
                                            MODD and counsel to confirm.</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.5
<U>Changes After Dates in Registration Statement</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.1.
<U>No Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Disclosure
Package and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no material adverse change in the
financial position or results of operations of the Company <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
the Subsidiary, nor any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective
material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets, properties
or prospects of the Company and the Subsidiary, taken as a whole (a &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
Adverse Change</B><FONT STYLE="font-weight: normal">&rdquo;); (ii)&nbsp;there have been no material transactions entered into by the
Company, other than as contemplated pursuant to this Agreement; and (iii)&nbsp;no officer or director of the Company or the Subsidiary
has resigned from any position with the Company or such Subsidiary.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.2.
<U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued any securities or incurred any liability or
obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other distribution on or
in respect to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.6
<U>Disclosures in Commission Filings</U>. Since January 1, 2020, (i) none of the Company&rsquo;s filings with the Commission contained
any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading; and (ii) the Company has made all filings with the Commission required
under the Exchange Act and the rules and regulations of the Commission promulgated thereunder (the &ldquo;</FONT><FONT STYLE="font-style: normal">Exchange
Act Regulations<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.7
<U>Independent Accountants</U>. To the Company&rsquo;s knowledge, Farber Hass Hurley LLP (the &ldquo;</FONT><FONT STYLE="font-style: normal">Auditor<FONT STYLE="font-weight: normal">&rdquo;),
whose report is filed with the Commission as part of the Registration Statement, the Disclosure Package and the Prospectus, is an independent
registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting
Oversight Board. The Auditor has not, during the periods covered by the financial statements included in or incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, provided to the Company any prohibited non-audit services, as
such term is used in Section 10A(g) of the Exchange Act.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.8 <U>Financial
Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules, included or incorporated by
reference in the Registration Statement, the Disclosure Package and the Prospectus, fairly present the financial position and the
results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been
prepared in conformity with U.S. generally accepted accounting principles (&ldquo;</FONT><FONT STYLE="font-style: normal">GAAP<FONT STYLE="font-weight: normal">&rdquo;),
consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end
audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the
supporting schedules, if any, included in the Registration Statement, the Disclosure Package and the Prospectus present fairly the
information required to be stated therein. Except as included therein, no historical or pro forma financial statements are required
to be included or incorporated by reference in the Registration Statement, the Disclosure Package or the Prospectus under the
Securities Act or the Securities Act Regulations. All disclosures contained in the Registration Statement, the Disclosure Package or
the Prospectus regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations of the
Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent
applicable. Each of the Registration Statement, the Disclosure Package and the Prospectus discloses all material off-balance sheet
transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with
unconsolidated entities or other persons required to be disclosed under Instruction 8 to Item 303(b) of Regulation S-K that may have
a material current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of
operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as
disclosed or incorporated by reference <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the Registration
Statement, the Disclosure Package and the Prospectus, (a) the Company has not incurred any material liabilities or obligations,
direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has
not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been
any change in the capital stock of the Company, (d) other than in the ordinary course of business and consistent with the
Company&rsquo;s prior policies, made any grants under any stock compensation plan, and (e) there has not been any material adverse
change in the Company&rsquo;s long-term or short-term debt.</FONT></FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.9
<U>Authorized Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Disclosure
Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Disclosure Package and the Prospectus, the Company will have on the Closing Date and each Option
Closing Date, if any, the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration
Statement, the Disclosure Package, the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option
Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued
shares of Common Stock or any security convertible or exercisable into shares of Common Stock, or any contracts or commitments to issue
or sell shares of Common Stock or any such options, warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.10
<U>Valid Issuance of Securities, etc.</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.10.1. <U>Outstanding
Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement
have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission
or the ability to force the Company to repurchase such securities with respect thereto, and are not subject to personal liability by
reason of being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal
or rights of participation of any holders of any security of the Company or similar contractual rights granted by the Company. The
authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in the Registration
Statement, the Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock, options,
warrants and other rights to purchase or exchange such securities for shares of Common Stock were at all relevant times either
registered under the Securities Act and the applicable state securities or &ldquo;blue sky&rdquo; laws or, based in part on the
representations and warranties of the purchasers of such shares of Common Stock, exempt from such registration requirements. The
description of the Company&rsquo;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights
granted thereunder, as described in the Registration Statement, the Disclosure Package and the Prospectus, accurately and fairly
present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and
rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.10.2. <U>Securities
Sold Pursuant to this Agreement</U>. The Firm Shares and the Option Shares have been duly authorized for issuance and sale and, when
issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to
personal liability by reason of being such holders; the Public Securities and the Underwriter&rsquo;s Securities are not and will
not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the
Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities and the
Underwriter&rsquo;s Securities has been duly and validly taken. The Public Securities and the Underwriter&rsquo;s Securities conform
in all material respects to all statements with respect thereto contained in the Registration Statement, the Disclosure Package and
the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Warrants and the
Underwriter&rsquo;s Warrant has been duly and validly taken; the shares of Common Stock issuable upon exercise of the Warrants and
the Underwriter&rsquo;s Warrant have been duly authorized and reserved for issuance by all necessary corporate action on the part of
the Company and when paid for and issued upon exercise in accordance with the Warrants <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
the Underwriter&rsquo;s Warrant, respectively, such shares of Common Stock will be validly issued, fully paid and non-assessable;
the holders thereof will not be subject to personal liability by reason of being such holders; and such shares of Common Stock will
not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the
Company. </FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.11
<U>Registration Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus,
no holders of any securities of the Company or any options, warrants, rights or other securities exercisable for or convertible or exchangeable
into securities of the Company have the right to require the Company to register the sale or resale of any such securities of the Company
under the Securities Act or to include any such securities in the Registration Statement or any other registration statement to be filed
by the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.12
<U>Validity and Binding Effect of Agreement</U>. The execution, delivery and performance of this Agreement, the Warrants, the Underwriter&rsquo;s
Warrant and the Warrant Agency Agreement between the Company and the Company&rsquo;s transfer agent (the &ldquo;</FONT><FONT STYLE="font-style: normal">Warrant
Agency Agreement<FONT STYLE="font-weight: normal">&rdquo;) have been duly and validly authorized by the Company, and, when executed and
delivered, will constitute valid and binding agreements of the Company, enforceable against the Company in accordance with their respective
terms, except: (i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally; (ii)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the federal or state
securities laws; and (iii)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject
to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.13
<U>No Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Warrant Agency Agreement, the
Warrants and the Underwriter&rsquo;s Warrant and all ancillary documents, the consummation by the Company of the transactions herein and
therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving
of notice or the lapse of time or both: (i)&nbsp;result in a material breach of, or conflict with any of the terms and provisions of,
or constitute a material default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance
upon any property or assets of the Company or the Subsidiary pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement
or any other agreement or instrument to which the Company or the Subsidiary is a party or as to which any property of the Company or the
Subsidiary is a party; (ii)&nbsp;result in any violation of the provisions of the Company&rsquo;s certificate of incorporation (as the
same may be amended or restated from time to time, the &ldquo;</FONT><FONT STYLE="font-style: normal">Charter<FONT STYLE="font-weight: normal">&rdquo;)
or the Company&rsquo;s bylaws (as the same may be amended or restated from time to time, the &ldquo;</FONT>Bylaws<FONT STYLE="font-weight: normal">&rdquo;);
or (iii)&nbsp;violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date
hereof, except in the case of clauses <U>(i)</U> or <U>(iii)</U>, as would not result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.14
<U>No Defaults; Violations</U>. No material default exists, and no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default, in the due performance and observance of any term, covenant or condition of any material license,
contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation
for borrowed money, or any other material agreement or instrument to which the Company or the Subsidiary is a party or by which the Company
or the Subsidiary may be bound or to which any of the properties or assets of the Company or the Subsidiary is subject. Neither the Company
nor the Subsidiary is (i) in violation of any term or provision of its Charter or Bylaws, or (ii) in violation of any franchise, license,
permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity, except in the case of clause <U>(ii)</U>, such
as would not result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.15
<U>Corporate Power; Licenses</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.1.
<U>Corporate Power</U>. The Company has all requisite corporate power and authority, as of the date hereof, the Applicable Time, the Closing
Date and any Option Closing Date, to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.2.
<U>Licenses</U>. The Company (A) possesses the licenses, permits, certificates, authorizations, consents and approvals (collectively,
&ldquo;</FONT>Authorizations<FONT STYLE="font-weight: normal">&rdquo;) issued by the appropriate Governmental Entities necessary to conduct
its business as currently conducted as described in the Registration Statement, the Disclosure Package and the Prospectus, and (B) has
obtained all necessary Authorizations from other persons necessary to conduct its business, except, in each case of <U>clauses (A)</U>
and <U>(B)</U>, (i) as described in the Registration Statement, the Disclosure Package or the Prospectus or (ii) to the extent that any
failure to possess any Authorizations, provide any notice, make any filing, or obtain any Authorizations would not, individually or in
the aggregate, reasonably be expected to result in a Material Adverse Change. Neither the Company nor the Subsidiary is in violation of,
or in default under, any Authorizations, except as would not reasonably be expected to result in a Material Adverse Change. All of the
Authorizations are valid and in full force and effect, except when the invalidity of such Authorizations or the failure of such Authorizations
to be in full force and effect would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.
The Company has not received any notice of proceedings relating to the revocation or modification of any Authorization which, individually
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.3.
<U>Transactions Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement, the Warrant Agency
Agreement, the Warrants and the Underwriter&rsquo;s Warrant and to carry out the provisions and conditions hereof, and all Authorizations
required in connection therewith have been obtained. No authorization of, and no filing with, any Governmental Entity is required for
the valid issuance, sale and delivery of the Public Securities and the Underwriter&rsquo;s Securities and the consummation of the transactions
and agreements contemplated by this Agreement, the Warrant Agency Agreement and the Warrants and as contemplated by the Registration Statement,
the Disclosure Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations
of the Financial Industry Regulatory Authority, Inc. (&ldquo;</FONT>FINRA<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.16
<U>D&amp;O Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the FINRA questionnaires (the &ldquo;</FONT><FONT STYLE="font-style: normal">Questionnaires<FONT STYLE="font-weight: normal">&rdquo;)
completed by each of the Company&rsquo;s directors, officers, and principal shareholders immediately prior to the Offering (the &ldquo;</FONT>Insiders<FONT STYLE="font-weight: normal">&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal shareholders as described in the Registration
Statement, the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreements (as defined in <U>Section 2.26</U>), provided
to the Underwriter is true and correct in all material respects and the Company has not become aware of any information that would cause
the information disclosed in the Questionnaires to become inaccurate and incorrect in any material respect.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.17
<U>Litigation; Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or the Subsidiary,
or to the Company&rsquo;s knowledge, any executive officer or director that has not been disclosed in the Registration Statement, the
Disclosure Package and the Prospectus, which if resolved adversely to the Company is reasonably likely to result in a Material Adverse
Change or is required to be disclosed. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.18 <U>Good
Standing</U>. Each of the Company and the Subsidiary has been duly organized and is validly existing as a corporation and is in good
standing under the laws of its jurisdiction of incorporation as of the date hereof, and is duly qualified to do business and is in
good standing in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such
qualification, except where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to
result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.19
<U>Insurance</U>. Each of the Company and the Subsidiary carries or is entitled to the benefits of insurance (including, without limitation,
as to directors and officers insurance coverage) with reputable insurers, in such amounts and covering such risks which the Company reasonably
believes are adequate, and all such insurance is in full force and effect. Neither the Company nor the Subsidiary have any reason to believe
that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result
in a Material Adverse Change.J</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.20
<U>Transactions Affecting Disclosure to FINRA</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.1.
<U>Finder&rsquo;s Fees</U>. There are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s,
consulting or origination fee by the Company, the Subsidiary or any Insider with respect to the sale of the Public Securities hereunder
or any other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that
may affect the Underwriter&rsquo;s compensation, as determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.2.
<U>Payments Within Twelve (12) Months</U>. The Company has not made any direct or indirect payments (in cash, securities or otherwise)
to: (i)&nbsp;any person, as a finder&rsquo;s fee, consulting fee or otherwise, in consideration of such person raising capital for the
Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp; any
person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior
to the Effective Date, other than the payment to the Underwriter as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.3.
<U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.4.
<U>FINRA Affiliation</U>. There is no officer or director of the Company or beneficial owner of 10% or more of any class of the Company&rsquo;s
securities or equity-linked securities that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA). Neither the Company nor any of its affiliates (within the meaning of FINRA&rsquo;s
Conduct Rule 5121(f)(i)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person
(within the meaning of Article 1, Section 1(ee) of the By-Laws of FINRA) of, any member of FINRA participating in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.5.
<U>Information</U>. All information provided by the Company in its FINRA questionnaire to Underwriter&rsquo;s Counsel specifically for
use by Underwriter&rsquo;s Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true,
correct and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.21 <U>Foreign
Corrupt Practices Act</U>. Neither the Company, the Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company, the Subsidiary nor any other person acting on behalf of the Company or the Subsidiary, has,
directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers
in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee
of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office
(domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company or the
Subsidiary (or assist it in connection with any actual or proposed transaction) that (i)&nbsp;might subject the Company <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
the Subsidiary to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii)&nbsp;if not given in
the past, might have had a Material Adverse Change or (iii)&nbsp;if not continued in the future, might adversely affect the assets,
business, operations or prospects of the Company or the Subsidiary. Each of the Company and each Subsidiary has taken reasonable
steps to ensure that its accounting controls and procedures are sufficient to cause the Company and the Subsidiary to comply in all
material respects with the Foreign Corrupt Practices Act of 1977, as amended.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.22
<U>Compliance with OFAC</U>. Neither the Company, the Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company, the Subsidiary nor any other person acting on behalf of the Company or the Subsidiary, is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;</FONT><FONT STYLE="font-style: normal">OFAC<FONT STYLE="font-weight: normal">&rdquo;),
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any U.S. sanctions administered by OFAC.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.23
<U>Money Laundering Laws</U>. To the Company&rsquo;s knowledge after due inquiry, the operations of the Company and the Subsidiary are
and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively,
the &ldquo;</FONT><FONT STYLE="font-style: normal">Money Laundering Laws<FONT STYLE="font-weight: normal">&rdquo;); and no action, suit
or proceeding by or before any Governmental Entity involving the Company or the Subsidiary with respect to the Money Laundering Laws is
pending or, to the best knowledge of the Company, threatened.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.24
<U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E
of the Exchange Act) contained in either the Registration Statement, the Disclosure Package or the Prospectus has been made or reaffirmed
without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.25
<U>Officers&rsquo; Certificate</U>. Any certificate pursuant to this Agreement signed by any duly authorized officer of the Company and
delivered to you or to Underwriter&rsquo;s Counsel shall be deemed a representation and warranty by the Company to the Underwriter as
to the matters covered thereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.26
<U>Lock-Up Agreements.</U> <U>Schedule 2</U> hereto contains a complete and accurate list of the Company&rsquo;s executive officers and
directors as well as any stockholders deemed to be affiliates through their ownership of shares of the Company&rsquo;s Common Stock (collectively,
the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up Parties<FONT STYLE="font-weight: normal">&rdquo;). The Company has caused
each of the Lock-Up Parties to deliver to the Underwriter an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit A
</U>(the &ldquo;</FONT>Lock-Up Agreement<FONT STYLE="font-weight: normal">&rdquo;), prior to the execution of this Agreement. </FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.27 <U>Subsidiaries</U>.
The Company owns all of the capital stock and/or the equity interests in Quasuras, Inc., a Delaware corporation (the
&ldquo;</FONT><FONT STYLE="font-style: normal">Subsidiary<FONT STYLE="font-weight: normal">&rdquo;). The Company has no other
interest, nominal or beneficial, direct or indirect, in any other corporation, partnership, limited liability company, joint venture
or other business entity. All of the outstanding shares of capital stock and/or equity interests of the Subsidiary have been duly
authorized and validly issued, are fully paid and non-assessable and, except to the extent set forth in the Registration Statement
or the Prospectus, are owned by the Company directly or indirectly through one or more wholly-owned subsidiaries, free and clear of
any claim, lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third party. Except
as disclosed in the Registration Statement or the Prospectus, no director, officer, or key employee of the Company named in the
Prospectus holds any direct equity, debt or other pecuniary interest in the Subsidiary or, to the best of the Company&rsquo;s
knowledge, any individual or entity with whom the Company or the Subsidiary does business or with which it is in privity of
contract.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.28
<U>Related Party Transactions</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.1.
<U>Business Relationships</U>. There are no business relationships or related party transactions involving the Company or the Subsidiary
or any other person required to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been
described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.2.
<U>No Relationships with Customers and Suppliers</U>. No relationship, direct or indirect, exists between or among the Company or the
Subsidiary on the one hand, and the directors, officers, 5% or greater shareholders, customers or suppliers of the Company or the Subsidiary
or any of the Company&rsquo;s affiliates on the other hand, which is required to be described in the Registration Statement, the Disclosure
Package and the Prospectus or a document incorporated by reference therein and which is not so described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.3.
<U>No Unconsolidated Entities</U>. There are no transactions, arrangements or other relationships between and/or among the Company or
the Subsidiary, any of the Company&rsquo;s affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated
entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected
to materially affect the Company&rsquo;s liquidity or the availability of or requirements for its capital resources required to be described
in the Disclosure Package and the Prospectus or a document incorporated by reference therein which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.4.
<U>No Loans or Advances to Affiliates</U>. There are no outstanding loans, advances (except normal advances for business expenses in the
ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of
the Company or any of their respective family members, except as disclosed in the Registration Statement, the Disclosure Package and the
Prospectus. All transactions by the Company with its officers or directors or control persons of the Company have been duly approved by
the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.29
<U>Board of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth in the Registration Statement,
each Preliminary Prospectus and the Prospectus. The qualifications of the persons serving as board members and the overall composition
of the board comply with the Exchange Act, the rules and regulations of the Commission under the Exchange Act Regulations, the Sarbanes-Oxley
Act of 2002 and the rules promulgated thereunder (the &ldquo;</FONT><FONT STYLE="font-style: normal">Sarbanes-Oxley Act<FONT STYLE="font-weight: normal">&rdquo;)
applicable to the Company and the listing rules of the NasdaqCM. At least one member of the Audit Committee of the Board of Directors
of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing
rules of the NasdaqCM. In addition, at least a majority of persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo;
as defined under the listing rules of the NasdaqCM.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.30
<U>Sarbanes-Oxley Compliance</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.30.1. <U>Disclosure
Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that comply with Rule 13a-15 or
15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure that information required to be
disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Commission&rsquo;s rules and forms and includes, without limitation, controls and
procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under
the Exchange Act is accumulated and communicated to the Company&rsquo;s management, including its principal executive and principal
financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.30.2.
<U>Compliance</U>. The Company is, or at the Applicable Time and on the Closing Date and each Option Closing Date, if any, will be, in
material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs
and taken reasonable steps to ensure the Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines
therefor) with all of the material provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.31
<U>Accounting Controls</U>. The Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as defined under
Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been designed
by, or under the supervision of, its principal executive and principal financial officer, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance
with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.
Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company is not aware of any material
weaknesses in its internal controls. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have
been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting which are known to the Company&rsquo;s management and that have adversely affected or are reasonably likely to adversely affect
the Company&rsquo;s ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company&rsquo;s
management, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
controls over financial reporting.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.32
<U>No Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof
as described in the Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register as an &ldquo;investment
company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.33
<U>No Labor Disputes</U>. No labor dispute with the employees of the Company or the Subsidiary exists or, to the knowledge of the Company
or the Subsidiary, is imminent. The Company is not aware that any key employee or significant group of employees of the Company or the
Subsidiary plans to terminate employment with the Company or the Subsidiary.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.34 <U>Intellectual
Property Rights</U>. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks, service
marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets software,
databases, know-how, internet domain names, other unpatented and/or unpatentable proprietary confidential information systems,
processes or procedures and similar rights (&ldquo;</FONT><FONT STYLE="font-style: normal">Intellectual Property Rights<FONT STYLE="font-weight: normal">&rdquo;)
necessary for the conduct of the business of the Company and the Subsidiary as currently carried on and as described in the
Registration Statement, the Disclosure Package and the Prospectus. The Intellectual Property Rights licenses described in the
Registration Statement, Disclosure Package and the Prospectus are valid, binding upon and enforceable against the parties thereto in
accordance with their respective terms. To the knowledge of the Company, no action or use by the Company or the Subsidiary necessary
for the conduct of its business as currently carried on and as described in the Registration Statement, the Disclosure Package and
the Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of
others. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of the Company nor the Subsidiary has
received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as
would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change (A) to the knowledge of
the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights
owned by the Company or the Subsidiary; (B) there is no pending or, to the knowledge of the Company, threatened action, suit,
proceeding or claim by others challenging the rights of the Company or the Subsidiary in or to any such Intellectual Property
Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or
in the aggregate, together with any other claims in this <U>Section 2.34</U>, reasonably be expected to result in a Material Adverse
Change; (C) the Intellectual Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property
Rights licensed to the Company or the Subsidiary have not been adjudged by a court of competent jurisdiction invalid or
unenforceable, in whole or in part, and there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit,
proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware
of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any
other claims in this <U>Section 2.34</U>, reasonably be expected to result in a Material Adverse Change; (D) there is no pending or,
to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the Company or the Subsidiary
infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, none of the
Company nor the Subsidiary has received any written notice of such claim and the Company is unaware of any other facts which would
form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this <U>Section
2.34</U>, reasonably be expected to result in a Material Adverse Change; and (E) to the Company&rsquo;s knowledge, no employee of
the Company or the Subsidiary is in or has ever been in violation in any material respect of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure
agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such
employee&rsquo;s employment with the Company or the Subsidiary, or actions undertaken by the employee while employed with the
Company or the Subsidiary and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse
Change. To the Company&rsquo;s knowledge, all material technical information developed by and belonging to the Company or the
Subsidiary which has not been patented has been kept confidential. None of the Company nor the Subsidiary is a party to or bound by
any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required
to be set forth in the Registration Statement, the Disclosure Package and the Prospectus and are not described therein. The
Registration Statement, the Disclosure Package and the Prospectus contain in all material respects the same description of the
matters set forth in the preceding sentence. None of the technology employed by the Company or the Subsidiary has been obtained or
is being used by the Company in violation of any contractual obligation binding on the Company or the Subsidiary or, to the
Company&rsquo;s knowledge, any of their officers, directors or employees, or otherwise in violation of the rights of any persons. </FONT></FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.35
<U>Taxes</U>. Each of the Company and the Subsidiary has filed all returns (as hereinafter defined) required to be filed with taxing
authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and the Subsidiary
has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed
against the Company or the Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part
of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including
the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriter, (i) no issues have been raised
(and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or
the Subsidiary, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or
requested from the Company <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or the Subsidiary. There are no
tax liens against the assets, properties or business of the Company or the Subsidiary. The term &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>taxes</B><FONT STYLE="font-weight: normal">&rdquo;
means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any
penalties, additions to tax or additional amounts with respect thereto. The term &ldquo;</FONT><B>returns</B><FONT STYLE="font-weight: normal">&rdquo;
means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.36
<U>Compliance with Environmental Laws</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus
and except as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, (i) none of the Company
nor the Subsidiary n is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent,
decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating
to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum
or petroleum products (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">Hazardous Materials<FONT STYLE="font-weight: normal">&rdquo;)
or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
&ldquo;</FONT>Environmental Laws<FONT STYLE="font-weight: normal">&rdquo;), (ii) each of the Company and the Subsidiary has all material
permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements, (iii)
there are no pending or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against
the Company or the Subsidiary and (iv) to the Company&rsquo;s knowledge, there are no events, conditions, incidents or circumstances that
might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting the Company or the Subsidiary relating to Hazardous Materials or any Environmental
Laws.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.37 <U>ERISA
Compliance</U>. The Company, each Subsidiary and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively,
&ldquo;</FONT><FONT STYLE="font-style: normal">ERISA<FONT STYLE="font-weight: normal">&rdquo;)) established or maintained by the
Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects with ERISA.
&ldquo;</FONT>ERISA Affiliate<FONT STYLE="font-weight: normal">&rdquo; means, with respect to the Company, any member of any group
of organizations described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations
and published interpretations thereunder (the &ldquo;</FONT>Code<FONT STYLE="font-weight: normal">&rdquo;) of which the Company is a
member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to
any &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates. No &ldquo;employee
benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee benefit
plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither
the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of
ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975
or 4980B of the Code. Each &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA
Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the Company,
nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. The execution of this
Agreement, or consummation of the Offering does not constitute a triggering event under any employee benefit plan or any other
employment contract, whether or not legally enforceable, which (either alone or upon the occurrence of any additional or subsequent
event) will or may result in any payment (of severance pay or otherwise), acceleration, increase in vesting, or increase in benefits
to any current or former participant, employee or director of the Company other than an event that is not material to the financial
condition or business of the Company and the Subsidiary taken as a whole.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.38
<U>Compliance with Laws</U>. Each of the Company and the Subsidiary: (A) is and at all times has been in material compliance with all
statutes, rules, or regulations applicable to the conduct of the business of the Company or the Subsidiary (collectively, the &ldquo;</FONT><FONT STYLE="font-style: normal">Applicable
Laws<FONT STYLE="font-weight: normal">&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from any other Governmental
Entity alleging or asserting noncompliance with any Applicable Laws or any Authorizations; (C) possesses all material Authorizations and
such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations;
(D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any Governmental Entity or third party alleging that any of the Company&rsquo;s activities is in violation of any Applicable Laws or Authorizations
and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action
to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action;
and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected
or supplemented by a subsequent submission).</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.39
<U>Company IT Systems</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company owns
or has a valid right to access and use all computer systems, networks, hardware, software, databases, websites and equipment used to process,
store, maintain and operate data, information and functions necessary for the conduct of its business (the &ldquo;</FONT><FONT STYLE="font-style: normal">Company
IT Systems<FONT STYLE="font-weight: normal">&rdquo;), except where the failure to own or have the right to access the Company IT Systems
would not reasonably be expected to have a Material Adverse Change. The Company IT Systems are adequate for, and operate and perform in
all material respects as required in connection with, the operation of the business of the Company as currently conducted except as would
not be reasonably expected, individually or in the aggregate, to have a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.40
<U>Health Care Authorizations</U>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and
current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments
thereto (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">Health Care Authorizations<FONT STYLE="font-weight: normal">&rdquo;)
issued or required by the appropriate local, state, federal, national, supranational or other foreign regulatory agencies or bodies (collectively,
&ldquo;</FONT>Health Regulatory Agencies<FONT STYLE="font-weight: normal">&rdquo;) necessary to conduct its business as described in the
Registration Statement, the Disclosure Package and the Prospectus, including, without limitation, all such Health Care Authorizations
required by the U.S. Food and Drug Administration (the &ldquo;</FONT>FDA<FONT STYLE="font-weight: normal">&rdquo;), the Department of
Health and Human Services, the European Commission, the EMA or any other Health Regulatory Agencies engaged in the regulation of Biologics
(as defined in the Public Health Service Act of 1944, as amended (42 U.S.C. 6A et seq.)), except as would not be reasonably expected to
result in a Material Adverse Change. The Company has not received any notice of proceedings, or have any knowledge of any threatened proceedings,
relating to the revocation or modification of, or non-compliance with, any such Health Care Authorization, except where such revocation,
modification or non-compliance would not result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.41 <U>Compliance
with Health Care Laws</U>. The Company is, and has been, in compliance in all material respects with all applicable Health Care
Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or
permissive exclusion from Medicare, Medicaid or any other state, federal or national health care program. For purposes of this
Agreement, &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Health
Care Laws</B><FONT STYLE="font-weight: normal">&rdquo; means all health care laws and regulations applicable to the Company,
including, but not limited to: the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Anti-Kickback Statute
(42 U.S.C. Section 1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act
(42 U.S.C. &sect; 1320a-7h), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C.
&sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286
and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996
(&ldquo;</FONT><B>HIPAA</B><FONT STYLE="font-weight: normal">&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42
U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection of Human Research Subjects &ldquo;Common Rule&rdquo;
as codified and enforced by the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by FDA under 21 C.F.R.
part 50, Laboratory Animal Welfare Act of 1966, HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act (42 U.S.C. Section 17921 et seq.), the Controlled Substances Act (2 U.S.C. &sect; 801, et seq.), Good Manufacturing
Practices (21 C.F.R. &sect;&sect;210 &amp; 211), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the
Social Security Act), any and all other applicable comparable local, state, federal, national, supranational and foreign health care
laws and the regulations promulgated pursuant to such laws, each as amended from time to time. The Company has not received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or
arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material
violation of any Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action is threatened. The Company has not received any written notice of adverse
filing, warning letter, untitled letter or other correspondence or notice from the FDA, the European Commission, the EMA, or any
other Health Regulatory Agencies, or any other court or arbitrator, alleging or asserting material noncompliance with the Health
Care Laws. The Company is not a party to and has no ongoing reporting obligations pursuant to any corporate integrity agreements,
deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar
agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, nor, to the knowledge of
the Company, any of its employees, officers or directors has been excluded, suspended or debarred from participation in any U.S.
federal health care program or human research study or trial or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension or
exclusion.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.42 <U>Research
Studies and Trials</U>. (A) The research studies and trials conducted by or, to the Company&rsquo;s knowledge, on behalf of, or
sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the
Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Disclosure Package
or the Prospectus, as applicable, were and, if still pending, are being, conducted in all material respects in accordance with
applicable experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific
standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules
and other regulations of the FDA, National Institute of Health Department of Health and Human Services, the European Commission, the
EMA, and any other Health Regulatory Agencies to which it is subject; (B) the descriptions of the results of such studies and trials
contained in the Registration Statement, the Disclosure Package and the Prospectus do not contain any misstatement of a material
fact or omit to state a material fact necessary to make such statements not misleading; (C) the Company has no knowledge of any
research studies or trials not described in the Registration Statement, the Disclosure Package or the Prospectus the results of
which reasonably call into question in any material respect the results of the research studies and trials described in the
Registration Statement, the Disclosure Package or the Prospectus or that suggest a reasonable possibility of any adverse side
effects not described in the Registration Statement, the Disclosure Package and the Prospectus; (D) the Company has not received any
notices or correspondence from the FDA, the European Commission, the EMA, or any Health Regulatory Agency or any institutional
review board or comparable authority requiring or threatening the premature termination, suspension, material modification or
clinical hold of any research studies or trials conducted by or on behalf of, or sponsored by, the Company or in which the Company
has participated that are described in the Registration Statement, the Disclosure Package or the Prospectus, and, to the
Company&rsquo;s knowledge, there are no reasonable grounds for the same; (E) there has not been any violation of applicable law or
regulation by the Company in any of its product development efforts, submissions or reports to the FDA, the European Commission, the
EMA, or any other Health Regulatory Agency that could reasonably be expected to require investigation, corrective action or result
in enforcement action, except where such violation would not, singly or in the aggregate, result in a Material Adverse Change; and
(F) the research studies and clinical trials of Company are being conducted in an ethical and humane manner under state, national or
supra-national applicable laws that are either equal or more stringent than applicable laws and regulations enforced by the
Department of Health and Human Services and FDA governing human, animal or non-human primate research participants and test subjects
and such studies and the clinical trials are conducted under the auspices of a neutral and independent Institutional Animal Care and
Use Committee or Institutional Review Board and applicable state, national, or supra national agencies responsible for
oversight<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.43
<U>Health Care Products Manufacturing</U>. The manufacture of the Company&rsquo;s products by the Company or, to the knowledge of the
Company, on behalf of the Company, is being conducted in compliance with all applicable Health Care Laws pertaining to the manufacture
and post market surveillance of Drugs, Devices, and Biologics, including, without limitation, the FDA&rsquo;s current good manufacturing
practice regulations pertaining to drugs (21 CFR Parts 210 and 211 et seq.), and, to the extent applicable, the respective counterparts
governing manufacturing operations promulgated by other Health Regulatory Agencies. Except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus, the Company has not had any manufacturing site (whether owned by the Company or, to the knowledge
of the Company, that of a third party manufacturer of the Company&rsquo;s products) subject to an FDA or other Health Regulatory Agency
consent decree, seizure, import alert, or export prohibition, nor received any FDA or other Health Regulatory Agency &ldquo;warning letters,&rdquo;
or &ldquo;untitled letters&rdquo; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make
material changes to the Company&rsquo;s products, processes or operations from the FDA or other Health Regulatory Agency, other than those
that have been satisfactorily addressed and/or closed with the FDA or other Health Regulatory Agency. To the knowledge of the Company,
none of the FDA or any other Health Regulatory Agency is considering such action.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.44 <U>Smaller
Reporting Company</U>. As of the effective date of the Registration Statement and the date of this Agreement, the Company was a
&ldquo;smaller reporting company,&rdquo; as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.45
<U>Industry Data</U>.&nbsp; The statistical and market-related data included in each of the Registration Statement, the Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.46
<U>Margin Securities</U>. None of the Company nor the Subsidiary owns any &ldquo;margin securities&rdquo; as that term is defined in Regulation
U of the Board of Governors of the Federal Reserve System (the &ldquo;</FONT><FONT STYLE="font-style: normal">Federal Reserve Board<FONT STYLE="font-weight: normal">&rdquo;),
and none of the proceeds of the Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security,
for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for
any other purpose which might cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings
of Regulation T, U or X of the Federal Reserve Board.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.47 <U>Integration</U>.
None of the Company nor the Subsidiary or affiliates, nor any person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering
to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
offering of any such securities under the Securities Act.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.48
<U>Title to Real and Personal Property</U>. Each of the Company and the Subsidiary has good and marketable title in fee simple to, or
has valid rights to lease or otherwise use, all items of real or personal property that are material to the business of the Company and
the Subsidiary taken as a whole, free and clear of all liens, encumbrances, security interests, claims and defects that do not, singularly
or in the aggregate, result in a Material Adverse Change and do not interfere with the use made of such property by the Company or the
Subsidiary; and all of the leases and subleases material to the business of the Company and the Subsidiary taken as a whole, and under
which the Company or the Subsidiary holds properties described in the Registration Statement, the Disclosure Package and the Prospectus,
are, to the Company&rsquo;s knowledge in full force and effect, and neither the Company nor the Subsidiary has received any notice of
any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or the Subsidiary under any of the
leases or subleases mentioned above, or affecting or questioning the rights of the Company or the Subsidiary to the continued possession
of the leased or subleased premises under any such lease or sublease, which would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.49
<U>Confidentiality and Non-Competition Agreements</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant
of the Company or the Subsidiary is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement
with any employer or prior employer that could materially affect his ability to be and act in his respective capacity of the Company or
the Subsidiary or be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.50
<U>Corporate Records</U>. The minute books of the Company and each Subsidiary have been made available to the Underwriter and the Underwriter&rsquo;s
Counsel, and such books (i) contain a summary of all meetings and actions of the board of directors (including each board committee) and
shareholders of the Company, and (ii) reflect all material transactions referred to in such minutes.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.51
<U>Diligence Materials</U>. The Company has provided to the Company and the Underwriter&rsquo;s Counsel all materials responsive in all
material respects to the diligence requests, if any, submitted to the Company or its counsel by the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.52
<U>Nasdaq Marketplace Rules</U></FONT><FONT STYLE="font-weight: normal">. <FONT STYLE="font-style: normal">&#9;The Company is, and after
giving effect to the Offering will be, in compliance in all material respects with all applicable corporate governance requirements set
forth in the Nasdaq Marketplace Rules.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal"><U>Covenants of the Company</U>. The Company covenants and agrees as
follows:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.1
<U>Amendments to Registration Statement</U>. The Company shall deliver to the Underwriter, prior to filing, any amendment or supplement
to the Registration Statement, any Preliminary Prospectus, any issuer Free Writing Prospectus, the Disclosure Package or the Prospectus
proposed to be filed after the Effective Date and not file any such amendment, supplement or document to which the Underwriter shall reasonably
object in writing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.2
<U>Federal Securities Laws</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.1. <U>Compliance</U>.
The Company, subject to <U>Section 3.2.2</U>, shall comply with the requirements of Rule 424(b) and Rule 430A of the Securities Act
Regulations, and will notify the Underwriter promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment
to the Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus
shall have been filed and when any post-effective amendment to the Registration Statement shall become effective<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;
(ii)&nbsp;of the receipt of any comments from the Commission; (iii)&nbsp;of any request by the Commission for any amendment to the
Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus or for
additional information; (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary
Prospectus or the Prospectus, or of the suspension of the qualification of the Public Securities for offering or sale in any
jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to
Section&nbsp;8(d) or 8(e) of the Securities Act concerning the Registration Statement; and (v)&nbsp;if the Company becomes the
subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Public Securities. The Company
shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period
required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly
whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event
that it was not, it will promptly file such prospectus. The Company shall use its commercially reasonable efforts to prevent the
issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest
possible moment.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.2. <U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange
Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in
the Registration Statement, the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public
Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;</FONT>Rule 172<FONT STYLE="font-weight: normal">&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or
condition shall exist as a result of which it is necessary, in the opinion of Underwriter&rsquo;s Counsel or Company Counsel (as
defined below), to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading; (ii)&nbsp;amend or supplement the Disclosure Package or the Prospectus in order that the Disclosure Package
or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is
delivered to a purchaser; or (iii)&nbsp;amend the Registration Statement or amend or supplement the Disclosure Package or the
Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations,
the Company will promptly (A)&nbsp;give the Underwriter notice of such event; (B)&nbsp;prepare any amendment or supplement as may be
necessary to correct such statement or omission or to make the Registration Statement, the Disclosure Package or the Prospectus
comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Underwriter with
copies of any such amendment or supplement; and (C)&nbsp;file with the Commission any such amendment or supplement; <I>provided,
however</I>, that the Company shall not file or use any such amendment or supplement to which the Underwriter or Underwriter&rsquo;s
Counsel shall reasonably object. The Company will furnish to the Underwriter such number of copies of such amendment or supplement
as the Underwriter may reasonably request. The Company will give the Underwriter notice of its intention to make any such filing
from the Applicable Time until the earlier of the last Option Closing Date, if any, and the expiration date of the Over-allotment
Option and will furnish the Underwriter with copies of the related document(s) a reasonable amount of time prior to such proposed
filing, as the case may be, and will not file or use any such document to which the Underwriter or Underwriter&rsquo;s Counsel shall
reasonably object. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3. <U>Exchange
Act Registration</U>. For a period of two (2) years after the date of this Agreement, the Company shall use its commercially
reasonable efforts to maintain the registration of the Common Stock under the Exchange Act. The Company shall not deregister the
Common Stock under the Exchange Act without the prior written consent of the Underwriter<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which consent shall not unreasonably be withheld.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.1.
<U>Free Writing Prospectuses.</U>&nbsp;The Company agrees that, unless it obtains the prior written consent of the Underwriter, it shall
not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule 433; <I><U>provided</U></I> that the Underwriter shall be deemed to have consented to each Issuer General Use Free
Writing Prospectus listed in <U>Schedule 1-B</U> and any &ldquo;road show that is a written communication&rdquo; within the meaning of
Rule 433(d)(8)(i) that has been reviewed by the Underwriter. The Company represents that it has treated or agrees that it will treat each
such free writing prospectus consented to, or deemed consented to, by the Underwriter as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including
timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would
conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Underwriter and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.3
<U>Delivery to the Underwriter of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available
to the Underwriter and Underwriter&rsquo;s Counsel, without charge, signed copies of the Registration Statement as originally filed and
each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also
deliver to the Underwriter, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto
(without exhibits) for the Underwriter. The copies of the Registration Statement and each amendment thereto furnished to the Underwriter
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.4
<U>Delivery to the Underwriter of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to the
Underwriter, without charge, as many copies of each Preliminary Prospectus and the Disclosure Package as the Underwriter reasonably requests,
and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to the
Underwriter, without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded
by Rule 172 of the Securities Act Regulations, would be) required to be delivered under the Securities Act, such number of copies of the
Prospectus (as amended or supplemented) as the Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto
furnished to the Underwriter will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.5 <U>Effectiveness
and Events Requiring Notice to the Underwriter</U>. The Company shall use commercially reasonable efforts to cause the Registration
Statement (or another registration statement registering the offer and sale of the Public Securities and the Underwriter&rsquo;s
Securities under the Securities Act) to remain effective with a current prospectus until the latest of (a) nine (9) months after the
Applicable Time, (b) the date that the Warrants have been exercised in full or expired by their terms and (c) the date that the
Underwriter&rsquo;s Warrant has been exercised in full or expired by its terms. The Company shall notify the Underwriter immediately
and confirm the notice in writing: (i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto;
(ii)&nbsp;of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that
purpose; (iii)&nbsp;of the issuance by any state securities commission of any proceedings for the suspension of the qualification of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that
purpose; (iv)&nbsp;of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration
Statement or Prospectus; (v)&nbsp;of the receipt of any comments or request for any additional information from the Commission; and
(vi)&nbsp;of the happening of any event during the period described in this <U>Section 3.5</U> that, in the judgment of the Company,
makes any statement of a material fact made in the Registration Statement, the Disclosure Package or the Prospectus untrue or that
requires the making of any changes in (a) the Registration Statement in order to make the statements therein not misleading, or (b)
in the Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such
qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting of such
order.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.6
<U>Review of Financial Statements.</U> For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall
cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.7
<U>Listing</U>. The Company shall use its commercially reasonable efforts to maintain the listing of the Common Stock (including the Public
Securities) on the NasdaqCM for at least two (2) years from the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.8
<U>Reports to the Underwriter</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.1.
<U>Periodic Reports</U>. For a period of two (2) years after the date of this Agreement, the Company shall furnish or make available to
the Underwriter copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also promptly furnish to the Underwriter: (i) a copy of each periodic report the
Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press
release and every news item and article with respect to the Company and its affairs which was released by the Company; (iii) a copy of
each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities
Act; (v) a copy of each report or other communication furnished to shareholders; and (vi) such additional documents and information with
respect to the Company and the affairs of any future subsidiaries of the Company as the Underwriter may from time to time reasonably request;
provided the Underwriter shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably
acceptable to the Underwriter and Underwriter&rsquo;s Counsel in connection with the Underwriter&rsquo;s receipt of such information.
Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Underwriter pursuant to
this <U>Section 3.8.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.2. <U>Transfer
Agent; Transfer Sheets</U>. For a period of two (2) years after the date of this Agreement, the Company shall retain a transfer
agent and registrar acceptable to the Underwriter (the&nbsp;&ldquo;</FONT>Transfer Agent<FONT STYLE="font-weight: normal">&rdquo;).
Colonial Stock Transfer, Inc. is acceptable to the Underwriter to act as Transfer Agent for the Common Stock. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.3.
<U>Trading Reports</U>. For a period of two (2) years after the date of this Agreement, the Company shall provide to the Underwriter,
at the Company&rsquo;s expense, such reports published by NasdaqCM relating to price trading of the Public Securities, as the Underwriter
shall reasonably request; provided that such provision shall not prevent a sale, merger or similar transaction involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.4.
<U>Payment of Expenses</U>. The Company hereby agrees to pay on the Closing Date and each Option Closing Date, if any, to the extent not
paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including,
but not limited to: (a) all filing fees and communication expenses relating to the registration of the Public Securities and the Underwriter&rsquo;s
Securities to be sold in the Offering (including the Option Securities) with the Commission, (b) all filing fees and other expenses (including
the reasonable fees and disbursements of Underwriter&rsquo;s Counsel) incurred in connection with qualification of the Public Securities
and the Underwriter&rsquo;s Securities for sale under the laws of such jurisdictions as the Underwriter designates, (c) costs and expenses
related to the review of the Offering by FINRA, including all filing fees and the reasonable fees and disbursements of counsel to the
Underwriter relating to such review, (d) costs and reasonable expenses relating to investor presentations or any &ldquo;road show&rdquo;
in connection with the Offering, including, without limitation, the costs of recording and hosting on the Internet of the Company&rsquo;s
road show presentation and any reasonable travel expenses of the Company&rsquo;s officers and employees and any other expenses of the
Company, (e) fees and expenses incident to listing or continued listing of the Public Securities and the Underwriter&rsquo;s Securities
on the NasdaqCM and on such other stock exchanges as the Company and the Underwriter together determine, (f) the fees, disbursements and
expenses of the Company&rsquo;s counsel, accountants and other advisors in connection with the Offering, (g) expenses incurred in preparing,
printing and distributing each Preliminary Prospectus and the Prospectus (including any amendments and supplements thereto) to the Underwriter
and for expenses incurred for preparing, printing and distributing any issuer free writing prospectuses to investors or prospective investors,
(h) reasonable fees, disbursements and expenses of the Underwriter&rsquo;s counsel, (i) the costs and expenses of a public relations firm
selected by the Company, if any, (i) the costs of preparing, printing and delivering certificates representing the Public Securities and
the Underwriter&rsquo;s Securities, (j) fees and expenses of the transfer agent for the delivery of the Public Securities and the Underwriter&rsquo;s
Securities, (k) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriter,
(l) to the extent approved by the Company in writing, the costs associated with post-closing advertising of the Offering in the national
editions of the Wall Street Journal and New York Times, (m) fees, expenses and disbursements relating to background checks of the Company&rsquo;s
officers and directors in connection with the Offering; <U>provided</U>, <U>however</U>, that the maximum amount of fees, costs and expenses
incurred by the Underwriter with respect to subparagraphs <U>(a)</U> through <U>(m)</U> above, including, without limitation, the fees,
disbursements and expenses of Underwriter&rsquo;s Counsel, that the Company shall be required to pay under this <U>Section 3.8.4</U> shall
not exceed $125,000. The Underwriter may deduct from the net proceeds of the Offering payable to the Company on the Closing Date or any
Option Closing Date, the expenses set forth herein to be paid by the Company to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9
<U>Application of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with
the application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Disclosure Package
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.10
<U>Delivery of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement,
an earnings statement (which need not be certified by an independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act)
covering a period of at least twelve (12) consecutive months ending after the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.11
<U>Stabilization</U>. Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent
of the Underwriter), has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Public Securities or the Underwriter&rsquo;s Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.12
<U>Internal Controls</U>. The Company shall use commercially reasonable efforts to maintain a system of internal accounting controls sufficient
to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance
with authorizations of management and directors of the issuer; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.13
<U>Accountants</U>. The Company shall retain an independent registered public accounting firm, as required by the Securities Act and the
Securities Act Regulations and the Public Company Accounting Oversight Board, reasonably acceptable to the Underwriter, and the Company
shall continue to retain an independent registered public accounting firm for a period of at least three (3) years after the date of this
Agreement. The Underwriter acknowledges that the Auditor is acceptable to the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.14
<U>FINRA</U>. For a period of 90 days from the later of the Closing Date or the last Option Closing Date, if any, the Company shall advise
the Underwriter (who shall make an appropriate filing with FINRA) if it is or becomes aware that any officer or director of the Company
or any beneficial owner of 10% or more of any class of the Company&rsquo;s securities or equity-linked securities is or becomes an affiliate
or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.15
<U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriter&rsquo;s responsibility to the Company is solely contractual
in nature and that none of the Underwriter or its affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.16 <U>Company
Lock-Up Agreements</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of
the Underwriter, it will not, for a period of ninety (90) days after the date of this Agreement (the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up
Period<FONT STYLE="font-weight: normal">&rdquo;), (a) offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or
dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or
exchangeable for shares of capital stock of the Company, (b) file or cause to be filed any registration statement with the
Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable
or exchangeable for shares of capital stock of the Company or (c) enter into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such
transaction described in <U>clause (a)</U>, <U>(b)</U> or <U>(c)</U> above is to be settled by delivery of shares of capital stock
of the Company or such other securities, in cash or otherwise. The restrictions contained in this <U>Section 3.16</U> shall not
apply to (i)&nbsp;sales of shares of capital stock of the Company under any trading plan pursuant to Rule 10b5-1 under the
Securities Exchange Act of 1934, as amended, existing as of the date of the Underwriting Agreement, (ii) the Public Securities to be
sold hereunder, (iii) the issuance by the Company of shares of capital stock of the Company upon the exercise of a stock option or
warrant or the conversion or vesting of a security outstanding on the date hereof, (iv) the issuance by the Company of equity awards
of the Company under any equity compensation plan of the Company, (v) the issuance by the Company of shares of capital stock of the
Company or securities convertible into, exchangeable for or that represent the right to receive shares of capital stock of the
Company in connection with the acquisition by the Company of the securities, business, technology, property or other assets of
another person or entity <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or (vi) the sale of shares of
capital stock of the Company to cover the payment of exercise prices or the payment of taxes associated with the exercise or vesting
of equity awards under any equity compensation plan of the Company.</FONT></FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">3.17
<U>Release of Lock-up Period</U>. If the Underwriter, in its sole discretion, agrees to release or waive the restrictions set forth in
the Lock-Up Agreements described in <U>Section 2.26</U> for an officer or director of the Company and provide the Company with notice
of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees
to announce the impending release or waiver by a press release substantially in the form of <U>Exhibit B</U> hereto through a major news
service at least two (2) Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">3.18
<U>Blue Sky Qualifications</U>. The Company shall use commercially reasonable efforts, in cooperation with the Underwriter, if necessary,
to qualify the Public Securities and the Underwriter&#8217;s Securities for offering and sale under the applicable securities laws of
such states and other jurisdictions (domestic or foreign) as the Underwriter may designate and to maintain such qualifications in effect
so long as required to complete the distribution of the Public Securities; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">provided,
however, <FONT STYLE="font-style: normal">that the Company shall not be obligated to file any general consent to service of process or
to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself
to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">3.19
<U>Reporting Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the
exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">3.20
<U>Press Releases</U>. Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other
communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise,
or earnings, business affairs or business prospects (except for routine oral marketing communications in the ordinary course of business
and consistent with the past practices of the Company and of which the Underwriter is notified), without the prior written consent of
the Underwriter, which consent shall not be unreasonably withheld, unless in the reasonable judgment of the Company and its counsel,
and after notification to the Underwriter, such press release or communication is required by law.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">3.21
<U>Sarbanes-Oxley</U>. The Company shall use commercially reasonable efforts to comply with all applicable provisions of the Sarbanes-Oxley
Act in effect from time to time.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">3.22
<U>IRS Forms</U>. The Company shall deliver to the Underwriter (or its agent), prior to or at the Closing Date, a properly completed
and executed Internal Revenue Service (&#8220;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">IRS<FONT STYLE="font-weight: normal">&#8221;)
Form W-9 or an IRS Form W-8, as appropriate, together with all required attachments to such form.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.
<U>Conditions of Underwriter&#8217;s Obligations</U>. The obligations of the Underwriter to purchase and pay for the Public Securities,
as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date
hereof, as of the Closing Date and each Option Closing Date, as applicable; (ii) the accuracy of the statements of officers of the Company
made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.1
<U>Regulatory Matters</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.1.1.
<U>Absence of Certain Commission Actions; Required Filings</U>. The Registration Statement is effective under the Securities Act, no
stop order suspending the effectiveness of the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration Statement
or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of <FONT STYLE="font-size: 10pt; font-weight: normal">any
Preliminary Prospectus, the Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to
Section 8A under the Securities Act shall have been initiated or threatened by the Commission, and all requests for additional information
on the part of the Commission (to be included or incorporated by reference in the Registration Statement or the Prospectus or otherwise)
shall have been complied with to the reasonable satisfaction of the Underwriter. The Prospectus containing the Rule 430A Information
shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) of the Securities Act Regulations
(without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared
effective by, the Commission in accordance with the requirements of Rule 430A under the Securities Act Regulations.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.1.2.
<U>FINRA Clearance</U>. The non-objection letter issued by FINRA with respect to the Registration Statement shall not have been rescinded,
withdrawn or suspended, nor shall FINRA have raised any subsequent objection to, or issued comments with respect to, the amount of compensation
allowable or payable to the Underwriter as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.1.3.
<U>NasdaqCM Market Clearance</U>. The Company shall have submitted the Listing of Additional Shares Notification Form to the NasdaqCM
with respect to the Offering of the Public Securities and the NasdaqCM shall not have raised any objection to the submission prior to
the Closing Date or each Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.2
<U>Counsel Matters</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.2.1.
<U>Closing Date Opinion of Counsel to the Company</U>. On the Closing Date and each Option Closing Date, if any, the Underwriter shall
have received (i) the favorable opinion and negative assurance letter of Lucosky Brookman LLP, counsel to the Company (&#8220;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Company
Counsel<FONT STYLE="font-weight: normal">&#8221;), and (ii) the favorable opinion of Schmeiser Olsen &amp; Watts LLP (&#8220;</FONT>IP
Counsel<FONT STYLE="font-weight: normal">&#8221;), in each case, dated the Closing Date and each Option Closing Date, as applicable,
and addressed to the Underwriter in form and substance reasonably satisfactory to the Underwriter.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.2.2.
<U>Opinion of Underwriter&#8217;s Counsel</U>. On the Closing Date and each Option Closing Date, if any, the Underwriter shall have received
from Underwriter&#8217;s Counsel negative assurance letter of Underwriter&#8217;s Counsel, dated the Closing Date and each Option Closing
Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.2.3.
<U>Reliance</U>. In rendering such opinion, Company Counsel and IP Counsel may rely: (i)&nbsp;as to matters involving the application
of laws other than the laws of the United States and jurisdictions in which it is admitted, to the extent such counsel deems proper and
to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the
Underwriter) of other counsel reasonably acceptable to the Underwriter, familiar with the applicable laws; and (ii)&nbsp;as to matters
of fact, to the extent is deems proper, on certificates or other written statements of officers of the Company and officers of departments
of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company, provided that
copies of any such statements or certificates shall be delivered to Underwriter&#8217;s Counsel if requested. The opinions of counsel
referred to in <U>Sections 4.2.1</U> above shall include a statement to the effect that it may be relied upon by Underwriter&#8217;s
Counsel in its opinion delivered to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.3
<U>Comfort Letters</U>. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.3.1.
<U>Cold Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements
and information of the type customarily included in accountants&#8217; comfort letters with respect to the financial statements and certain
financial information </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">contained in the Registration Statement, the Disclosure
Package and the Prospectus, addressed to the Underwriter and in form and substance satisfactory in all respects to you and to the Auditor,
dated as of the date of this Agreement<FONT STYLE="font-size: 10pt; font-weight: normal">, from the Auditor.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.3.2.
<U>Bring-down Comfort Letter</U>. At the Closing Date and each Option Closing Date, if any, the Underwriter shall have received from
the Auditor a letter, dated as of the Closing Date or such Option Closing Date, as applicable, to the effect that the Auditor reaffirms
the statements made in the letter furnished pursuant to <U>Section 4.3.1</U>, except that the specified date referred to shall be a date
not more than three (3) Business Days prior to the Closing Date or Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.4
<U>Company Certificates</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.4.1.
<U>Officers&#8217; Certificate</U>. The Company shall have furnished to the Underwriter a certificate, dated the Closing Date and such
Option Closing Date, as applicable, of its Chief Executive Officer and its Senior Director, Finance stating that (i) such officers have
carefully examined the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in
their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date or such Option
Closing Date, as applicable, did not include any untrue statement of a material fact and did not omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading, and the Disclosure Package, as of the Applicable Time
and as of the Closing Date and such Option Closing Date, as applicable, any Issuer Free Writing Prospectus as of its date and as of the
Closing Date and such Option Closing Date, as applicable, the Prospectus and each amendment or supplement thereto, as of the respective
date thereof and as of the Closing Date or Option Closing Date, as applicable, did not include any untrue statement of a material fact
and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which
they were made, not misleading, (ii) since the date of this Agreement, no event has occurred which should have been set forth in a supplement
or amendment to the Registration Statement, the Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable
investigation, as of the Closing Date or such Option Closing Date, as applicable, the representations and warranties of the Company in
this Agreement are true and correct in all material respects, except for such representations and warranties qualified by materiality
or material adverse change which shall be true and correct in all respects and the Company has complied in all material respects with
all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or such
Option Closing Date, as applicable, and (iv) there has not been, subsequent to the date of the most recent audited financial statements
included or incorporated by reference in the Disclosure Package, any material adverse change in the financial position or results of
operations of the Company, or any change or development that, singularly or in the aggregate, would involve a material adverse change
or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets
or prospects of the Company, except as set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.4.2.
<U>Secretary&#8217;s Certificate</U>. At the Closing Date and each Option Closing Date, if any, the Underwriter shall have received a
certificate of the Company signed by the Secretary of the Company, dated the Closing Date or each Option Closing Date, as applicable,
certifying: (i)&nbsp;that each of the Charter and the Bylaws is true and complete, has not been modified and is in full force and effect;
(ii)&nbsp;that the resolutions of the Company&#8217;s Board of Directors and/or any committee thereof relating to the Offering are in
full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company
or Company Counsel and the Commission; and (iv)&nbsp;as to the incumbency of the officers of the Company. The documents referred to in
such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.5
<U>No Material Changes</U>. Prior to and on the Closing Date and each Option Closing Date: (i)&nbsp;there shall have been no Material
Adverse Change or development involving a prospective material </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates as of which
such condition is set forth in the Registration Statement, the Disclosure Package and the Prospectus; (ii)&nbsp;no action, suit or proceeding,
at law or in equity, shall have been pending or threatened against the Company or any <FONT STYLE="font-style: normal; font-weight: normal">Insider
before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or
finding may materially adversely affect the business, operations, prospects or financial condition or income of the Company, except as
set forth in the Registration Statement, the Disclosure Package and the Prospectus; (iii)&nbsp;no stop order shall have been issued under
the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; (iv)&nbsp;no action shall have
been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued by any Governmental Entity which
would prevent the issuance or sale of the Public Securities or materially and adversely affect or potentially materially and adversely
affect the business or operations of the Company or the Subsidiary; (v) no injunction, restraining order or order of any other nature
by any federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Public
Securities or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company
or the Subsidiary; and (vi) the Registration Statement, the Disclosure Package and the Prospectus and any amendments or supplements thereto
shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations,
and neither the Registration Statement, the Disclosure Package, the Prospectus nor any Issuer Free Writing Prospectus nor any amendment
or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.6
<U>Corporate Proceedings</U>. All corporate proceedings and other legal matters incident to the authorization, form and validity of each
of this Agreement, the Public Securities, the Registration Statement, the Disclosure Package, each Issuer Free Writing Prospectus, if
any, and the Prospectus and all other legal matters relating to this Agreement and the transactions contemplated hereby and thereby shall
be reasonably satisfactory in all material respects to Underwriter&#8217;s Counsel and the Company shall have furnished to such counsel
all documents and information that they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.7
<U>Delivery of Agreements</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.7.1.
On or before the date of this Agreement, the Company shall have delivered to the Underwriter executed copies of the Lock-Up Agreements
from each of the persons listed in <U>Schedule 2</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.7.2.
On the Closing Date, the Company shall have delivered to the Underwriter the Firm Shares and the Firm Warrants, and on each Option Closing
Date, if any, the Company shall have delivered to the Underwriter the applicable Option Shares and/or Option Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">4.7.3.
On the Closing Date and each Option Closing Date, if any, the Company shall have delivered to the Underwriter an executed copy or copies
of the Underwriter&#8217;s Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.8
<U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct on
the date hereof and on and as of the Closing Date or each Option Closing Date, if any, as the case may be; and the statements of the
Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing
Date or each Option Closing Date, if any, as the case may be.</FONT></P>




<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">4.9
<U>Additional Documents</U>. At the Closing Date and each Option Closing Date, if any, Underwriter&#8217;s Counsel shall have been furnished
with such documents and opinions as they may require for the purpose of enabling Underwriter&#8217;s Counsel to deliver an opinion to
the Underwriter, or in order to evidence the accuracy of any of the representations or warranties, or the fulfilment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities as herein
contemplated shall be satisfactory in form and substance to the Underwriter and Underwriter&#8217;s Counsel.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>Indemnification</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">5.1
<U>Indemnification by the Company</U>. The Company shall indemnify, defend and hold harmless the Underwriter, its affiliates and each
of its and their respective directors, officers, members, employees, representatives and agents and each person, if any, who controls
the Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &#8220;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">Underwriter
Indemnified Parties<FONT STYLE="font-weight: normal">,&#8221; and each an &#8220;</FONT>Underwriter Indemnified Party<FONT STYLE="font-weight: normal">&#8221;)
against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), to
which such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage,
expense, liability, action, investigation or proceeding arises out of or is based upon (A) any untrue statement or alleged untrue statement
of a material fact contained in any Preliminary Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any &#8220;issuer
information&#8221; filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement
or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, (B) the omission or alleged
omission to state in any Preliminary Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221;
filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus,
or in any amendment or supplement thereto or document incorporated by reference therein, a material fact required to be stated therein
or necessary to make the statements therein not misleading or (C) any breach of the representations and warranties of the Company contained
herein or any certificate delivered pursuant to this Agreement or failure of the Company to perform its obligations hereunder or pursuant
to any law, any act or failure to act, or any alleged act or failure to act, by the Company in connection with, or relating in any manner
to, this Agreement, the Public Securities or the Offering, and which is included as part of or referred to in any loss, claim, damage,
expense, liability, action, investigation or proceeding arising out of or based upon matters covered by <U>subclause (A)</U>, <U>(B)
</U>or <U>(C)</U> above of this <U>Section 5.1</U> (provided&nbsp;that the Company shall not be liable in the case of any matter covered
by this <U>subclause (C)</U> to the extent that it is determined in a final judgment by a court of competent jurisdiction that such loss,
claim, damage, expense or liability resulted directly from any such act or failure to act undertaken or omitted to be taken by the Underwriter
through its gross negligence or willful misconduct), and shall reimburse the Underwriter Indemnified Party promptly upon demand for any
legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing
to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such
loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred;&nbsp;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>provided</U><FONT STYLE="font-style: normal">,
</FONT><U>however</U><FONT STYLE="font-style: normal">,&nbsp;that the Company shall not be liable in any such case to the extent that
any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement in, or omission from any Preliminary
Prospectus, the Disclosure Package, any Registration Statement or the Prospectus, or any such amendment or supplement thereto, or any
Issuer Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by or on behalf
of the Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriter&#8217;s Information.
This indemnity agreement is not exclusive and will be in addition to any liability, which the Company might otherwise have and shall
not limit any rights or remedies which may otherwise be available at law or in equity to each Underwriter Indemnified Party.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">5.2
<U>Indemnification by the Underwriter</U>. The Underwriter shall indemnify, defend and hold harmless the Company, the Company&#8217;s
directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &#8220;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal">Company
Indemnified Parties<FONT STYLE="font-weight: normal">&#8221; and each a </FONT>&#8220;Company Indemnified Party<FONT STYLE="font-weight: normal">&#8221;)
against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), to
which such Company Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage,
expense, liability, action, investigation or proceeding arises out of or is based upon (i) any untrue statement of a material fact contained
in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed
pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement, the Disclosure Package, or the Prospectus, or
in any amendment or supplement thereto, or (ii) the omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus,
any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration
Statement, the Disclosure Package, or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, but
in each case only to the extent that the untrue statement or omission was made in reliance upon and in conformity with written information
furnished to the Company by or on behalf of the Underwriter specifically for use therein, which information the parties hereto agree
is limited to the Underwriter&#8217;s Information and shall reimburse the Company Indemnified Parties for any legal or other expenses
reasonably incurred by any Company Indemnified Party in connection with investigating or preparing to defend or defending against or
appearing as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as
such fees and expenses are incurred. Notwithstanding the provisions of this <U>Section 5.2</U>, in no event shall any indemnity by the
Underwriter under this <U>Section 5.2</U> exceed the total discount and commission received by the Underwriter in connection with this
Offering.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">5.3
<U>Procedure</U>. Promptly after receipt by an indemnified party under this <U>Section 5</U> of notice of the commencement of any action,
the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section 5</U>, notify
such indemnifying party in writing of the commencement of that action; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><I><U>provided</U></I><FONT STYLE="font-style: normal">,
</FONT><I><U>however</U></I><FONT STYLE="font-style: normal">, that the failure to notify the indemnifying party shall not relieve it
from any liability which it may have under this <U>Section 5</U> except to the extent it has been materially adversely prejudiced by
such failure; and, provided, further, that the failure to notify an indemnifying party shall not relieve it from any liability which
it may have to an indemnified party otherwise than under this <U>Section 5</U>. If any such action shall be brought against an indemnified
party, and it shall notify the indemnifying party thereof, the indemnifying party shall assume the defense of such action with counsel
reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party,
be counsel to the indemnifying party). After notice from the indemnifying party to the indemnified party of its assumption of the defense
of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under <U>Section 5</U>
for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than
reasonable costs of investigation; </FONT><I><U>provided</U></I><FONT STYLE="font-style: normal">, </FONT><I><U>however</U></I><FONT STYLE="font-style: normal">,
that any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such
action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified
party unless (i) the employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification
under <U>Section 5.1</U> or the Underwriter in the case of a claim for indemnification under <U>Section 5.2</U>, (ii) such indemnified
party shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or
additional to those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the defense of such action
and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement
of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such
indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying
</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">party, the indemnifying party shall not have the right to assume
the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend)
such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently
incurred by such indemnified party in connection with the defense of such action; <FONT STYLE="font-size: 10pt; font-weight: normal"><I><U>provided</U></I><FONT STYLE="font-style: normal">,
</FONT><I><U>however</U></I><FONT STYLE="font-style: normal">, that the indemnifying party shall not, in connection with any one such
action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations
or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time any such indemnified
party (in addition to any local counsel), which firm shall be designated in writing by the Underwriter if the indemnified party under
this <U>Section 5</U> is an Underwriter Indemnified Party or by the Company if an indemnified party under this <U>Section 5</U> is a
Company Indemnified Party. Subject to this <U>Section 5.3</U>, the amount payable by an indemnifying party under <U>Section 5</U> shall
include, but not be limited to, (x) reasonable legal fees and expenses of counsel to the indemnified party and any other expenses in
investigating, or preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred
in connection with, any action, investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the foregoing. No
indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry
of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution
could be sought under this <U>Section 5</U> (whether or not the indemnified parties are actual or potential parties thereto), unless
such settlement, compromise or consent (i) includes an unconditional release of each indemnified party in form and substance reasonably
satisfactory to such indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as
to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the
following sentence, no indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever
that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written
consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the
indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such
settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the
indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated herein effected without its written consent if (i) such settlement is entered into more than forty-five (45) days
after receipt by such indemnifying party of the request for reimbursement, (ii) such indemnifying party shall have received notice of
the terms of such settlement at least thirty (30) days prior to such settlement being entered into and (iii) such indemnifying party
shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</FONT></FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">5.4
<U>Contribution</U>. If the indemnification provided for in this <U>Section 5</U> is unavailable or insufficient to hold harmless an
indemnified party under <U>Section 5.1</U> or <U>Section 5.2</U>, then each indemnifying party shall, in lieu of indemnifying such indemnified
party, contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage,
expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be
appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriter on the other hand from the Offering,
or (ii) if the allocation provided by <U>clause (i)</U> of this <U>Section 5.4</U> is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in <U>clause (i)</U> of this <U>Section 5.4</U> but also the
relative fault of the Company on the one hand and the Underwriter on the other with respect to the statements, omissions, acts or failures
to act which resulted in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof)
as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriter
on the other with respect to such offering shall be deemed to be in the same proportion as the total proceeds from the Offering purchased
under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discount and commissions received
by the Underwriter in connection with the Offering, in each case as set forth in the table on the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">cover
page of the Prospectus. The relative fault of the Company on the one hand and the Underwriter on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company on the one hand or the Underwriter on the other, the intent of the parties
and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure
to act; provided that the parties hereto agree that the written information furnished to the Company by or on behalf of <FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">the
Underwriter for use in any Preliminary Prospectus, any Registration Statement, the Disclosure Package or the Prospectus, or in any amendment
or supplement thereto, consists solely of the Underwriter&#8217;s Information. The Company and the Underwriter agree that it would not
be just and equitable if contributions pursuant to this <U>Section 5.4</U> be determined by pro rata allocation or by any other method
of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to above in this <U>Section
5.4</U> shall be deemed to include, for purposes of this <U>Section 5.4</U>, any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in
respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding.
Notwithstanding the provisions of this <U>Section 5.4</U>, the Underwriter shall not be required to contribute any amount in excess of
the total discount and commission received by the Underwriter in connection with the Offering less the amount of any damages which the
Underwriter has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission,
act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>Additional
                                            Covenants</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">6.1
<U>Board Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as
members of the Board of Directors and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act, the Exchange
Act and the listing rules of the NasdaqCM or any other national securities exchange, as the case may be, in the event the Company seeks
to have its Common Stock listed on another exchange or quoted on an automated quotation system, subject to any applicable cure period,
and (ii)&nbsp;if applicable, at least one member of the Audit Committee of the Board of Directors qualifies as an &#8220;audit committee
financial expert,&#8221; as such term is defined under Regulation S-K and the listing rules of the NasdaqCM.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">6.2
<U>Prohibition on Press Releases and Public Announcements</U>. Prior to the last Option Closing Date, if any, the Company shall not issue
any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition,
financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing communications in the
ordinary course of business and consistent with the past practices of the Company and of which the Underwriter is notified), without
the prior written consent of the Underwriter (not to be withheld unreasonably), unless in the judgment of the Company and its counsel,
and after notification to the Underwriter, such press release or communication is required by law or applicable NasdaqCM rules.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>Effective
                                            Date of this Agreement and Termination Thereof</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">7.1
<U>Effective Date</U>. This Agreement shall become effective when both the Company and the Underwriter have executed the same and delivered
counterparts of such signatures to the other party.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">7.2
<U>Termination</U>. The Underwriter shall have the right to terminate this Agreement at any time prior to the Closing Date, (i)&nbsp;if
any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially
disrupt, general securities markets in </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">the United States; or (ii)&nbsp;if
trading on the New York Stock Exchange or <FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Nasdaq Stock Market
LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges
for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction;
or (iii)&nbsp;if the United States shall have become involved in a new war or an increase in major hostilities; or (iv)&nbsp;if a banking
moratorium has been declared by a New York State or federal authority; or (v)&nbsp;if a moratorium on foreign exchange trading has been
declared which materially adversely impacts the United States securities markets; or (vi)&nbsp;if the Company shall have sustained a
material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not
such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Units or the Option
Securities; or (vii)&nbsp;if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii)&nbsp;if
the Underwriter shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of the
Company, or such adverse material change in general market conditions as in the Underwriter&#8217;s judgment would make it impracticable
to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriter for the sale
of the Public Securities.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">7.3
<U>Expenses</U>. Notwithstanding anything to the contrary in this Agreement, in the event that this Agreement shall not be carried out
for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall
be obligated to pay to the Underwriter its reasonable accountable out-of-pocket expenses actually incurred related to the transactions
contemplated herein then due and payable (including the fees and disbursements of Underwriter&#8217;s Counsel) up to $75,000 and upon
demand the Company shall pay the full amount thereof to the Underwriter on behalf of the Underwriter; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">provided,
however, <FONT STYLE="font-style: normal">that such expense cap in no way limits or impairs the indemnification and contribution provisions
of this Agreement. Notwithstanding the foregoing, any advance received by the Underwriter will be reimbursed to the Company to the extent
not actually incurred in compliance with FINRA Rule 5110(g)(4).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">7.4
<U>Survival of Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any
termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of <U>Section 5</U> shall remain
in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this
Agreement or any part hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">7.5
<U>Representations, Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i)&nbsp;any investigation made by or on behalf of the Underwriter or its affiliates or selling agents, any person controlling the
Underwriter, its officers or directors or any person controlling the Company or (ii)&nbsp;delivery of and payment for the Public Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.1
<U>Notices</U>. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed
(registered or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall
be deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to the
Underwriter:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newbridge Securities Corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1200 North Federal Highway, Suite 400</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca Raton, Florida 33432</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chad D. Champion, Senior Managing
    Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cchampion@newbridgesecurities.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel. No:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(561) 453-2270</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not constitute
    notice) to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">McGuireWoods LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1251 Avenue of the Americas, 20th Floor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10020</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Older, Esq.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David S. Wolpa, Esq.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solder@mcguirewoods.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dwolpa@mcguirewoods.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modular Medical, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10740 Thornmint Road</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Diego, CA 92127</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Besser</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jeb@modular-medical.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel. No:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(858) 800-3500</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not constitute
    notice) to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucosky Brookman LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101 Wood Avenue South</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Woodbridge, NJ 08830</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Metelitsa</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lmetelitsa@lucbro.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel. No:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(732) 395-4405</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.2
<U>Headings</U>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.3
<U>Absence of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
the Underwriter&#8217;s responsibility to the Company is solely contractual in nature, the Underwriter has been retained solely to act
as an underwriter in connection with the Offering and no fiduciary, advisory or agency relationship between the Company and the Underwriter
has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether either the Underwriter
has advised or is advising the Company on other matters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)
the price of the Public Securities set forth in this Agreement was established by the Company following discussions and arms-length negotiations
with the Underwriter, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions
of the transactions contemplated by this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)
it has been advised that the Underwriter and its respective affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Underwriter has no obligation to disclose such interests and transactions
to the Company by virtue of any fiduciary, advisory or agency relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.4
<U>Research Analyst Independence</U>. The Company acknowledges that the Underwriter&#8217;s research analysts and research departments
are required to be independent from its investment banking division and are subject to certain regulations and internal policies, and
that the Underwriter&#8217;s research analysts may hold views and make statements or investment recommendations and/or publish research
reports with respect to the Company and/or the offering that differ from the views of their investment banking division. The Company
acknowledges that the Underwriter is a full service securities firm and as such from time to time, subject to applicable securities laws,
rules and regulations, may effect transactions for its own account or the account of its customers and hold long or short positions in
debt or equity securities of the Company; provided, however, that nothing in this <U>Section 8.4</U> shall relieve the Underwriter of
any responsibility or liability it may otherwise bear in connection with activities in violation of applicable securities laws, rules
or regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.5
<U>Amendment</U>. This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.6
<U>Entire Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.7
<U>Binding Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Underwriter, the Company and
the controlling persons, directors and officers referred to in <U>Section 5</U>, and their respective successors, legal representative,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term &#8220;successors and assigns&#8221; shall not include
a purchaser, in its capacity as such, of securities from the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.8
<U>Governing Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in
state and federal courts located in the Borough of Manhattan in the City of New York, and irrevocably submits to such jurisdiction, which
jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in <U>Section 9.1</U>. Such mailing
shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees
that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&#8217;
fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on
its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates) and the Underwriter hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of
or relating to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.9
<U>Execution in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">other parties hereto. Delivery of a signed counterpart
of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">8.10
<U>Waiver, etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not
be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Signature
Page Follows]</FONT></P>




<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">If
the foregoing correctly sets forth the understanding between the Underwriter and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -42pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: -42pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly
    yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -42pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: -42pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">MODULAR
    MEDICAL, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -0.5in; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: -0.5in; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.3in; padding-right: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Besser, Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed as of
    the date first written<BR>
    above mentioned:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEWBRIDGE SECURITIES
    CORPORATION</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chad D. Champion</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Managing Director</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature Page]&nbsp;</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Modular Medical, Inc. &ndash; Underwriting Agreement</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>SCHEDULE
1-A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pricing
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Firm Shares:</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<FONT STYLE="font-size: 10pt">&#9679;]</FONT></FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of shares underlying
    Firm Warrants:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Option Shares:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of shares underlying
    Option Warrants:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Public Offering Price per Unit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting Discount
    per Unit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds to Company
    per Unit (before expenses)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 1-A</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>SCHEDULE
1-B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Issuer
General Use Free Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">[None.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 1-B-1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>SCHEDULE
2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>List
of Lock-Up Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEB Partners, L.P.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manchester Explorer, L.P.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manchester Management LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sio Capital Management, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul DiPerna</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Febbo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Felsher</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan C. Frank</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ellen O&rsquo;Connor Vos</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip Sheibley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carmen Volkart</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Schmid</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 2-1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form
of Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(See
attached.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXHIBIT
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form
of Lock-Up Agreement<BR>
</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">________________,
2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Newbridge
Securities Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1200 North
Federal Highway, Suite 400</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Boca Raton,
Florida 33432</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ladies and
Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
undersigned understands that Newbridge Securities Corporation (the &ldquo;<B>Underwriter</B>&rdquo;) proposes to enter into an Underwriting
Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with Modular Medical, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;),
providing for the public offering (the &ldquo;<B>Public Offering</B>&rdquo;) of shares of Common Stock, par value $0.001 per share (the
&ldquo;<B>Shares</B>&rdquo;), and warrants of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
induce the Underwriter to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of the Underwriter, the undersigned will not, during the period commencing on the date hereof and ending ninety
(90) days after the date of the final prospectus (the &ldquo;<B>Prospectus</B>&rdquo;) relating to the Public Offering (the &ldquo;<B>Lock-Up
Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares
of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the
Company, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires
the power of disposition (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;); (2) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of Lock-Up Securities, whether any such transaction
is to be settled by delivery of shares of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with
respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition,
or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Underwriter
in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions after the completion of the Public
Offering; <I>provided</I> that no filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;), shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in
such open market transactions; (b) transfers of Lock-Up Securities as a <I>bona fide</I> gift, by will or intestacy or to a family member
or trust for the benefit of a family member (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means any relationship
by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution;
(d) if the undersigned, directly or indirectly, controls a corporation, partnership, limited liability company or other business entity,
any transfers of Lock-Up Securities to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned,
as the case may be, or (e) the sales of Shares to cover the payment of the exercise prices or the payment of taxes associated with the
exercise or vesting of equity awards under any equity compensation plan of the Company; <I>provided</I> that in the case of any transfer
pursuant to the foregoing <U>clauses&nbsp;(b)</U>, <U>(c)</U> or <U>(d)</U>, (i) any such transfer shall not involve a disposition for
value, (ii) each transferee shall sign and deliver to the Underwriter a lock-up agreement substantially in the form of this lock-up agreement
and (iii) no filing under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made, except for a Form 5.
The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar
against the transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance with this lock-up agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the undersigned is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally
applicable to any issuer-directed or &ldquo;friends and family&rdquo; Shares that the undersigned may purchase in the Public Offering;
(ii) the Underwriter agrees that, at least three (3) Business Days (as that term is defined in the Underwriting Agreement) before the
effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Underwriter
will notify the Company of the impending release or waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce
the impending release or waiver by press release through a major news service at least two (2) Business Days before the effective date
of the release or waiver. Any release or waiver granted by the Underwriter hereunder to any such officer or director shall only be effective
two (2) Business Days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release
or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing
to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect
at the time of such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
provision in this agreement shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities
exercisable or exchangeable for or convertible into Shares, as applicable; <I>provided</I> that the undersigned does not transfer the
Public Securities (as that term is defined in the Underwriting Agreement) acquired on such exercise, exchange or conversion during the
Lock-Up Period, unless otherwise permitted pursuant to the terms of this lock-up agreement. In addition, no provision herein shall be
deemed to restrict or prohibit the entry into or modification of a so-called &ldquo;10b5-1&rdquo; plan at any time (other than the entry
into or modification of such a plan in such a manner as to cause the sale of any Lock-Up Securities within the Lock-Up Period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
undersigned understands that the Company and the Underwriter are relying upon this lock-up agreement in proceeding toward consummation
of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the
undersigned&rsquo;s heirs, legal representative, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
undersigned understands that, if the Underwriting Agreement is not executed by July 31, 2023, or if the Underwriting Agreement (other
than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Public
Securities to be sold thereunder, then this lock-up agreement shall be void and of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Whether
or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only
be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Name - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Signature)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Name of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Title of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 31.2pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 31.2pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXHIBIT
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form
of Press Release</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>MODULAR
MEDICAL,</B></FONT><B> <FONT STYLE="font-family: Times New Roman, Times, Serif">INC.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[Date]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Modular
Medical, Inc. (the &ldquo;Company&rdquo;) announced today that Newbridge Securities Corporation acting as Underwriter for the Company&rsquo;s
recent public offering of&nbsp;____ shares of the Company&rsquo;s Common Stock, is [waiving] [releasing] a lock-up restriction with respect
to _________&nbsp; shares of the Company&rsquo;s Common Stock held by [certain officers or directors] [an officer or director] of the
Company.&nbsp; The [waiver] [release] will take effect on&nbsp; _________, 20___, and the shares may be sold on or after such date.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>This
press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is
prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act of 1933, as amended.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXHIBIT
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Form
of Underwriter&rsquo;s Warrant</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><U>(See
attached.)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>ea177987ex4-5_modular.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>MODULAR
MEDICAL, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</FONT></TD>
    <TD STYLE="text-align: right; padding-left: 0.25in; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Issue Date: ___________, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date: ________,
2023 </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on _______, 2028 (the
&ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Modular Medical, Inc., a company incorporated
under the laws of the State of Nevada (the &ldquo;<U>Company</U>&rdquo;), up to ___ shares of Common Stock (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in <U>Section 2(b)</U>. This Warrant shall initially be issued and maintained in the form of a security held in book-entry
form and The Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this
Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency
Agreement, in which case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this <U>Section 1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined in good faith by an independent appraiser
selected in good faith by the Board of Directors, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1, as amended and supplemented (File No. 333- [&#9679;]).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Colonial Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 7840 S 700
E, Sandy, UT 8407018, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underwriting
Agreement</U>&rdquo; means the underwriting agreement, dated as of [&#9679;], 2023 between the Company and Newbridge Securities Corporation,
as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price per share of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price per share of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the Company
and the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Agent</U>&rdquo; means the [Transfer Agent]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT> and any successor
warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Exercise
of Warrant</U>. Subject to the provisions of <U>Section 2(e)</U> herein, exercise of the purchase rights represented by this Warrant may
be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Warrant Agent (with a copy to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment)
of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;), and, unless the cashless exercise
procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise, delivery of the aggregate Exercise
Price of the Warrant Shares specified in the applicable Notice of Exercise as specified in this <U>Section 2(a)</U>. Within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <U>Section 2(d)(i)</U>
herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified
in the applicable Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s check drawn on a United States
bank unless the cashless exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Warrant Agent until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
exercised in full, in which case, the Holder shall surrender this Warrant to the Warrant Agent for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Warrant Agent. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Company and
the Warrant Agent shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than
the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding the foregoing in this
<U>Section 2(a)</U>, a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant held
in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made
pursuant to this <U>Section 2(a)</U> by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction
form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable),
subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement,
in which case this sentence shall not apply.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
<B>Note</B>: MODD to confirm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $[&#9679;], subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Cashless
Exercise</U>. The Company shall use commercially reasonable best efforts to cause the Registration Statement to remain effective with
a current prospectus and to maintain the registration of the shares of Common Stock under the Exchange Act for as long as this Warrant
remains outstanding. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing ((A-B)(X)) by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD>
    <TD STYLE="width: 0.1in">=</TD><TD STYLE="text-align: justify"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to <U>Section
2(a)</U> hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a Trading
Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the
federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by
Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed
during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2)
hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> hereof or (iii) the VWAP
on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
is both executed and delivered pursuant to <U>Section 2(a)</U> hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD>
    <TD STYLE="width: 0.1in">=</TD><TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD>
    <TD STYLE="width: 0.1in">=</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this <U>Section 2(c)</U>. Upon receipt of an Election to Purchase for a cashless exercise, the Warrant Agent will promptly
deliver a copy of the Election to Purchase to the Company to confirm the number of Warrant Shares issuable in connection with the cashless
exercise. The Company shall calculate and transmit to the Warrant Agent in a written notice, and the Warrant Agent shall have no duty,
responsibility or obligation under this section to calculate, the number of Warrant Shares issuable in connection with any cashless exercise.
The Warrant Agent shall be entitled to rely conclusively on any such written notice provided by the Company, and the Warrant Agent shall
not be liable for any action taken, suffered or omitted to be taken by it in accordance with such written instructions or pursuant to
the Warrant Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this <U>Section 2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"> i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.   <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.   <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <U>Section 2(d)(i)</U>
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.   <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <U>Section
2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.   <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.   <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.   <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties to the extent such issuance would exceed such limitation. Except as set forth in the preceding
sentence, for purposes of this <U>Section 2(e)</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to
the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and neither the Company nor the Warrant Agent shall have any obligation to
verify or confirm the accuracy of such determination and neither of them shall have any liability for any error made by the Holder or
any other Person. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally
and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance
of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this <U>Section 2(e)</U>, provided that the Beneficial Ownership Limitation in no event exceeds 9.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this <U>Section 2(e)</U> shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
<U>Section 2(e)</U> to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of
any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent this Warrant has not been partially or completely exercised at the time of such Distribution, such portion
of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power
of the then outstanding common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock or 50% or more of the voting power of the then outstanding
common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(together, the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this <U>Section 3(d)</U> pursuant to written agreements in form and substance reasonably satisfactory to the Warrant
Agent and the holders of Warrants representing at least a majority of the shares of Common Stock underlying the Warrants then outstanding
(the &ldquo;<U>Required Holders</U>&rdquo;) and approved by the Required Holders (without unreasonable delay) prior to such Fundamental
Transaction and shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may
exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same
effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Calculations</U>.
All calculations under this <U>Section 3</U> shall be made by the Company to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this <U>Section 3</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)   <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.   <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the Company shall promptly
deliver to the Warrant Agent pursuant to the Warrant Agency Agreement and to the Holder by facsimile or email a notice setting forth the
Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.   <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)   <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Transferability</U>.
This Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder
has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>New
Warrants</U>. If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined
with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names
and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with <U>Section
4(a)</U>, as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant
or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers
or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number
of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Warrant
Register</U>. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except as expressly
set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U> herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of any Warrant held in book
entry form through DTC, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding the foregoing, nothing
in this paragraph shall limit or restrict the federal district court in which a Holder may bring a claim under the U.S. securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)   <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)   <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. No provision of this Warrant shall be construed
as a waiver by the Holder of any rights that the Holder may have under U.S. federal securities laws and the rules and regulation of the
Commission thereunder. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)   <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder to the Warrant Agent including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or sent by a nationally recognized overnight courier
service, first-class mail, postage prepaid, addressed to the Warrant Agent, at <B>[</B>&#9679;<B>]</B>, Attention: [&#9679;], email address:
[&#9679;], or such other facsimile number, email address or address as the Company may specify for such purposes <FONT STYLE="background-color: white">by
notice to the Holders and the Company. Any and all notices or other communications or deliveries to be provided to the Company shall be
in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight courier service, at 16772 W. Bernardo Drive,
San Diego, CA 92127, Attention: James Besser, chief executive officer, email address: jbesser@mgfund.com, or such other facsimile number,
email address or address as the Company may specify for such purposes by notice to the Warrant Agent Holders. Any and all notices or other
communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail,
or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile nu</FONT>mber, e-mail address or
address of such Holder appearing on the books of the Warrant Agent. Any notice or other communication or deliveries hereunder shall be
deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the e-mail address set forth in this <U>Section 5(h)</U> prior to 5:30 p.m. (New York City time)
on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or via e-mail at the e-mail address set forth in this <U>Section 5(h)</U> on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent
that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)   <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)   <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)   <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)   <U>Amendment
and Waiver</U>. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Required Holders. Any such amendment shall apply to all Warrants outstanding and be binding upon all registered holders of such
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)   <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)   <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)   <U>Warrant
Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject
to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency
Agreement, the provisions of this Warrant shall govern and be controlling with respect to the rights and obligations between the Holders
and the Company, provided that, with respect to the rights, duties, obligations, protections, immunities and liability of the Warrant
Agent, the Warrant Agency Agreement shall govern and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>MODULAR MEDICAL, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Besser</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: <B>MODULAR
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)   <FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)   <FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#9744; in lawful money of the
United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#9744; if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)   <FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none"> _________________________________________</U></FONT>__</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U> </U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</font></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">___________________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>___________________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>___________________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:<U> </U></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:<U> </U></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>4
<FILENAME>ea177987ex4-6_modular.htm
<DESCRIPTION>FORM OF UNDERWRITER'S WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.6</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underwriter&rsquo;s Warrant Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE REGISTERED HOLDER OF THIS PURCHASE WARRANT
BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD
OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) NEWBRIDGE SECURITIES CORPORATION OR AN
UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF NEWBRIDGE SECURITIES CORPORATION
OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO [&#9679;], 2023. VOID AFTER 5:00 P.M., EASTERN TIME, [&#9679;], 202[6][7].</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">COMMON STOCK PURCHASE
WARRANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">MODULAR MEDICAL,
Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</FONT></TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; width: 35%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Issue Date: ___________, 2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
Exercise Date: ________, 2023</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<B>Warrant</B>&rdquo;) certifies that, for value received, [Newbridge Securities Corporation] [other designee] or its assigns
(the &ldquo;<B>Holder</B>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after [&#9679;]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>, 2023 (the &ldquo;<B>Initial
Exercise Date</B>&rdquo;) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to 5:00 p.m. (New York City time) on the date that
is four (4) years following the Effective Date (the &ldquo;<B>Termination Date</B>&rdquo;) but not thereafter, to subscribe for and purchase
from Modular Medical, Inc., a company incorporated under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), up to ___
shares of Common Stock (as subject to adjustment hereunder, the &ldquo;<B>Warrant Shares</B>&rdquo;). The purchase price of one share
of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in <U>Section 2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this <U>Section 1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bid Price</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined in good faith by an independent appraiser
selected in good faith by the Board of Directors of the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Note
to Draft</B>: This will be six months after the effective date of the Form S-1.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business
Day</B>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commission</B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock Equivalents</B>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective
Date</B>&rdquo; means the effective date of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration
Statement</B>&rdquo; means the Company&rsquo;s registration statement on Form S-1, as amended and supplemented (File No. 333-271003).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rule 144</B>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading
Day</B>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading
Market</B>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer
Agent</B>&rdquo; means Colonial Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 7840 S 700
E, Sandy UT 84070, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Underwriting
Agreement</B>&rdquo; means the underwriting agreement, dated as of [&#9679;], 2023 between the Company and Newbridge Securities Corporation,
as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price per share of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price per share of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrants</B>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company as underwriting compensation pursuant to the Underwriting
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a) <U>Exercise
of Warrant</U>. Subject to the provisions of <U>Section 2(e)</U> herein, exercise of the purchase rights represented by this Warrant may
be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the
address of the Holder appearing on the books of the Company) of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<B>Notice of Exercise</B>&rdquo;), and, unless the cashless
exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise, delivery of the aggregate
Exercise Price of the Warrant Shares specified in the applicable Notice of Exercise as specified in this <U>Section 2(a)</U>. Within the
earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <U>Section
2(d)(i)</U> herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s check drawn on
a United States bank unless the cashless exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice
of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $[&#9679;]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT>,
subject to adjustment hereunder (the &ldquo;<B>Exercise Price</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c) <U>Cashless
Exercise</U>. The Company shall use commercially reasonable efforts to cause the Registration Statement to remain effective with a current
prospectus and to maintain the registration of the shares of Common Stock under the Exchange Act for as long as this Warrant remains outstanding,
provided for avoidance of doubt the foregoing covenant shall not require the Company to maintain registration following the completion
of a Fundamental Transaction (as defined below) as a result of which this Warrant becomes exercisable for Alternate Consideration (as
defined below). If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing ((A-B)(X)) by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(A) =</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a day that is not
a Trading Day or (2) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a Trading Day prior to the opening of &ldquo;regular
trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
(ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to <U>Section
2(a)</U> hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(X) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this <U>Section 2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify"><B>Note to Draft</B>: This will be 125% of the effective
per-share offering price.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this <U>Section
2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<B>DWAC</B>&rdquo;) if the Company is then a participant in such system
and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant
to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the
Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2)&nbsp;Trading Days after the delivery to the Company
of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company
of the Notice of Exercise (such date, the &ldquo;<B>Warrant Share Delivery Date</B>&rdquo;). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of
Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason
to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, then the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<B>Standard Settlement Period</B>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to <U>Section 2(d)(i)</U>
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of <U>Section
2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <I><U>provided</U></I>, <I><U>however</U></I>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">viii <U>Signature</U>.
This <U>Section 2</U> and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to
exercise this Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Warrant. No additional
legal opinion, other information or instructions shall be required of the Holder to exercise this Warrant. The Company shall honor exercises
of this Warrant and shall deliver Shares underlying this Warrant in accordance with the terms, conditions and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties to the extent such issuance would exceed such limitation.&nbsp; Except as set forth in the preceding
sentence, for purposes of this <U>Section 2(e)</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to
the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall not have any obligation to verify or confirm the accuracy
of such determination and neither of them shall have any liability for any error made by the Holder or any other Person. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the
number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
<U>Section 2(e)</U>, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this <U>Section 2(e)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this <U>Section 2(e)</U> to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights; <I><U>provided</U></I>, <I><U>however</U></I>, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than
cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution</B>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I><U>provided</U></I>,
<I><U>however</U></I>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation). To the extent this Warrant has not been partially or completely exercised at
the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder
has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power
of the then outstanding common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock or 50% or more of the voting power of the then outstanding
common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(together, the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this <U>Section 3(d)</U> pursuant to written agreements in form and substance reasonably satisfactory to the Company
and the holders of Warrants representing at least a majority of the shares of Common Stock underlying the Warrants then outstanding (the
&ldquo;<B>Required Holders</B>&rdquo;) and approved by the Required Holders (without unreasonable delay) prior to such Fundamental Transaction
and shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e) <U>Calculations</U>.
All calculations under this <U>Section 3</U> shall be made by the Company to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this <U>Section 3</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">f) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a) <U>Transferability</U>.
Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Effective Date
or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">i. by
operation of law or by reason of reorganization of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">ii. to
any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this <U>Section 4(a)</U> for the remainder of the time period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">iii. if
the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">iv. that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or
otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.25in">v. the
exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this <U>Section 4(a)</U>
for the remainder of the time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the foregoing restriction,
the Securities Act and any other applicable securities laws, and the conditions set forth in <U>Section 4(d)</U>, this Warrant and all
rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 4(a)</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant
Register</B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except as expressly
set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U> herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">The Company covenants that,
during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary
Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or
of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. No provision of this Warrant shall be construed
as a waiver by the Holder of any rights that the Holder may have under U.S. federal securities laws and the rules and regulation of the
Commission thereunder. Without limiting any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and
knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay
to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo;
fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Required Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">MODULAR MEDICAL, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Besser</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature Page]</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">Modular Medical, Inc. &ndash; Underwriter&rsquo;s Warrant</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TO:</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt; text-transform: uppercase">MODULAR MEDICAL, INC.</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.35in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(4) <U>Accredited
Investor</U>. If the Warrant is being exercised via cash exercise and the registration statement registering the issue of the shares under
the Warrant is no longer effective, the undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%; font-size: 10pt">Name&nbsp;of&nbsp;Investing&nbsp;Entity:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 82%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 20%; font-size: 10pt"><I>Signature of Authorized Signatory of Investing
Entity</I>:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 80%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; width: 20%">Name of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; width: 20%">Title of Authorized Signatory:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 80%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; width: 4%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 96%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email Address:</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U></U></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>ea177987ex5-1_modular.htm
<DESCRIPTION>OPINION OF LUCOSKY BROOKMAN LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 70%; padding: 0.25pt; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: bottom; width: 30%; padding: 0.25pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>LUCOSKY BROOKMAN LLP</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">May 5, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 5.75pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">101 Wood Avenue South</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">5th floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Woodbridge, NJ 08830</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T - (732) 395-4400</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F - (732) 395-4401</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modular Medical, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10740 Thornmint Road</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, California 92127</P></TD>
    <TD STYLE="vertical-align: top; padding: 3.25pt 0.25pt 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">111 Broadway</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Suite 807</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, NY 10006</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T - (212) 332-8160</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F - (212) 332-8161</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">www.lucbro.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 46px; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Amendment No. 1 to Registration Statement on Form S-1</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to you, Modular Medical,
Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the Company&rsquo;s Registration Statement on Form S-1 filed
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant to the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;) (File No. 333-271413) (the &ldquo;Registration Statement&rdquo;) with respect to (i) 2,116,402 Units (the &ldquo;Units&rdquo;),
with each Unit consisting of two shares of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;),
and one warrant to purchase one share of Common Stock (the &ldquo;Warrant&rdquo;) at an exercise price equal to 120% of the public offering
price of the Units; (ii) up to 2,116,402 shares of Common Stock issuable upon exercise of the Warrants (the &ldquo;Warrant Shares&rdquo;);
(iii) up to 634,920 shares of Common Stock, purchased pursuant to over allotments, if any (the &ldquo;Over Allotment Shares&rdquo;); (iv)
up to 317,460 Warrants to purchase 317,460 shares of Common Stock, issued pursuant to over-allotments, if any (the &ldquo;Over-Allotment
Warrants&rdquo;); (v) up to 317,460 shares of Common Stock underlying the Over-Allotment Warrants (the &ldquo;Underlying Over-Allotment
Warrant Shares&rdquo;); (vi) up to 296,296 warrants to purchase 296,296 shares of Common Stock, issued to the representative of the underwriter
(the &ldquo;Representative Warrants&rdquo;); and (vii) up to 283,334 shares of Common Stock underlying the Representative Warrants (the
&ldquo;Representative Warrant Shares&rdquo;). This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of
Regulation S-K under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion, we have examined
the originals or copies certified or otherwise identified to our satisfaction of the following: (a) Articles of Incorporation of the Company,
as amended to date, (b) Bylaws of the Company, as amended to date, and (c) the Registration Statement and all exhibits thereto. In addition
to the foregoing, we also have relied as to matters of fact upon the representations made by the Company and its representatives and we
have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to
original documents of all documents submitted to us certified or photostatic copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the foregoing and in reliance thereon,
and subject to the qualifications, limitations, exceptions and assumptions set forth herein, we are of the opinion that: (i) the shares
of Common Stock included in the Units, when issued against payment therefor as set forth in the Registration Statement, will be validly
issued, fully paid and non-assessable; (ii) the Warrants included in the Units, when issued as set forth in the Registration Statement,
will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms; (iii) the
Warrant Shares, when issued upon exercise of the Warrants against payment therefor as set forth in the Registration Statement, will be
validly issued, fully paid and non-assessable; (iv) the Units, when issued against payment thereof as set forth in the Registration Statement,
will be validly issued, fully paid and non-assessable, and will be legal, valid and binding obligations of the Company, enforceable against
the Company in accordance with their terms; (v) the Over-Allotment Shares, when issued against payment therefor as set forth in the Registration
Statement, will be validly issued, fully paid and non-assessable; (vi) the Over-Allotment Warrants, when issued as set forth in the Registration
Statement, will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms;
(vii) the Underlying Over-Allotment Warrant Shares when issued upon exercise of the Over-Allotment Warrants against payment therefor as
set forth in the Registration Statement will be validly issued, fully paid and non-assessable; (viii) the Representative Warrants, when
issued as set forth in the Registration Statement, will be legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms; and (ix) the Underlying Representative Warrant Shares when issued upon exercise of the Representative
Warrants against payment therefor as set forth in the Registration Statement will be validly issued, fully paid and non-assessable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is limited to the federal laws of
the United States and Chapter 78 of the Nevada Revised Statutes. We express no opinion as to the effect of the law of any other jurisdiction.
Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof
on the opinions expressed herein) that hereafter may come to our attention. This opinion letter is limited to the laws in effect as of
the date the Registration Statement is declared effective by the Commission and is provided exclusively in connection with the public
offering contemplated by the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter speaks only as of the date
hereof and we assume no obligation to update or supplement this opinion letter if any applicable laws change after the date of this opinion
letter or if we become aware after the date of this opinion letter of any facts, whether existing before or arising after the date hereof,
that might change the opinions expressed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter is furnished in connection
with the filing of the Registration Statement and may not be relied upon for any other purpose without our prior writ ten consent in each
instance. Further, no portion of this letter may be quoted, circulated or referred to in any other document for any other purpose without
our prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this opinion
with the Commission as an exhibit to the Registration Statement and to the use of our name as it appears in the Prospectus included in
the Registration Statement. In giving such consent, we do not thereby admit that we come within the category of persons whose consent
is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. This opinion
is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking to advise you of any subsequent
changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Very Truly Yours,</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>/s/ Lucosky Brookman LLP</I></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Lucosky Brookman LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>6
<FILENAME>ea177987ex10-29_modular.htm
<DESCRIPTION>WARRANT AGENCY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.29</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This WARRANT AGENCY AGREEMENT, dated as of [______],
2023 (&ldquo;<U>Agreement</U>&rdquo;), between Modular Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), and Colonial
Stock Transfer Company, Inc., a New York limited liability trust company (the &ldquo;<U>Warrant Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>W I T N E S S E T H</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to a registered
offering by the Company of shares of common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), warrants to purchase
shares of Common Stock (the &ldquo;<U>Warrants</U>&rdquo;) pursuant to an effective registration statement on Form S-1 (File No. 333-271413)
(collectively, the &ldquo;<U>Registration Statement</U>&rdquo;), the Company wishes to issue the Warrants in book-entry form entitling
the respective holders of the Warrants (the &ldquo;<U>Holders</U>,&rdquo; which term shall include a Holder&rsquo;s transferees, successors
and assigns and &ldquo;Holder&rdquo; shall include, if the Warrants are held in &ldquo;street name,&rdquo; a Participant (as defined below)
or a designee appointed by such Participant) to purchase an aggregate of up to [_________] shares of Common Stock upon the terms and subject
to the conditions hereinafter set forth (the &ldquo;<U>Offering</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the shares of Common
Stock and the Warrants to be issued in connection with the Offering shall be immediately separable and will be issued separately, but
will be purchased together in the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company wishes
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration,
transfer, exchange, exercise and replacement of the Warrants and, in the Warrant Agent&rsquo;s capacity as the Company&rsquo;s transfer
agent, the delivery of the Warrant Shares (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1. <U>Certain Definitions</U>.
For purposes of this Agreement, the following terms have the meanings indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home,&rdquo; &ldquo;shelter-in-place,&rdquo; &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) &ldquo;<U>Close of Business</U>&rdquo;
on any given date means 5:00 p.m., New York City time, on such date; <U>provided</U>, <U>however</U>, that if such date is not a Business
Day it means 5:00 p.m., New York City time, on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) &ldquo;<U>Person</U>&rdquo;
means an individual, corporation, association, partnership, limited liability company, joint venture, trust, unincorporated organization,
government or political subdivision thereof or governmental agency or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) &ldquo;<U>Warrant Certificate</U>&rdquo;
means a certificate in substantially the form attached as <U>Exhibit 1</U> hereto, representing such number of Warrant Shares as is indicated
therein, provided that any reference to the delivery of a Warrant Certificate in this Agreement shall include delivery of notice from
the Depositary or a Participant (each as defined below) of the transfer or exercise of a Warrant in the form of a Global Warrant (as defined
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) &ldquo;<U>Warrant Shares</U>&rdquo;
means the shares of Common Stock underlying the Warrants and issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other capitalized terms
used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2. <U>Appointment
of Warrant Agent</U>. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance with the terms and conditions
hereof, and the Warrant Agent hereby accepts such appointment. The Company may from time to time appoint a Co-Warrant Agent as it may,
in its sole discretion, deem necessary or desirable. The Warrant Agent shall have no duty to supervise, and will in no event be liable
for the acts or omissions of, any co-Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3. <U>Global Warrants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Warrants shall be issuable
in book entry form (the &ldquo;<U>Global Warrants</U>&rdquo;). All of the Warrants shall initially be represented by one or more Global
Warrants deposited with the Warrant Agent and registered in the name of Cede &amp; Co., a nominee of The Depository Trust Company (the
&ldquo;<U>Depositary</U>&rdquo;), or as otherwise directed by the Depositary. Ownership of beneficial interests in the Warrants shall
be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its nominee for
each Global Warrant or (ii) institutions that have accounts with the Depositary (such institution, with respect to a Warrant in its account,
a &ldquo;<U>Participant</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If the Depositary subsequently
ceases to make its book-entry settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding other
arrangements for book-entry settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the
Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant
Agent for cancellation each Global Warrant, and the Company shall instruct the Warrant Agent to deliver to each Holder a Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) A Holder has the right to
elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate Request Notice (as defined
below). Upon written notice by a Holder to the Warrant Agent for the exchange of some or all of such Holder&rsquo;s Global Warrants for
a Warrant Certificate evidencing the same number of Warrants, which request shall be in the form attached hereto as <U>Annex A</U> (a
&ldquo;<U>Warrant Certificate Request Notice</U>&rdquo; and the date of delivery of such Warrant Certificate Request Notice by the Holder,
the &ldquo;<U>Warrant Certificate Request Notice Date</U>&rdquo; and the deemed surrender upon delivery by the Holder of a number of Global
Warrants for the same number of Warrants evidenced by a Warrant Certificate, a &ldquo;<U>Warrant Exchange</U>&rdquo;), the Warrant Agent
shall promptly effect the Warrant Exchange and shall promptly issue and deliver, at the expense of the Company, to the Holder a Warrant
Certificate for such number of Warrants in the name set forth in the Warrant Certificate Request Notice. Such Warrant Certificate shall
be dated the original issue date of the Warrants, shall be executed by manual or facsimile signature by an authorized signatory of the
Company and shall be in the form attached hereto as <U>Exhibit 1</U>. In connection with a Warrant Exchange, the Company agrees to deliver,
or to direct the Warrant Agent to deliver, the Warrant Certificate to the Holder within two (2) Business Days of the Warrant Certificate
Request Notice pursuant to the delivery instructions in the Warrant Certificate Request Notice (&ldquo;<U>Warrant Certificate Delivery
Date</U>&rdquo;). If the Company fails for any reason to deliver to the Holder the Warrant Certificate subject to the Warrant Certificate
Request Notice by the Warrant Certificate Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as
a penalty, for each $1,000 of Warrant Shares evidenced by such Warrant Certificate (based on the Weighted Average Price (as defined in
the Warrant Certificate) of the Common Stock on the Warrant Certificate Request Notice Date), $10 per Business Day for each Business Day
after such Warrant Certificate Delivery Date until such Warrant Certificate is delivered or, prior to delivery of such Warrant Certificate,
the Holder rescinds such Warrant Exchange. The Company covenants and agrees that, upon the date of delivery of the Warrant Certificate
Request Notice, the Holder shall be deemed to be the holder of the Warrant Certificate and, notwithstanding anything to the contrary set
forth herein, the Warrant Certificate shall be deemed for all purposes to contain all of the terms and conditions of the Warrants evidenced
by such Warrant Certificate and the terms of this Agreement, other than Sections 3(c) and 9 herein, shall not apply to the Warrants evidenced
by the Warrant Certificate. In the event a beneficial owner requests a Warrant Exchange, upon issuance of the paper Warrant Certificate,
the Company shall act as warrant agent and the terms of the paper Warrant Certificate so issued shall exclusively govern in respect thereof.
For purposes of clarity, the Company and the Warrant Agent acknowledge and agree that, with respect to the terms of the Warrants, the
Warrant Certificate or Global Warrant shall set forth the terms of the Warrants and, in the event of any conflict between the Warrant
Certificate or the Global Warrant and this Agreement, the Warrant Certificate or the Global Warrants, as the case may be, shall control.
For purposes of Regulation SHO, a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant
held in book-entry form through DTC shall be deemed to have exercised its interest in this Warrant upon instructing its broker that is
a Participant to exercise its interest in this Warrant, except that, if the date of exercise is a date when the stock transfer books of
the Company are closed, such Person shall be deemed to have become the holder of such shares at the open of business on the next succeeding
date on which the stock transfer books are open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4. <U>Form of Warrant</U>.
The Warrants, together with the form of election to purchase Common Stock (the &ldquo;<U>Exercise Notice</U>&rdquo;) and the form of assignment
to be printed on the reverse thereof, whether a Warrant Certificate or a Global Warrant, shall be in the form of <U>Exhibit 1</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5. <U>Countersignature
and Registration</U>. The Warrant Certificates shall be executed on behalf of the Company by its Chief Executive Officer, Chief Financial
Officer or Vice President, either manually or by electronic signature, and have affixed thereto the Company&rsquo;s seal or a facsimile
thereof which shall be attested by the Secretary or an Assistant Secretary of the Company, either manual or electronic signature. The
Warrant Certificates shall be countersigned by the Warrant Agent by either manual or by facsimile signature and shall not be valid for
any purpose unless so countersigned. In case any officer of the Company who shall have signed any of the Warrant Certificates shall cease
to be such officer of the Company before countersignature by the Warrant Agent and issuance and delivery by the Company, such Warrant
Certificates, nevertheless, may be countersigned by the Warrant Agent, issued and delivered with the same force and effect as though the
person who signed such Warrant Certificate had not ceased to be such officer of the Company; and any Warrant Certificate may be signed
on behalf of the Company by any person who, at the actual date of the execution of such Warrant Certificate, shall be a proper officer
of the Company to sign such Warrant Certificate, although at the date of the execution of this Agreement any such person was not such
an officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Agent will keep
or cause to be kept, at its office designated for such purpose, books for registration and transfer of the Warrant Certificates issued
hereunder. Such books shall show the names and addresses of the respective Holders of the Warrant Certificates, the number of warrants
evidenced on the face of each of such Warrant Certificate and the date of each of such Warrant Certificate. The Warrant Agent will create
a special account for the issuance of Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6. <U>Transfer, Split
Up, Combination and Exchange of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates</U>. Subject to the provisions
of the Warrant Certificate and the last sentence of this first paragraph of Section 6 and subject to applicable law, rules or regulations,
or any &ldquo;stop transfer&rdquo; instructions the Company may give to the Warrant Agent, at any time after the closing date of the Offering,
and at or prior to the Close of Business on the Expiration Date (as such term is defined in the Warrant Certificate), any Warrant Certificate
or Warrant Certificates or Global Warrant or Global Warrants may be transferred, split up, combined or exchanged for another Warrant Certificate
or Warrant Certificates or Global Warrant or Global Warrants, entitling the Holder to purchase a like number of shares of Common Stock
as the Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants surrendered then entitled such Holder to purchase.
Any Holder desiring to transfer, split up, combine or exchange any Warrant Certificate or Global Warrant shall make such request in writing
delivered to the Warrant Agent, and shall surrender the Warrant Certificate or Warrant Certificates to be transferred, split up, combined
or exchanged at the office of the Warrant Agent designated for such purpose, provided that no such surrender is applicable to the Holder
of a Global Warrant. Any requested transfer of Warrants, whether in book-entry form or certificate form, shall be accompanied by evidence
of authority of the party making such request that may be reasonably required by the Warrant Agent. Thereupon the Warrant Agent shall,
subject to the last sentence of this first paragraph of Section 6, countersign and deliver to the Person entitled thereto a Warrant Certificate
or Warrant Certificates, as the case may be, as so requested. The Company may require payment from the Holder of a sum sufficient to cover
any tax or governmental charge that may be imposed in connection with any transfer, split up, combination or exchange of Warrant Certificates.
The Company shall compensate the Warrant Agent per the fee schedule mutually agreed upon by the parties hereto and provided separately
on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt by the Warrant
Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence
shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case
of loss, theft or destruction, of indemnity in customary form and amount, and satisfaction of any other reasonable requirements established
by Section 8-405 of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company and the Warrant
Agent of all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate
if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery to the Holder
in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7. <U>Exercise of
Warrants; Exercise Price; Expiration Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Warrants shall be exercisable
commencing on the Initial Exercisability Date (as such term is defined in the Warrant Certificate). The Warrants shall cease to be exercisable
and shall terminate and become void, and all rights thereunder and under this Agreement shall cease, at or prior to the Close of Business
on the Expiration Date (as such term is defined in the Warrant Certificate). Subject to the foregoing and to Section 7(b) below, the Holder
of a Warrant may exercise the Warrant in whole or in part upon surrender of the Warrant Certificate, if required, with the executed Exercise
Notice and payment of the Exercise Price (as such term is defined in the Warrant Certificate) (unless exercised via a cashless exercise)
pursuant to Section 1(a) of the Warrant Certificate, to the Warrant Agent at the office of the Warrant Agent designated for such purpose.
In the case of the Holder of a Global Warrant, the Holder shall deliver the executed Exercise Notice and the payment of the Exercise Price
pursuant to Section 1(a) of the Warrant Certificate. Notwithstanding any other provision in this Agreement, a holder whose interest in
a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through the Depositary (or another established clearing
corporation performing similar functions), shall effect exercises by delivering to the Depositary (or such other clearing corporation,
as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by the
Depositary (or such other clearing corporation, as applicable). The Company acknowledges that the bank accounts maintained by the Warrant
Agent in connection with the services provided under this Agreement will be in its name and that the Warrant Agent may receive investment
earnings in connection with the investment at Warrant Agent risk and for its benefit of funds held in those accounts from time to time.
Neither the Company nor the Holders will receive interest on any deposits or Exercise Price. No ink-original Exercise Notice shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Exercise Notice be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Upon receipt of an Exercise
Notice for a cashless exercise pursuant to Section 1(d) of the Warrant Certificate (each, a &ldquo;<U>Cashless Exercise</U>&rdquo;), the
Warrant Agent shall deliver a copy of the Exercise Notice to the Company and the Company shall promptly calculate and transmit to the
Warrant Agent in writing the number of Warrant Shares issuable in connection with such Cashless Exercise. The Warrant Agent shall issue
such number of Warrant Shares in connection with such Cashless Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Upon the Warrant Agent&rsquo;s
receipt of a Warrant Certificate at or prior to the Close of Business on the Expiration Date set forth in such Warrant Certificate, with
the executed Exercise Notice and payment of the Exercise Price pursuant to Section 1(a) of the Warrant Certificate, the shares to be purchased
(other than in the case of a Cashless Exercise) and an amount equal to any applicable tax, governmental charge referred to in Section
6 by wire transfer, or by certified check or bank draft payable to the order of the Company (or, in the case of the Holder of a Global
Warrant, the delivery of the executed Exercise Notice and the payment of the Exercise Price pursuant to Section 1(a) of the Warrant Certificate
(other than in the case of a Cashless Exercise) and any other applicable amounts as set forth herein), the Warrant Agent shall cause the
Warrant Shares underlying such Warrant Certificate or Global Warrant to be delivered to or upon the order of the Holder of such Warrant
Certificate or Global Warrant, registered in such name or names as may be designated by such Holder, no later than the Share Delivery
Date (as such term is defined in the Warrant Certificate). If the Company is then a participant in the DWAC system of the Depositary and
either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
by Holder or (B) the Warrant is being exercised via Cashless Exercise, then the certificates for Warrant Shares shall be transmitted by
the Warrant Agent to the Holder by crediting the account of the Holder&rsquo;s broker with the Depositary through its DWAC system. For
the avoidance of doubt, if the Company becomes obligated to pay any amounts to any Holders pursuant to Section 1(c) of the Warrant Certificate,
such obligation shall be solely that of the Company and not that of the Warrant Agent. Notwithstanding anything else to the contrary in
this Agreement, except in the case of a Cashless Exercise, if any Holder fails to duly deliver payment to the Warrant Agent of an amount
equal to the aggregate Exercise Price of the Warrant Shares to be purchased upon exercise of such Holder&rsquo;s Warrant as set forth
in Section 7(a) hereof, the Warrant Agent will not be obligated to deliver such Warrant Shares (via DWAC or otherwise) until following
receipt of such payment, and the applicable Share Delivery Date shall be deemed extended by one Business Day for each Business Day (or
part thereof) until such payment is delivered to the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) The Warrant Agent shall
deposit all funds received by it in payment of the Exercise Price for all Warrants in the account of the Company maintained with the Warrant
Agent for such purpose (or to such other account as directed by the Company in writing) and shall advise the Company via email at the
end of each day on which Exercise Notices are received or funds for the exercise of any Warrant are received of the amount so deposited
to its account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) In case the Holder of any
Warrant Certificate shall exercise fewer than all Warrants evidenced thereby, upon the request of the Holder, a new Warrant Certificate
evidencing the number of Warrants equivalent to the number of Warrants remaining unexercised may be issued by the Warrant Agent to the
Holder of such Warrant Certificate or to his duly authorized assigns in accordance with Section 1(a) of the Warrant Certificate, subject
to the provisions of Section 6 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 8. <U>Cancellation
and Destruction of Warrant Certificates</U>. All Warrant Certificates surrendered for the purpose of exercise, transfer, split up, combination
or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled
form, or, if surrendered to the Warrant Agent, shall be canceled by it, and no Warrant Certificates shall be issued in lieu thereof except
as expressly permitted by any of the provisions of this Agreement. The Company shall deliver to the Warrant Agent for cancellation and
retirement, and the Warrant Agent shall so cancel and retire, any other Warrant Certificate purchased or acquired by the Company otherwise
than upon the exercise thereof. The Warrant Agent shall deliver all canceled Warrant Certificates to the Company, or shall, at the written
request of the Company, destroy such canceled Warrant Certificates, and in such case shall deliver a certificate of destruction thereof
to the Company, subject to any applicable law, rule or regulation requiring the Warrant Agent to retain such canceled certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9. <U>Certain Representations;
Reservation and Availability of Shares of Common Stock or Cash</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) This Agreement has been
duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery hereof by the Warrant Agent,
constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance with its terms, and the
Warrants have been duly authorized, executed and issued by the Company and, assuming due execution thereof by the Warrant Agent pursuant
hereto and payment therefor by the Holders as provided in the Registration Statement, constitute valid and legally binding obligations
of the Company enforceable against the Company in accordance with their terms and entitled to the benefits hereof; in each case except
as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting
creditors&rsquo; rights generally or by general equitable principles (regardless of whether such enforceability is considered in a proceeding
in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) As of the date hereof, the
authorized capital stock of the Company consists of (i) 50,000,000 shares of Common Stock, of which 10,949,389 shares of Common Stock
are issued and outstanding, and [___________] shares of Common Stock are reserved for issuance upon exercise of the Warrants, and (ii)
5,000,000 shares of preferred stock, of which no shares are issued and outstanding. Except for awards granted pursuant to an equity incentive
plan or as otherwise disclosed in the Registration Statement, there are no other outstanding obligations, warrants, options or other rights
to subscribe for or purchase from the Company any class of capital stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) The Company covenants and
agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Common Stock or its authorized
and issued shares of Common Stock held in its treasury, free from preemptive rights, the number of shares of Common Stock that will be
sufficient to permit the exercise in full of all outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) The Warrant Agent will create
a special account for the issuance of Common Stock upon the exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) The Company further covenants
and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges which may be payable in respect
of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock upon exercise of the Warrants.
The Company shall not, however, be required to pay any tax or governmental charge which may be payable in respect of any transfer involved
in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for Common Stock in a name other than
that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue or deliver any certificate for
shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall have been paid (any such tax
or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender) or until it has been established
to the Company&rsquo;s reasonable satisfaction that no such tax or governmental charge is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 10. <U>Common Stock
Record Date</U>. Each Holder shall be deemed to have become the holder of record for the Warrant Shares pursuant to Section 1(a) of the
Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 11. <U>Adjustment
of Exercise Price, Number of Shares of Common Stock or Number of the Company Warrants</U>. The Exercise Price, the number of shares covered
by each Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided in Section 2 of the Warrant
Certificate. In the event that at any time, as a result of an adjustment made pursuant to Section 2 of the Warrant Certificate, the Holder
of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than shares of Common
Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time
to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares contained in Section
2 of the Warrant Certificate, and the provisions of Sections 7, 9 and 13 of this Agreement with respect to the shares of Common Stock
shall apply on like terms to any such other shares. All Warrants originally issued by the Company subsequent to any adjustment made to
the Exercise Price pursuant to the Warrant Certificate shall evidence the right to purchase, at the adjusted Exercise Price, the number
of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants, all subject to further adjustment as
provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 12. <U>Certification
of Adjusted Exercise Price or Number of Shares of Common Stock</U>. Whenever the Exercise Price or the number of shares of Common Stock
issuable upon the exercise of each Warrant is adjusted as provided in Section 11 or 13, the Company shall (a) promptly prepare a certificate
setting forth the Exercise Price of each Warrant as so adjusted, and a brief statement of the facts accounting for such adjustment, (b)
promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate and (c) instruct the
Warrant Agent to send a brief summary thereof to each Holder of a Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 13. <U>Fractional
Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company shall not issue
fractions of Warrants or distribute Warrant Certificates which evidence fractional Warrants. Whenever any fractional Warrant would otherwise
be required to be issued or distributed, the actual issuance or distribution shall reflect a rounding of such fraction either up or down
to the nearest whole Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) The Company shall not issue
fractions of shares of Common Stock upon exercise of Warrants or distribute stock certificates which evidence fractional shares of Common
Stock. Whenever any fraction of a share of Common Stock would otherwise be required to be issued or distributed, the actual issuance or
distribution in respect thereof shall be made in accordance with Section 1(a) of the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 14. <U>Conditions
of the Warrant Agent&rsquo;s Obligations</U>. The Warrant Agent accepts its obligations herein set forth upon the terms and conditions
hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the Holders from time to
time of the Warrant Certificates shall be subject:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) Compensation and Indemnification.
The Company agrees promptly to pay the Warrant Agent the compensation detailed on <U>Exhibit 2</U> hereto for all services rendered by
the Warrant Agent and to reimburse the Warrant Agent for reasonable out-of-pocket expenses (including reasonable counsel fees) incurred
without gross negligence, bad faith or willful misconduct by the Warrant Agent in connection with the services rendered hereunder by the
Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it harmless against, any loss, liability or expense
incurred without gross negligence, bad faith or willful misconduct on the part of the Warrant Agent, arising out of or in connection with
its acting as Warrant Agent hereunder, including the reasonable costs and expenses of defending against any claim of such liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Agent for the Company. In
acting under this Warrant Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the
Company and does not assume any obligations or relationship of agency or trust for or with any of the Holders of Warrant Certificates
or beneficial owners of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Counsel. The Warrant Agent
may consult with counsel satisfactory to it, which may include counsel for the Company, and the written advice of such counsel shall be
full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in
accordance with the advice of such counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) Documents. The Warrant Agent
shall be protected and shall incur no liability for or in respect of any action taken or omitted by it in reliance upon any Warrant Certificate,
notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to
have been presented or signed by the proper parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) Certain Transactions. The
Warrant Agent, and its officers, directors and employees, may become the owner of, or acquire any interest in, Warrants, with the same
rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable law, it or they
may engage or be interested in any financial or other transaction with the Company and may act on, or as depositary, trustee or agent
for, any committee or body of Holders of Warrants or other obligations of the Company as freely as if it were not the Warrant Agent hereunder.
Nothing in this Warrant Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to which the
Company is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) No Liability for Interest.
Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any monies at any time received by
it pursuant to any of the provisions of this Agreement or of the Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) No Liability for Invalidity.
The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or any of the Warrant Certificates (except
as to the Warrant Agent&rsquo;s countersignature thereon).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) No Responsibility for Representations.
The Warrant Agent shall not be responsible for any of the recitals or representations herein or in the Warrant Certificates (except as
to the Warrant Agent&rsquo;s countersignature thereon), all of which are made solely by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) No Implied Obligations.
The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrant Certificates specifically set forth
and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant
Agent shall not be under any obligation to take any action hereunder which may tend to involve it in any expense or liability, the payment
of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be accountable or under
any duty or responsibility for the use by the Company of any of the Warrant Certificates authenticated by the Warrant Agent and delivered
by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the Warrant Certificates. The
Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements
contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from a Holder of a Warrant Certificate
with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt
to initiate any proceedings at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 15. <U>Purchase or
Consolidation or Change of Name of Warrant Agent</U>. Any Person into which the Warrant Agent or any successor Warrant Agent may be merged
or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Warrant Agent or any successor
Warrant Agent shall be party, or any Person succeeding to the stock transfer or other shareholder services business of the Warrant Agent
or any successor Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing of any
paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor
Warrant Agent under the provisions of Section 17. In case at the time such successor Warrant Agent shall succeed to the agency created
by this Agreement any of the Warrant Certificates shall have been countersigned but not delivered, any such successor Warrant Agent may
adopt the countersignature of the predecessor Warrant Agent and deliver such Warrant Certificates so countersigned; and in case at that
time any of the Warrant Certificates shall not have been countersigned, any successor Warrant Agent may countersign such Warrant Certificates
either in the name of the predecessor Warrant Agent or in the name of the successor Warrant Agent; and in all such cases such Warrant
Certificates shall have the full force provided in the Warrant Certificates and in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In case at any time the name
of the Warrant Agent shall be changed and at such time any of the Warrant Certificates shall have been countersigned but not delivered,
the Warrant Agent may adopt the countersignature under its prior name and deliver Warrant Certificates so countersigned; and in case at
that time any of the Warrant Certificates shall not have been countersigned, the Warrant Agent may countersign such Warrant Certificates
either in its prior name or in its changed name; and in all such cases such Warrant Certificates shall have the full force provided in
the Warrant Certificates and in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.55pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16. <U>Duties of
Warrant Agent</U>. The Warrant Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions,
by all of which the Company, by its acceptance hereof, shall be bound:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Warrant Agent may consult
with legal counsel reasonably acceptable to the Company (who may be legal counsel for the Company), and the written advice of such counsel
shall be full and complete authorization and protection to the Warrant Agent as to any action taken or omitted by it in good faith and
in accordance with such opinion or advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) Whenever in the performance
of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established
by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein
specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chief Executive Officer,
Chief Financial Officer or Vice President of the Company; and such certificate shall be full authorization and protection to the Warrant
Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Subject to the limitation
set forth in Section 14, the Warrant Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct,
or for a breach by it of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) The Warrant Agent shall
not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the Warrant Certificates
(except its countersignature thereof) by the Company or be required to verify the same, but all such statements and recitals are and shall
be deemed to have been made by the Company only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) The Warrant Agent shall
not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution
hereof by the Warrant Agent) or in respect of the validity or execution of any Warrant Certificate (except its countersignature thereof);
nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant Certificate;
nor shall it be responsible for the adjustment of the Exercise Price or the making of any change in the number of shares of Common Stock
required under the provisions of Section 11 or 13 or responsible for the manner, method or amount of any such change or the ascertaining
of the existence of facts that would require any such adjustment or change (except with respect to the exercise of Warrants evidenced
by Warrant Certificates after actual notice of any adjustment of the Exercise Price); nor shall it by any act hereunder be deemed to make
any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement
or any Warrant Certificate or as to whether any shares of Common Stock will, when issued, be duly authorized, validly issued, fully paid
and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f) Each party hereto agrees
that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further
and other acts, instruments and assurances as may reasonably be required by the other party hereto for the carrying out or performing
by any party of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g) The Warrant Agent is hereby
authorized to accept instructions with respect to the performance of its duties hereunder from the Chief Executive Officer, Chief Financial
Officer, Vice President or Controller of the Company, and to apply to such officers for advice or instructions in connection with its
duties, and it shall not be liable and shall be indemnified and held harmless for any action taken or suffered to be taken by it in good
faith in accordance with instructions of any such officer, provided the Warrant Agent carries out such instructions without gross negligence,
bad faith or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) The Warrant Agent and any
shareholder, director, officer or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the
Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to
the Company or otherwise act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing herein shall preclude
the Warrant Agent from acting in any other capacity for the Company or for any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) The Warrant Agent may execute
and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney
or agents, and the Warrant Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney
or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct, provided reasonable care was exercised
in the selection and continued employment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 17. <U>Change of Warrant
Agent</U>. The Warrant Agent may resign and be discharged from its duties under this Agreement upon 30 days&rsquo; notice in writing sent
to the Company and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates. The Company may remove
the Warrant Agent or any successor Warrant Agent upon 30 days&rsquo; notice in writing, sent to the Warrant Agent or successor Warrant
Agent, as the case may be, and to each transfer agent of the Common Stock, and to the Holders of the Warrant Certificates. If the Warrant
Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Warrant Agent.
If the Company shall fail to make such appointment within a period of 30 days after such removal or after it has been notified in writing
of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by the Holder of a Warrant Certificate (who shall,
with such notice, submit his Warrant Certificate for inspection by the Company), then the Holder of any Warrant Certificate may apply
to any court of competent jurisdiction for the appointment of a new Warrant Agent, provided that, for purposes of this Agreement, the
Company shall be deemed to be the Warrant Agent until a new warrant agent is appointed. Any successor Warrant Agent, whether appointed
by the Company or by such a court, shall be a Person, other than a natural person, organized and doing business under the laws of the
United States or of a state thereof, in good standing, which is authorized under such laws to exercise stock transfer powers and is subject
to supervision or examination by federal or state authority and which has at the time of its appointment as Warrant Agent a combined capital
and surplus of at least $50,000,000. After appointment, the successor Warrant Agent shall be vested with the same powers, rights, duties
and responsibilities as if it had been originally named as Warrant Agent without further act or deed; but the predecessor Warrant Agent
shall deliver and transfer to the successor Warrant Agent any property at the time held by it hereunder, and execute and deliver any further
assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall
file notice thereof in writing with the predecessor Warrant Agent and each transfer agent of the Common Stock, and mail a notice thereof
in writing to the Holders of the Warrant Certificates. However, failure to give any notice provided for in this Section 17, or any defect
therein, shall not affect the legality or validity of the resignation or removal of the Warrant Agent or the appointment of the successor
Warrant Agent, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 18. <U>Issuance of
New Warrant Certificates</U>. Notwithstanding any of the provisions of this Agreement or of the Warrants to the contrary, the Company
may, at its option, issue new Warrant Certificates evidencing Warrants in such form as may be approved by its Board of Directors to reflect
any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities or property
purchasable under the several Warrant Certificates made in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 19. <U>Notices</U>.
Notices or demands authorized by this Agreement to be given or made (i) by the Warrant Agent or by the Holder of any Warrant Certificate
to or on the Company, (ii) by the Company or by the Holder of any Warrant Certificate to or on the Warrant Agent or (iii) by the Company
or the Warrant Agent to the Holder of any Warrant Certificate, shall be deemed given when in writing (a) on the date delivered, if delivered
personally, (b) on the first Business Day following the deposit thereof with Federal Express or another recognized overnight courier,
if sent by Federal Express or another recognized overnight courier, (c) on the fourth Business Day following the mailing thereof with
postage prepaid, if mailed by registered or certified mail (return receipt requested), and (d) the date of transmission, if such notice
or communication is delivered via facsimile or email attachment at or prior to 5:00 p.m. (New York City time) on a Business Day and (e)
the next Business Day after the date of transmission, if such notice or communication is delivered via email attachment on a day that
is not a Business Day or later than 5:00 p.m. (New York City time) on any Business Day, in each case to the parties at the following addresses
(or at such other address for a party as shall be specified by like notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) If to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">San Diego, CA 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Attention: CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Email: jim@modular-medical.com
and warrants@modular-medical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) If to the Warrant Agent,
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Colonial Stock Transfer Company,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7840 S 700 E</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Sandy, UT 84070</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Attention: [&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">[&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For any notice delivered by email to be deemed
given or made, such notice must be followed by notice sent by overnight courier service to be delivered on the next Business Day following
such email, unless the recipient of such email has acknowledged via return email receipt of such email.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) If to the Holder of any
Warrant Certificate, to the address of such Holder as shown on the registry books of the Company. Any notice required to be delivered
by the Company to the Holder of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding any other provision
of this Agreement, where this Agreement provides for notice of any event to a Holder of any Warrant, such notice shall be sufficiently
given if given to the Depositary (or its designee) pursuant to the procedures of the Depositary or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 20. <U>Supplements
and Amendments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) The Company and the Warrant
Agent may from time to time supplement or amend this Agreement without the approval of any Holders of Global Warrants in order (i) to
add to the covenants and agreements of the Company for the benefit of the Holders of the Global Warrants, (ii) to surrender any rights
or power reserved to or conferred upon the Company in this Agreement, (iii) to cure any ambiguity, (iv) to correct or supplement any provision
contained herein which may be defective or inconsistent with any other provisions herein, or (v) to make any other provisions with regard
to matters or questions arising hereunder which the Company and the Warrant Agent may deem necessary or desirable, provided that such
addition, correction or surrender shall not adversely affect the interests of the Holders of the Global Warrants or the Warrant Certificates
in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) In addition to the foregoing,
with the consent of Holders of Warrants entitled, upon exercise thereof, to receive not less than a majority of the shares of Common Stock
issuable thereunder, the Company and the Warrant Agent may modify this Agreement for the purpose of adding any provisions to or changing
in any manner or eliminating any of the provisions of this Agreement or modifying in any manner the rights of the Holders of the Global
Warrants; <U>provided</U>, <U>however</U>, that no modification of the terms (including but not limited to the adjustments described in
Section 11 upon which the Warrants are exercisable or reducing the percentage required for consent to modification of this Agreement may
be made without the consent of the Holder of each outstanding warrant certificate affected thereby; provided further, however, that no
amendment hereunder shall affect any terms of any Warrant Certificate issued in a Warrant Exchange. As a condition precedent to the Warrant
Agent&rsquo;s execution of any amendment, the Company shall deliver to the Warrant Agent a certificate from a duly authorized officer
of the Company that states that the proposed amendment complies with the terms of this Section 20. No supplement or amendment to this
Agreement shall be effective unless duly executed by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 21. <U>Successors</U>.
All covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit
of their respective successors and assigns hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 22. <U>Benefits of
this Agreement</U>. Nothing in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrant Certificates
and the Warrant Agent any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for the sole and
exclusive benefit of the Company, the Warrant Agent and the Holders of the Warrant Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 23. <U>Governing Law;
Jurisdiction</U>. This Agreement and each Warrant Certificate issued hereunder shall be governed by, and construed in accordance with,
the laws of the State of New York without giving effect to the conflicts of law principles thereof. The Company hereby agrees that any
action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts
of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent
an inconvenience forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 24. <U>Counterparts</U>.
This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original,
and all such counterparts shall together constitute but one and the same instrument. A signature to this Agreement transmitted electronically
shall have the same authority, effect and enforceability as an original signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 25. <U>Captions</U>.
The captions of the sections of this Agreement have been inserted for convenience only and shall not control or affect the meaning or
construction of any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 26. <U>Severability</U>.
Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 27. <U>Force Majeure</U>.
Notwithstanding anything to the contrary contained herein, Warrant Agent shall not be liable for any delays or failures in performance
resulting from acts beyond its reasonable control including, without limitation, acts of God, terrorist acts, shortage of supply, breakdowns
or malfunctions, interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties
with information storage or retrieval systems, labor difficulties, war, or civil unrest, it being understood that the Warrant Agent shall
use reasonable best efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable
under the circumstances. Notwithstanding anything herein to the contrary, this Section 27 shall not affect the Company&rsquo;s obligations
to the Holders of the Warrants as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp; &nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>MODULAR MEDICAL, INC.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:&nbsp;</TD>
    <TD STYLE="font-size: 10pt">James E. Besser</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>COLONIAL STOCK TRANSFER COMPANY, INC.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page to Warrant Agency Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 12; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex A: Form of Warrant Certificate Request
Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Colonial Stock Transfer Company, Inc. as Warrant
Agent for Modular Medical, Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;Warrants&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in">1.</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Name of Holder of Warrants in form of Global Warrants: _____________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">3.</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants: _____________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">4.</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Number of Warrants for which Warrant Certificate shall be issued: _____________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: _______________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">6.</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">Warrant Certificate shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the
number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Investing Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: _______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 1: Form of Warrant Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit 2: Compensation of Warrant Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payable at Closing: $[&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional Monthly Fee: $[&nbsp;&nbsp;&nbsp;] (subject to adjustment from time to time
upon mutual agreement of the Company and the Warrant Agent)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ea177987ex23-1_modular.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.05pt 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We consent to the inclusion in
this Amendment No. 1 to the Registration Statement on Form S-1, as filed with the Securities and Exchange Commission, of our report dated
June 28, 2022, with respect to the consolidated balance sheets of Modular Medical, Inc. as of March 31, 2022 and 2021 and the related
consolidated statements of operations, stockholders&rsquo; equity/(deficit), and cash flows for the years then ended. We also consent
to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%">/s/ Farber Hass Hurley LLP</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Chatsworth, California</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>May&nbsp;5, 2023</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>ea177987ex-fee_modular.htm
<DESCRIPTION>FILING FEE TABLES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT
</FONT>107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
S-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">MODULAR
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Table
1: Newly Registered Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Security
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Type</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Security
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Class
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Title</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fee
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Calculation
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>or
                                            Carry </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward
                                            Rule</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amount
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registered</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Proposed
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Maximum
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Offering
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Price
                                            Per </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unit</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Maximum
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Aggregate
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Offering
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Price
                                            <SUP>(1)(2)(3)</SUP></B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fee
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rate</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amount
                                            of </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fee</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Carry
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Form
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Type</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Carry
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>File
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Carry
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Initial
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>effective
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>date</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Filing
                                            Fee </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Previously
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Paid
                                            In </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Connection
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>with
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unsold
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Securities
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>to
                                            be</B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Carried
                                            </B></FONT></P> <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward</B></FONT></P></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="43" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Newly
    Registered Securities</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 4.8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    to Be<BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 17%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Units,
    each Unit consisting of: (i) two shares of common stock, $0.001 par value per share, and (ii) one warrant to purchase one share of
    common stock</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">457</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,200,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00011020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,013.84</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    to Be<BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, $0.001
    par value per share, included in the Units<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    to Be<BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
    included in the Units<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    to Be<BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock, $0.001 par value per share, underlying the warrants included in the Units</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">457</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,520,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00011020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">608.31</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    to Be<BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriter&rsquo;s
    Warrants<SUP>(5)</SUP></FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">457</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    to Be<BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock, $0.001
    par value per share, underlying Underwriter&rsquo;s Warrants<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">457</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">805,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00011020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">88.71</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    <BR> Previously <BR>
    Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="42" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carry
    Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carry
    <BR> Forward <BR> Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Offering Amounts</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,525,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00011020</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,710.86</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Fees Previously Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,563.16</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Fee Offsets</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Fee Due</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">147.70</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes up to an additional
    15% of the aggregate offering price to cover the underwriter&rsquo;s option to purchase securities to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 416(a)
    promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), we are also registering an indeterminate
    number of shares of common stock as may from time to time become issuable by reason of stock splits, stock dividends, or similar
    transactions.</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the
    purpose of computing the amount of the registration fee pursuant to Rules 457(o) under the Securities Act.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    shares of common stock and warrants to purchase shares of common stock are included in the Units.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">No
    fee required pursuant to Rule 457(g) under the Securities Act.</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Estimated solely for the purpose of calculating
    the registration fee pursuant to Rule 457(g) under the Securities Act. The Representative&rsquo;s Warrants are exercisable at a per
    share exercise price equal to 125% of the public offering price. As estimated solely for the purpose of calculating the registration
    fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the representative&rsquo;s
    warrants is $805,000, which is equal to 125% of $644,000 (which is 7% of $9,200,000).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q +P# 2(  A$! Q$!_\0
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M %?G)M#^P-:]$H2B[204ZL*BO!W ]*\8T\X\6VY_Z>A_.O9STKQ:RX\50?\
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #% +<# 2(  A$! Q$!_\0
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M (1O2<\6H_.E_P"$<TK_ )]1^=:88$?>I"P_O"EJ5==S-_X1S2_^?4?F:/\
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MFZ0R_;KV& R'"!S@DU;>ZAB@,\CJL0!)8G  I<[)_L^CV/-+7X5W=E.)X-8
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MK<T&DR!CGK2YS0]@,/Q1_P @9_\ ?7^=%'BC_D#O_OC^=%6MB2>T_P"0L_\
MUP7^;5J'M67:?\A5_P#K@O\ -JU#2EN-;%#5-2M](M&N[M]D*D GKZUYYXV\
M7:'KGAFZL;:2.:9@-B2*0":Z3XC ?\(C<>NY:\#)8+TQ]*TA"ZN>5C<9.C)*
M!TEA>LFFZ):7E_;W%O:OYDL3@YSV7/M72VWBG3=,U*_ODDAE%]((RL:X$:8Q
MFO-02#QD?2DY'0=:T]F<3S2L=K;C0"^F&XO(\V\K-(X!&02<"M+PGK.DZ%KU
M_=S7T:6\[L8XHP2#DGFO.<^W7KQ3@3D<>_2CV28+,ZQ].:;J=OJMHEU:ONA;
M.#ZU<4^]<?X"E2W\%VDDCJB@,2Q^IKK(W5T5U8%2 1[U@U8]ZE+FBFR;O2']
M*0$[J4U!J9!UVR26>.:58A _ELS'@FK U2S<+BYB.[ 4ANM<CKVEQ"6_NOM\
M"A29BC#.!WR*JS^%K:ZLH+LZB;=6B41L?EP_'-;<J:,W(["XN]*O5>SGD@E#
M+\T;D$%:@-_HMEH;2P^2-/C!&U!E![5@2>&;9=6EN%O80HC^ZS8(X_E6D^G6
M$GAH:/#<6RM(NP,,<GUJ>5!S,58O"NDW$MS'!90SQJ'<QH-PJW=7>BZC;02W
M"0S@QB:))!DD=<C-8=SX<B.JS&:\A02Y8*1\^34,GASS;N.:34X EK&L9 ."
MN%Q34= YSHKX:)J6FV]WJ4$$D# -&)E!Q5J#4M,A"6D,\";5W+&IP HK&N](
M,^BZ;;+=P%[8AD+C*N .E9W_  CT<^I-+]NML%3(R@8/W2OY4**8.5CISK^G
M^=;Q"X5VG8HA7G)P36N.G6N"TW08K*6SG:_MBL=P6B Y7E2,5W@(P,'(/>IF
MDMBHNYC>*/\ D#O_ +X_G12^*/\ D#/_ +Z_SHH6P$UI_P A5_\ K@O\VK4-
M9=I_R%F_ZX+_ #:M0TGN-'(_$8_\4C<?[R_UKP,D[17OGQ&_Y%"X_P!Y?ZUX
M$3\H%;TMF?.YK_$0$G)YHR?6@]328K9,\H7)]:4$[AS24H'S"@#W#PGIR:M\
M/K>TF=@LBL,@X(Y-5-/O]1\'72:?J;-/I['$4QY*_6MGX>C/@^R[##?^A&M^
M_L(-1M7M[A Z,,'(Z5R\R3LSZZDFZ:MY?DB:"YBN(5EB<,C $$<C%3'D$&N$
MB2_\(794L\^F,> >2E=E9WL-[ LT3@JV#P>E3*-M4;1E?0Y&?P?>3ZA>2--'
MY<JR $C+'<".:T]5T&>>"P$!A)MA@I(NY3QZ5TF>?QI"2#GL!DTN8KE3.%O?
M"&I7NI3SM=1JLD;H H(&#G ZU/=^#'DU>TN8I%2WC"@QJ,8QCIBM:'Q?H3O<
M1K?QXMB%D). #6K'?VLMR]LLJF6, NN>15<[%RHY+6=#O-1\3%H@J1"-093G
M(Z=*@M_ \Z_:_.G#&20MGD9&<\\UTA\2Z*HN"=0A*PG$A#<J:D7Q%I32P1K?
M1%YP&C&[[P-',QV1E>*M*EN-/M(+,%)ED55*#  [UFQ>#+J#4KNX@N0!)%B(
MMR1QC!]J[HY;)'6E"G.>F>?QH4V@<4SB]'\&SVUS!+>21R+%(9"F#C.TBNU"
M@* !P.G:@C)IV#CDU$G<:5C$\4?\@9_]]?YT4GBC_D#/_OK_ #HJEL#)[3_D
M+-_UP7^;5J&LNT_Y"S?]<%_FU:AI/<2.1^(W_(H7'^\O]:\"/05[]\1?^10N
M!_M+_6O V08SG\*WIGS^::5EZ#21NYH[\5VVCZ!;7.DPS,EL2V<EW((-8_B?
M3HM/O(XHEA *@DQMFJO8XIX9P@IWT,#'XTX=?I5VRT>^U*-I;2'>B]<54EC:
M&0I(N&4X(%:73,7"22;/??AX/^*-LOHW_H1KJ1UKE_AZ?^*-LO\ @7_H1KJA
MTKCE\1]?0TIH@G@2:-DD4.I'0BN"U>2Y\+7)_L^4M%-DA",[37H9Z],BH)K.
M"X4"6)'&.ZTZ4^5^\%2#M>.YG^'M2.I:7'-(<N% ;ZUJ2?<('4C ST-5K6PM
MK%&2VB"!B20#Q7E7B/X@ZWINO7=E#Y!CBD(&Y,G%-KF>AE5KJA&\S,L/!FLM
M_P )+:Q:9Y5G<%C$L[;G+<X(; _E70:9:^(=#\4:KJ%Y;-/:7$C!E1N2I^[M
MXR.W<USP^*7B'O\ 93G_ *9GC]:0_%'7SU6V(/.-A('ZT>S9S_VG3-EOAP_E
MZ^0DOERN?LJ!\''UP?ZU+;>&+^TU;0+:331+;VD2-)<!]K-+@=?8>@Q6%_PM
M+Q#G&+4_6,Y'ZTA^*/B'/_+MG_</^-'LV']I4CW2/@8'2I*\L\#>-M5US6_L
MEV(O+*D_*N#FO4 3P*AJQV4:ZJKF1)0:0$4IZ5)N87BC_D#/_OK_ #HH\4?\
M@9_]]?YT5HB2>T_Y"S?]<%_FU:AK+M/^0LW_ %P7^;5J&I>X(Y+XC?\ (GW&
M.NY?ZUX/!$]Q,L*+EVX [5[Q\1?^10G/^TO]:\3T0C^VH". 3@@?C6]/8\',
M4G75^Q<>[BT>S6T7;<3[LR;B=H'IQ4.I0K?*;ZS8%%0&2(GE/IG/%7= T:+5
M7NS);/+L<\AL&KU_H\6EBX$<,D0DMVX=LT=3%TY2IW>R$\(Z/<WEE//!J#0!
MCM*CD?TKEKZ![/4KBV:0NT<K*SGOR:W-*EDAT>W,?FX,Q&Y6V@<FLS71_P 3
MV] Y(G8Y]>:J.Y%:WLHV/;OA[_R)ME]&_P#0C75CI7*?#XY\&V1]0W_H1KJQ
MTKGEN?14/X:]/\A>U)WI>U)4FS&LN0>:^=?&A_XJ_40/^>A_G7T41FOG7QF&
M/B[40/\ GJ:VIGDYK_#1SYHS001R>@K0M='U*]4FVLII 1D$+P:WNCP(PD_A
M5RAD4#&15^[T35+(%KJPE0#DDKD#\JH8 Q1=#E3DM]#N/A=C_A*1C^X:]Q%>
M&_"\$>*QGNAKW(5S3W/HLL_@?,=ZTO:DI>U9O8]-&)XH_P"0,_\ OK_.BCQ1
M_P @9_\ ?7^=%4MB636G_(6;_K@O\VK4-9=I_P A9O\ K@O\VK4-)[@CD?B+
M_P BA/\ [RUXGH0SK,'IG_&O;/B*,^$9_P#>6O";:>2TN4GC'S(<C/(K>GL>
M#F3_ 'R_KJCKO!VKV.ER7RW<XC#OP#WJYK^JV6J"4VDXE\NU8/@8Q7,'6[5V
M!DTNW)/4XZTRYUI6M98;>SB@\P89E')H4=;D/$KV;@6="U&VAM6@N+7S?*.\
M?-@5DWMU]KOKBY"[/-D9@HYP#444[VY?RR"&&#FHP?EYZYZBM+:'!*JW%1['
MT!\/1CP=9 ]1N!_[Z-=4.E<K\/>?!ME_P+_T(UU0^[7++<^MH?PT+VI!2]J0
M4C40_=-?.GC,D>+]1([2'BOHL_=-?.GC,X\7:B?24U=+<\C-/X:(_"=A#J'B
M.U@N5+PELLOK7H%E8:QXJM#=V>H?V?;!BJPQKC !KBO \A?Q3:(!@EL"NJ\-
M^,K'PMIITS4(I4N(Y&R,8'>KD<N%Y>5>TT6OX6L6KO3-9\+VGVNZU+[;;E@K
MQ2+GK7!>,+.WL_$MQ';#;&V) H[9YKMO$'C6P\2V TRQCE-Q(RD<9':N1\<J
M%\53# !"*,#GM1 G%^RY5R,U/A><^*QG^X<5[@/ZUX=\+QM\5*!_<->XCI^-
M35^(]#+?X H^]3J:/O4[UK)GIF'XH_Y S_[Z_P Z*/%'_(&?_?7^=%6MB2>T
M_P"0LW_7!?YM6H:R[3_D+-_UP7^;5J&I>X(Y'XC?\BA<?[R_UKP/<0/KQ7OG
MQ&_Y%&?_ 'EKP,_= K>DM&?/9H_WB#/;L*,\8I.>:.:UL>3?H'%*.&XI.:49
MR#3\@1] ?#T_\4;9?1O_ $(UU0Z5ROP\_P"1,LOHW_H1KJEZ5QO<^SH?PUZ(
M7M244&D;"$\$>U?.OC/ \8:CW'FFOHDG@U\[>- ?^$OU$_\ 34_SK6DM3R,U
M_AH=X*D6'Q=9$L!^\ KO-9U#2+VQO[_5-#(:W<HH8$%J\E222&59(G9'5MP9
M>"#7:VGQ+O19BVU"SM[M.Y=.O]*N43@PN(C&#C(Z31KW2+#3;/4M-T/!N)/+
M9E4DKVKAO';QR^,;MD/&0#@YP:UI_B7=I:&WT^RM[1.BF-,8KB))9;F>2>9R
M\DC%F8]231&-AXG$1E3Y8G:_"[!\5J?]@U[D!P/K7AGPN!'BH?[AKW)3Q^-9
M5-STLM_@?,=TYI>U)FE[5F]CTS$\4?\ (&D_WU_G11XH_P"0,_\ OK_.BJ6P
MB:T_Y"S?]<%_FU:A!-9=I_R%G_ZX+_-JU:4MP1R?Q BDG\+3Q1(SN6& .:\.
M_L;4>?\ 1)N#@Y6OI6]ECAMI)91E$4L1ZUBZ7KUEJ</FF)80Q)0,<D@5<9\J
ML>?BL'[:7,W8\#_L?4?^?28?\!H&C:EC/V.;'^Y7T"^M:9O$<+Q2N6"X!'&:
M>-8T@B0BYA(B&6Z'%5[4Y?[*_O'SW_8VI?\ /G-_WQ2C1=2X_P!#F_[XKZ#3
M6-':-'-S!AB<=*LVMS97C2+;LCF,X;;@X-/VH?V5_>,?P%%)!X1M(I8V1QNR
M",'J:ZA/NBFJBHH"@ >@IXZ5BV>Q3CRQ40Q2&G4AI%D9(&?RKP+Q?I=_/XJU
M"2.VE:-I20P&0:^@#]*J7;16MM+<O$I$:EC@8)Q5QERG)BL-[=6N?-O]C:EC
M_CSFYY'RT'1M2'/V.8>P6O=M(\2V&JN83#Y#X4@/SNS5V;7-'@"F2YA4$9!X
MJW4N<']EK^8^?/[&U+&393_]\FE&C:GG_CSFY_V:^@&US1UA68W$11B1T]*L
MVU[I]W/Y,#QR.H!(49 %'M1?V4OYCRCX:Z=>V_B423VTB*%/S,,5[0#CKZTU
M(8U.0B@^H&*D_"LY.[/2PU#V,.0.<TN.**4]*@Z3#\4_\@:3_?7^=%)XH_Y
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K4/[D7Y4#QAJ!_AB_*BBCDC;8.A!J?B&[N["195C(!' 'N****.5=B3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O +X# 2(  A$! Q$!_\0
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M"E1ED),D001JK'?YB[.'^7[V.O%5?".H&_LK@LS%TE 8,D:D94'_ )9DCO\
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M=0VJ6T1NT*62HGFQHYR(@"2QXW^9GUR,<8.:])AB:&!(VE>5E4 R28W,?4X
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MTBYOQ 9C"H;RP2-W('7!Q^5<_%KMO974MU;6$+I<FWGO[F&ZWJ#(?*1DX^?
M09^[@>IXKJ;F%Y[=XX[B2!F&!+&%++[C<"/TK%7PCI\;0[)KH(@3S8_,&VX*
MR&12_'7>Q/&.N.G% '0URFMZ_I+W-]IUY$DR:?&MU(AF"NTB;945%ZG&%)Z
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MG.-O48Z\]JI)$-M/0Z6+6M/GL9[R&Y22" %I&7^$ ;CQ].:;'KE@;19YKB.
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(!A1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, @8# 2(  A$! Q$!_\0
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MF_\ D6N@II(4$DX ZT 8/VSQ?_T ]#_\',W_ ,BT?;/%_P#T ]#_ /!S-_\
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M -(K6N@KG_#W_(<\6?\ 853_ -(K6N@H *C=%E1HY%#(PPRD9!%24QE61"K
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M/^ASUS_OS9?_ "/0!T%%<_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\
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M_%__ $'-#_\ !--_\E5T%% SG_L?B_\ Z#FA_P#@FF_^2J/L?B__ *#FA_\
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M-Q*I.X,^T$N%(SU; ( )XJA+H,LGA_7+1_#S/:+J]I>6UO%IK)&L/[K?Y<3
MGIOR ,GYL@9Q7KQG47:V^)-[(7!$3;< @8+8V@\],Y//& :L52EK?^M[DI65
MOZVL<5XWC4>$[*"#3[QHS>6A%O:6KNT<:2HS?+&"5 53_(<XKFVMYEDU:WMM
M&OCHD>N)-<V8L)$6:V,(5O+0J/,7S06*KG//!!Y]9K.O-8TZQO[.QNKN..ZO
M69;:(_>D(&3@>PH3_K[O\A]+'F\EK/926+6VG:BNDOX@BN;.V2RF)MX%BPQ*
M!<Q+O)PI P.@QT;-8W1U#3Y9] OY]=M]>\VYNH[8X>WS)L(E.%*!2O&[Y3U
M)Y]4AN$F\S8)!L<H=\;)DCTR!D>XR*GI+^OP_P A/7^O7_,X+PE9W-AXENH/
ML#/;LCRF]DM'MY0[,IV2$_+,Q'\:\C9@]:Q?%6DI#JOC2XBT&XFN+[28X[:X
MMK!I69R)%8!E4G).S(],$\#(]7HH6EO(:T=_F>17UK>-/KL.@Z?JMNMQ86,C
M%+&2$S%7)F :1-IE,;*/FR3T.<$#K_ ^D6>DZ?<#3WU0VT\@E$=_:K;"-L8(
M2)8X]@XY^7!/(SS7744[BMI8****0SR#]HS_ ))[8?\ 85C_ /14M%'[1G_)
M/;#_ +"L?_HJ6B@#U^BBB@ HHHH **** "BBB@ HHHH *\V\::]-%JKZ>\I2
MT  ...<=Z])KA/%7A6ZO+J>]M$2YCE +P-PP([K28T<G$X*#:P=#W![5(9=G
M(W ]\<5D/IYMW:.)FB8$@QR?+C\:C%O<M(KB3*QD%E#Y)_"HU+->74)+<D22
M;,#/SMC%":A+<PK(LY9#T*\ BLB=(I5FNYD$Y2)E7S%W>6N#6=IVO(T<4<C@
M,RX4'BJ39%D=S;3HJJ4MXQ*1TSDFF"_,\LD#2_9YA]T2*0OY]?YURJ:U#$1Y
MZN"."X4G%0W_ (E:5#;^<X!&8A'RQ_'G^E/F)<3H;DE(62_E6U4DE9X'#@]/
MX>?4>AKG1JL^C7;,K,=F3#<+E58GU]/\BJ$"75U"L;1J5!SND7))^E:MIH\3
M@"X#3?[_ "!^%.UP'V'B6RGN0+J6..9\DR1Q\9]\=*Z^TM[:=!)'*DRGG(;<
M/TK,M/"MNR@F!2#TR,$5H#PSI]A*LLMU)$W7;&^"?RYIK03UV-:*V4*,.0/1
M1BK44 R1%'T[GDBLJXUZTLI8X43?*P&U'RSD>NT9/YXIR#5M6N&CA@( &,.,
MJO\ P$' _$FCF[$V9K;X@VU2UQ-T$4/)S[GI6I:6%S-"#(HM&SR4Y;'UK-TG
MPA-#*L][>2M*IR,/G;].@'Z_6NN48&,YHN4D1V\"6\0CC7 '7/)-3444B@HH
MHH Y_P /?\ASQ9_V%4_](K6N@KG_  ]_R'/%G_853_TBM:Z"@ HHHH ****
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MBDI: .?\/?\ (<\6?]A5/_2*UKH*Q;WPGX<U*[DN[_0-*N[J3&^:>SCD=L#
MRQ!)P !^%0_\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\
M$T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0
M_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_
M ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q-
M '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__
M  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H
M5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=
M#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\
M(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A
M4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T
M/_Q- '045S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '04
M5S__  @OA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @O
MA#_H5-#_ /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_
M /!=#_\ $T?\(+X0_P"A4T/_ ,%T/_Q- '045S__  @OA#_H5-#_ /!=#_\
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MM.M:M/<KU,$?R1Y_K^E;-CHVG:;\UI9Q1.1@N%^8_CUK0HJ7)L!,>E+11FI
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M+L,8(?XG"C+'Z#UK0H Y_P"V>+_^@'H?_@YF_P#D6C[9XO\ ^@'H?_@YF_\
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M/IMRL<+<'YW,>U>"#DD#!!H L_;/%_\ T ]#_P#!S-_\BT?;/%__ $ ]#_\
M!S-_\BUN1R)-&LD;*Z.-RL#D$&I* .?^V>+_ /H!Z'_X.9O_ )%H^V>+_P#H
M!Z'_ .#F;_Y%KH*YZ^\8Z-IVH36-R]ZLT"B24KIUPZ(AZ,75"H7KSG'!]#0
MOVSQ?_T ]#_\',W_ ,BT?;/%_P#T ]#_ /!S-_\ (M2V_B73[O7(M*MVDEDF
ML_ML<RI^Z>/*CY7Z,?F'3/OCBM>21(D+R,J*.I8X% &']L\7_P#0#T/_ ,',
MW_R+1]L\7_\ 0#T/_P ',W_R+7044 <_]L\7_P#0#T/_ ,',W_R+1]L\7_\
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M5)$:%0S^PW$#)]R![T 8OVSQ?_T ]#_\',W_ ,BT?;/%_P#T ]#_ /!S-_\
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MV)M:OK?Q->1VDTE_<W*32V<<5VX:/;$VU9;9L!4W @.N-S;0:]*HHEK?SO\
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M_C-=!10!S_\ PF6F?\^NN?\ @BO?_C-'_"9:9_SZZY_X(KW_ .,UT%% '/\
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MA:4CH9G+C\CQ6F.E% 60U0 ,   4[%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ G # 2(  A$! Q$!_\0
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MW-]W\/TQ7LU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[W_(M4445Q'LA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %&*** #%)@4M% !BC%%% !1BBB@ HP*** #%&*** #%&*** #
M HQ110 8HHHH ,48HHH ,4444 &**** #%&*** #%%%% "$9%,\J/S ^Q=_]
M['-244"LA,"EQ110,,48HHH ,48HHH ,"BBB@ Q1110 8HQ110 UU##! (/4
M&DC147:JA0.@ Q3Z* L%&*** "BBB@ HQ110 8HHHH ,"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &<_RJ"+Q5H\Z(\5WN1TWJP1L'DC'3KD'CVKL6/KI6N>1/),')WY;>C,C2?
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MV/S(N^3N[=?P]*IW/BBTM;^>T>"<M!M#.%^5BV.%YYP&&:CB\8Z/*K[)V:5
M"T*H2V<9P,=2!R<=*='!4:3O%:A5Q56JK2>AT &*6L^[UBRL8H9+J;REF'R$
MCK[<=Z@_X2/3F!V3%GP,(%.6R5"X^NY<?45V',:]%8R^)=-^U0VDDK1W,K^6
ML3*<[^,C(XX) )Z9K8!R* %HHHH *:44@@C(/451GUBRM[UK2:=4E6,2D-P
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ML6F2*D<CW)BD8D6\GS-EFP?F.2<>]7[?Q+X61$EEL/LT<)\R(/"3(&W.&.T
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M$=HZP79;8'QAB,\ [1DUHVN@>#+?6H+BVN(1>-(AAC%V6^90"H"Y]P?QJ,>
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MX=Z#;QR1Q1SJCAUP)/NJV,J#CIQQ]:ZVB@# _P"$2TPV4-G)YTL$+S,B/)G
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MT444 %%%% !1110 4444 %%%)F@!:*3-&: %HI V:6@ HHHH **** "BBB@
MHHHS0 44F:,T +11FB@ HHHH **** "BBB@ HHHH **3-&: %HI,T9H 6BBB
M@ HHHH **** "BBB@ HI,T9H 6BC-% !1110 4444 %%%% !5:.[66\GMA'(
M&AP2S+A6SZ'O2WLEQ%;%K6!9ILC",VW///-3CIR,&@!11110 4444 %%%% !
M1110 4444 %%%% !1110 4C'%+FL#Q%J+0QBUA;#R#+$=A6->M&C!SET-*5.
M56:A$74/$,=NYBM@)9!P6)^4?XUB2ZUJ$I.;EE]DXJM#;K*C/)(L<:8!8@GD
M]!BI/(M/^?W'_;$U\U6Q.(JZWLO5(]VGAZ%+2UWZ7)8M9U"(C%RS#T?FMK3_
M !%'.ZQ70$;G@,/NG_"L#R;0?\OV?^V)IDT 2-98Y5DC8E=P&,$=L4J6)Q%+
M6]UZW"I0H5-+6?I8[\-FG5SWAW46D!LY6)91E"3U'I70 U]+0K1K4U.)X=6E
M*E-PD+1116YD%%%% !112$T -DD6)6=V"J!DDG  KA-9^("Q.T.DQK(0<&>3
M[OX#O57QYK[R7!TBW<B-,&<@_>/9?I7$8]!]*]G!X&,HJI5^X^3S3.)QFZ&'
M=K;O_(V)_%6N7))?4I5!YQ'\H_2I+;QAKMLP(OVE4?PS ,#_ %J Z-' JKJ&
MH6]I.PR(6#.RYZ;L?=JG>V,UA*JRE&21=T<L;920>H-=\8X>?NJ*^X\257&T
M_?<W]_YJ_P"9Z/X?\;VVIR+;7JK;7+'"\_(Y]CV/L:ZT$&O L<#VKU;P;KQU
M;3/*G/\ I5OA'_VAV:O+QN#5)<\-OR/H\IS65>7L:WQ='W.IHI!2UY9](%%%
M% !111F@!#TK/U#5H-/7#DO(1D(.O_UJEU&]6QLGFX+#A1ZFN'EEDGE:65BS
ML<DFO,Q^-]@N6'Q,[\)A/;/FELC1N-?OIV^200KV"#^M5DU2_0Y%W+GW.:C@
MMA)&9))EBCW; 2I.34[V$,<8D:\PAX!,1YKP^?$S][F?WGJ\N'A[O+^!?M/$
MLR$+=H)$_O+P1^'>NDM[B*YB$L3AD/<5P4\+6\S1,02.X[U=TC46L+H*Q_<R
M'##T]Z[,)F$X3]G6>GY'-B<%"4>>D=M12 @C(I:^C/$"BBB@ HHHH *:S!02
MQ  &232Y KS[Q[K[B3^R+9]H(#7##OZ+_C6U"C*M-0B<F,Q4,+2=67_#LL:W
MX_CMY6M]+19F'!F?[@/L.]<G<>*]<N"=VHRJ#VCP@_2L7]**^CI8.C36U_4^
M"Q&:8JO*[DTNRT-NV\6ZY;,"NH/(!_#* P/]:['0?'=O?RI;:@BV\[<+(#\C
M'^E>:B-V1G5&*)C<P'"Y]:;ZBE5P=&HK6L_(O#9IBJ$D^9M=F>_@@]Z6N)\#
M>(Y+]9-.O)"\T2[HW/5E[C\*[4'-?-U:4J4W"1]YA<3#$TE5ALQ:***S.D**
M** "HIIXX(FDD<(BC))J0FN.US46O+HQ(?W$1Q@?Q'N:Y,7B5AX<SWZ'1AZ#
MK3Y5L6KWQ+(S%;- J_WW')_"LQ]5OY#\UW(#['%5X8A*7'FHA R W&ZIELU$
M:-/<QP%QE58$DCU..E?.2KXFL^;F_&Q[<:6'I>[;]2Q!KU_ 06D$J^CC^M=%
MINL0:A\HS'*.J-_3UKDFMFB\WS9$1HS@*3RQ]O:HD=XY%D0E64Y!'8UI1QM>
MC)<^J\R*N$HUDW#1GH@.:6J&E7XO[)9#_K%^5Q[U?'2OIX34XJ4=F>#*+C)Q
M>Z"BBC(JR0I-RYQGGKBJ]S=_9YK=!#+)YS[-R#(3CJ?:E^Q0?;A>[/W^SR]V
M?X<YZ4 ):17,8E%S.)MSEDPN-J]A[U9HHH **** "BBB@ HHHH **** $+ #
M)( ]31N &21CUJ*XM8KJV>WF7=$Z[67.,BDDM();(VCIF IL*Y_A]* )MPVY
MR,=<T;AC.1CKFH3:0M9?9"N8=GE[<G[N,8S2BUA%E]D"?N/+\O;G^'&,?E0!
M+N!&01CUHW#;G(QZU!'9P1V0LU3]P$V!<G[OIFE-K";/[(4_<[/+VY_AQC%
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MA]PW!_G7M((#;<C/IFO$-$B>?7+&-!RTZ?H<_P!*]I:S@DO8[QD)G1"BMD\
M]>*X,T2]I'T/;X=<O8S3VO\ H6-PSC(R>V:"P! R,GH*@>S@DO8KMDS-$I5&
MR> >M+)9P2W<-TZ9FA!"-D\9ZUY1],3%@" 2,GH,]:-P#!<C)Z"H);.":ZAN
M)$S+#GRSD\9ZT/9027D5VR9GB4JC9/ /7B@!E_/Y%C.X.&"$CUK@QG.379ZO
M8Q7-N\Q3,\4;"-LGC/7BN,'(KYW-V^>*\CV\L2Y9$B3O&CHJI\_!)4$_A6O
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M[SXWY')(*8/;%6]#T7Q)9^+!J-U,QTV:!4EADN \H<!MK,P #  XP,=<\XH
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M-M!Y)&,'/ ZUT6T'K0!SNB7.O274,>HQ-Y0A&]WC"9;"\C!ZD[@1VP/6NCI
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ME#>6.-S!0<$@[N,] #5W4=?O;76+FSM['[1'!&K,55BW(SG@8[8QUJ'^WM;
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MST-'VJ;_ )Z&BB@ ^U3?\]#1]JF_YZ&BB@ ^U3?\]#1]JF_YZ&BB@ ^U3?\
M/0T?:IO^>AHHH /M4W_/0T?:IO\ GH:** #[5-_ST-'VJ;_GH:** #[5-_ST
M-'VJ;_GH:** #[5-_P ]#1]JF_YZ&BB@ ^U3?\]#1]JF_P">AHHH /M4W_/0
MT?:IO^>AHHH /M4W_/0T?:IO^>AHHH /M4W_ #T-'VJ;_GH:** #[5-_ST-'
MVJ;_ )Z&BB@ ^U3?\]#1]JF_YZ&BB@ ^U3?\]#1]JF_YZ&BB@ ^U3?\ /0T?
M:IO^>AHHH /M4W_/0T?:IO\ GH:** #[5-_ST-'VJ;_GH:** #[5-_ST-'VJ
M;_GH:** #[5-_P ]#1]JF_YZ&BB@ ^U3?\]#1]JF_P">AHHH /M4W_/0T?:I
MO^>AHHH /M4W_/0T?:IO^>AHHH /M4W_ #T-'VJ;_GH:** #[5-_ST-'VJ;_
M )Z&BB@ ^U3?\]#1]JF_YZ&BB@ ^U3?\]#1]JF_YZ&BB@ ^U3?\ /0T?:IO^
M>AHHH /M4W_/0T?:IO\ GH:** #[5-_ST-'VJ;_GH:** #[5-_ST-'VJ;_GH
M:** $^TS?\]#53[! VH_VJ5;[8%V[]QZ=.E%% $UW"FIVDEK=CS(7X9?6G1.
M]M"L$;L$C&U<G)P*** (+?3[>VU":_B5A=3\/(6R2./7I2WUI%J\ M[T&2(,
*& SCD?2BB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %R G # 2(  A$! Q$!_\0
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M^-^K/KJ?P+T"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'N5!P3W^M65^'7A]-/TBQ$,_D:3.;BT'G'*N3GD]QF@#B--T>Q\,?'A=.T:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M94YO9&[G%=2&BGQQ2RN4CC=F'4!>E$L,L#;9HG0_[0QFER2M>V@^>-[7&44
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MO671:[]6;UG"511:6BZO3Y$'B>W0)%<!<.Q*L1WJQ=_\BLO_ %R7^E1^)_\
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M>GVUZH$\08CH>A%6Z*^[E%25I(^/3:=T<]I>AHK2O>09(?\ =@G(Q6^% 7:
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MJ*OA:GQOU9]=3^!>@4445!84444 %%%% !1110 4444 %%%% !1110 4444
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MSU)QA&+DUL4;7PC;7@W0:3"4_O$8%-N?"=K9\W&E0JO]X+D5Z6D:HH51A1P
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MHO9[G+LKHY1T*L.H(Y%6M,L9+Z[4*I\M2"[=@*@GN9[IMTTA<^IJQ::K>69
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M<\@=S_GFLX$'H>E&*WEBN:]T<\<+:S3+MK#&\:,8A)E]LF6QL'K3;QT\BV1
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MC_ST3_O@4?\ "0:C_P ]$_[X%9E%:?6Z_P#.R/JM'^5%^?6;ZXA:&212C##
M(!56VN9;.830L X& 2,U%16<JU24E*3NT6J-.*<4M&:?_"0:C_ST3_O@4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_2_X5BW>IZ5!(8X;"&9AP2(U S^59U:U.DKS=BZ=*=1V@KFW_:-E_P _EO\
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M4_N9#U'\)K@PE2%/%7GYG9BH2GA[1\CLCBL7Q)"KZ>)#@-&PP?K6J)T,(E#
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M=DU1HP/QIO$2?02P\1:*,T5S'2%%&:,T %%&:0'- "T4F12T %%%% !1110
M4M)2T >@S2I#"\LAPB#+'&<"LZ+Q!I$T4<B7L9223RT8@@%O3D5J&N>DT2^^
MP6-BDUN]O#(7G616'F_-N4#'0 \^^!7WI\<:EMJEC=W#V]O<H\L>0R#KP<''
MK@\<4@U?3FMQ<"\B,/G?9PX;CS,[=OUSQ5#3M%NK:\AEN)X7BMVF,(C4ACYC
M9.XD]O:J47A*2)@/M:&(.)A'LX\WS,E_^^/E^O- &U#K>F3>8([V([#AN<8^
M;;^(SQ6C7+)X9O'BBCGNH,09$6Q#R#*'.XGOA<5U(H K7UVEE;/._11P/4]J
MXJ[O[B]E+S2''90< 5O^*6(M8%!X,AS^5<QWKYO-*\_:>S3T1[F7T8\GM&M6
M&*OZ=JT]C*NYF>$G#*QS@>HJA17ETJLZ<N:+U/1J4XU(\LD>AI()(U=#E6&0
M:QM<U=[3%O V)6&2V/NC_&K.AL6TBW).3@C]:YC5W+ZO<D]GP/RKZ/&8F4<-
M&<='*WY'A87#QE7<9;*Y49VD<N[LS'J6.:$=HVW(S*P[@XI**^9YG>]SZ#E5
MK6.IT/5GO,V]P<RJ,JW]X?XULR2"*-G9L*HR3[5Q.D,4U>V*]VP?QKJ-<8KH
M]Q@XR /UKZ7!8F4L,Y2U<;_D?/8JA&-=1CLSFM1U:>^E8*Y2#/RJ#C(]ZH=:
M!17SE6K.K)RF[GO4Z<::Y8HL6M]<6,@>&0X[J3D&NUL;M+VT2=/XNH]#Z5P5
M=-X78FTN%)X#C _"O5RNO-5/9MZ,\[,:,>3VBW+>M:H=/@ CP9G^[GL/6N1E
MFEN',DLC.Q[L:TO$;EM5*GHJ*!656&88B<ZSA?1&V!H1C24NK $CD$@^H-;N
MB:S*)UM;ARR-PC'J#Z5A4H)5E8<$$$5RX>O.C-2BSHKT8U8-,]$[5RNLZS+)
M.UO;.4B4X9E/+'_"NE9C]F+=]F?TKS[.22>N>M>YFE><(*,':YX^7T8SFY2Z
M"GGJ2?J:E@N9K6020RLI';/'XBHJ.U?.QE*+NGJ>ZXQ:LT=OI6HC4+02<"1?
ME=?0T_4+Y;"T:=N<<*/4UA>%B?M-RO;:#CWS4WBECLMD[$DFOIXXJ?U/VO7^
MD?//#Q^M>RZ?TS#NKVXO9"\\A/HH. *@Q117S$IRD^:3NSZ&,(Q5HHOZ;JT]
MA*H9R\!/S*><>XKM$</&KJ<JPR#7G9Y%=KHK%M(MBQR<$?K7NY57G)NG)Z(\
M?,J,8VG$SM<UB2*4VMLV& ^=QU'L*YPDN<LQ)/4DU-=L6O9RQR?,;^=0UY>*
MKSJU&V]#T<-0C3@K+45'>-@T;LK#H5.*ZG0]6:\#6\Y!F49#?WA7*U=T=BFK
MVQ'=MI_&M,%B)TZL4GHW8C%T(U*;;W17G5GOI$499I2 /?-=;INC06<:F1!)
M,?O,1T^E<_8*#XB4$9_>L?YUV0ZUZ>74(-RJ26MV>?CJLDHTUM87:,8QQ5#4
M-*M[V,AD"R?PN!R#6A2'I7L3IQFN62T/,C)Q=XO4\]GA>WGDAD&'0X-7=(TW
M^T;@E\B%/O8[^U2^(E"ZJ2!R4!-:_AM NE[AU9R37S5#"Q>+=)[*Y[M;$26&
M51;LU(+6"W0)%$J*.F!4C1HPPR@CT(IU%?3J*2LD>#=MW9S6MZ-&D375JFS;
MRZ#H1ZBN=SP"*]!N0#:S ]-A_E7!V:AKNW4]#(H/YU\YF6'C&K%QTYO\SV\!
M6DZ<E+H=-I&BQ0Q+/<H'F89 ;HM;2JH&  !Z"E XI:]ZC1A2BHQ1X]2I*I+F
MDRM=6-M=QE)HE8'OCD5QFHV+:?>-$260\H?45WE<YXJ4".V;'.XBN#,J$947
M.VJ.S 5I1JJ'1G.5<LXHY(3OP6WG:I; 8[3@?G5(48SG'UKYNE)1E=JY[E6+
ME&R=C4:)'6(21HKI!D1@Y&=W/&:CV6\9SY(.9PFUVZ*1S6?MP%)! (R">]&
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M:..+S$W+EG Y'XU]Z?'&]17F]O\ $*_%W/=W%H%TR2-# CJ4:,X<,6..<NA
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %@ G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N:\4_?MOQKI:YKQ3]^V_&N',/\ =Y'7@_X\3GJ***^0/I@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]&HH
MHK[T^."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *YKQ3]^V_&NEKFO%/W[;\:X<P_W>1UX/^/$YZBBBOD#Z8**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /1J***^]/C@HHHH 0FC-9?B6\GT[PQJE[;,%GM[626,D9PP4D5XY!XD^(
M<WPX'C!?$^F[ C2&T>U4,0&((SZ\4 >\"DS7G^D?%'31X/T+5M?W6=QJ9\M$
M2,D,X."1Z ]:ZJX\0:=%X@M]!>9EU"YMVGB4+QL'4YH ULT9KP_4_$-]9_"3
M7]0TWQ7=ZC=0Z@$6Z*&-H?F *#/;_&NWF^(&D^%O"6BW6N7<LEW>6R,D:*7D
ME.!DX'UH [G-&><5X=H/CBZ\0?$WQ D&LW::*-.EEB1E(\@A1EMIYR#GBNK\
M/^.=#T#P;H\^K>(Y]06]DD2.^FB*ER#SD=@.E 'H]%<;H/Q/\-^(M=?1[*>9
M;L F-9HBGF@=US5?5/BYX3TG69M,N+J9Y+<D3R0PLZ1$=F(H [JDS65X?\1:
M?XHTB/5-+E:6TD9E5F4KD@X/%>>0_&%/^%H7'AV:%1IB-Y*2K$YD,O P1Z9[
MT >L9I:\%\)_%0:'KOBA?$NH7UU%%<A;6)4,FQ0S9Z= !CK7K'_"<>'QX6'B
M4ZA'_91'$V#G.<;<=<Y[4 =%17'^%_B5X>\6:@]A82SQW84NL5Q$4,B#^)<]
M16OXC\4:7X4TU-0U>8PVS2B(.%+?,>G\J -FBN*TGXJ>%]9U]='MKJ5;B3_4
M-+$42;_=)ZU'KOQ8\+Z!JDFG3S7%Q<0-BX%M"9!#_O$4 =S29KROQY\7[?0M
M+T:]T%H+U-08MN=&*B,<'&/XL]JP?%7Q'EA\=^$[ZUU.[@T*XC$ES"J,-X!(
M.4QDT >YT5ROA3X@Z#XQFN(-+FD%S;\R031E' SC.#VK*^*7Q D\"Z/;RVD4
M<M[/* B2HQ0KWY'0T =_17%S?$WP]8^%K#6[VXD1+P8BB$3>9(XZA5Z]>]7O
M"GCS0_&*S+IDSBX@ ,UM,A21/P- '345D>(?$NE>%M,.H:O=+;V^[:"1DL?0
M =:Q/#GQ-\.^)KJ2SM99X+Q(VE\BXA*,R#JPSUXYH [*C-<S:^/= O?"]UXC
MAN7.F6K%99#&<@@@'C\17(>.?C!;Z#;Z++I$:W O]LS&:)L" ]QC^+VH ]5S
M17(:Q\2/#NB:19:C=7$I6^3?;0)$3+(/]WJ/QIVF?$?PYJV@7^LV]TXM]/7=
M=H\95XOJM '6T5Y\/C/X.:[M85NYS'<X"S^0PC5CT4GUK9\4^/\ 0O"/DQZC
M.[W,XS%;0(7D<>N!VH ZBBN3T_XC>&]2\-WNNV]X?L=B/])5D(DB/H5Z]ZR4
M^-'@Q[Z"W-],D4RY6Y>!EBSZ9]: /0J*XS0/BAX;\1ZZVCV4TZW>"T8FB*"4
M#NN:@UKXM^%=#U:33I[B>:6%MMPUO"72#_>(H [JBN:O?'OAZPL=+OI;X-;:
MI(([62-2P=C_ "JW-XITNW\46_AR29AJ5Q$9HX]IP5&>_P"!H VJ*X"\^,?A
M&RU.2S>YN'2)S'+=1P,T,;],%J[JVN8KNWCN()%DAE4.CJ<A@>AH EHHHH *
M*** #M7->*?OVW_ JZ6N:\4_?MO^!5PYA_N\CKP7\>)SU%%%?('TP4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >C4445]Z?'!1110!A^,N/!.N?]>,W_ * :^<=,T_X>R?# 3ZEK=S'K?DN1
M;).Q D!.WY,8]*^IIH8KB%X9HUDB=2K(PR&!Z@BL9?!?A='#+X>TP,.01:IQ
M^E '@7BFXU*]^&'@35-4B\L0791VV;,(&^0X[945W_\ ;NEZY\=-%;2[Z&Z2
M'29E=HCD GG&?I7I][IECJ-D;.]LX+BVX_<R(&7CIQ5>Q\.:+IDD<ECI5G;2
M1*51XH54J#U /O0!\[0G_BQ'BSG_ )C7_LRUT&HW%MIGCWX>ZGJTB1Z:-,11
M+*N41MIX)^I%>U?\(]HWV&6Q_LJS^R3/YDD/DKL=O4CH33KW0]*U&RCL[W3K
M:XMH\;(I(@57Z#M0!X3I^H66I_%_QG=Z?-'+;2:3<;)(_NMB, D>M8%P%?X;
M_#M7 93J4N0>1]\5])6WAW1;,DVVE6<),1AS'"J_NSU7IT]J#X<T4P6\!TFR
M\FV8O!'Y*[8R>ZC'!H \O\6QHGQ]\(%$5&:W8$J,$\-BN=\ ZQHOA[0?&VF>
M()H;75S)-O6XY:48( 'KS_.O>IM+L)[Z&^FLH)+N 8BF:,%T'L>HKSOQ-X"\
M1ZMK5S-:W6A-;W98&XN=/!N+92,85N_U- $WP*_Y)58_]=IO_0S7-1W=MI7[
M2UW)J$L=M%/:A8FE.T.2H  ]\UZAX.\+VW@[PS;:+:S23)#EC(_5F8Y)_.KM
M]X?TC4[N*ZOM-M;FXA(,<LL09EP<C!H \:^%L44NI_$9)$1U+MD, 1_RTKB;
MFUOIO@3HMQ;$_8[?5IFN0!D#GY6(]!S^=?3]KH^FV3W+VMA;0M<\SF.,*9/]
M[UZFB#1]-M=/:P@L+:*S?.Z!8P$.>N5Z<T >/^&K<:OX_P##^I7/C;2M2N;>
MW?R+:SMBC&/;R&QP,>]:_P"T 0/A] 6'RB_B)X[8:O0M-\,Z'H\[SZ;I-G:3
M,,%X80I(],BN>^)_A*_\9^&(=-TZ6&.9+I)BTQ(&%SZ?6@#SGQIK&B^(=1^'
M]EH$L5U?1W$3,+<?-'&,9!QTY!XI+WQ=+J&M>,;:35M*\/VMH9(_)^R*9KO@
MC)/4Y_K7L.D>%M&TEHKBWTJRAOA&%>>*(!B<<G..]2W'A?0;O4#?W.CV,MV>
MLSP*6/XXH ^;KY2OP+\)W&W]U%JLAD8=%&X]:[#Q/>V>I?&7P%<V<T5Q;2(F
MUXR"IY->R_\ "/:.=+_LS^S+3[!G/V;REV9ZYQ3(/#6AVS6K0:391M:?\>[+
M"H,7?Y?2@#SS1HXXOVCM=$:(@.F(2%&,D[,FI_CW&6^&Y=4)V7D3,0.@YKT=
M--L4U!]02T@6]D78]P$&]E]">N*DN[*VU"U>VNX(YX)!AXY%#*WU!H \.U_4
M]+3X@^!O$%[)'-H'V,1+<*=T23#/7T()7-7-&N(=<_:*N=1T&>.:PAL0MS-"
M/D8X QD<$YQ^5>L?\(YHITH:6=*LS8 Y%N85V ]<XJ73-%TS1HFBTRPM[2-S
MEEAC"Y/OB@#A?C#XBE\/Z1I7DVUDSW5X(OM%Y")4MACE\'O7$Z7<?:OC?:*=
M?@UF1=)E0SP1A%!V-\HQP>M>Z:AIECJMJ;;4+2&Z@)SY<R!AGUP:IV?AC0M.
MFBFL]'LK>6$$1R1P*&4'K@XH ^?M$\0Z39? ?Q'HUS?11:D\\@6U8X<Y9<<?
M@:T/&++'\*?AW.^%CCN(B[GH!CO7MK^$/#DEU+<OH>GM/+GS':W4EL]<\5;N
M-#TJ[TU=.N-/MI+%  MN\0*+CI@=J /']=O[.S^.NBZ[J=Y"VAW-GBQN3S$A
MP1UZ=>?QK'U&XMM5U+XG:KI!W:2=-$3RH?DDER.1Z]#7ND_AW1KK3HM.N-,M
M);.$8B@>(%4^@[4ZWT#2+739-.M]-M8[*08>!8@$?ZCO0!X/XQ2./X ^#2B(
MI,\1) QDX;)K76[M=$^.]G?Z]-'#:7&D(MK<3C"!MHXR>AZ\^]>Q3:'I5Q80
MV,VFVLEI 08H'B!1".F!T%&HZ%I.K01P:CIUK=11_<2:(,%^F>E 'SY<S6VI
MR?%+5M)0_P!CR6BHLJC"/)N7)'UP33_%\<?_  J+X=_(G,R]O7K7T#%H>E0:
M8VFQ:=:I8L,-;K$ C?4=#22Z#I$]I;VDVFVDEO;<PQ-$"L?^Z.U 'D_C*.*/
MXY>!RB*K-'@[1C/!Q6/X$UC0O#VA>-=-\0O#:ZH9YC*ER 6E4@A0,_>Y_G7N
MDVDZ?<7L%[-96\EU!_J9GC!>/Z'M56_\+Z#JMT+J_P!'LKFX'226%6;\S0!\
MX)97EE\*?"%]>JT=I'K?F[G&-D98<_0X)KN[G7-+UG]H'3+C3KJ.]ABTR1)#
M =P)VL<#U.#VKU^ZTNPO;#[#=6<$UI@#R'0%,#IQ5>S\-Z)ITT4UEI-E;RQ*
M5C>*%590>H! H ^>O[0M?#FAZKJ?AGQ!97&F27.Z?0=7MU\XONY 4\U]">&K
MP7_AO3;L6HM1-;H_D 8$>1T ]*BG\(^'+F^-[/H>GR73-N,K6ZEB?4G'6ME5
M"@!1@ 8 ':@!:*** "BBB@ KFO%/W[;\:Z6N:\4_?MOH:X<P_P!WD=>#_CQ.
M>HHHKY ^F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#T:BBBOO3XX**** $8XY)P*QH/%GA^ZU'^SX-;L9+O
M.WR5F4MGT]S67\3[J\L_AQK<]@SK<+;D!D&2 2 V/PS7GFG>%/ )^&'A[4;^
M\CT^4E)1J"'$S3'DKG&3S_*@#LM/\5ZK<_&/5?#,DD1TVVLUFC41_,&(7JWX
MFNF?Q3H$>I_V:^LV*WN=OD&9=V?3'K7E+S7,'QE\63V'[VY30@T!8_>;8N#7
M(V&C:!=? *_UV[6+^VUNF<76[]\9=WR@GJ,C/% 'T9JFN:7HD2RZIJ%M9QMP
MK32!=WTS4EAJVGZI9_:["]@N;;G,L3AE&.O(KQ+4-)U'7KGP?JT<FFZGK$6E
MIYNBZBP7S1@Y< \9_P *SSJ5C#\/?'$&FZ3<:%J\)1;ZTCF+Q*"V,IZ<9!H
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MBO+Q>&5"?*G<]'#5_;0YFCT:BBBOL3Y<**** "BBB@ HHHH *,444 &****
M"BBB@ HHHH **** "BBB@ Q1110 4444 %%%% !BBBB@ HHHH **** "BBB@
M HHHS0 45#-<P6Z[IIHXUR!EV Y/2J+:OYN18VD]T<'# ;$R#R"QZ&@#4IC.
MJ L[!5]2<"L[R]7N6R\L%HF[.$7>Q7'()/ /N*!H=LY!NVEO&QC]^^0>?[HX
M_'% "R:U9HY2)VN) 2NR%2QSZ$] :9]HU:X.8+2*V3@AKABQ([C:.AK2CB2)
M=L:*H]%&*DH RO[)><$7U]<7 ((*+^[4@^H'\ZN6]C:VO^IMXT)QDA>3CIDU
M9HH **** "BBB@ KFO%/W[;Z-72US7BG[]M]#7#F'^[R.O!_QXG/5M>'/]=/
M_NBL6MGPY_KI_P#=%?/Y=_O$3VL;_ 9T-%%5K^[6QT^XNWC9U@C:0JIY.!G%
M?7'S19HKEW\;V*66CW(MYF.J/L5,@&+L2WT/%'_";6N'F-A<K9GS!!<G 69D
M!)4#J,X.#0!U%%<BOCV%;!IYM*NX9]D<D=NS#,B.<*P/3K6MIVOQ7L5X)K>6
MTNK+_CXMI/F91C((QU!% &Q16)HGB)-8O+FS>RGL[B!$E,<N,E'^Z>._M6W0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=K?_ "#'^HKEJZK6
MO^08_P!17*U\QFO\;Y'OY;_"?J>C4445].> %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BDS45Q<P6T323
MRI%&O5G8 "@":C-9?]LQ2L4M+>>Y()4E$(4'W)_G32-9N@-K6]BIP>GFN/4'
MM^- &J6 !)( '4FJ$VLV44HB$IEE+!=D2ER">F<=/QJ,:+"[;KJ>XNCDX$K_
M "@'M@8&/K5Z&VBMT"0Q)&@& %&.* ,_[7JMTI^S6*6X(R&NFYSGH5'MWS4P
ML;N4'[1?R$$GY8E"#!'3/7\:O@4M &?;Z-8VQ#"$22;0ADF)=F .1DGK5\#%
M+10 4444 %%%% !1110 4444 %%%% !7->*?OVWT-=+7->*?OVWXUPYA_N\C
MKP?\>)SU;/AS_73_ .Z*QJV?#G^NG_W17S^7?[Q$]K&_P&=#5;4;5KW3;FT5
M]C31E QYQGO5FBOKCYHXQ? 2K<-*+TD>9$R(P)"!>7 _WB,U*_@R>6 64FI!
MK"#>UK&8L.KL"/F;N!DUUU% '%OX'NY]*2*YU-'O8HHX8)!%B-$1@1\O<G%;
M6F:)/8RW]_+=K-JMZJB2;R]J#:,* OH*VJ* .?\ #6AZCHTEX]]?07C7+;VD
M6(JY;W.>GH*Z"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
M_6O^08_U%<K75:U_R#'^HKE:^8S7^-\CW\M_A/U/1J***^G/ "BBB@ HHHH
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M$[I&IE+N"<B,[>,9.?0$BK<>CV$<:HMLA"]"<YZ8/Z4Y-+L8\!+6-0H91@=
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M_45RM=5K7_(,?ZBN5KYC-?XWR/?RW^$_4]&HHHKZ<\ **** "BBB@ HHHS0
M4451GU:R@;8;A7DP2(X_G9L=0 ._M0!>HK.CO[BX.8-/F"'!#S$(&!]NO'H0
M*C-IJER")[Y+=2,;;9>0<]=Q]O:@#0EGCA4M+(B*!G+'%4#KENYQ:QSW;<']
MPF1@]\G J2+1K))?-:+S9-VX/*2Y!]L]*O*BHNU5 4= !Q0!F;M8N3@)!9ID
MC+'S'QV(Z#\#2C1HY6#7EQ/=,&# .Y"@^RCM[5J44 0P6T-M&(X(8XE'144
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M]:TKS0]=U&XM+J:TM(I+.*%$C2;)E*N&;+8X&!P/>NVHH X1O#.LC6H];%O
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MEW.GZUK]Q-&J0WERDD&".5"XZ=N:WJ** "BBB@ HHHH **** "BBB@ HHHH
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MG'^5'_"07?\ SSB_*LHFC-=/UVO_ #,Y_JE'^4UO^$@N_P#GG%^5'_"07?\
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M\J/^$@N_^><7Y5E9&>:3(SC(H^NU_P"9A]4H_P IK?\ "07?_/.*C_A(+O\
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M\"6UM%;QYV1($7/H!B@"6BBB@"TOW13J:OW13J "BBB@"H?O'ZTE*?O'ZTE
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MCK4D$0$'E@S(O"$L%#*#D^X)J"]\2:Q96YN);"#:TWEQH Q8#)&2.!V!Z]*
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M4 96N>'=,\10PPZE!YJ0R"1,'&#_ (5-<Z1;7,]I*RE?LN/*4=!CI6;XMO\
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M6N];O]/:*%MARD<ADD7)"GAL@=\FI+'6]1N-3LX)(E6&1>7*%?,']X>GI@T
M=+1110!:7[HIU-7[HIU !1110!4/WC]:2E/WC]:2@#G+Z]\21^+[*VM+!'T1
MD_TB<XR"<^]13:CJ46L7]O&[8\Y%@5H6.$.T$@_=QR:ZB@9Z=J .6CO]5BO;
MNXDCE:,%(]@C)S@-EU'X#\ZFL-2U:ZM()FC"G#NRO'@N V /;BNBYS]*7- '
M*/KNK![000^<))660M$R;"/X>GZU8BU6^^RZC=%6:2%/E3R6&T[B,8_BXYXK
MH\FC)XY/% '*W>N:FDSI:1-,!&#&3;L-PVYW^W/&*<U_K0G/++L:2)%,)VR$
M8(8^G4_E74;C29- '*:EJ.JF26S197*.JL4B(PH*G>#WSDC'M5BZNKZPU74;
MHF:6%BL<*"(D+\O&,>_>NC&:49'0T <Y)J.KQH\K(HC/'$1)C&>6QW^E4&U3
M6(KFY=?-NMLV8U,!150Q@Y'KSGBNR_&C)QUH Y9-8U8J\PC9X(L$'R"&E!;!
M(';CFJEOJ>KZA?Q,89D5&,88H0&RP()''2NTH)/KF@#F]+U'4I+JVLYG\WS
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M!J=GI\1^6($O[G%;X7#1JZST6WS,<37E3TAON<P058JP((."#14EU_Q]S?\
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M444 6E^Z*=35^Z*=0 4444 5#]X_6DI3]X_6DH **** "BBB@ HHHH ****
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GE*Z6T5^)<MO^/:+_ '!4M16W_'M%_N#^52UYE7XWZGH4_@7H?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ F@"+ P$1  (1 0,1 ?_$ )8   (" P$
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M(_ZPV_)^'U^37F]';_?_ !<O\-=GU[_3E^S/[7<S7W^5>7:]0C(QMH;_ !I
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MV!6Y%B;T B\45F8H7.Z@$#Q#4&@4E))F2,3Z2(>TZ_LJ<!A,/+E:SR\B_P"
M48-8X?1\5'#2HLYVM(Q?7MY12R,+/'Z?TJX'T:V-]4+)MK]]+(\5WT['Z7'X
MA@<Y O:21R"/E1D86WU&)S?Y"#S6MR#R\OE_MK0,-7=QR$J;D,-][=E;H33(
M#CEM<KH"=J \RQR1L#?F)T<_>:D\D98\?D]-F(;6Q' ]U+!K+VA::7-PD8J,
ME<B!7^+0D_&UB@I2#92I!&,('TRK1$ L>)V/WTS3PH8Q(#J&=;\^VM I3DB6
M1C(C.;GD(.QW%13@BIS1,18@-X:J%1(XF)-R%!'W_*F0Z1$1J?3]4C?6WVT
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<_+\=_P .^]!0C^/\7]EH-__9              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ C@"7 P$1  (1 0,1 ?_$ )0   $$ P$!
M      ,"! 4&  $(!PD!  ,! 0$!               ! @,$!080  (! P,!
M!04& P8%!0    $" P 1!"$2!3%!42(3!F%Q@3('D:&Q0B,4P5((8G*2HK)#
M,U.CLS0D9!5U%Q$! 0 " @,  P # 0        $1 B$#,1($05$383(4(O_:
M  P# 0 "$0,1 #\ ZIH#* 9<UF#"XK*RC_LQLP]]M/OK/MVQK5]<SM'CR BY
M8W8ZD]Y.MZ\/;;+V)Q2'/?0HW8]:FK@3&W6G#)+JRD4P'8 Z4!OVT -R;Z4
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MZ7N 1?H+&M?Z,/Y4IN6XU02\HV@$ :C\/N[?;1_2%_*FF9ST)3R\.-F<=)I
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94)#(QM-3;L^:WX4!_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D *H# 2(  A$! Q$!_\0
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MP@_&F!U#RI&I+, !U).!5>UU(3ZC;K:+YH,F"P/&.YKFDT+4M7<-JMXQ0_\
M+" [5'U/4_I7;:#HEOI<($,*Q@#  '2@5S<J&:!95((J:BF2<W?:65)*CBL2
M>V*D@BN\= ZX(S67>Z:K@E10,\VUKPY:ZI"R21KN([C@FO*M;\,7NBRL51I8
M <YQE@*]_N;-D8@BLF\L([B,QRH&!]>HIB/GIWW1$ Y![5#;R%001WXKT3Q'
MX =G:?3Q@GDJ!P:Y:/P=K;2;!:MDGKT%(#/2=ATXI3<L[!0"['C"C)-=AIGP
MTO)V5KV78#U5:[K2/!.F:: 5A#..K$9-%AG!Z!X<U+4DC MEMEQ\\T@W.?\
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F1110 4444 %%%% "$ TW:O7 HHH&.  I:**!!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4_%$7B9&WHLD?AZYM+B_BNTWS64T09&1TS^57_!5/]J7]F3QW^P/^R%\-?\
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M-=5T[6;V]*:C>OJ5WJ<>H,B6MKJ_AN>\TR.R#7<5?G/^S+^PY\"?VH_V6O\
M@N/\:/C*GCSQ+XS_ &<OC)\;M<^"RV_Q#\5:7X<\$>(=/T_Q7XB;Q'8^&K'4
M(M&O=8U&XTRTT^_N]3M+SS=&0V,$=N6$R_U6_L;_ /!$C]F#]D3XWZ?^TE>_
M$#X]_M*_&_POX?F\)?#CQU^TE\2M0^(MU\,?#4T$EJVF^"K.[BCMM.E2REGL
M+>\D$\ME:7-TMBMM+<32OZ1\%/\ @DG^S?\  CX0?MF_!;P?X@^)=UX5_;DU
MWQ=X@^+5SK7B&RN]6TR]\9Z;JVEZHG@ZZCTN"/2X([?6;EK2.XAO3#(L3%G"
MD-E5C)T:L?:.=9X#-*="I).+HUL9F.78K#4H2YG)1P]&AB4JU^6$ZTJ="-.F
MTC6G-1J4WRJ$%B\ME6C%WC6HX7!9E0Q-22LFY5ZF)PL72=W4IT(5*MZB9_%W
M\8OV8_ VB?\ !!_]CC_@I_%XI^+>H?MK:E\9/AMH*_&+6/BIXSU/4-)\)Z-X
MV\;>$O#GA'0-/N=4:PT;P_X:TGP7H?\ 84%C!%>6=RMV[7<L5R8E_2?6_P!F
MSX7_ +?G_!PUXI^%W[3">*/%'P_\2_\ !.?X&_$;Q1X2T/QKXA\&:9XN\11>
M"?!-W';:ZGAO4=.N-0TB#4=6DUT:3%+#"VJ:=IU[+OCL]C?O9XN_X(O?LN>,
MO^">7PN_X)J:IXF^*T7P(^$_BS2O%_AO6K3Q+81>/[G4]'\1>)/$UK%J>M-I
M#6EQ:F_\4:C'+$FGQ,UM';1[@R%V_&#XO_\ !-/6_P!I+_@OE\3/#'B*']IO
MX3_!;P[^PQ\+M&^''[2_P<U_Q3\-M1T7QOX*\-^%_#=I9Z9\2]'ABL-1U";1
MY=5L-<\.2RO!J$<MP+BVQ" O0ZD)XN:4;TIXG&UZ,)1480IOA]4*W-JH0E5Q
MJ550U]M5@JBYZFLN=)PPL&Y.-6GAX4:LX^].4I<04Z^&BK>]*-+!25+F22I4
M^:FN6FFE\8_L_?&#P#^Q_P#L\_\ !>W]D?XA?&[]H6Q_8N_9O^-?@OP9\)M:
M^$'BN&;XMV$GQ'\5^)?#MQ\,O ?BK63<:?HD7CW^QM/T37]1C\B#3[*RUS5]
MGVJ\NQ-Y)X4^'/B7]CC]NW_@C5\0/A'^R1XB_82L?CIXST30KW4IOVDKKXP^
M,?VD/ /B5_"=G>ZG\8]"L[R31]!UF[T;Q"MWJ=A900Z+>WFM)]DL;63285A_
MK*^$?_!$7]A7X5_L=?%G]BRY\(^*OB%\/?CSKD/B[XR^-/'/BF[U#XH>./&U
ME/#>:-XNN/%MM%;2Z;J_AN^A6^\/&P@C@TZ\DNKEX[F:^O9+CP#P5_P;I_L8
M>!O&WP&^)EI\4_VJ_$WQ"_9U\>^'O&?P\\3^/_C9J_CJ33M,\*ZA:W^@> +3
M3/$=I>Z7HW@6PDM54Z-H-KIOG"69GER8A#.':I8K!SK3]K]7_LF%:NXMRQ-/
M"X?$T<8Y4[JHY59U8**JU94ZF'35:G.M::JO>IAL9"FN26(_M:=.DVN6A4Q=
M3#3PSC-+DBH*E5G*5.FITL1-.C4A1YH2_([]C_\ 8)^#O[=7_!:?_@K$WQV\
M1?%27PY^SU^TMH'Q'\#^"O!_CS4_#'AF^\<0^++Z;3-=\3V4 N%U<:/%H\=O
MIUD$MX8X[N[+2'>$KCOA#X5^*OQ-_:._X.<OAS\(?C3HOP.^)GBS4? 'ASP-
M\2/&GCG_ (0?PWH5[>>.O%?VS1'\77UU%;>%9?&>D1:AX/M=5A>%K2ZUN&=2
M#$"/ZJ/V;O\ @GM\%_V8/VEOVK?VIO .L>-[_P"(?[8'B.S\4?$S3_$.L6U[
MX<T[4+&]OK^*/PO80V-O-IMN9K^=7CGN;MB@4;P5.?";/_@C#^QM<>)/V\=;
M\9Z;XR^(>D_\%$)=(G^._A+Q3KZ2:%9W/A_5M1U[1+WP-]@L[._\.:CI.M7Z
MZGI]ZMY<S6UY8V4JDB)TDYX1<</0H/2,,CQ6"J1BVE]=KSPS=1346WSPP[BZ
MGPVC&,E[.4K]#J)XBO7;?-/-L+B:<^52<<)A^>2@X<R^&<Y25-24I.3DIWY;
M?S+?L:?#/X"_LJ_M<_\ !/+PE^T/^S%^US_P3,_:D?6;#P?H/QS\!_$NT^*W
M[.G[<GBJZ.EP:AI_CO79M>UZP@T3Q0EQ"UVN@2W&GPCQ/9I?VUE:-I]Y:^U_
MLC?LB_"3_@L9^U;_ ,%>OBG^W[XB\<:YXL^!/Q7O_@]\'O"Y\?Z]X6TS]GOP
M98KXV2QU[1-&L-0M;:WDT4>&K)[>6_BETZ62/5[K5+>\O+][A/VI^!?_  0>
M_9D^$?Q>^#OQ:\<?&7]J+]I(_LW7BWO[./@'X_?%N]\9_#_X-7$"11:=/X=T
M%+*R6]N-(BM[-=.?5)KB.(V%AYD,L=E:QPR_M5_\$'?V3_VF_CAX[_: T;XC
M?M%?LX>.OC%:?V?\=H?V=_BGJ/@#P[\:+%T2*\3QQH5O!-:7EQJL09-:G0"/
M57(N+RWDN3---K5YJBW3E*AF5&$U'V:PM7&/!O#XN%-.2C6I1H5:=6.&G"E!
M5%+!QI-U%+*FN1NS<8J>7U'K*I+$1PGUOVV%E.24I4*KK4:E*6(BZO/2E#%2
MJT_9N/\ (+XY^-?Q@^/7_!&?]CCPW\3OB+XU\0R_"C_@JSK'P \!_$@Z]J,/
MBVY^&^B^']+ET#R/$?FF^N[_ ,.'7+J'2-2DFN&L[9=+MHOW>GPJ/V#\0?LJ
M_"G_ ()O?\'!G_!-WP7^RG<>.? _A+]HOX,_%*]^-&EZYX^\3^,(O&UY9:3X
MRM[K5?$%UXBU&\N;ZXO[G3M/\0:F;B4VW]N:?#J5K#9X:.OVY^)/_!%#]BOQ
M[^S5^SG^R=HVD>,OAK\(?V9/B9IOQ9\"6/@CQ$EOK>M>-; RR76K^-=:U.QU
M"Z\17>M7,TMYK%S*(I[B9ECB>"UA@MXO?_C'_P $[O@G\;OVS_V;/VY/%VK>
M-H?BS^R[X6\1^$? .D:5J]K;^#-2TKQ3%J\6I_\ "3:1-833:E,8]9O%@:.\
MMD11&'1PK!M(SC&NJMY-O,)U:U1KEG6PSX>I9=*4U%V3JX^$JTZ*7N^[5DY5
M'S+*I&<Z3I*T8K!5*=.G?W:.(EG=?'4XTVUJJ&#J4Z5.J]7:5-6BM?XN/CI^
MRX?A!J?[9/Q>_P""A'[./QO_ &L? ?CWX[ZMXX\&?\%7_P!C/X^V7C_7O@%X
M.&O6LNEZ6/!L'B@Z7H8\-QR66GWVE:]I^G?V8]\--L=0ACM])O8_[JOV.?$?
MA7Q=^RI^SSXF\"?%'Q-\;/!FM_"+P-?^&?BQXTBCA\7^/]$FT*T^P>)?%,<<
M,"+XAO[<1OK&(U9M06X9M[%G;\GO'7_!NW^Q]XJ\0?$BS\*_%S]JGX0_ ?XS
M>+KGQQ\6OV6OA=\9-0\/? [QGX@O[\:CJ3MH#V5U>:1I^H7*H\^FZ?>I;*$6
M*()!%;Q0?MW\,_AMX(^#7P[\$_"KX;>'['PIX ^'GAK2/!_@_P .:<&6RT7P
M]H=G%8:;86_F,\CK!;01J9)'>6:3=+(S2.Q,4K0PBI2TG#ZFHI)-*-##2I5?
M:67+*ISM>SK4H4JE>GSU<9&6(DI1VK>_B75C_#?UF4G)N_-6Q$:E/V;;<X0]
MFG[2C.=2E1GR4\(X486E_/E_P0K6Y\4W7_!8GQSJZM=_$'QK_P %!/C98>))
MI POKA-&TVZM] LY%<F1(;8:E>PVD!"+$K.B  8'A?\ P:C7MG:_L*?M2:?=
M7EK;W^B?M2?$>36;*:XBBN=(CDT#37BDU*%W$EE%(EM<LDMRL4;K;SLK$1/M
M^U?V??A?\1OV!O\ @K!^T?X9@\!^+?$?[*7_  4RUB'XU^!_B#X9T2\UG0OA
M+^TMX7T;4;CXB>"O'\MC%(OA72?'6GM?^(?#6MW4::=>72V^D--%<6K;JGQP
M_P"#>#]CKXJ_%CXB?%?X=?%']IW]F"7XSZE>:K\9/ O[/'Q?U;P)\//B+>ZE
M++-JS:IX8ABFMK>WU::XNY[VPA9M-,]W</;V5NLCQG*E&2HT&[-5LBPV5U&W
MRRH8K!3HTZSE"UYQYZ53X4I3IUJ%6$JD:M1P)J,JM12NIT<XK9E"RYHU</BZ
M564(1DW[K5.M&*<M(3P]6E*,.6GS?SU?\$\=%_83\>_\$L/^"C'@K_@H!\5+
MKX._ /XN_P#!1V]\-^!?BWI>D^)M:ET7XK/X4MM9\$:MH;>&?#WB6*1DBT[4
MO.DU:TCT"^TYK[3KR^MI+R&0?;_QO^,'_!0[_@C=\,/@GK7[5'Q#_9X_X*@?
M\$UM6\7^"? 6@W7C+PAIFE_'/PKX>U#3YY/"&I::NI0:GH_BJ;1O"EC<O87L
MZ:YYFV"RFN].CNX[A?Z&?"G_  2M_8:\(_L8W/[ MG\$M'U/]FW4$GN=6\-:
M[>7NHZ]K/B:XN5O7\=ZCXK:2+6G\<K?QQ7L'B*WN+>YM9(8K:V2&P0VA^$/
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M** "BBB@ HHHH *,#THHH **** "BBB@ HHHH **** # ]!1@>E%% !1110
M8'I1110 4444 %%%% !1@'J,T44 %%%% !1110 4444 %%%%%@# /49HHHH
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M+)=.K?S:47Z7C&*=K748IW25DDHN\?==T[JZU4G)/1K:3<EV;;6[OY;-\'/
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MZVVOJ)12V26[T26KT;]6FU?>VCN@HHHH&%%%% !1110 4444 %%%% !1110
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M_M2)&KDGD[LGDUTTJCFW%[Q2=^Z?];G%7I1IM<K>O1]/1]CTNBBBMS ****
M"C_/^>E%% '\2O\ P5)_X.@_VAOV4?VU_B9^RM^S5^S7X3^(&E_"7['INN:_
MXEU'Q!-KFL:S+:1W=_-9Z/H6EWQM],L3*L!D?)=@'#*I!/Y[/_P=\_\ !1V
M$W'[&GPVA52NYIO^$^C&7)"*=WAC*E@#MR,,%)7.#C\Q_P#@IU\6M>^"O_!;
MW]L'QOX9UJ#P[JT'BC4;%=6N#<".&WNM(M&F@)M8+B;-X(5M!B,!?-\SS(RH
M+?)GQ$_:_P#B3XXTN;Q'XHEN-6&LMI,]UIL^H3-8LUFL\6G$GRHF+62W5TML
M[KOVS,&)^4+SXC$5:..P]"5/#QP->"C#$.K-XKZRK*4'15*-/V5G[LG5<[WN
MK6MI@\#FN.K8N6%P=*IE^ P4\=C,6\71C5ITX24.58><>9MS:Y4I<TDFXJU[
M?O>G_!W]_P %%Y!OA_8P^&L\>YEWQ2>/I4!09=2R>&,952"XZJ""0!Q3;C_@
M[Z_X*-6\GDWO[&/P[TV4*'$=V?'UI(\;'Y)$6X\*9,1'1\;6'.:_GU^'W[=7
MQ"^&0O+?0_#6D7FFWR3B?1]3U+53IPDO$2"]EVV4]G.\E]8J=/N5>9D:U=RB
M).$E&EKO[7?C_P#:!^(.F3_$"*ZO;B>Q_L:QN(I-8\476@:%8+=7=MHVCZ6L
MZZCJ%G;&:X^SVK7LMS&)2?->.-8QTM).S>BE9NU].:S=NKLG9=7IU(2=TG:]
M[.]TM];N*;2[N*;2NTFTD_W\'_!WK_P4<3#-^QE\.=K1K+ND?QZ!Y;)O64,/
M":J(F4$JP!5L@AL!B.6F_P"#R[]NB&9X9OV8_@7;RQ.8Y8)?$7BB.6&08W1R
MJ^A@JZYPRD94_>Q7YY_ 'QC\6?B?H/B.\L/$^CZ-;6#R^#Y$\7:E)H36^G:?
M!XBM?]"A:RGG%U#8Z0+*_P!/N&DNK.^UC3;81L\CRQ?A%XY7'C7Q;MC>)?\
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M!S'C;4;G1_!GB[5K*1HKS2_#&OZC:2HBR/'<V.E7=S!(B,K*[)+$C*C*RL0
M5(.*_P >OXJ_&OQ%\0/BAK?C#X]?$SP[\3OB+XPO;?Q+K'B3Q#\2K#Q1)K&H
MZQ>:;;+Q#?O8V]YIL6H0B73I+>P32-.TZ\MXX4BL I_V"?B*Q7X?>.F'5?!O
MB=AQGD:)?$<=_IWK_%4_88T[X<7?QG\:6_Q0T^9[*$278O-/L[&\U_2;?^T-
M0BN[O1HM0EMHD<S7>FB>1+BWE$6T"58_-4]6 P%7,L?AL'3Q$<.JSJ0<I4?:
MMR<'*'*N>+E*\'"%*.M6=2-Y1Y5S>1GN9_V-E6-S3D=6."H^TE23IPYE.K1H
MJ4JU2,XTJ5*515*T_9S<:49R2;2B]?5/CW\.?B9H_C/1%T*QT?6-'\+ZY?:9
M?ZO>VVGKJMSIH(:RT6XM;B,W5](@:>VMY)D-TD96&.:8I&?UM_X-X?B3XL\3
M?\%+/V = BNK718KO6?BQXK\13:+8Q:,GB*4:!XPT.6PU*'24L[>[METK3]+
MBCBNH[F))+2*0*DCL[?@G^V';^ ;/]HGQI8_#:S-CX/MKG34TN.XM;2PU"19
M+*&X:;5[.R9K.#6-THCU$6Q$37*M(.7K]Q_^#<A[=?\ @HK_ ,$Z[J*$I>+X
MP^-VD7$XQB:VF\.>(;V&,Y''E$2<#KYA/'.9Q>'>%Q6(PSG&H\/5G1<XQY5)
MTWRM\K;<7=-23;:FIJ[M=]>7XQ9AE^!QZI3H+&X3#XE4:CBYT_;04E%N,8IW
M24DU%<T9P=DY67^K]1117.=@4444 %%%% !1110!_GT?\%"_^"<O[67[8/\
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MW%RHPKQ<9RJPC:O3I0E-5:*E*E5A[.,H-QES1=2#Y;\R\,^ >H1^(_BI\?\
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M*8U!D(7=]T5<+2IRE)NG44ERTW'F4H=6YIVBUT5G<3O>VC7>_P"ECU&BBB@
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MJX )_P!7:=O^WNC_ %TX%_Z-#D'_ (E7&7X_[5K^ _\ B$WC#_TDQQF[Z?\
M)O?#*^ZV:R_1Z6O9Z-V5[-?%&B_MH?&O4](TW4+G]FW7;&XO;*"YGLY$UW?;
M2RKN>%MVFJV8SP=R@YZBM/\ X;#^,G_1O&M?]\:Y_P#*ZOLZ\^)>CV5S);26
M.IL\:PLS(EJ5(F@BN%QNNE;A)5#9488$#(P36_X6KHG_ #X:K_WQ:?\ R77\
MV9APGQABL?CL5A/$S.<MPF)QN+Q&%RZCP_PW7HY?AJ^)KUL/@:-?$T98BO2P
M5&K2PM.MB)2KU:>'A4K2=6=1O^R,KXJX0P669;@\=X89/FV-PF7X'"XS-:_$
M7$^%KYIB\-A,-A\5F5?#83$1PN'K9AB*-?&UL/A8QPU"KBZE+#QC0ITHKXZ_
MX;#^,G_1O&M?]\:Y_P#*ZC_AL/XR?]&\:U_WQKG_ ,KJ^Q?^%JZ)_P ^&J_]
M\6G_ ,ET?\+5T3_GPU7_ +XM/_DNN/\ U,XX_P"CLY[_ .(SPK_\SG=_KGP-
M_P!&AR+_ ,2GB[_YI/CK_AL/XR?]&\:U_P!\:Y_\KJ/^&P_C)_T;QK7_ 'QK
MG_RNK[&_X6IHF,_V?JN/799__)?Z4?\ "U-$_P"@?JO7'W+/KZ?\??6C_4SC
MC_H[6>_^(UPI_P#,X?ZY<#?]&@R+_P 2GB[_ .:3XY_X;#^,G_1O&M?]\:Y_
M\KJ/^&P_C)_T;QK7_?&N?_*ZOL7_ (6IHF<?V?JN?3R[3Z_\_='_  M31/\
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M[_HQWQK_ -\>*/\ Y15^LW_"U=$_Y\-5_P"^+3_Y+H_X6KHG_/AJO_?%I_\
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M'ZKUQ]RSZ_\ @7[TG_"U-$'_ ##]5]?]7:?_ "71_KIP+_T:'(/_ !*^,O\
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M;+S/[07&7 Z23\(<A;ZO_6GB_5V5W_O5E=INRT5WY'QU_P -A_&3_HWC6O\
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M=M7]!/\ PM31/^@?JO'7Y+/_ .2_>C_A:FB?] _5>F?N6?3_ ,"Z/]=>!?\
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M1;%%D8YW$M(KJ['=DY9B2<'@](V^$%O)&(I;ZRDB!D(B?2+62(&5C)*1&X*
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MW3-!\&V/BGXBSMXE\6C6-!N;K7_AUX1U+PIX:T]?!+V6K>+O#^O_ !%@FO\
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MR3G^V0?^W3'\IJ3_ (5.?^@R/_ 0_P#QZ@?-'H_OT9XY6SH?_'U<?]@[4/\
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M8[G/VC3]0AOY$A>+2);&[35Y+!K:8)2=[VUM:Z6K7-R\MTF[7YE:^^J6L9*
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MMXH==(M]-\,>&+?QA:G4/">C:%XLM]$U#2-4O=#D@TO6;#3Y/$.DZ5H-E?\
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M.:R3>J<E%6W=XJ5[)O36S=U[RDDO=N_K&BBC(R!W.<?AU_G5E!1110 4444
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M:W2^EEU>S=VY2<FUS24Y:R3D^9[WDFI>7O7N].BTM&/*4444QA1110 4444
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MY5:DHI.53G2:<_>5H\L%)I1ORO\ =U.5645RTFU9Z2Y(7;2BH_,U_P#LV_\
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M1_T#[_\ .#_XNO"3U./6DI"Y(]OQ9[O_ ,+4TC_H'W_YP?\ Q='_  M32/\
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M_A:FD?\ 0/O_ ,X/_BZ\,F_ULO\ UT?_ -"-1T!R1[?BSW?_ (6II'_0/O\
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M[^&NBWMQ)<RWFIK)(L*L$EM@H\B"*W4@-:L1E(E+98_,6(P" *W_  JO0O\
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M,S8\VUP-Q)P/]$S@9XR2?>D_X57H7_/[JO\ W]M/_D2O3:* YI=W_7R/,O\
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M5O\ A:FB_P#/CJ'_ 'S%_P#%UX_K_P#R%[K_ *YV'_IMLZQZ/P\PY(]G]_\
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M%J]W+\)-/@\-:QJ5M\5;RPF\5Z?;^([N6\CTBTF#ZM%I\%F]]:]'^S1\+?\
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M_D>Z_P#"U=%_Y\=0_P"^8O\ XNC_ (6KHO\ SXZA_P!\Q?\ Q=>#@$G &2>
M!U)]*"""01@C@@]0?0TPY(]G_P"!?\ ]X_X6KHO_ #XZA_WS%_\ %T?\+5T7
M_GQU#_OF+_XNO"""."""0",@C((R#SV(((/0@Y'%)0')'L_O_P" >\?\+5T7
M_GQU#_OF+_XNI[7XF:3=W,-K'97PDGD6-&=8P@9C@%B'SC/7 -> 5J:)_P A
M;3_^OJ+_ -"H#DCV?W_\ ]E;XIZ,K,IL=0RK%3\L7.#C(^?I2?\ "U=%_P"?
M'4/^^8O_ (NO"YO];+_UT?\ ]"-1T!R1[/[_ /@'O'_"U=%_Y\=0_P"^8O\
MXNC_ (6KHO\ SXZA_P!\Q?\ Q=>#TJJS,%52S,<*J@EF/H ,DGV% <D>S_\
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M]G]__ />/^%JZ+_SXZA_WS%_\71_PM71?^?'4/\ OF+_ .+KPC!P3@X&,G'
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M[+=M*32T\U;9VNVD]FXJ\HJ]M4K]KM*_RN^JZZI7:L(&0X8^60< R1[U1B&
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MKWB?X(?$L^(=/U> 0FT6+X:?$*+PCHD2RF?2=>\0>)_M+0WFB:4C1-\(:/\
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MK_H#67_?L_\ Q5='10%WW?WLYS_A$?#7_0&LO^_9_P#BJ/\ A$?#7_0&LO\
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MQ)_<T_\ [\/_ /%UYW14CLNR^Y'HG_"SO$G]S3_^_#__ !=(?B?XD )\O3^
M?^6#_P#Q=>>4C=#]#_*@.5=E]QZKJOQ%U^SOY[:%+$QQI:LN^%BV9K.WG?)W
M]-\K8]%P.<5G_P#"SO$G]S3_ /OP_P#\77)Z_P#\A>Z_ZYV'_IMLZQZ Y5V7
MW'HG_"SO$G]S3_\ OP__ ,71_P +.\2?W-/_ ._#_P#Q=>=T4!9=E]R/1/\
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MKA>ZCJUJHM[I--6]YM#E%)JT4]K-+>^FJ>J:5WJE\,NBL?87_"SO$G]S3_\
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MN>G'TXKU"BC^OOW^_J'/+O\ @CR[_A5>D?\ 00O_ ,H/_B*/^%5Z1_T$+_\
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M^@A?_E!_\17J-% <\N_X(\N_X57I'_00O_R@_P#B*/\ A5>D?]!"_P#R@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q .4# 2(  A$! Q$!_\0
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M  7X1\3>+KFW^)OQ&-Y%X8\.:KXAGL;>X\+:9#]LN5TRWN3:1EB3#),BAG!
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M[2:JPFH3A1H1IU90YIM5'*5FW)ODY5H[];*VO42:>M[ZZ6VZ:-ZW//OV_?\
M@G/^W9_P2K_X*"ZQ_P %+_\ @G/X)U'XG?"KQ3XMU_QOXI\(>%M'F\17_A ^
M,Y7E^(?@?QKX/L VMZUX*\37DESJ&G:_HL4EQI$DPC<PBV$K]QXT_P"#IO\
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MES\S-<01R19K]@?^"0O_  79\ ?\%)K/QC\*?&_@:'X(?M7_  ^\,:IXAO/
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M/]<B75AX2T_R=5TN#38?#^@RV;W#-;LC27D,6S*9K]__ /@D!^U5\3/VS_\
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MEX:\7ZM9:AJ9CNM36]L]1GMK&UMG,]SI<4YN3;O)%'-&A/FH17W-_P '!_\
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M^%O!D.L>1J]J^K1>&]'LM'34'@&GN+=[O[$)S;*Y\IGV;F"YK^$JT_X(B?\
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M8EU\5=(_X*=:[X#_ &@Y]-T'Q?HEII'AN2ZO/#>LW_Q*O;58V29O'PM=WV*
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M\"^ ;+4-/D :"_T^[^)L]A>6-QD$-;7=K>2QN -N0C$,5X/V<_CAIG_! /\
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M+V[J]RW"5W:RUTU_K8_E+U3X$^(_C9_P3@_;M_X*L_'"UN]4^(/QC_:Q\ >
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M?A7Q#HGB.P34_@9XA:>,W<6FRS075[X/U:20:>EBGV6*=89+>0_LQ_P;L?\
M!/S]LK]DG]M/]KWXC?M&?L\>+_@WX"\?>'M7M_ ^M>(I_#UQ;:M+J7Q$U/7;
M.T@?2=4NYH7CTFZ@$JB(;YXF<O@@U[+_ ,'"_P#P1(U[]L6RL/VNOV2/ \.I
M_M0^'5T[1_B)\/=%&GZ?/\;O#,#)#I&L)/=S6FF?\)KX6<Q>1/J,I@OM+0+<
MGS;6)W;JT7B8PJR4J,(P49:632;;O%[7TWTVO9A*,DKK1_?\MCHO^#18,/\
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M61_Q\1_[C_THHKP:/_(PK>GZS/;_ .7,/1?^DQ(/^7*3_MK_ .C120?ZX?\
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A(&HHJ'T]?\Q+9>B_)":M_P N_P#VU_\ :=%%%"_5C/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
